ISSN 1881-5464

JSBMS Letters
Vol.40 Supplement, 2015

第 40 回 日本医用マススペクトル学会年会
The 40th Annual Meeting of the Japanese Society
for Biomedical Mass Spectrometry
プログラム・抄録集
年会長 瀬藤光利

浜松医科大学・解剖学講座 細胞生物学分野

教授( 同・メディカルフォトニクス研究センター 教授 )会 期 2015 年 9 月 17 日（木）・18 日（金）会 場 アクトシティ浜松 コングレスセンターJapanese Society for
Biomedical Mass Spectrometry
日本医用マススペクトル学会┠ ḟ㛤ദ࡟࠶ࡓࡗ࡚ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 2఍ሙ᱌ෆ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 3ᖺ఍᱌ෆ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 8᪥⛬⾲· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·13ࣉࣟࢢ࣒ࣛ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

14

ㅮ₇せ᪨
ᣍᚅㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·26

ᯇᮏຬ㈹ཷ㈹ㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · ·28≉ูㅮ₇ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·30ࢩ࣏ࣥࢪ࣒࢘ 1 · · · · · · · · · · · · · · · · · · · · · · · · · · ·33ࢩ࣏ࣥࢪ࣒࢘ 2 · · · · · · · · · · · · · · · · · · · · · · · · · · ·37ࢩ࣏ࣥࢪ࣒࢘ 3 · · · · · · · · · · · · · · · · · · · · · · · · · · ·41ࢩ࣏ࣥࢪ࣒࢘ 4 · · · · · · · · · · · · · · · · · · · · · · · · · · ·45

࣏ࢫࢱ࣮Ⓨ⾲ · · · · · · · · · · · · · · · · · · · · · · · · · · · ·49ࣛࣥࢳ࣭࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮ · · · · · · · · · · · · · · · · · · 112
ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ · · · · · · · · · · · · · · · · · · · · · · 117
Ꮫ఍㈶ຓ఍ဨ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 126
ᖺ఍༠㈶௻ᴗ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 127ᒎ♧௻ᴗ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 128ᖺ఍㐠Ⴀጤဨ୍ぴ · · · · · · · · · · · · · · · · · · · · · · · · · · · 129௻ᴗᗈ࿌ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 130ḟᅇᖺ఍ண࿌

➨ 40 ᅇ᪥ᮏ࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍㛤ദ࡟࠶ࡓࡗ࡚
グᛕࡍ࡭ࡁ➨ 40 ᅇࡢ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍ࡣ὾ᯇࡀᢸᙜࡉࡏ࡚࠸ࡓࡔࡃ
ࡇ࡜࡟࡞ࡾࡲࡋࡓࠋ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ࡣࠊ㉁㔞ศᯒἲࡢ་Ꮫ࡜ࡑࡢ㛵㐃㡿ᇦ࡬ࡢᛂ⏝ࢆ┠ⓗ࡜ࡋࠊ᫛࿴ 51 ᖺ࠿ࡽ௒᪥ࡲ࡛╔ᐇ࡞Ⓨᒎࢆ㐙ࡆ࡚ཧࡾࡲࡋࡓࠋ
➨ 40 ᅇᖺ఍࡛ࡣࠊᖜᗈ࠸ศ㔝࡛᭱᪂ࡢヰ㢟࡟ࡘ࠸࡚㆟ㄽࡋࡓ࠸࡜⪃࠼࡚࠾ࡾࡲࡍࠋ
ࡑࡇ࡛ࠊᣍᚅㅮ₇࡜ࡋ࡚ⱥᅜ Imperial College London ࡢ Dr. Jeremy K Nicholson Ặࠊ≉ูㅮ₇࡜ࡋ࡚஑ᕞ኱Ꮫࡢ୰ᒣᩗ୍ᩍᤵࢆ࠾ᣍࡁࡋࡲࡋࡓࠋࡑࢀࡒࢀࡢඛ⏕࡟ࡼࡾࠊ
ࠕSystems Medicine in a Changing World: The Challenge of Measuring and Visualising
Personal and Public Healthcare Data.ࠖࠊࠕḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶࡢゎ᫂ࠖࡢ࠾ヰࢆ㡬ࡃணᐃ࡛ࡍࠋࡲࡓࠊࢩ࣏ࣥࢪ࣒࡛࢘ࡣࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽ
ࣥࢢࠊ㉁㔞࢖࣓࣮ࢪࣥࢢࠊࢺࣛࣥࢫ࣑࢜ࢡࢫࠊ༴㝤ࢻࣛࢵࢢࠊࡢ㸲ࡘࡢࢸ࣮࣐ࢆ௻⏬࠸ࡓࡋࡲࡋࡓࠋࡉࡽ࡟ 4 ♫࡟ࡼࡿࣛࣥࢳ࣭࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮ࠊ8 ♫ࡢ༠㈶௻ᴗ࡟ࡼ
ࡿࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ௻ᴗㅮ₇ࠊࡉࡽ࡟ᶵჾ࣭ၟရᒎ♧࣭௻ᴗᗈ࿌࡟࠾࠸࡚ࡶከᩘ
ࡢ௻ᴗ࡟ࡈ༠ຊࢆ㡬ࡁࡲࡋࡓࠋ῝ࡃឤㅰࢆ⏦ࡋୖࡆࡿḟ➨࡛ࡍࠋ୍⯡₇㢟ࡣࠊ࠾࠿ࡆࡉࡲ࡛ྜィ 62 㢟࡜㐣ཤ᭱ከࡢ⏦ࡋ㎸ࡳࢆ㡬ࡁࡲࡋࡓࠋ࣏ࢫࢱ࣮
₇㢟࡜ࡋ࡚ 2 ᪥㛫࡟ࢃࡓࡾウㄽࢆ⾜࠺ணᐃ࡛ࡍࠋⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࢆ௻⏬ࡋ࡚࠾ࡾࡲࡍࡢ࡛ࠊホ㆟ဨࡢⓙᵝ࡟ࡣ✚ᴟⓗ࡞ᢞ⚊ࢆ࠾㢪࠸⏦ࡋୖࡆࡲࡍࠋ᠓ぶ఍ሙ࡟࡚⾲ᙲࢆ⾜࠸ࡲࡍࠋ᠓ぶ఍ࡣᖺ఍ึ᪥ࡢ 18 ᫬༙࠿ࡽཷ௜㛤ጞࠊ19 ᫬ࡼࡾ఍ሙ㏆ࡃࡢ࣐࢖࣭ࣥࢩࣗ
ࣟࢫ࡟࡚㛤ᐗ࠸ࡓࡋࡲࡍࠋከᩘࡢࡈཧຍࢆ࠾ᚅࡕ⏦ࡋୖࡆࡲࡍࠋ
ࡉࡽ࡟ࡣࠊ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍୺ദࡢࠕ་⏝㉁㔞ศᯒㄆᐃኈไᗘࠖࡢ➨ 3 ᅇ┠ㅮ⩦఍ࢆᖺ఍⩣᪥࡟ணᐃࡋ࡚࠸ࡲࡍ㸦9 ᭶ 19 ᪥㸦ᅵ㸧࢔ࢡࢺࢩࢸ࢕὾ᯇࢥࣥࢢࣞࢫ
ࢭࣥࢱ࣮㸲㝵㸧ࠋ⮫ᗋ᳨ᰝࡸデ⒪࡟࠾ࡅࡿ㉁㔞ศᯒᢏ⾡ࡢᬑཬ࣭ᶆ‽໬ࡢࡼࡾ୍ᒙࡢ㐍ᒎࢆᮇᚅࡋ࡚࠾ࡾࡲࡍࠋ
ᮎ➹࡞ࡀࡽࠊᮏᖺ఍ࡢ㛤ദ࡟ྥࡅ࡚ࡈᨭ᥼࠸ࡓࡔࡁࡲࡋࡓᮏᏛ఍ࡢᙺဨ࣭఍ဨࡢⓙᵝࠊ
༠㈶࠸ࡓࡔࡁࡲࡋࡓ௻ᴗྛ♫࡟ᚰࡼࡾ࠾♩⏦ࡋୖࡆࡲࡍࠋ
ᮏᖺ఍ࡀࡈཧຍ࠸ࡓࡔ࠸ࡓⓙᵝࡢάⓎ࡞ウㄽ࡟ࡼࡾ௒ᚋࡢⓎᒎ࡟ࡘ࡞ࡀࡿࡇ࡜ࢆ♳ᛕ࠸ࡓࡋࡲࡍࠋ

➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍

ᖺ఍㛗

℩⸨

ග฼

὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝 ᩍᤵྠ࣭࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮ ᩍᤵ

́́

́́

́́

➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍఍ሙぢྲྀࡾᅗ‫ە‬1㹄࢚ࣥࢺࣛࣥࢫࣟࣅ࣮࣭ᦙධཱྀ

‫ە‬2㹄 ఍㆟ᐊ‫ە‬4㹄఍㆟ᐊ࣭ࣛࣥࢳ࣮ࣙࣥࣔࢽࣥࢢࢭ࣑ࢼ࣮࣭ㅮ⩦఍఍ሙ́́௻ᴗᒎ♧ࣈ࣮ࢫ㓄⨨ᅗձ ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫ղ ࢔ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫ճ ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫մ ࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫յ ᰴᘧ఍♫࢚࣮ࣅ࣮ࢧ࢖࢚ࢵࢡࢫն ࢪ࣮࢚ࣝࢧ࢖࢚ࣥࢫᰴᘧ఍♫շ ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ఍♫ո ࢩࢢ࣐࢔ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ఍♫չ ᰴᘧ఍♫ᓥὠ〇సᡤ
պ ኱ሯ〇⸆ᰴᘧ఍♫ջ 㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡᣺⯆㈈ᅋ

́́᠓ぶ఍఍ሙࡢࡈ᱌ෆ
࠙᪥᫬࣭ሙᡤࠚ9 ᭶ 17 ᪥㸦ᮌ㸧19㸸00㹼㸦18㸸30㹼ཷ௜㛤ጞࠊ19㸸00 㛤ᐗ㸧ࡣࡲࡲࡘᆅࣅ࣮ࣝᕤᡣ

࣐࢖࣭ࣥࢩࣗࣟࢫ

ఫᡤ㸸㟼ᒸ┴὾ᯇᕷ୰༊୰ኸ 3 ୎┠ 8-1
㟁ヰ㸸053-452-1146

́́ᖺ ఍ ᱌ ෆ࠙఍ᮇࠚ ᖹᡂ 27 ᖺ 9 ᭶ 17 ᪥㸦ᮌ㸧࣭18 ᪥㸦㔠㸧
㸦9 ᭶ 19 ᪥(ᅵ)࡟་⏝㉁㔞ศᯒㄆᐃኈㅮ⩦఍㛤ദ㸧࠙఍ሙࠚ ᖺ ఍ ఍ ሙ 㸸࢔ࢡࢺࢩࢸ࢕὾ᯇ ࢥࣥࢢࣞࢫࢭࣥࢱ࣮
࣓࢖ࣥ఍ሙ㸸㸲㸯఍㆟ᐊᒎ ♧ ఍ ሙ 㸸㸲㸱㸩㸲㸲఍㆟ᐊ
ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮఍ሙ㸸㸲㸯఍㆟ᐊࠊ㸰㸰㸩㸰㸱఍㆟ᐊ
࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮఍ሙ㸸㸲㸯఍㆟ᐊ࠙ཧຍᡭ⥆ࡁ࡟ࡘ࠸࡚ࠚ
ཷ௜㸸㸲F ࣟࣅ࣮

᫬㛫㸸17 ᪥㸦ᮌ㸧9:00㹼ࠊ18 ᪥㸦㔠㸧8:30㹼

࣭ཧຍⓏ㘓῭ࡳࡢ᪉ࡣࠊཷ௜࡛ྡᮐࢆ࠾Ώࡋࡋࡲࡍࠋ
࣭ᙜ᪥ཧຍࡢ᪉ࡣࠊཷ௜࡟࡚ཧຍ㈝ࢆ࠾ᨭᡶ࠸ࡃࡔࡉ࠸ࠋ
ṇ఍ဨ㸸7,000 ෇ࠊ㠀఍ဨ㸸12,000 ෇ࠊᏛ⏕఍ဨ㸸3,000 ෇࣭ᖺ఍ᮇ㛫୰ࡣᚲࡎࢿ࣮࣒ࣉ࣮ࣞࢺࢆࡈ╔⏝ࡃࡔࡉ࠸ࠋ
࠙ᗙ㛗ࡢ᪉࡬ࠚ
࣭ᢸᙜ᫬㛫ࡢ 10 ศ๓࡟ࡣࠊ఍ሙෆࡢḟᗙ㛗ᖍ࡟࠾㉺ࡋࡃࡔࡉ࠸ࠋ
࠙₇⪅ࡢ᪉࡬ࠚ
࣭ㅮ₇᫬㛫ࡣࠊࢩ࣏ࣥࢪ࣒࢘ࡢᗙ㛗ࡢᣦ♧㏻ࡾ࡟࠾㢪࠸࠸ࡓࡋࡲࡍࠋ
࣭ᣍᚅㅮ₇ࠊ≉ูㅮ₇ࡣ 60 ศࠊཷ㈹ㅮ₇ࡣ 30 ศࠊࢩ࣏ࣥࢪ࣒࢘ࡣ࠾୍ே 20㹼30 ศࠊࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛࡣ୍♫ 15 ศࡢᣢࡕ᫬㛫࡜࡞ࡾࡲࡍ㸦ࡍ࡭࡚㉁␲ᛂ⟅㎸㸧ࠋ࣭Ⓨ⾲᫬㛫ࡢཝᏲࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ
࣭Ⓨ⾲ࢫࣛ࢖ࢻ࡟ࠊ฼┈┦཯㸦COI㸧ࡢグ㍕ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋᏛ఍ࡢ࣮࣒࣮࣍࣌ࢪ
㸦http://www.jsbms.jp/㸧ࡲࡓࡣᖺ఍ࡢ࣮࣒࣮࣍࣌ࢪ࠿ࡽ COI Ⓨ⾲⪅㛤♧࡞ࡋ㸦ᵝᘧ
1-A㸧ࠊࡲࡓࡣ COI Ⓨ⾲⪅㛤♧࠶ࡾ㸦ᵝᘧ 1-B㸧ࢆࢲ࣮࢘ࣥࣟࢻࡋ࡚ࡈ౑⏝ࡃࡔࡉ࠸ࠋ
‫ۑ‬Ⓨ⾲᫬ࡢࡈὀព࡜࠾㢪࠸࣭ࡍ࡭࡚ PC (PowerPoint)࡟ࡼࡿⓎ⾲࡜࡞ࡾࡲࡍࠋ
࣭PC ཷ௜࡛ࡢⓎ⾲ࢹ࣮ࢱཷ௜⤊஢ᚋࠊⓎ⾲ 10 ศ๓ࡲ࡛࡟ࡈㅮ₇఍ሙෆࡢḟ₇⪅ᖍ࡟࠾㉺ࡋࡃࡔࡉ࠸ࠋ
࣭₇ྎୖ࡟࣮ࣞࢨ࣮࣏࢖ࣥࢱ࣮ࢆ⏝ព࠸ࡓࡋࡲࡍࡢ࡛ࠊࡈ౑⏝ࡃࡔࡉ࠸ࠋ
‫ۑ‬Ⓨ⾲ࢹ࣮ࢱཷ௜࡟ࡘ࠸࡚
࣭ࡈⓎ⾲ࡢ 30 ศ๓ࡲ࡛࡟ࠊPC ཷ௜࡟࡚Ⓨ⾲ࢹ࣮ࢱࡢᥦฟࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ
࣭ࡈⓎ⾲๓࡟ࠊPC ཷ௜࡟࡚Ⓨ⾲ࢹ࣮ࢱࡢືస☜ㄆࢆ⾜ࡗ࡚࠸ࡓࡔࡁࡲࡍࠋUSB ࣇࣛࢵ́́ࢩ࣓ࣗࣔࣜ࡟࡚ࠊⓎ⾲ࢹ࣮ࢱࢆࡈᣢཧࡃࡔࡉ࠸ࠋUSB ࣇࣛࢵࢩ࣓ࣗࣔࣜࡣヨ෗⤊஢ᚋࠊ㏉༷࠸ࡓࡋࡲࡍࠋ఍ሙ࡛ࡢᥦฟࡣᚲせ࠶ࡾࡲࡏࢇࡀࠊᛕࡢࡓࡵ఍ሙ࡟ࡣࡈᣢཧࡃ
ࡔࡉ࠸ࠋ࣭࠾㡸࠿ࡾࡋࡓⓎ⾲ࢹ࣮ࢱࡣࠊⓎ⾲⏝ࣃࢯࢥࣥ࡟ࢥࣆ࣮ࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࡀࠊᮏᏛ఍
ᖺ఍ࣉࣞࢮࣥࢸ࣮ࢩࣙࣥ௨እ࡟౑⏝ࡍࡿࡇ࡜ࡣ࠶ࡾࡲࡏࢇࠋᖺ఍⤊஢ᚋࠊᖺ఍஦ົᒁ
ࡀ㈐௵ࢆᣢࡗ࡚ᾘཤ࠸ࡓࡋࡲࡍࠋ
‫ۑ‬Ⓨ⾲ࢹ࣮ࢱཷ௜᫬ࡢࡈὀព
࣭ື⏬ࡸ㡢ኌࢆࡈ౑⏝࡟࡞ࡿሙྜࡣࠊᚲࡎ࣮࢜࣌ࣞࢱ࣮࡟⏦ࡋฟ࡚ࡃࡔࡉ࠸ࠋ
࣭ࢹ࣮ࢱࢆࣁ࣮ࢻࢹ࢕ࢫࢡ࡟ࢥࣆ࣮ࡋࠊヨ෗⏝ࣃࢯࢥࣥ࡟࡚ືసࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ
࣭PC ཷ௜࡛ࡢࢹ࣮ࢱࡢಟṇࠊኚ᭦ࡣ࡛ࡁࡲࡏࢇࠋ
࣭࢘࢖ࣝࢫᐃ⩏ࢹ࣮ࢱࢆ᭱᪂ࡢࡶࡢ࡟᭦᪂ࡋࡓ≧ែࡢࢭ࢟ࣗࣜࢸ࢕ࢯࣇࢺ࡟࡚ᚲࡎ஦
๓࡟ࡈ⮬㌟࡛࢘࢖ࣝࢫࢳ࢙ࢵࢡࢆ࠾㢪࠸ࡋࡲࡍࠋPC ཷ௜࡛ࠊᣢࡕ㎸ࡲࢀࡿ࣓ࢹ࢕࢔
඲࡚ࢆ࢘࢖ࣝࢫࢳ࢙ࢵࢡࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࠋ
‫ࢱ࣮ࢹۑ‬㸦USB ࣇࣛࢵࢩ࣓ࣗࣔࣜ㸧ࢆᣢཧࡉࢀࡿ᪉࡬
࣭࠾ᣢࡕ㎸ࡳ࠸ࡓࡔࡅࡿࢹ࣮ࢱࡣࠊUSB ࣇࣛࢵࢩ࣓ࣗࣔࣜࡢࡳ࡛ࡍࠋ
࣭ࡲࡓࠊࡈ⮬㌟ࡢࣃࢯࢥࣥ௨እ࡛ᩥᏐ໬ࡅ➼ࡀ࡞ࡃࠊࢹ࣮ࢱࢆㄞࡳ㎸ࡵࡿ࠿ᚲࡎࡈ☜ㄆࡃࡔࡉ࠸ࠋ࣭Ⓨ⾲᫬ࡢࢺࣛࣈࣝࢆ㜵ࡄࡓࡵ࡟ࡶࠊᣢࡕ㎸ࡲࢀࡿ࣓ࢹ࢕࢔࡟ࡣࠊⓎ⾲⏝ࡢࢹ࣮ࢱ㸦᏶ᡂ∧㸧௨እධࢀ࡞࠸ࡼ࠺࡟ࡋ࡚ࡃࡔࡉ࠸ࠋࣇ࢓࢖ࣝྡࡣࠕ₇㢟␒ྕ࣭₇⪅ྡ.pptࠖࠊࡲࡓࡣࠕ₇㢟␒ྕ࣭₇⪅ྡ.pptxࠖ࡜ࡋ࡚ࡃࡔࡉ࠸ࠋ
࣭఍ሙ࡛ࡈ⏝ពࡍࡿࣃࢯࢥࣥ
OS㸸Windows 8 pro࢔ࣉࣜࢣ࣮ࢩࣙࣥ㸸PowerPoint2013
࣭Ⓨ⾲࡟౑⏝࡛ࡁࡿࢹ࣮ࢱ
Microsoft PowerPoint2003 ௨㝆࡛సᡂࡉࢀࡓࣇ࢓࢖ࣝ㸦Ⓨ⾲⪅ࢶ࣮ࣝᶵ⬟ࡣࡈ౑⏝࡟࡞ࢀࡲࡏࢇ㸧࣭ᩥᏐࡢࣇ࢛ࣥࢺ
᪥ᮏㄒ㸸MS ࢦࢩࢵࢡ/MSP ࢦࢩࢵࢡ/MS ᫂ᮅ/MSP ᫂ᮅࡢ 4 ✀㢮ࡢࡳࠋⱥㄒ㸸Times New Roman/Arial/Arial Black/Arial Narrow/Century/Century

Gothic/Courier/Courier New/Georgia/ Symbol ࡢྜィ 10 ✀㢮ࡢࡳࠋୖグ௨እࡢࣇ࢛ࣥࢺࢆ౑⏝ࡉࢀࡓሙྜࡣࠊ⾲♧࡟୙ලྜࡀⓎ⏕ࡍࡿྍ⬟ᛶࡀ࠶ࡾࡲࡍࠋ
࣭⏬㠃ࡢゎീᗘࡣ XGA㸦1024x768㸧࡛ࡍࠋࡇࢀࡼࡾ኱ࡁ࠸ሙྜࠊࢫࣛ࢖ࢻࡢ࿘ᅖࡀษ
ࢀ࡚ࡋࡲ࠸ࡲࡍࠋࡲࡓࠊ⏬㠃ࡢࡂࡾࡂࡾࡲ࡛౑⏝ࡍࡿ࡜෌⌧⎔ቃࡢ㐪࠸࡟ࡼࡾᩥᏐࡸ
⏬ീࡢࡣࡳฟࡋ➼ࡢཎᅉ࡟࡞ࡿࡇ࡜ࡀ࠶ࡾࡲࡍࠋ
࣭ື⏬ࢆ౑⏝ࡍࡿሙྜࠊࢫࣛ࢖ࢻࣇ࢓࢖ࣝ࡜ື⏬ࢹ࣮ࢱࢆ୍⥴࡟ಖ⟶ࡋ࡚ࡃࡔࡉ࠸ࠋ
࡞࠾ࠊື⏬ࣇ࢓࢖ࣝࡣ Windows Media Video㸦WMV ࣇ࢓࢖ࣝ㸧ᙧᘧ࡜ࡋࠊᣑᙇᏊ
㸦.wmv㸧ࢆᚲࡎࡘࡅ࡚ࡃࡔࡉ࠸ࠋ

́́‫ࡈࢆࣥࢥࢯࣃۑ‬ᣢཧࡉࢀࡿ᪉࡬
࣭ࢥࢿࢡࢱࡢᙧ≧ࡣ࢔ࢼࣟࢢ VGA㸦D-Sub15 ࣆࣥ㸧࡟㝈ࡾࡲࡍࠋኚ᥮ࢣ࣮ࣈࣝࡀᚲせ࡞ᶵ✀㸦Macintosh ➼㸧ࢆࡈ౑⏝ࡢሙྜࡣࠊኚ᥮ࢣ࣮ࣈࣝࢆࡈᣢཧࡃࡔࡉ࠸ࠋ
࣭ࡈ⮬㌟ࡢࣃࢯࢥࣥ࠿ࡽእ㒊ࣔࢽࢱ࣮࡟ṇࡋࡃฟຊ࡛ࡁࡿࡇ࡜ࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ
ಶࠎࡢࣃࢯࢥࣥࡸ OS ࡟ࡼࡾタᐃ᪉ἲࡀ␗࡞ࡾࡲࡍࡢ࡛ࠊ஦๓࡟ࡈ☜ㄆࡃࡔࡉ࠸ࠋ
࣭⏬㠃ࡢゎീᗘࡣ XGA㸦1024x768㸧࡛ࡍࠋࡇࢀࡼࡾ኱ࡁ࠸ሙྜࠊࢫࣛ࢖ࢻࡢ࿘ᅖࡀษ
ࢀ࡚ࡋࡲ࠸ࡲࡍࠋ
࣭Ⓨ⾲୰࡟ࢫࢡ࣮ࣜࣥࢭ࣮ࣂ࣮ࡸ┬㟁ຊ࣮ࣔࢻ࡟࡞ࡽ࡞࠸ࡼ࠺஦๓࡟タᐃࢆ࠾῭ࡲࡏࡃࡔࡉ࠸ࠋ࣭㟁※ࢥࣥࢭࣥࢺࢆ⏝ពࡋ࡚࠾ࡾࡲࡍࡢ࡛ࠊᚲࡎ㟁※ࢣ࣮ࣈࣝࢆ࠾ᣢࡕ࠸ࡓࡔࡁࠊࣂࢵ
ࢸ࣮࡛ࣜࡢࡈⓎ⾲ࡣࡈ㐲៖ࡃࡔࡉ࠸ࠋ
࣭ࡈ⮬㌟ࡢࣃࢯࢥࣥ࠿ࡽヨ෗⏝ࣉࣟࢪ࢙ࢡࢱ࣮࡟ࠊⓎ⾲ࢹ࣮ࢱࡀṇࡋࡃฟຊ࡛ࡁࡿࡇ࡜
ࢆ☜ㄆࡋ࡚ࡃࡔࡉ࠸ࠋ≉࡟ື⏬ࠊ⏬ീࢹ࣮ࢱࡣࠊᮏయ⏬㠃࡟ࡣ⾲♧ࡉࢀ࡚ࡶࠊእ㒊ฟຊ࡟᥋⥆ࡋࡓ⏬㠃࡟ࡣ⾲♧ࡉࢀ࡞࠸ሙྜࡀ࠶ࡾࡲࡍࠋ༑ศ࡟ὀពࡋ࡚ࡈ☜ㄆࡃࡔࡉ࠸ࠋ
࣭୓ࡀ୍ࡢࢺࣛࣈࣝࡢሙྜ࡟ഛ࠼ࠊணഛ࡜ࡋ࡚ࡢࢹ࣮ࢱ㸦USB ࣇࣛࢵࢩ࣓ࣗࣔࣜ㸧ࢆᣢཧ㡬ࡁࡲࡍࡼ࠺࠾㢪࠸࠸ࡓࡋࡲࡍࠋ
࣏࠙ࢫࢱ࣮Ⓨ⾲ࡢ᪉࡬ࠚ࣭࣏ࢫࢱ࣮࣮࣎ࢻࡢ኱ࡁࡉࡣࠊᶓ 120 ੉⦪ 180 ੉࡛ࡍࠋᢲࡋࣆࣥࡣ஦ົᒁ࡛⏝ព࠸ࡓࡋࡲࡍࠋᡤᐃࡢ࣮࣎ࢻ࡟ᥖ♧ࡋ࡚ࡃࡔࡉ࠸ࠋⓎ⾲᫬㛫୰ࡣࠊ࣏ࢫࢱ࣮๓࡛㉁␲ᛂ⟅ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋ
࣭Ⓨ⾲࣏ࢫࢱ࣮࡟฼┈┦཯㸦COI㸧ࡢグ㍕ࢆ࠾㢪࠸࠸ࡓࡋࡲࡍࠋᏛ఍ࡢ࣮࣒࣮࣍࣌ࢪ
㸦http://www.jsbms.jp/㸧ࡲࡓࡣᖺ఍ࡢ࣮࣒࣮࣍࣌ࢪ࠿ࡽ COI Ⓨ⾲⪅㛤♧࡞ࡋ㸦ᵝᘧ
1-A㸧ࠊࡲࡓࡣ COI Ⓨ⾲⪅㛤♧࠶ࡾ㸦ᵝᘧ 1-B㸧ࢆࢲ࣮࢘ࣥࣟࢻࡋ࡚ࡈ౑⏝ࡃࡔࡉ࠸ࠋ
࣭࡞࠾ࠊ➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍࡛ࡣࠊⱝᡭ◊✲⪅㸦35 ṓ௨ୗ㸧ࡢඃࢀࡓ࣏ࢫࢱ࣮࡟ࠕⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࠖࢆ㉗ࡾࡲࡍࠋヲ⣽ࡣࠊู࡟♧ࡍ㏻ࡾ࡛ࡍࠋ
࣭ᥖ♧᫬㛫㸸9 ᭶ 17 ᪥㸦ᮌ㸧9:00㹼9 ᭶ 18 ᪥㸦㔠㸧15:00
㸦࣏ࢫࢱ࣮ᥖ♧ࡣ 9 ᭶ 17 ᪥㸦ᮌ㸧9:00㹼10:00 ࡲ࡛ࡢ㛫࡟࠾㢪࠸࠸ࡓࡋࡲࡍࠋ㸧
9 ᭶ 17 ᪥㸦ᮌ㸧13:00㹼14:00
࣭Ⓨ⾲᫬㛫㸸 ወᩘ₇㢟
അᩘ₇㢟

9 ᭶ 18 ᪥㸦㔠㸧13:00㹼14:00

࣭᧔ཤ᫬㛫㸸9 ᭶ 18 ᪥㸦㔠㸧15:00㹼16:00
㸦᫬㛫ࢆ㐣ࡂ࡚ࡶ᧔ཤࡉࢀ࡚࠸࡞࠸࣏ࢫࢱ࣮ࡣ஦ົᒁ࡟࡚᩿ࡾ࡞ࡃฎศࡋࡲࡍࠋ㸧࣭⾲ᙲᘧሙ㸸9 ᭶ 17 ᪥㸦ᮌ㸧19:00 ᠓ぶ఍఍ሙ࠙௻ᴗᒎ♧ࡢ᪉࡬ࠚ
࣭㸯ᒎ♧ࢫ࣮࣌ࢫࡣࠊ㛫ཱྀ 200 cm ዟ⾜ 100 cm 㧗ࡉ 240 cm ࡢࣈ࣮ࢫ࡜࡞ࡗ࡚࠾ࡾ
ࡲࡍࠋࡲࡓࠊࣈ࣮ࢫࡢ୰࡟ࡣᮘ㸦ᖜ 180 cm ዟ⾜ 60 cm 㧗ࡉ 70cm㸧ࢆ⏝ព࠸ࡓࡋࡲࡍࠋ㟁※ࡣ 1 ࣈ࣮ࢫ 500 W ࡲ࡛౑⏝࡛ࡁࡿࡼ࠺࡟☜ಖࡋ࡚࠸ࡲࡍࠋ́́࠙᠓ぶ఍ࠚ࣭᠓ぶ఍ࡣࠊ17 ᪥(ᮌ)19:00 ࡼࡾ㸦18:30 ཷ௜㛤ጞࠊ19:00 㛤ᐗ㸧ࠊ࣐࢖࣭ࣥࢩࣗࣟࢫ
࡟࡚⾜࠸ࡲࡍࠋ࡞࠾ࠊ᠓ぶ఍ሙࡲ࡛ࡣࠊᚐṌ࡟࡚ࡢ⛣ືࢆ࠾㢪࠸࠸ࡓࡋࡲࡍ㸦⣙ 5 ศ㸧ࠋಀࡢ⪅ࡀࡈ᱌ෆ⏦ࡋୖࡆࡲࡍࠋᙜ᪥ཧຍ⪅ࡣࠊᖺ఍ཷ௜ࡲࡓࡣ᠓ぶ఍ሙ࡟࡚᠓ぶ఍㈝ࢆ࠾ᨭᡶ࠸ࡃࡔࡉ࠸㸦7,000 ෇㸧ࠋ࠙⌮஦఍ࠚ࣭⌮஦఍ࡣ 16 ᪥㸦Ỉ㸧14:30 ࡼࡾࠊ㸰㸯఍㆟ᐊ࡟࡚⾜࠸ࡲࡍࠋ࣭᪂⌮஦఍ࡣ 16 ᪥㸦Ỉ㸧15:30 ࡼࡾࠊ㸰㸯఍㆟ᐊ࡟࡚⾜࠸ࡲࡍࠋ࠙♫ဨ⥲఍࣭఍ဨ㞟఍ࠚ࣭♫ဨ⥲఍ࡣ 17 ᪥㸦ᮌ㸧12:00㹼12:30ࠊ2F 㸰㸰㸩㸰㸱఍㆟ᐊ࡟࡚⾜࠸ࡲࡍࠋ࣭఍ဨ㞟఍ࡣ 17 ᪥㸦ᮌ㸧15:00㹼15:30ࠊ㸲㸯఍㆟ᐊ࡟࡚⾜࠸ࡲࡍࠋ࠙ࡑࡢ௚ࠚ࣭఍㆟ᐊ࠾ࡼࡧࣟࣅ࣮࡛ Wi-Fi ᥋⥆ࡀྍ⬟࡛ࡍࠋ࣭㸲F ࡟ࢡ࣮ࣟࢡࡣタ⨨ࡋ࡚࠾ࡾࡲࡏࢇࠋ
࣭࣏ࢫࢱ࣮ࢭࢵࢩࣙࣥ୰࡟༠㈶௻ᴗ࠿ࡽࡢࢻࣜࣥࢡࢆᩘ㔞㝈ᐃ࡛ࡈ⏝ពࡋࡲࡍࠋ
࣭࢔ࢡࢺࢩࢸ࢕὾ᯇࢥࣥࢢࣞࢫࢭࣥࢱ࣮ࡢ㥔㌴ሙࢆࡈ฼⏝࡟࡞ࢀࡲࡍ㸦᭷ᩱ㸧ࠋ࠙ၥ࠸ྜࢃࡏඛࠚ
➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍஦ົᒁ
(TEL/FAX: 053-435-2092ࠊE-mail: jsbms40.hamamatsu㸾hama-med.ac.jp)́́࣏ࢫࢱ࣮Ⓨ⾲⪅ྛ఩ᖺ఍࡛ⱝᡭ◊✲⪅㸦35 ṓ௨ୗ㸧ࡢඃࢀࡓ࣏ࢫࢱ࣮࡟ࠕⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࠖࢆ㉗ࡾࡲࡍࠋࠐⱝᡭඃ⚽࣏ࢫࢱ࣮㈹ࡢᑂᰝ࠾ࡼࡧཷ㈹⪅ࡢⓎ⾲᪉ἲⱝᡭඃ⚽࣏ࢫࢱ࣮㈹࡬ᛂເࡉࢀࡓ᪉ࡣࠊⓎ⾲⪅Ặྡ࡟ୗ⥺ࢆグࡋ࡚ࡃࡔࡉ࠸ࠋ
ᑂᰝࡣ 9 ᭶ 17 ᪥(ᮌ)ࡢⓎ⾲⤊஢ᚋࠊᢞ⚊࡟ࡼࡗ࡚⾜࠸ࡲࡍࠋᢞ⚊⏝⣬ࡣ♫ဨ⥲఍࡛㓄ᕸࡋࠊᢞ⚊⟽ࡣ࣏ࢫࢱ࣮఍ሙධࡾཱྀ࡟タ⨨ࡋࡲࡍࡢ࡛ࠊホ㆟ဨ㸦♫ဨ㸧ࡢ᪉ࡣᚲࡎ
ᢞ⚊ࢆ࠾㢪࠸ࡋࡲࡍࠋ9 ᭶ 17 ᪥㸦ᮌ㸧ࡢ᠓ぶ఍࡟࡚⾲ᙲᘧࢆ⾜࠸ࡲࡍࠋྛ࣏ࢫࢱ࣮Ⓨ⾲⪅ࡣࠊୗグࡢ᮲௳࡟ࡈ␃ពࡃࡔࡉ࠸ࠋ
‫࣮ࢱࢫ࣏ۑ‬Ⓨ⾲᫬㛫ࢆཝᏲࡋ࡚ࡃࡔࡉ࠸ࠋ
‫ۑ‬₇㢟ࡣ᪥ᮏㄒ࡜ⱥㄒࢆేグࡋ࡚ࡃࡔࡉ࠸ࠋ
‫ۑ‬ᅗ୰ࡢᩥᏐ࡜ᅗࡢ࢟ࣕࣉࢩࣙࣥࡣᚲࡎⱥㄒ࡛グ㍕ࡋ࡚ࡃࡔࡉ࠸ࠋ
‫ۑ‬᪤ᐃࡢ᫬㛫ࡲ࡛࡟࣏ࢫࢱ࣮ࢆᥖ♧ࡋࠊࡲࡓつᐃࡢ᫬㛫ࡼࡾ๓࡟᧔ཤࡋ࡞࠸࡛ࡃࡔࡉ࠸ࠋ
ᑂᰝᇶ‽௨ୗࡢᑂᰝᇶ‽ࢆࡶ࡜࡟ࠊ⥲ྜⓗ࡟ุ᩿ࡋࡲࡍࠋ
‫ࡢ✲◊ۑ‬㉁࡟㛵ࡍࡿᇶ‽㡯┠࣭◊✲ࡢ᭷⏝ᛶ࣭᪂つᛶࠊ⊂๰ᛶ࣭ᐇ㦂ࡢ⤌ࡳ❧࡚ࡢጇᙜᛶࠋ
࣭⛉Ꮫⓗ࡞㘒ㄗࡀ࡞࠸࠿ࠋ
‫࡟ࣥࣙࢩ࣮ࢸࣥࢮࣞࣉۑ‬㛵ࡍࡿᇶ‽㡯┠࣭࣏ࢫࢱ࣮ࢆぢΏࡋ࡚ࠊㄝ᫂ࢆ⪺࠿࡞ࡃ࡚ࡶせⅬࢆࡍࡄ࡟⌮ゎࡍࡿࡇ࡜ࡀ࡛ࡁࡿ࠿࡝࠺࠿ࠋ
࣭ᩥᏐࡸᅗࡢ኱ࡁࡉࡀ㐺ᙜ࠿ࠋ࠶ࡿ⛬ᗘ㞳ࢀ࡚࠸࡚ࡶゎㄞ࡛ࡁࡿ࠿ࠋ
࣭ᅗ⾲ࡢⱥㄒㄝ᫂ࡀ⌮ゎ࡛ࡁࡿ࠿ࠋ
࣭᝟ሗࡀ㐣ከ࡛ࡣ࡞࠸࠿ࠋ
࣭⏝ㄒࡀṇࡋࡃ౑⏝ࡉࢀ࡚࠸ࡿ࠿ࠋ
࣭Ⓨ⾲⪅ࡢㄝ᫂ࡀ⡆⣲࠿ࡘࢃ࠿ࡾࡸࡍࡃࠊㄝ᫂᫬㛫ࡀ㐺ᙜ࠿ࠋ
࣭㉁ၥ࡟ᑐࡍࡿᅇ⟅ࡀ⡆⣲࠿ࡘⓗ☜࡛࠶ࡿ࠿࡝࠺࠿ࠋ
࣭ࡑࡢ௚ࠊయ⿢ࡀつᐃࢆ㐓⬺ࡋ࡚࠸࡞࠸࠿ࠋ
➨ 40 ᅇ᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍ᖺ఍஦ົᒁ́́᪥ ⛬ ⾲
࠙㸯᪥┠ࠚ9 ᭶ 17 ᪥㸦ᮌ㸧

ሙ

ᡤ

9㸸0
00㹼

ཷ௜㛤ጞ

㸲㹄ࣟࣅ࣮

9㸸5
55㹼 10㸸㸸00㛤఍ࡢ㎡㸲㸯఍㆟ᐊ㸦㸲㹄㸧

10㸸0
00㹼 12㸸㸸00ࢩ࣏ࣥࢪ࣒࢘ 1

ࠌ12㸸000㹼 12㸸㸸30♫ဨ⥲఍㸰㸰㸩㸰㸱఍㆟ᐊ㸦㸰㹄㸧

12㸸0
00㹼 13㸸㸸00ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮1ࠊ2

㸲㸯఍㆟ᐊ㸦㸲㹄㸧㸰㸰㸩㸰㸱఍㆟ᐊ㸦㸰㹄㸧

13㸸0
00㹼 14㸸㸸00

࣏ࢫࢱ࣮Ⓨ⾲㸦ወᩘ₇㢟㸧㸲㸱㸩㸲㸲఍㆟ᐊ㸦㸲㹄㸧

14㸸0
00㹼 15㸸㸸00

ᣍᚅㅮ₇

㸲㸯఍㆟ᐊ㸦㸲㹄㸧

15㸸000㹼 15㸸
㸸30

఍ဨ㞟఍

ࠌ

15㸸3
30㹼 16㸸
㸸00

ᯇᮏຬ㈹ཷ㈹ㅮ₇ࠌ16㸸000㹼 17㸸㸸30ࢩ࣏ࣥࢪ࣒࢘㸰ࠌ

17㸸3
30㹼 18㸸
㸸30

≉ูㅮ₇

ࠌ

18㸸3
30㹼

᠓ぶ఍㸦18㸸30㹼ཷ௜㛤ጞࠊ19㸸00 㛤ᐗ㸧 ᠓ぶ఍ሙ࠙㸰᪥┠ࠚ9 ᭶ 18 ᪥㸦㔠㸧

ሙ

ᡤ

8㸸3
30㹼

ཷ௜㛤ጞ

㸲㹄ࣟࣅ࣮

9㸸0
00㹼 10㸸㸸00࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮

㸲㸯఍㆟ᐊ㸦㸲㹄㸧

10㸸0
00㹼 12㸸㸸00ࢩ࣏ࣥࢪ࣒࢘㸱ࠌ

12㸸0
00㹼 13㸸㸸00ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮3

ࠌ

13㸸0
00㹼 14㸸㸸00

࣏ࢫࢱ࣮Ⓨ⾲㸦അᩘ₇㢟㸧㸲㸱㸩㸲㸲఍㆟ᐊ㸦㸲㹄㸧

14㸸0
00㹼 15㸸㸸30ࢩ࣏ࣥࢪ࣒࢘㸲㸲㸯఍㆟ᐊ㸦㸲㹄㸧

15㸸3
30㹼 17㸸㸸30ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ

ࠌ

17㸸3
30㹼 17㸸
㸸35

㛢఍ࡢ㎡

ࠌ

۵࠙ㅮ⩦఍ࠚ9 ᭶ 19 ᪥㸦ᅵ㸧᪥ᮏ་⏝࣐ࢫࢫ࣌ࢡࢺࣝᏛ఍୺ദ ➨㸱ᅇ་⏝㉁㔞ศᯒㄆᐃኈㅮ⩦఍ࢆ࢔ࢡࢺࢩࢸ࢕὾ᯇ
ࢥࣥࢢࣞࢫࢭࣥࢱ࣮㸲㝵࡟࡚㛤ദ࠸ࡓࡋࡲࡍࠋ
ཷㅮᩱ 5,000 ෇ࠊ➨ 40 ᅇᖺ఍ཧຍ⪅ 3,000 ෇㸦㈨ᩱ௦ྵࡴ㸧́́ࣉࣟࢢ࣒ࣛ
9 ᭶ 17 ᪥㸦ᮌ㸧9㸸00

ཷ௜㸦4㹄ࣟࣅ࣮㸧

9㸸55㹼10㸸00㛤఍ࡢ㎡㸦41 ఍㆟ᐊ㸧

10㸸00㹼12㸸00ࢩ࣏ࣥࢪ࣒࢘㸯㸸ࠕ඲ᅜ⮬἞య࡛஦ᴗ໬ࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࡬ࡢᑐᛂࠖ
㸦41 ఍㆟ᐊ㸧࣮࢜࢞ࢼ࢖ࢨ࣮㸸㔜ᯇ㝧௓㸦⚟஭኱Ꮫ㸧ᗙ㛗㸸▼ẟಙஅ㸦⚟஭኱Ꮫ㸧
㹑1-1ࠕࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ⾜࠺㝧ᛶ౛ࡢホ౯࡜ᑐᛂࠖ❑⏣ ‶㸦ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮⥲ྜデ⒪㒊㸧

㹑1-2ࠗࠕ඲ᅜ⮬἞య࡛஦ᴗ໬ࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࡬ࡢᑐᛂࠖ⢭ᐦ᳨ᰝ࡬ࡢ
ᑐᛂࡢ⌧ἣ࠘
㛗㇂ᕝ᭷⣖㸦ᓥ᰿኱Ꮫ་Ꮫ㒊ᑠඣ⛉㸧

㹑1-3ࠕṇᖖ᳨య࡜ᝈ⪅ࢹ࣮ࢱ᝟ሗ཰㞟࡟ࡼࡿࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢ⢭ᗘ⟶⌮ࠖⰼ஭₶ᖌ 1, ⚟ኈ ຾ 2, ▼ẟಙஅ 3, ⏣ᓮ㝯஧ 4㸦1 ᮐᖠᕷ⾨⏕◊✲ᡤ, 2 ᮐᖠ࢖࣒ࣀࢲ
࢖࢔ࢢࣀࢫࢸ࢕ࢵࢡࣛ࣎ࣛࢺ࣮ࣜ, 3(බ㈈)ᮾி㒔ண㜵་Ꮫ༠఍, 4(୍㈈)໬Ꮫཬ⾑Ύ⒪
ἲ◊✲ᡤ㸧

㹑1-4

ࠕLC-MS/MS ࡟ࡼࡿ஧ḟ᳨ᰝἲࡢ㛤Ⓨࠖ㔜ᯇ㝧௓ 1, ⏿㑳Ụ 2, ୰ᓥⱥつ 3㸦1 ⚟஭኱Ꮫ་Ꮫ㒊೺ᗣ⛉Ꮫ, 2 ⚟஭኱Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ,3ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ㸧

12㸸00㹼12㸸30♫ဨ⥲఍㸦22㸩23 ఍㆟ᐊ㸧

12㸸00㹼13㸸00ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮1㸦41 ఍㆟ᐊ㸧ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫㹊㹑-1ࠕ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟࠾ࡅࡿ㧗ศゎ⬟࣭㧗⢭ᗘࣁ࢖ࢫ࣮ࣝࣉࢵࢺࡢ౑࠸ศࡅࠖ㡞⃝ ᓫ㸦ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫㸧

12㸸30㹼13㸸00ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮2㸦22㸩23 ఍㆟ᐊ㸧ᰴᘧ఍♫࢚࣮ࣅ࣮࣭ࢧ࢖࢚ࢵࢡࢫ
㹊㹑-2ࠕ࣐ࣝࢳ࣑࢜ࢵࢡࢫ࡞ࢹ࣮ࢱゎᯒࠊಖ⟶ࠊඹ᭷ࢆྍ⬟࡟ࡍࡿ BaseSpace ࢡࣛ࢘ࢻࠖ
㛵඾ᗈ㸦࢖࣑ࣝࢼᰴᘧ఍♫ ࣉࣟࢲࢡࢺ࣐࣮ࢣࢸ࢕ࣥࢢ㒊㸧

13㸸00㹼14㸸00
㹎-1

࣏ࢫࢱ࣮Ⓨ⾲㸦ወᩘ₇㢟㸧
㸦43㸩44 ఍㆟ᐊ㸧

ࠕHILIC-MS/MS ἲ࡟ࡼࡿࣄࢺయᾮ୰ tegafur ཬࡧ 5-fluorouracil ࡢ㧗ឤᗘศᯒἲࠖ

́́ᑠῲᚊᏊ 1,2, ᮤ ᬡ㭉 1, ⇃⃝Ṋᚿ 1, ᘅ⃝ᵞᏊ 2, 㛗㇂ᕝᬛ⳹ 3, ධᡞ㔝 ᫴ 1, 㧗ᶫ᫓⏨ 2, బ⸨ၨ㐀 1㸦1 ᫛࿴኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ, 2 ᫛࿴኱Ꮫ་Ꮫ㒊║⛉Ꮫㅮᗙ, 3 ᮾ㑥኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ㸧㹎-3ࠕḟளሷ⣲㓟࡟ࡼࡾ㓟໬ࡉࢀࡓ࣍ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥࡢ LC/QTOF-MS ࢆ⏝࠸ࡓศᯒࠖ
ᫍᒸభ⨾ 1, Ᏻ㒊ᐶᏊ 1, ▮ᓥ኱௓ 1, ᒾ℩༤ኴ㑻 1,2㸦1 ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᮾி኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ㸧

㹎-5

ࠕHSD10 ⑓ࡢ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒ࡟ࡼࡿ໬Ꮫデ᩿ࠖ
5 1⚟஭኱Ꮫ་Ꮫ㒊೺ᗣ⛉Ꮫ,㔜ᯇ㝧௓ 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 3, ణ㤿 ๛ 4, ▼ẟಙஅ㸦

㹎-72⚟஭኱Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ,

4ᗈᓥ኱Ꮫ኱Ꮫ㝔ᑠඣ⛉Ꮫ◊✲ᐊ, 5 ᮾி㒔ண㜵་Ꮫ༠఍ᑠඣࢫࢡ࣮ࣜࢽࣥࢢ⛉㸧

ࠕGC/MS ศᯒ࡟ࡼࡿࢩࢺࣝࣜࣥ⾑⑕ᝈ⪅ᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢ⮫ᗋព⩏ࠖ㜲㹎-9᐀ᾏ, ᮤ ወ, 㔠 ᫂ጲ, ᙇ ᫓ⰼ㸦࣑ࣝࢫ࢖ࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊㸧

ࠕLC-MS/MS ἲ࡟ࡼࡿࣄࢺᒀ୰࡟࠾ࡅࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟ࠊ࣍ࣔࣂࢽࣜࣥ㓟ࠊ࣓ࢱࢿࣇࣜࣥࠊࣀ࣓ࣝࢱࢿࣇࣜࣥ࠾ࡼࡧࢡࣞ࢔ࢳࢽࣥࡢྠ᫬ᐃ㔞ἲࡢ᳨ウࠖሷᕝுኴ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼஭࿴ኵ 1㸦1 ᮥᯘ኱Ꮫಖ೺Ꮫ㒊,2

㹎-11ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊㸧

ࠕDried Blood Spot(DBS)࡜ᒀ୰ࡢከ⢾㢮ࢹ࢟ࢫࢺࣛࣥཬࡧࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ࣮ࢳ
ࡢศᯒࠖᑠᓥ㯞ᐇ 1, ᒸ㔝㞞ே 1, ᅵ⫧⨾ᬛᏊ 2, 㝜ᒣಙ஧ 1㸦1 ᰴᘧ఍♫ LSI ࣓ࢹ࢕࢚ࣥࢫ ࢔ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ, 2 ᅜ❧ࢫ࣏࣮ࢶ⛉Ꮫࢭࣥࢱ࣮ ࣓ࢹ࢕࢝ࣝࢭࣥࢱ࣮㸧㹎-13ࠕ኱⭠⒴ᝈ⪅∎୰ගᏛ␗ᛶయ௦ㅰ≀ࡢศᯒࠖすᑿඃử, 㛬 ಇဴ, ㎘ᮌሀ୍㑻, Ỉ㔝 ึ, ㇏ᒸ฼ṇ㸦㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊㸧

㹎-15ࠕ࢖ࣥࢻ࢟ࢩࣝ◲㓟ࡣṧᏑ⭈ᶵ⬟ࡢపୗ࡜࡜ࡶ࡟⾑୰࡟⵳✚ࡋ࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽ
࢔࡟㛵ಀࡍࡿࠖ
బ⸨ᜨ⨾Ꮚ 1,2, ᳃ ᘓᩥ 1, 㕥ᮌள㔛Ἃ 1, Ⳣཎ┿ᜨ 1, ಴⃝ዉ✑ 1, ୕ᯞ኱㍜ 3, ኱ሙ㑳Ꮚ 1, Ọ἟⤮⌮ 1, బ⸨ ༤ 1,2, ୹⩚฼඘ 4, ఀ⸨㈆჆ 1㸦1 ᮾ໭኱Ꮫ኱Ꮫ㝔 ་Ꮫ⣔◊✲⛉, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔 ⸆Ꮫ◊✲⛉, 3 ᮾ໭࣓ࢹ࢕࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 4 ಟᩥ኱Ꮫ೺ᗣᰤ㣴Ꮫ㒊㸧㹎-17ࠕ᥈㔪࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ/ࢱࣥࢹ࣒㉁㔞ศᯒ(PESI/MS/MS)࡟ࡼࡿ࣐࢘ࢫ⫢⮚ෆࡢ࣓ࢱ࣮࣒࣎ࣟ┤᥋ศᯒἲ㸦࢖ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࡢᵓ⠏ࠖᯘ⏤⨾ 1,2, ㈈ὠ

᱇ 1,2, ᮧ⏣໷ 3, ኱ཎ೔⨾ 1, ୰ษ೺ኴ 1, ⲡ㔝㯞⾰Ꮚ 1, 㑣㡲ẸỤ 4, ୰ᓥᏹᶞ 3, ▼ᕝဴஓ 1, ᅵᶫᆒ 1, ▼஭᫭ 1㸦1 ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 2 ྡྂᒇ኱Ꮫ㧗➼◊✲㝔, 3 ᓥὠ〇సᡤ, 4 ୰㒊኱Ꮫ⏕࿨೺ᗣ⛉Ꮫ㒊㸧
㹎-19ࠕ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈ࡟ࡼࡿ࣐࢘ࢫ⫢⮚⅖⑕㒊࡟࠾ࡅࡿ GC-MS/MS ௦ㅰࣉࣟࣇ࢓
࢖ࣜࣥࢢゎᯒࠖ

́́ᕤ⸨ᜤᙪ, ୰す ㇦, ᕝྡಟ୍, ᆏ஭೺ᮁ, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ඾⾜㸦ᰴᘧ఍♫ ᓥὠ〇సᡤ㸧
㹎-21

ࠕᐇ ࡟ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࣛ࢖ࣈ࣮ࣛࣜࢆ⏝࠸ࡓ㓟໬ࣜࣥ⬡㉁ࡢໟᣓⓗ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡢ☜❧ࠖ㟷ᰗⰋᖹ 1,2, ụ⏣࿴㈗ 1,2, ᭷⏣ ㄔ 1,2㸦1 ⌮໬Ꮫ◊✲ᡤ⤫ྜ⏕࿨་⛉Ꮫࢭࣥࢱ࣮࣓ࢱ࣎
࣮࣒ࣟ◊✲ࢳ࣮࣒, 2 ᶓ὾ᕷ❧኱Ꮫ⏕࿨་⛉Ꮫ◊✲⛉ศᏊ࢚ࣆࢤࣀ࣒⛉Ꮫ◊✲ᐊ㸧㹎-23ࠕ⬡⫫⣽⬊ࡢ⬡⫫⁲࡟࠾ࡅࡿ㐣㓟໬ࢺࣜࢢࣜࢭࣜࢻࡢศᯒࠖ᝴ ῄⴍ, ⦾ᐩ㸦ᰩᯘ㸧㤶⧊, ᑠᯘ ᝆ, ༓ⴥோᚿ㸦໭ᾏ㐨኱Ꮫ ኱Ꮫ㝔ಖ೺⛉Ꮫ◊✲㝔㸧

㹎-25ࠕ࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ࡼࡿዷፎ㧗⾑ᅽ⭈⑕἞⒪ᶆⓗศᏊࡢ᥈⣴ࠖὠᅧ⏤ెᏊ 1, బ⸨ᜨ⨾Ꮚ 1,2, అ㛫ᬛྐ 1, బ⸨ ༤ 1,2, 㧗ᶫಙ⾜ 1,2, ୕ᯞ኱㍜ 2,3
㸦1 ᮾ໭኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 3 ᮾ໭኱Ꮫᮾ໭࣓ࢹ࢕
࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ㸧㹎-27ࠕ࣐࢖ࢡࣟࣇ࣮ࣟLC/MS/MS ࡟ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻ୍ᩧศᯒἲࠖ኱⏣ṇつ, బ⸨඘ᙪ, 㝜ᒣಙ஧, ᒸ㔝㞞ே㸦ᰴᘧ఍♫ LSI ࣓ࢹ࢕࢚ࣥࢫ ࢔ࣥࢳࢻ࣮
ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ㸧

㹎-29

ࠕLC-MS/MS ἲ࡟ࡼࡿ኱㇋࢖ࢯࣇࣛ࣎ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝ࡜ࡑࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒἲࡢ᳨ウࠖᮌୗ⍞㈗ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼஭࿴ኵ 1㸦1 ᮥᯘ኱Ꮫಖ೺Ꮫ㒊,2

㹎-31ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊㸧

ࠕLC/ESI-MS/MS ࡟ࡼࡿ⾑₢୰ 25-hydroxyvitamin D3 ཬࡧࡑࡢ◲㓟ᢪྜయࡢྠ᫬ᐃ㔞ἲࡢ㛤Ⓨࠖᚋ⸨ᙬె 1, ᶓ⏣㯞⾰ 1, ᑠᕝ⚈஧㑻 1, ᑠᯇ㈼ྖ 2, ᮡᾆᓫᾈ 2, ᮾ 㐩ஓ 1㸦1 ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊, 2 㟼ᒸ῭⏕఍⥲ྜ⑓㝔㸧

㹎-33ࠕ㔜Ỉ⣲໬ࣀࣅࣞࢳࣥࡢྜᡂ࡜ LC/MS/MS ࡟ࡼࡿࣀࣅࣞࢳࣥᐃ㔞࡬ࡢᛂ⏝ࠖ
1 1୰㒊኱Ꮫᛂ⏝⏕≀Ꮫ㒊,ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ㸦2

㹎-35୰㒊኱Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ఍♫ Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮㸧ࠕ㸰✀㢮ࡢᏳᐃྠ఩యᶆ㆑ἲࢆ⏝࠸ࡓ⭤⬔⒴ࡢ⾑୰ࣂ࢖࣐࣮࣮࢜࢝ࢱࣥࣃࢡ㉁ࡢ᥈⣴ࠖᖹ⏣ెஓ 1, 㐲⸨ඞஓ 1, ᩪ⸨㐩ஓ 1,2, ᕝᓥ♸௓ 2, ༡⏣ ㄽ 3, ᯇᮏ࿴ᑗ 3, ᒾᮧṇႹ 3,ᑠᑎ⩏⏨ 1,2㸦1 ໭㔛኱Ꮫ⌮Ꮫ㒊⏕≀≀⌮Ꮫ◊✲ᐊ, 2 ໭㔛኱Ꮫ⌮Ꮫ㒊㝃ᒓ⑌ᝈࣉࣟࢸ࣑࢜
ࢡࢫࢭࣥࢱ࣮, 3 ໭㔛኱Ꮫ་Ꮫ㒊Ἢᒀჾ⛉㸧

㹎-37ࠕᏳᐃྠ఩యᶆ㆑ἲࢆ⏝࠸ࡓࢫࢺࣞࢫ㞀ᐖࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࣮࣒࢜ኚືࡢゎᯒࠖᑠ㧗㡴Ꮚ 1, ᑠᯘ༓἞ 1, ຍ⸨฼ె 1,2, 㧗ᶫᯞ㔛 1, ᩧ⸨㐩ஓ 1,2, ᕝᓥ♸௓ 2, ᯈ಴ ㄔ 3,ᒣ᳃᪩⧊ 3, Ọᒣ༤㏻ 3, 㣤⏣ㅍᐅ 4, ᐑᒸ ➼ 4, 㧗ᶫṇ㌟ 3, ᑠᑎ⩏⏨ 1,2㸦1 ໭㔛኱Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉⏕≀≀⌮Ꮫ◊✲ᐊ, 2 ໭㔛኱Ꮫ⌮Ꮫ㒊㝃ᒓ⑌ᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮, 3 ໭㔛኱Ꮫ་Ꮫ㒊⏕໬Ꮫ◊✲ᐊ, 4 ໭㔛኱Ꮫ་Ꮫ㒊⢭⚄⛉㸧

́́

㹎-39

ࠕH-D ஺᥮཯ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢࢧࣟࢤ࣮ࢺ≀㉁ྜᡂࠖ
ᶓᒣ⿱ኈ 1, ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷῭Ὀ 1,2,3, ሐෆ せ 1㸦1 ୰㒊኱Ꮫᛂ⏝⏕≀Ꮫ㒊, 㸰୰㒊኱Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ఍♫Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮㸧
㹎-41

ࠕMALDI-TOF MS ࡟ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃ࡟ࡘ࠸࡚ࠖ
ụࣨ㇂ెᑑᏊ, ᅵᒇ ᠇㸦㟼ᒸᕷ❧ΎỈ⑓㝔 ᳨ᰝᢏ⾡⛉㸧

㹎-43ࠕᚠ⎔ჾ⑓㛵㐃⤌⧊࡟࠾ࡅࡿ㹊㹇㹋ࢻ࣓࢖ࣥࢱࣥࣃࢡ㉁」ྜయゎᯒࠖᒣ୰ᐶ᫂ 1, ᑎ⏣ ᜨ 1, ⳥ᆅἋ⪨Ꮚ 1, ᔱ⏣ᓫྐ 2, ᳜⏣ึỤ 3, 㣤ཎᘯ஧ 4, ụᕝ㞞ဢ 1
㸦1 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉, 2 ᓥὠ〇సᡤᇶ┙ᢏ⾡◊✲ᡤ, 㸱ᅜ❧ᚠ⎔ჾ⑓◊✲ࢭࣥࢱ࣮⑓⌮㒊, 4 ஑ᕞ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔⬻⚄⤒እ⛉㸧

㹎-45ࠕ⫵⥺⥔໬࡟㛵㐃ࡋࡓ⬡㉁ࡢ⥙⨶ゎᯒࠖ኱ᒣྜྷᖾ 1,2, ṇᮌ⣖㝯 2, Ἑ㔝㞞ே 1, ᴮᮏ⣖அ 1, ୰ᮧ♸ኴ㑻 1, ⸨⃝᭸ᖾ 1, ஝ ┤㍤ 1, 㡲⏣㝯ᩥ 1, ℩⸨ග฼ 2㸦1 ὾ᯇ་⛉኱Ꮫ ෆ⛉Ꮫ➨஧ㅮᗙ, 2 ྠ ゎ๗Ꮫㅮᗙ⣽⬊⏕
≀Ꮫศ㔝㸧

㹎-47

ࠕ⏕య࢔࣑ࣥ໬ྜ≀ࢆᑐ㇟࡜ࡋࡓ᪂つㄏᑟయ໬ἲ࡟ࡼࡿ࣐࢘ࢫ⬻ࡢ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࠖ῝㔝 ⳹ 1, ⬥ ⣖ᙪ 1, Ṋ஭ྐ㑻 1,2, ℩⸨ග฼ 2, ▮ᑿ⫱Ꮚ 1㸦1 ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕
࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝㸧

㹎-49

ࠕ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࢹ࣮ࢱࢆ⏝࠸ࡓ⤌⧊ษ∦ࡢ࢚ࣥࢺࣟࣆ࣮࢖࣓࣮ࢪࣥࢢゎᯒࠖబ⸨㥴ᖹ, బ⸨ᬛோ, ṇᮌ⣖㝯, ℩⸨ග฼㸦὾ᯇ་⛉኱Ꮫ ゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝㸧

㹎-51ࠕ◲㓟࢔ࣥࣔࢽ࣒࢘ࡣ࣐ࢺࣜࢵࢡࢫῧຍ๣࡜ࡋ࡚ MALDI-IMS ࡟࠾ࡅࡿ⬻ෆ࢝ࣝࢽࢳࣥࠊ
࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥࠊࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ⏤᮶ࡢࢩࢢࢼࣝࢆ 10 ಸ௨ୖቑᙉࡍࡿࠖ
ᮡᒣᰤ஧, ṇᮌ⣖㝯, ᯇୗ⚈Ꮚ, ℩⸨ග฼㸦὾ᯇ་⛉኱Ꮫ་Ꮫ⣔◊✲⛉ゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝㸧

㹎-53ࠕ๓㢌ഃ㢌ⴥኚᛶ⑕ᝈ⪅⬻ෆ࡟࠾ࡅࡿࢱ࢘ࣜࣥࡢ⃰ᗘ࠾ࡼࡧศᕸゎᯒࠖᯇୗ⚈Ꮚ 1, ṇᮌ⣖㝯 1, ㏆⸨㇦ 1, Ṋ஭ྐ㑻 1, ㉥ὠ⿱ᗣ 2,3, ⛅⏣ኳᖹ 4, ᮡᒣᰤ஧ 1,⚟⏣ᩔኵ 4, ▮ᑿ⫱Ꮚ 5, ℩⸨ග฼ 1㸦1 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 2 ⚟♴ᮧ⑓㝔㛗ᑑ་Ꮫ◊✲ᡤ, 3 ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ᆅᇦ་⒪ᩍ⫱Ꮫ, 4 ὾ᯇ་⛉኱Ꮫ⚄⤒⏕⌮Ꮫㅮᗙ, 5 ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫࢭࣥࢱ࣮ග࢖࣓࣮ࢪࣥ
ࢢ◊✲ᐊ㸧

㹎-55

ࠕ⫢ษ㝖㔞࡟╔┠ࡋࡓ࣐࢘ࢫ⫢ษ㝖ᚋ⫢෌⏕ࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࠖ஭ཱྀබኴ 1, ㎷ 㞝኱ 2, ୰ᕝ♸㍤ 2, ୰㑦ᬛஅ 3, Ἴከ㔝ᝋᮁ 1, ୖᮏఙ஧ 1, ụᕝ㞞ဢ 2
㸦1 ி㒔኱Ꮫ་Ꮫ◊✲⛉⫢⫹⮅⛣᳜እ⛉, 2 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉,3

㹎-57

㛵す་⛉኱Ꮫ⸆⌮Ꮫㅮᗙ㸧ࠕ㹑㹂㹒ࣛࢵࢺࡢ⮅⮚ࢆᑐ㇟࡜ࡋࡓࣉࣟࢸ࣑࢜ࢵࢡ㉁㔞࢖࣓࣮ࢪࣥࢢࠖ┈ᒣ ៞ 1, ᒾᓮ஢ᩍ 2, ⴱཎ⏤㈗ 3, ⱝᅬ ༤ 1, 㡞⃝ ᓫ 2, ⸨ࣨ㇂ᾈᩥ 1, ᮾᒣ┿⃈ 1,᪥ẚ኱௓ 1, ᰗᾈ⏤⣖ 1, ᐟ㇂┿⏤ 3, ụᕝ㞞ဢ 3㸦1 ᑠ㔝⸆ရᕤᴗ, 2 ࣈ࣮ࣝ࢝ࢲࣝࢺࢽ
ࢡࢫ, 3 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉㸧

́́

㹎-59

ࠕࡆࡗṑ㢮⢭ᕢ࡟࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࠖ୰す຾அ 1, ㎷ 㞝኱ 1, ୰ᕝ♸㍤ 1, ஭ཱྀබኴ 1, ゅ⏣ఙே 1, ୰㑦ᬛஅ 2, ᯇ஭႐அ 3,ᕷᒸ೺ኴ㑻 4, ᑠᕝ ಟ 3, ụᕝ㞞ဢ 1㸦1 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉,2

㹎-61

㛵す་⛉኱Ꮫ⸆⌮Ꮫㅮᗙ, 3 ி㒔኱Ꮫ኱Ꮫ㝔Ἢᒀჾ⛉Ꮫ, 4 ࠸ࡕ࠾࠿Ἢᒀჾ⛉ࢡࣜࢽࢵࢡ㸧ࠕ᪂㩭෾⤖ங⒴⤌⧊ษ∦ࢆ⏝࠸ࡓ MALDI-IMS ゎᯒ࡟ࡼࡿங⒴≉␗ࢱࣥࣃࢡศᏊೃ⿵ࡢྠᐃࠖ
బ⸨୐ኤᏊ 1,2, ୰す㇏ᩥ 2, ᒾᮏ඘ᙪ 1, ෆᒣ࿴ஂ 1㸦㸯኱㜰་⛉኱Ꮫ㝃ᒓ⑓㝔࣭ங⭢ෆศἪእ⛉, 2 ኱㜰་⛉኱Ꮫ࣭⮫ᗋ᳨ᰝ་Ꮫᩍᐊ㸧

14㸸00㹼15㸸00

ᣍᚅㅮ₇㸦41 ఍㆟ᐊ㸧ᗙ㛗㸸℩⸨ග฼㸦὾ᯇ་⛉኱Ꮫ㸧

㹊-1

ࠕSystems Medicine in a Changing World: The Challenge of Measuring and Visualising
Personal and Public Healthcare Data.ࠖ
Jeremy K. Nicholson㸦Department of Surgery and Cancer Imperial College London㸧

15㸸00㹼15㸸30఍ဨ㞟఍㸦41 ఍㆟ᐊ㸧

15㸸30㹼16㸸00

ᯇᮏຬ㈹ཷ㈹ㅮ₇㸦41 ఍㆟ᐊ㸧ᗙ㛗㸸୹⩚฼඘㸦ಟᩥ኱Ꮫ㸧

㹊-2

ࠕ㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝࡟㛵ࡍࡿ◊✲ࠖ㔝ᮧᩥኵ㸦༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ㸧

16㸸00㹼17㸸30ࢩ࣏ࣥࢪ࣒࢘㸰㸸ࠕ㉁㔞࢖࣓࣮ࢪࣥࢢゎᯒ̿ᇶ♏࠿ࡽᛂ⏝࡬ࡢ᪂ᒎ㛤ࠖ
㸦41 ఍㆟ᐊ㸧࣮࢜࢞ࢼ࢖ࢨ࣮࣭ᗙ㛗㸸୰す㇏ᩥ㸦኱㜰་⛉኱Ꮫ㸧

㹑2-1ࠕ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟࠾ࡅࡿ㧗ឤᗘᐃࡢࡓࡵࡢ஧ẁ㝵࣐ࢺࣜࢵࢡࢫ౪⤥ἲ࡜ᡭἲ᭱㐺໬ࠖ᪂㛫⚽୍㸦኱㜰኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉㸧
㹑2-2ࠕ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟ࡼࡿ᳜≀ྵ᭷ᡂศࡢゎᯒࠖᖹ ಟ 1, ➃ᓮ㔛ᕹ 1, ∦㔝 ⫕ 1, 㔠Ꮚ኱స 2, ୰す㇏ᩥ 3㸦1 ⚟஭┴❧኱Ꮫ⏕≀㈨※Ꮫ㒊, 2 ஑ᕞᕤᴗ኱Ꮫ, 3 ኱㜰་⛉኱Ꮫ㸧

㹑2-3ࠕ⤫ྜኻㄪ⑕἞⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ࡟ࡼࡿ⚄⤒ẘᛶⓎ⌧ᶵᵓࡢゎᯒ㸸㉁㔞࢖࣓࣮ࢪࣥࢢ
ᡭἲ࡟ࡼࡿ⬻ෆࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢྍど໬ࠖྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ஬༑ᔒ୍㞝 4㸦1 ㏆␥኱Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 ኱㜰་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 ኱㜰኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་⸆ศᯒ༠఍㸧

㹑2-4ࠕ࢔ࣝࢶࣁ࢖࣐࣮⑓⬻◊✲ࡢࡓࡵࡢ㉁㔞࢖࣓࣮ࢪࣥࢢゎᯒࠖụᕝ㞞ဢ 1, ᐑᆏ▱ᏹ 1, ゅ⏣ఙே 1, ᒾᓮ஢ᩍ 2, 㡞⃝ ᓫ 2, 㝮ⶶ኱ᖾ 3, ᮧᒣ⦾㞝 3,஭ཎᗣኵ 4㸦1 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊, 2 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫओ, 3 ᮾி㒔೺ᗣ㛗ᑑ་⒪ࢭࣥࢱ࣮◊✲ᡤ㧗㱋⪅ࣈࣞ࢖ࣥࣂࣥࢡ, 4 ྠᚿ♫኱Ꮫ⬻⛉Ꮫ◊✲⛉㸧́́17㸸30㹼18㸸30≉ูㅮ₇㸦41 ఍㆟ᐊ㸧ᗙ㛗㸸℩⸨ග฼㸦὾ᯇ་⛉኱Ꮫ㸧

㹊-3ࠕḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶࡢゎ᫂ࠖ୰ᒣᩗ୍㸦஑ᕞ኱Ꮫ ⏕య㜵ᚚ་Ꮫ◊✲ᡤ ศᏊ་⛉Ꮫศ㔝 ࣄࢺࣉࣟࢸ࣮࣒࢜◊✲ࢭࣥࢱ࣮㸧

19㸸00㹼 ᠓ぶ఍㸦ࡣࡲࡲࡘᆅࣅ࣮ࣝᕤᡣ

࣐࢖࣭ࣥࢩࣗࣟࢫ

18㸸30 ཷ௜ࠊ19㸸00 㛤ጞ㸧

9 ᭶ 18 ᪥㸦㔠㸧
8㸸30ཷ௜㸦㸲㹄ࣟࣅ࣮㸧

9㸸00㹼10㸸00࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮㸦41 ఍㆟ᐊ㸧ࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫㹋㹑-1

ࠕLC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝࡬ࡢྲྀࡾ⤌ࡳࠖబ⸨ Ᏺ㸦༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ㸧

10㸸00㹼12㸸00ࢩ࣏ࣥࢪ࣒࢘㸱㸸ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡀษࡾᣅࡃḟୡ௦་⒪࡟࠾ࡅࡿࣂ࢖࣐࣮࣮࢜࢝᥈⣴ࠖ
㸦41 ఍㆟ᐊ㸧࣮࢜࢞ࢼ࢖ࢨ࣮࣭ᗙ㛗㸸୕ᯞ኱㍜㸦ᮾ໭኱Ꮫ㸧ᗙ㛗㸸ᯇ⏣ྐ⏕㸦኱㜰኱Ꮫ㸧
㹑3-1ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒ࡟ࡼࡿ࢖ࣥࢫࣜࣥ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡࡢ෌ᵓ⠏ࠖᰆᮌඞஅ 1, ஂಖ⏣ᾈ⾜ 2,3, 㯮⏣┿ஓ 1,4㸦1 ᮾி኱Ꮫ኱Ꮫ㝔⌮Ꮫ⣔◊✲⛉࣭⏕≀⛉Ꮫᑓᨷ, 2 ஑ᕞ኱Ꮫ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ࢺࣛࣥࢫ࣑࢜ࢡࢫ་Ꮫ◊✲ࢭࣥࢱ࣮࣭⤫ྜ࣑࢜ࢡࢫศ㔝, 3JST ࡉࡁࡀࡅ, 4JST CREST㸧

㹑3-2ࠕ⬡㉁ࢡ࢜ࣜࢸ࢕࠿ࡽゎࡁ᫂࠿ࡍ⑓ែ࣭ࣂ࢖࢜ࣟࢪ࣮◊✲ࠖ᭷⏣ㄔ 1,2㸦1 ⌮໬Ꮫ◊✲ᡤ⤫ྜ⏕࿨་⛉Ꮫ◊✲ࢭࣥࢱ࣮࣭࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒,2

㹑3-3

ᶓ὾ᕷ❧኱Ꮫ኱Ꮫ㝔⏕࿨་⛉Ꮫ◊✲⛉㸧ࠕ௦ㅰࣇࣛࢵࢡࢫゎᯒ࡜୰ᚰ௦ㅰࡢࢺࣛࣥࢫ࣑࢜ࢡࢫࠖ
ᯇ⏣ྐ⏕, ΎỈ ᾈ㸦኱㜰኱Ꮫ኱Ꮫ㝔᝟ሗ⛉Ꮫ◊✲⛉㸧

㹑3-4

ࠕ኱つᶍࢥ࣮࣍ࢺ࣑࢜ࢡࢫゎᯒ࡟ࡼࡿ⑌ᝈண㜵࣐࣮࣮࢝᥈⣴ࠖ
୕ᯞ኱㍜ 1,2㸦1 ᮾ໭኱Ꮫᮾ໭࣓ࢹ࢕࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉㸧

12㸸00㹼13㸸00ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮3㸦41 ఍㆟ᐊ㸧࢔ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫㹊㹑-3

ࠕLC-QTOF ࢆ⏝࠸ࡓ༴㝤ࢻࣛࢵࢢࡢศᯒࠖ
⁪ᇣᫀᙪ㸦࢔ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫㸧́́13㸸00㹼14㸸00
㹎-2

࣏ࢫࢱ࣮Ⓨ⾲㸦അᩘ₇㢟㸧
㸦43㸩44 ఍㆟ᐊ㸧ࠕ⤌⧊ษ∦୰ࢪࣇ࢙ࢽࢪࣥࡢ MALDI-MS(/MS)࡟ࡼࡿ┤᥋ศᯒࠖ༡᪉࠿ࡼᏊ 1, 㕥ᮌ㞞Ꮚ 2, 㔝⃝⚽ᶞ 1, ᒣᓊ ᱁ 1, 㛗㇂ᕝᘯኴ㑻 1, 㜿Ẹ໚᪥௚ 1,ᶒᏲ㑥ኵ 1, Ώ㒊ຍዉᏊ 1, 㕥ᮌಟ 1㸦1 ὾ᯇ་⛉኱Ꮫ኱Ꮫἲ་Ꮫ, 2 ὾ᯇ་⛉኱Ꮫᐇ㦂ᐇ
⩦ࢭࣥࢱ࣮

㹎-4

ࠕἲ་ヨᩱ࡟࠾ࡅࡿ⸆≀୰ẘࡢࣂ࢖࣐࣮࣮࢜࢝᥈⣴ (2)ࠖᏳ㒊ᐶᏊ 1, ᫍᒸభ⨾ 1, ᑠᲚဴ㞝 2, ዉⰋ᫂ዉ 1, Ọ⃝᫂ె 1, ▮ᓥ኱௓ 1, ᒾ℩༤ኴ㑻 1,3
㸦1 ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᰴᘧ఍♫࢚࣮ࣅ࣮ࢧ࢖࢚ࢵࢡࢫ, 3 ᮾி኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ㸧

㹎-6

ࠕ㉁㔞ศᯒ࡟ࡼࡿ௦ㅰ␗ᖖ⑕࡜⸆≀௦ㅰࡢ㚷ูࠖᙇ ᫓ⰼ, ᮤ ወ, ㉿ ᑀ, 㔠 ᫂ጲ, 㜲 ᐀ᾏ㸦࣑ࣝࢫ࢖ࣥࢱ࣮ࢼࢩࣙࢼࣝ◊✲㛤Ⓨ㒊㸧

㹎-8

ࠕGCMS ࡟ࡼࡿ⣅౽୰⭉ᩋ⏘≀ࡢ ᐃࠖⅲ⹒ཧ୹, ⚟ཎ⨾௦Ꮚ, ஂ⏣㈗⩏㸦ᰴᘧ఍♫ࢸࢡࣀࢫ࣭ࣝ࢞ࣛ࣎㸧

㹎-10

ࠕLC-MS/MS ࡟ࡼࡿᒀ୰ࢥࣝࢳࢰ࣮ࣝཬࡧࢥࣝࢳࢰࣥࡢ 6Ș- / 6ș-Ỉ㓟໬௦ㅰ≀ࡢศ㞳ᐃ㔞ἲࠖᶓᕝᙲ᭸ 1, ඵ㒓㞞ᘯ 1, ᖹ㔝Ⰻᖹ 1, ⣽⏣㤶⧊ 2, ▼஭࿴ኵ 2, ྂ⏣ 㝯 1, ᰘᓮᾈ⨾ 1
㸦1 ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊, 2 ᮥᯘ኱Ꮫಖ೺Ꮫ㒊㸧

㹎-12ࠕℐ⣬⾑ࢆ⏝࠸ࡓ᪂⏕ඣࡢࢡࣞ࢔ࢳࢽࣥࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ◊✲ࠖ୰㔝 ඃ 1, ୖᮧ ἞ 2, ୰ᓥⴥᏊ 3, ఀ⸨ဴဢ 3, ᮏ⏣㞞ᩗ 4, 㰻⸨ఙ἞ 1㸦1 ྡྂᒇᕷ❧኱Ꮫᑠඣ⛉, 2 ࠶࠸ࡕᑠඣಖ೺་⒪⥲ྜࢭࣥࢱ࣮⭈⮚⛉, 3 ⸨⏣ಖ೺⾨⏕኱Ꮫᑠඣ⛉,4

㹎-14ᮾி㒔❧ᑠඣಖ೺་⒪ࢭࣥࢱ࣮㸧

ࠕUPLC-MS/MS ࡟ࡼࡿࣆ࣑ࣜࢪࣥሷᇶ௦ㅰ≀ࡢᐃ㔞࡟ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖ⑕ࢫࢡࣜ
࣮ࢽࣥࢢࠖ๓⏣ᗣ༤ 1, ⓙᕝ┿㔛 1, ୰ᓥⴥᏊ 2, ᚋ⸨ెዉ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ⩏ᾈ 1,ఀ⸨ဴဢ 2, ᮌᮧ࿴ဴ 1,3㸦1 ྡྂᒇᕷ❧኱Ꮫ ኱Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ೺⾨⏕኱Ꮫ ་Ꮫ㒊ᑠඣ⛉, 3 ྡྂᒇᕷ❧኱Ꮫ ኱Ꮫ㝔་Ꮫ◊✲⛉㸧

㹎-16ࠕ➽ࢪࢫࢺࣟࣇ࢕࣮ᝈ⪅ࡢᒀ୰ࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ࠾ࡼࡧ E2 ௦ㅰ≀ࡢኚືࠖ➉ෆᩔᏊ 1, ⿬ฟⰋ༤ 2, ᯇᑿ㞞ᩥ 3㸦1 ⚄ᡞ⸆⛉኱Ꮫ, 2 ⟃Ἴ኱Ꮫᅜ㝿⤫ྜ╧╀་⛉Ꮫ◊✲ᶵᵓ, 3 ⚄ᡞᏛ㝔኱Ꮫ⥲ྜࣜࣁࣅࣜࢸ࣮ࢩࣙࣥᏛ㒊㸧

㹎-18ࠕ㧗⬡⫫㣗ᦤྲྀࡀᘬࡁ㉳ࡇࡍ⭠ෆ⎔ቃࡢኚ໬࡟ᑐࡍࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ࡼࡿホ౯ࠖすᾏ ಙ 1, ྜྷ⏣ ඃ 1,2㸦1 ⚄ᡞ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉, 2 ᅜ❧◊✲㛤Ⓨἲே᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ, AMED-CREST㸧

㹎-20

ࠕUPLC/MS/MS ࡟ࡼࡿ᪥ᮏேࣉࣟࣆ࢜ࣥ㓟⾑⑕ᝈ⪅ࡢࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ࣮ࣛ
ࢮάᛶ ᐃࠖ
ᚋ⸨ెዉ 1, ๓⏣ᗣ༤ 1, ୰ᓥⴥᏊ 2, ఀ⸨ဴဢ 2, ๓⏣㝧Ꮚ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3,́́ᕝฟ⩏ᾈ 1, ᮡᒣᡂྖ 4, ᮌᮧ࿴ဴ 1,3㸦1 ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ೺⾨⏕኱Ꮫᑠඣ⛉, 3 ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉, 4 ឡ▱Ꮫ㝔኱Ꮫ⸆Ꮫ㒊㸧
㹎-22ࠕࢫࢸࣟ࢖ࢻ᳨ᰝヨᩱ࡜ࡋ࡚ࡢ∎ࡢホ౯:ᕥྑࡢᡭࡢ∎୰ࢫࢸࣟ࢖ࢻࡢྵ㔞ᕪࠖᑠᕝ⚈஧㑻1, ຍ⸨⏤㑣1, 㧗㔝 㤶1, ୰␁ຬኴ㑻1, ᒣᙧ᠇୍㑻1, 㛬 ಇဴ2, ᮾ 㐩ஓ1
㸦1ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊, 2㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊㸧

㹎-24

ࠕLC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝ ̿ࣅࢱ࣑ࣥ D ௦ㅰ≀ ᐃࢆᇶ┙࡟̿ࠖ
బ⸨Ᏺ 1, ▼ẟᓫஅ 2, ᑠᕝ⚈஧㑻 3, すᮧᇶ 2,4, ᯇୗ୍அ 2,4, ᮾ㐩ஓ 3, 㔝ᮧᩥኵ 1
㸦1 ༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2 ༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔᳨ᰝ㒊, 3 ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊⮫ᗋศᯒ⛉Ꮫ◊✲ᐊ, 4 ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔ศᏊ⑓ែゎᯒᏛ㸧

㹎-26ࠕ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ୚࣐࢘ࢫ⫢⤌⧊࡟ᑐࡍࡿ LC/MS ࢆ⏝࠸ࡓ௦ㅰ≀୍ᩧศᯒࠖ୰す ㇦, ᕤ⸨ᜤᙪ, ᕝྡಟ୍, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ඾⾜㸦ᰴᘧ఍♫ ᓥὠ〇సᡤ㸧

㹎-28

ࠕnano LC/MS/MS ࢆ⏝࠸ࡓࣛࢵࢺ⫢⮚୰⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ࠖὸ㔝཭⨾ 1,2, ㈈ὠ
ẸỤ 4, ᅵᶫ

᱇ 1, ℧೺ኴᮁ 1, ⲡ㔝㯞⾰Ꮚ 1, ໭᳃୍ဢ 2, ෆ⸨ஂ㞝 3, 㑣㡲ᆒ 1, ▼஭᫭ 1㸦1 ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 2 㔠ᇛᏛ㝔኱Ꮫ⏕ά⎔ቃᏛ㒊, 3 ⸨⏣ಖ೺⾨⏕኱Ꮫ་Ꮫ㒊, 4 ୰㒊኱Ꮫ⏕࿨೺ᗣ⛉Ꮫ㒊㸧
㹎-30ࠕ⮫ᗋ᳨ᰝࢆ┠ⓗ࡜ࡋࡓ LC-MS/MS ࡟ࡼࡿ⾑Ύ୰࢔ࢩࣝ࢝ࣝࢽࢳࣥࡢᐃ㔞ศᯒἲࡢ㛤Ⓨࠖᑠᯘᘯ඾ 1, ᒣ⏣೺἞ 1, ᆓ ு㍜ 1, 㛗㇂ᕝ᭷⣖ 1, ᒣཱྀΎḟ 1, ᇛୗ཭⩏ 2, ఀ⸨฼ᑗ 2,஭ᡭ㔝 ᫭ 2, ኱ཎ฼ᡂ 2㸦1 ᓥ᰿኱Ꮫ་Ꮫ㒊ᑠඣ⛉, 2 ✚Ỉ࣓ࢹ࢕࢝ࣝᰴᘧ఍♫㸧

㹎-32

ࠕLC-MS/MS ࡟ࡼࡿ⾑Ύ࢚ࢫࢺࣟࢤࣥ࠾ࡼࡧࣉࣟࢤࢫࢸࣟࣥࡢྠ᫬ᐃ㔞ࠖᐑᯘభ⾰ 1, బ⸨ Ᏺ 2, ⁪⬥ṇ㈗ 2, すᮧ ᇶ 1, ᯇୗ୍அ 1, 㔝ᮧᩥኵ 2㸦1 ༓ⴥ኱Ꮫ኱Ꮫ㝔 ་Ꮫ◊✲㝔 ศᏊ⑓ែゎᯒᏛ, 2 ༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺࣜ
᳨࣮ᰝデ᩿Ꮫ㸧

㹎-34ࠕࣄࢺ㠌ᖏ࡟࠾ࡅࡿࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥࡢゎᯒࠖ㛗Ꮚᬕ⨾ 1, ཎ ఙṇ 1, ᪥ྜྷᓠ㯇 1, Ἑ㔝㏻ᛌ 2, ෆᑿ♸ྖ 2, ᅵᒇ⨾ຍᏊ 1㸦ᓥ᰿኱Ꮫ
་Ꮫ㒊

㹎-36

1

⏕໬Ꮫㅮᗙ, 2 ᩚᙧእ⛉Ꮫㅮᗙ㸧

ࠕAbcd1 ࣀࢵࢡ࢔࢘ࢺ࣐࢘ࢫࡢ⬻ࡢࣜࣥ⬡㉁ゎᯒࠖ℈ᘯኴ㑻 1, ⸨ཎඃᏊ 1, Ᏺ⏣㞞ᚿ 2, ௒୰ᖖ㞝 2, ୗ⃝ఙ⾜ 3, ᶓᒣ࿴᫂ 1㸦1 ᖇி኱࣭⸆, 2 ᐩᒣ኱࣭⸆, 3 ᒱ㜧኱࣭⏕࿨⛉Ꮫ⥲ྜ◊✲ᨭ᥼ࢭࣥࢱ࣮㸧

㹎-38

ࠕEffects of preanalytical variables on serum peptidome profiling for long-term
storage using matrix-assisted laser desorption/ionization time-of-flight mass
spectrometryࠖᅵ⏣⚈ኸ 1, బ⸨Ᏺ 1, ᱵᮧၨྐ 2, ᭮ᕝ୍ᖾ 3, ⁪⬥ṇ㈗ 1, ูᗓ⨾ዉᏊ 4, すᮧᇶ 4, ᑠᑎ⩏⏨ 5, ᯇୗ୍அ 4, 㔝ᮧᩥኵ 1㸦1 ༓ⴥ኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ࣮ࣜ

́́᳨ᰝデ᩿Ꮫ, 2 ᒸᒣ኱Ꮫ኱Ꮫ㝔་ṑᏛ⥲ྜ◊✲⛉, 3 㯞ᕸ኱Ꮫ⏕࿨⎔ቃ⛉Ꮫ㒊⮫ᗋ᳨ᰝᢏᖌᏛ⛉, 4 ༓ⴥ኱Ꮫ་Ꮫ㒊་Ꮫ◊✲㝔ศᏊ⑓ែゎᯒᏛ, 5 ໭㔛኱Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉㸧
㹎-40

ࠕMALDI-TOF MS ࡟࠾ࡅࡿ Neisseria meningitidis ࡢㄗྠᐃ୍౛ࠖ
኱㔝ᬛᏊ㸦ឡ▱་⛉኱Ꮫ⑓㝔ឤᰁไᚚ㒊㸧

㹎-42

ࠕMALDI mass spectrometry imaging ࡟ࡼࡿ෾⤖⤌⧊࢔ࣞ࢖ໟᇙஙࡀࢇ⤌⧊ࡢపศᏊ௦
ㅰ⏘≀ࣉࣟࣇ࢓࢖ࣜࣥࢢࠖ
ᐥ⏣ಙ༤ 1, ஂಖ ┿ 1, ୕ᾆ኱඾ 3, ኱ෆ⏣◊ᐂ 1, ᐑᓮဴஅ 2, ⸨ᮧ⏤⣖ 3, ᪩ᕝⱥ௓ 3,኱ሯ㝯⏕ 1, ᐑᆏ⩏ᾈ 1, ┿㘠㐩ஓ 1, ᑠ⏣⩏┤ 2, Ỉඖ୍༤ 4, ୰ᮧ㞞ྐ 1㸦1 ஑ᕞ኱Ꮫ⮫ᗋ࣭⭘⒆እ⛉, 2 ஑ᕞ኱Ꮫᙧែᶵ⬟⑓⌮, 3 ஑ᕞ኱Ꮫඛ➃⼥ྜ་⒪ࣞࢻࢵࢡࢫࢼࣅ◊✲ᣐ
Ⅼ, 4 ஑ᕞ኱Ꮫ⑓㝔 ࡀࢇࢭࣥࢱ࣮㸧

㹎-44ࠕࣄࢺ⫾┙࡟࠾ࡅࡿ⤊ᮎ⤧ẟ࡜ᖿ⤧ẟ࡟࠾ࡅࡿࣜࣥ⬡㉁ศᕸࣃࢱ࣮ࣥࡢ≉ᚩ࡜⫾┙⑓⌮ᡤぢࡢ┦㛵࡟ࡘ࠸࡚ࠖ
ᒣ㷂㤶⧊ 1, ṇᮌ⣖㝯㸰, ᖾᮧ཭ᏘᏊ 1, ᪩ᆏᏕᏹ 3, ఀᮾᏹ᫭ 1, 㔠ᒣᑦ⿱ 1, ℩⸨ග฼㸰
㸦1 ὾ᯇ་⛉኱Ꮫ⏘፬ே⛉Ꮫㅮᗙ, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 3 ໭ᾏ㐨኱Ꮫ኱Ꮫ㝔ಖ೺⛉Ꮫ◊✲㝔㸧

㹎-46ࠕࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈங⒴ࡢ෌Ⓨண ᅉᏊࡢ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ᥈ồࠖ⣽ᕝඃᏊ 1, ṇᮌ⣖㝯 2, ᯇୗ⚈Ꮚ 2, ᮡᒣᰤ஧ 2, ᑠ಴༤அ 1, ᳝㇂⣖ᙪ 1, ℩⸨ග฼ 2
㸦1 ὾ᯇ་⛉኱Ꮫ➨୍እ⛉, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝㸧

㹎-48ࠕ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ୚࣐࢘ࢫ⫢⤌⧊࡟ᑐࡍࡿྛ✀࢖࣓࣮ࢪࣥࢢᢏ⾡ࡢ㐺⏝ࠖᒣཱྀு 1, ᒣᮏ༟ᚿ 1, ୰ᕝ⸅ 1, Ώ㒊┤ᶞ 2, ➉ෆ

1 1
ྖ 1, ᑿᓥ඾⾜ 㸦ᰴᘧ఍♫ᓥὠ〇సᡤ, 2 ࣞࢽࢩ࣮ࣙᰴᘧ఍♫㸧
㹎-50ࠕ࢔ࣥࢺࢩ࢔ࢽࣥࡢయෆືែゎᯒࠖ㈈‶ಙᏹ 1, ✄ⴥᰭ㔛 1, ⸨᳃㝯㐨 1, Ⲯཝဴဢ 2, ᑠᯘἋ⧊ 2, ᳃ᒣ㐩ဢ 1㸦1 ㏆␥኱Ꮫ㎰Ꮫ㒊, 2 ᰴᘧ఍♫࣡࢝ࢧ⏕ά㸧

㹎-52ࠕ⾪✺᩿㠃✚࡟ᇶ࡙ࡃ MALDI ࢖࣓࣮ࢪࣥࢢཬࡧ MS/MS ࣇࣛࢢ࣓ࣥࢺࢹ࣮ࢱࡢ㛵㐃௜ࡅ࡟ࡼࡿ⬡㉁ࡢྠᐃ࡜ᒁᅾ໬ゎᯒࠖᑎᓮ┿ᶞ 1, Mark Towers 2, Emmanuelle Claude 2, Johannes PC Vissers 2㸦1 ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫, 2 ࢛࣮࢘ࢱ࣮ࢬ࣭ࢥ࣮࣏࣮ࣞࢩࣙࣥ㸧

㹎-54

ࠕ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓ࢜ࣜࢦࢹࣥࢻࣟࢧ࢖ࢺศ໬㐣⛬ࡢྍど໬ࠖᖹཎᖾᜨ㸯, ⱝᯘẎಇ㸯, ᳃ ᚭ⮬ 1,2, ▮ᑿ⫱Ꮚ 3, ὠ⏣㞞அ 4, ᮏᐙᏕ୍ 5, ᑠụኴ㑻㸯,ᚋ⸨ோᚿ 6, ᑠ㔝຾ᙪ 6, ᒣ⏣ஂኵ㸯㸦1 㛵す་኱࣭་࣭ゎ๗Ꮫ➨୍, 2 㫽ྲྀ኱Ꮫ࣭་࣭ಖ
೺Ꮫ⛉, 3 ὾ᯇ་኱࣭࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 4 㧘▱኱Ꮫ࣭⥲◊, 5 㧘▱኱Ꮫ࣭་࣭⏕໬Ꮫ, 6 ி㒔ᗓ་኱࣭⏕≀Ꮫ㸧

㹎-56

ࠕ㉁㔞㢧ᚤ㙾࡟ࡼࡿࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝࡢ࣐࢘ࢫ⢭ᕢ࡟࠾ࡅࡿྍど໬ࠖ⇃⏣࢔ࣥࣜ࢜ࣂࢹ࢕࢔㸯, ㇂ཱྀஂဴ㸰, ▮ᑿ⫱Ꮚ㸱, ྂ⏣ாྐ㸲, ᯇ⏣බᚿ㸰, ఀ⸨ㄔ஧㸯́́㸦1 㛵す་⛉኱Ꮫ་໬Ꮫㅮᗙ, 2 ⭈Ἢᒀჾእ⛉Ꮫㅮᗙ, 3 ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺ
ࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 4 ᒱ㜧኱Ꮫ་Ꮫ⣔◊✲⛉㸧
㹎-58ࠕ⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࡟࠾ࡅࡿ⬨㧊ᚋゅࡢ⬡㉁ኚ໬ࠖ
ᆏ㔝཭ၨ 1, ṇᮌ⣖㝯㸯, ኱ᮧጾኵ㸯, ୕ཎ၏ᬦ㸯, ᚎ෤㛼㸯, ᯇᒣᖾᘯ 1, ℩⸨ග฼㸯
㸦1 ὾ᯇ་⛉኱Ꮫ་Ꮫ⣔◊✲⛉㸧

㹎-60

ࠕ㉁㔞࢖࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓࣁࣟ࣌ࣜࢻ࣮ࣝ⏤᮶ࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢ⬻ෆศᕸ࡟㛵ࡍࡿྍど໬ࡢ᳨ウࠖ
4 1㏆␥኱Ꮫ་Ꮫ㒊ἲ་Ꮫ,ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ᕴ ಙ஧ 1, ஬༑ᔒ୍㞝㸦2኱㜰་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 㸱኱㜰኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ, 4 ୍⯡♫ᅋἲே་

⸆ศᯒ༠఍
㹎-62

LC/MS ゎᯒ࡟ࡼࡿ⾑୰ CRP 」ྜయ࡟ࡘ࠸࡚ࡢ᳨ウᑠ಴ᙬୡᏊ 1,3, 㔛ᮧཌྖ 1, ᫍ㔝 ᛅ 1, Ⲩᓥᗣ཭ 1, ᚿ᪉࠼ࡾࡉ 1, ⸨ᒸ࿴⨾ 1, ୗ⃝㐩㞝 3, ୰ᒣᬛ⚈ 1㸦1 ᪥ᮏ኱Ꮫ་Ꮫ㒊 ⑓ែ⑓⌮Ꮫ⣔ ⮫ᗋ᳨ᰝ་Ꮫศ㔝, 2 ᪥ᮏ኱Ꮫ⑓㝔 ⮫ᗋ᳨ᰝ་Ꮫ⛉, 3 ᮾி኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔 ᳨ᰝ㒊)

14㸸00㹼15㸸30ࢩ࣏ࣥࢪ࣒࢘㸲㸸ࠕ༴㝤ࢻࣛࢵࢢࡢ ㉁㔞ศᯒ◊✲ࡢ᭱๓⥺ࠖ㸦41 ఍㆟ᐊ㸧࣮࢜࢞ࢼ࢖ࢨ࣮࣭ᗙ㛗㸸㕥ᮌ ಟ㸦὾ᯇ་⛉኱Ꮫ㸧

㹑4-1ࠕ⌧ሙ࡛᥇ྲྀྍ⬟࡞ᚤ㔞ࡢ⾑ᾮ, ၚᾮཬࡧờ࠿ࡽࡢ⸆≀᳨ᰝࠖ᱓ᒣ೺ḟ㸦⛉Ꮫ㆙ᐹ◊✲ᡤ㸧

㹑4-2ࠕ࢝ࢳࣀࣥ⣔༴㝤ࢻࣛࢵࢢࡢ௦ㅰ㸫໬Ꮫᵓ㐀ࡀ௦ㅰ࡟ཬࡰࡍᙳ㡪࡟ࡘ࠸࡚㸫ࠖᚿᦶ඾᫂ 1, 㙊⏣ᐶᜨ 1, ᯇ⏣㥴ኴᮁ 1, ᥃ᶫ⚽┤ 1, ୕ᮌ᫛ᏹ 1, ∦ᮌ᐀ᘯ 1, ᅵᶫ ᆒ 2
㸦1 ኱㜰ᗓ㆙⛉Ꮫᤚᰝ◊✲ᡤ, 2 ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉㸧

㹑4-3ࠕ༴㝤ࢻࣛࢵࢢὶ㏻ᐇែㄪᰝ࡟࠾ࡅࡿ㉁㔞ศᯒࡢᙺ๭ࠖ
ⰼᑼ㸦ᮌ಴㸧⍠⌮㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ㸧

15㸸30㹼17㸸30

㹒㹄-1ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ㸸㉁㔞ศᯒᢏ⾡㛵㐃ࡢᶵჾ࠾ࡼࡧ௻ᴗၟရࡢ⤂௓
㸦41 ఍㆟ᐊ㸧ᗙ㛗㸸ụୖᾈྖ㸦὾ᯇ་⛉኱Ꮫ㸧ࠕ᭱᪂ࡢ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ࡜࢖࢜ࣥࣔࣅࣜࢸ࢕࣮QTofࠖᑎᓮ┿ᶞ 1, ࢱࢼ࢖ ࣃࢡࢫࢺࣥ 1㸦1 ᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫㸧

㹒㹄-2

ࠕAgilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF ࡢ⤂௓ࠖ⁪ᇣᫀᙪ㸦࢔ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫㸧

㹒㹄-3ࠕ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡢ࣎ࢺࣝࢿࢵࢡࢆゎᾘࡍࡿ rapifleX™ MALDI Tissuetyper™ࠖ๓⏣ᩧ჆㸦ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫㸧

㹒㹄-4

ࠕ㉁㔞ศᯒィࢆ᳨ฟჾ࡜ࡍࡿయእデ᩿⏝་⒪ᶵჾ Prelude MD ࡢ⤂௓ࠖ❑⏣㞞அ㸦ࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫㸧

́́

㹒㹄-5

ࠕSWATH® Next-Generation Proteomics ࡜ OneOmics™࡟ࡼࡿ⥙⨶ⓗ࡞ࢱ࣮ࢤࢵࢺᐃ㔞ࣉࣟࢸ࣮࣒࢜ゎᯒࠖᰘ⏣ ⊛㸦ࢧ࢖࢚ࢵࢡࢫ ࢔ࣉࣜࢣ࣮ࢩࣙࣥࢧ࣏࣮ࢺ㸧㹒㹄-6ࠕࣜࣥ⬡㉁ࡢ㝖ཤ࡜ࣜࣥ⬡㉁ࢆᢳฟࡍࡿ๓ฎ⌮〇ရ࡟ࡘ࠸࡚ࠖ㕥ᮌ೺୍, ኴ⏣ⱱᚨ, ⏤஭ኤ†㸦ࢪ࣮࢚ࣝࢧ࢖࢚ࣥࢫᰴᘧ఍♫㸧

㹒㹄-7ࠕHybrid SPE®-Phospholipid ࢆ⏝࠸ࡓࣜࣥ⬡㉁㝖ཤ࡟ࡼࡿ㧗ឤᗘศᯒࠖ
ᯇᓥỤ㔛㤶㸦ࢩࢢ࣐࢔ࣝࢻࣜࢵࢳ ࢪࣕࣃࣥྜྠ఍♫㸧

㹒㹄-8

ࠕLC-MS/MS ࡟ࡼࡿ⾑୰་⸆ရศᯒࡢࡓࡵࡢ඲⮬ື๓ฎ⌮ࢩࢫࢸ࣒ࠖ
ᑿᓥ඾⾜ 1, ✄ᇉ▱Ꮚ 1, ሯᮏከ▴ 1, ᰘ⏣ග 1,2, ᕝୖ኱㍜ 1㸦1(ᰴ)ᓥὠ〇సᡤศᯒィ஦ᴗ㒊, 2Shimadzu Scientific Instruments Inc.㸧

17㸸30㹼17㸸35㛢఍ࡢ㎡㸦41 ఍㆟ᐊ㸧

́́

ㅮ₇せ᪨
㸦L-1㸸ᣍᚅㅮ₇࣭L-2㸸ᯇᮏຬ㈹ཷ㈹ㅮ₇࣭L-3㸸≉ูㅮ₇㸧

́́

L-1
Systems Medicine in a Changing World : The Challenge of Measuring and
Visualising Personal and Public Healthcare Data.
Jeremy K. Nicholson
Department of Surgery and Cancer
Imperial College London
Changes in climate and population densities and distribution plus increasing socioeconomic stresses
placed on healthcare systems pose a unique series of challenges in 21st Century medicine. A tension
exists between the development of new investigative, diagnostic and prognostic technologies andthe ability of scientists and healthcare professionals to deliver effective translational solutions.
Systems biology tools can be applied at both individual and population levels to understandintegrated biochemical function in relation to disease pathogenesis but there are still barriers to theclinical actionability of these modelling tools that present barriers to translation. The complex
gene-environment interactions that create individual and population disease risks are also
responsible for the expression of metabolic phenotypes in different body compartments and fluids.
Thus metabolic phenotyping offers an important window on human systemic activity andspectroscopic tools can be employed to help characterize personalised profiles, disease processes andresponses to therapy (1). We have developed new scalable and translatable strategies for“phenotyping the patient journey” (2) using top-down systems biology tools that capitalize on theuse of metabolic datasets (3) for diagnostic and prognostic biomarker generation to aid clinicaldecision-making at point-of-care. These have been shown to be of value in the development ofprognostic marker models for both clinical efficacy and drug toxicity in cancer patients. Suchapproaches, including those for near real-time applications as in surgery, molecular pathology,
oncology and critical-care, can be extremely sensitive for the detection of diagnostic and prognostic
biomarkers in a variety conditions (4,5). These methods also provide a powerful adjunct toconventional procedures for disease assessment that are required for future developments in“precision medicine” including understanding of the symbiotic influences on patient state (6). Finally,
the “Metabolome Wide Association Study” (7) concept provides powerful new tool to generatedisease risk biomarkers (e.g. for cancer or cardiometabolic diseases) from epidemiological sample
collections. Such population risk models can also link to individual patient healthcare models thus
closing the personal and public healthcare modelling triangle. The ultimate challenge is to takecomplex validated data sets and models on human biology and to visualise these in engaging formats
and forms that clinically actionable in an ever changing background of human health.

́́1. Nicholson J.K. and Lindon, J.C. (2008) Nature 455 1054-1056.
2. Nicholson, J.K. et al (2012) Nature 491 384-392.
3. Clayton, T.A. et al (2006) Nature 440 1073-1077.
4. Balog, J et al (2013) Science Translational Medicine 5 (194) 194ra93.
5. Veselkov, K.A. et al (2014) PNAS doi 10.1073pnas.
6. Mirnezami, R. Nicholson, J.K. and Darzi, A. (2012) New Eng. J. Med. 366 (6) 489-491.
7. Holmes, E. et al (2008) Nature 453 396-400.
Professor Nicholson obtained his BSc from Liverpool University (1977) and his PhD from
London University (1980) in Biochemistry working on the application of analytical electron
microscopy and the applications of energy dispersive X-Ray microanalysis in molecular
toxicology and inorganic biochemistry. He was appointed Lecturer in Chemistry (Birkbeck
College, London University, 1981-83) and Lecturer in Experimental Pathology at The London
University School of Pharmacy (1983-85) returning to Birkbeck as a Senior Lecturer in
Chemistry, then Reader (1989) and Professor of Biological Chemistry (1992). In 1998 hebecame Head of Biological Chemistry at Imperial College London then Head of Biomolecular
Medicine (2006). Since 2009 he has been Head of the Department of Surgery and Cancer at
Imperial where he runs a series of programs in stratified medicine, molecular phenotyping andmolecular systems biology. In 2012 he became the Director of world’s first National Phenome
Centre specialising in large-scale phenotyping. Professor Nicholson is the author of over 600
peer-reviewed scientific papers and many other articles/patents on the development andapplication of novel spectroscopic and chemometric approaches to the investigation of metabolic
systems failure, MWAS studies and pharmaocometabonomics. His research has been recognisedby awards such as: the RSC Silver (1992) and Gold (1997) Medals for Analytical Chemistry; theChromatographic Society Jubilee Silver Medal (1994); the Pfizer Prize for Chemical andMedicinal Technology (2002); the RSC medal for Chemical Biology (2003); the RSC
Interdisciplinary Prize (200&) the RSC Theophilus Redwood Lectureship (2008); the Pfizer
Global Research Prize for Chemistry (2006); the NIH Stars in Cancer and Nutrition
Distinguished Lecturer (2010) and the Semelweiss-Budapest Prize for Biomedicine (2010).
Professor Nicholson was also elected as a Fellow of the UK Academy of Medical Sciences in2010. He was elected Lifetime honorary membership of the US Society of Toxicology (2013),
Honorary lifetime membership of the International Metabolomics society (2013). He currently
holds honorary professorships at 8 International Universities and in 2014 was Elected an
Einstein Professor of the Chinese Academy of Sciences. ISi highly cited researcher (h= 99). He
is a consultant to many pharmaceutical/healthcare companies in the UK, Europe and the USA
and is a founder director of Metabometrix, an Imperial College spin-off company specializing inmolecular phenotyping, clinical diagnostics and toxicological screening via metabonomics andmetabolomics.

́́

L-2
㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝࡟㛵ࡍࡿ◊✲㔝ᮧᩥኵ༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ ≉௵ᩍᤵ

Applications of mass spectrometry to laboratory medicine
Fumio Nomura
Division of Clinical Mass Spectrometry, Chiba University Hospital㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝࡟ࡣ኱ࡁࡃ 2 ࡘࡢ࢔ࣉ࣮ࣟࢳࡀ࠶ࡿࠋ᪂つࣂ࢖࣐࣮࣮࢜࢝
㸦᳨ᰝ㡯┠㸧ࡢⓎぢࢆ┠ⓗ࡜ࡋࡓࣉࣟࢸ࣮࣒࢜ゎᯒ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟࠾ࡅࡿ㉁㔞ศᯒἲࡢ฼⏝࡜᪤Ꮡࡢ⮫ᗋ᳨ᰝ࡟࠾ࡅࡿ㉁㔞ศᯒἲࡢά⏝࡛࠶ࡿࠋẚ㍑ࣉࣟࢸ࣮࣒࢜ゎᯒࡢࡓࡵ
ࡢ㉁㔞ศᯒᢏ⾡ࡢ㐍Ṍࡣ┠ぬࡲࡋࡃࠊከࡃࡢデ᩿ࣂ࢖࣐࣮࣮࢜࢝ೃ⿵ࡀぢฟࡉࢀ࡚࠸ࡿࡀࠊ
ᐇ㝿ࡢ⮫ᗋᛂ⏝ࡲ࡛฿㐩ࡋ࡚࠸ࡿࡶࡢࡣ͆A drop in the ocean͇࡜⾲⌧ࡉࢀࡿࡼ࠺࡟ࡁࢃࡵ࡚
ᑡ࡞࠸ࠋ࣐࣮࣮࢝ࡢⓎぢ࠿ࡽᐇ⏝໬ࡲ࡛ࡢ㐨ࡢࡾࡣ㛗࠸ࡀࠊ⏘Ꮫࡀᐦ࡟㐃ᦠࡍࡿࡇ࡜࡟ࡼ
ࡾࠊձᑐ㇟⑌ᝈࡢ㐺ษ࡞㑅ᢥࠊղ⮫ᗋ᝟ሗࡀ௜ࡉࢀࡓ⮫ᗋ᳨యࡢ㐺ษ࡞᥇ྲྀ࡜ಖᏑࠊճ▱ⓗ㈈⏘ࡢ☜ಖ࡜⥔ᣢࠊմయእデ᩿⸆ࡢᢎㄆ⏦ㄳࠊ࡞࡝ࡀྍ⬟࡜࡞ࡿࠋ₇⪅ࡽࡣ SELDI-TOF MSࢆ⏝࠸࡚ぢฟࡋࡓ⾑Ύ୰ࡢ 5.9kD ࣌ࣉࢳࢻࡀ࢘࢖ࣝࢫᛶ៏ᛶ⫢㞀ᐖ࡟࠾ࡅࡿ㗦ᩄ࡞⥺⥔໬࣐࣮࣮࢝࡜࡞ࡿྍ⬟ᛶࢆ♧ࡋࡓࠋ⌧ᅾ⮫ᗋ᳨ᰝデ᩿⸆࡜ࡋ࡚ࡢᢎㄆ࡟ྥࡅ࡚ࠊ⊂❧⾜ᨻἲே་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸦PMDA㸧࡛ᑂᰝ୰࡛࠶ࡿࠋࡲࡓࠊཎⓎᛶ⫢⣽⬊⒴ (HCC)ᝈ⪅ࡢ⫢ษ㝖⤌⧊ࡢ⒴㒊ࠊ㠀⒴㒊ࡢẚ㍑ࣉࣟࢸ࣮࣒࢜ゎᯒࡢ⤖ᯝࠊ⑓⌮デ᩿࡟᭷⏝࡞࣐࣮࣮࢝
࡜ࡋ࡚ clathrin heavy chain ࡜ formiminotransferase cyclodeaminase ࢆぢฟࡋࡓࠋ⒴㒊࡛㧗Ⓨ⌧ࡋ࡚࠸ࡿ⺮ⓑ㉁࡛ࡣ⩻ヂᚋಟ㣭࡞࡝࡟ࡼࡿᢠཎᛶࡢኚ໬ࡀ᝿ᐃࡉࢀࡿࡢ࡛ࠊࡇࢀࡽࡢ⺮ⓑ㉁࡟ᑐࡍࡿ⾑୰⮬ᕫᢠయ ᐃ࡟ࡼࡿ HCC ࡢ᪩ᮇデ᩿ࡢྍ⬟ᛶࢆ᳨ウࡋ࡚࠸ࡿࠋ
୍᪉ࠊ⌧ᅾ⑓㝔᳨ᰝᐊ࡟࠾ࡅࡿ᪂ࡓ࡞᳨ᰝἲ࡜ࡋ࡚ࡢ㉁㔞ศᯒἲࡢᙺ๭ࡀᛴ㏿࡟㧗ࡲࡾࡘࡘ࠶ࡿࠋ᭱ࡶᡂຌࡋ࡚࠸ࡿࡢࡣ MALDI-TOF MS ࢆ⏝࠸ࡓ⳦యࡢࣉࣟࢸ࣮࣒࢜ゎᯒ࡟ࡼࡿ⣽⳦࣭┿⳦ࡢ㎿㏿ྠᐃ࡛࠶ࡿࠋᮏἲࡣ⡆౽ࠊṇ☜ࠊ㎿㏿࡛࠶ࡾࠊࡉࡽ࡟ࣛࣥࢽࣥࢢࢥࢫࢺ
ࡶపࡃࠊ⮫ᗋ⣽⳦᳨ᰝ࡟㠉࿨ⓗ࡞ኚ໬ࢆࡶࡓࡽࡋ࡚࠸ࡿࠋᡃࠎࡶ 2010 ᖺ࠿ࡽᮏᢏ⾡ࢆඛࡎ◊✲ᐊ࡛ࣞ࣋ࣝᑟධࡋࠊ2012 ᖺ࠿ࡽࡣ⑓㝔᳨ᰝ㒊࡟ᑓ⏝ᶵჾࢆタ⨨ࡋ࡚࣮ࣝࢳ᳨ࣥᰝ࡜ࡋ
࡚ᐇ᪋ࡋ࡚࠸ࡿࠋin-house ࢹ࣮ࢱ࣮࣋ࢫࡢసᡂࡸࠊ⳦యᵓ㐀࡟ྜࢃࡏࡓ๓ฎ⌮ࡢᕤኵ࡞࡝࡟
ࡼࡾྠᐃ⋡ࡢྥୖ࡟ດࡵ࡚࠸ࡿࠋ≉࡟⾑ᾮᇵ㣴⤖ᯝࡸ⣽⳦ᛶ㧊⭷⅖ࡢ㉳⅖⳦ࡢ㎿㏿ሗ࿌࡞࡝࡟ࡼࡾឤᰁ⑕デ⒪࡟㈉⊩ࡋ࡚࠸ࡿࠋࡋ࠿ࡋࠊᢠ⳦⸆࡟ᑐࡍࡿឤཷᛶ࣭⪏ᛶࡢุูࡀࡲࡔ
༑ศ࡛ࡁ࡞࠸ࡇ࡜ࠊ」ᩘ⳦࡬ࡢᑐᛂࡀᐜ࡛᫆࡞࠸ࡇ࡜ࠊ࡞࡝ㄢ㢟ࡶከ࠸ࠋ⌧ᅾࠊࢫࢸࣟ࢖
ࢻ࣍ࣝࣔࣥ࡞࡝ࡢపศᏊ໬ྜ≀ࡢᐃ㔞࡟ࡣ࢖࣒ࣀ࢔ࢵࢭ࢖ࡀከ⏝ࡉࢀ࡚࠸ࡿࡀࠊഃ㙐ᵓ㐀ࡢᚤᑠ࡞㐪࠸ࢆᢠయࡢࡳ࡛

ࡾศࡅࡿࡇ࡜࡟ࡣ㝈⏺ࡀ࠶ࡾࠊLC/MS/MS ࡬ࡢ⛣⾜ࡢᶵ㐠ࡀ㧗ࡲࡗ࡚࠸ࡿࠊ௨ୖࡢࡼ࠺࡟㉁㔞ศᯒᢏ⾡ࡢ⮫ᗋ᳨ᰝᛂ⏝ࡀ௒ᚋᛴ㏿࡟ᬑཬࡍࡿࡇ࡜࡟ഛ࠼
࡚ࠊᮏᢏ⾡ࡢᇶ♏ࢆᏛࡪ࡜ྠ᫬࡟᳨ᰝἲࡢᶆ‽໬ࡢࡓࡵࡢඹ㏻ᇶ┙ࢆᣢࡘࡇ࡜ࢆ┠ᶆ࡜ࡋ
࡚ࠊ2013 ᖺࡼࡾᮏᏛ఍࡟࠾࠸࡚་⏝㉁㔞ศᯒㄆᐃኈไᗘࡀࢫࢱ࣮ࢺࡋࠊ⌧᫬Ⅼ࡛ 184 ྡࡀㄆᐃࡉࢀ࡚࠸ࡿࠋ

́́

Ӑ␎

Ṕӑ

᫛࿴ 50 ᖺ༓ⴥ኱Ꮫ་Ꮫ㒊༞ᴗࠊ➨㸯ෆ⛉ධᒁ
᫛࿴ 53 ᖺ࠿ࡽ 4 ᖺ㛫 ࢔ ࣓ ࣜ ࢝ ྜ ⾗ ᅜ ࢽ ࣗ ࣮ ࣚ ࣮ ࢡ ᕷ ❧ ኱ Ꮫ ་ Ꮫ 㒊 Mount Sinai
Hospital ࣞࢪࢹࣥࢺ࠾ࡼࡧ࢔ࣝࢥ࣮ࣝ࡜⫢◊✲ᡤ◊✲ဨ㸦Charles S. Lieber ᩍᤵ㸧ᖐᅜᚋ ༓ⴥ኱Ꮫ་Ꮫ㒊➨ 1 ෆ⛉࡟࠾࠸࡚⫢⑌ᝈࡢデ⒪࡜◊✲࡟ᚑ஦᫛࿴ 58 ᖺ༓ⴥ኱Ꮫ་Ꮫ㒊➨ 1 ෆ⛉ຓᡭ

ᖹᡂ 5 ᖺ

⟃Ἴ኱Ꮫ⮫ᗋ་Ꮫ⣔ㅮᖌ

ᖹᡂ 6 ᖺ

ྠຓᩍᤵ

ᖹᡂ 11 ᖺ 10 ᭶༓ⴥ኱Ꮫ་Ꮫ㒊⮫ᗋ᳨ᰝ་Ꮫㅮᗙ
㸦ᖹᡂ 13 ᖺ 4 ᭶ࡼࡾ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔ศᏊ⑓ែゎᯒᏛ㸧ᩍᤵ࠾ࡼࡧ㝃ᒓ⑓㝔᳨ᰝ㒊㛗
ᖹᡂ 18 ᖺ 5 ᭶ ࡼࡾ㝃ᒓ⑓㝔⑌ᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮㛗වົ

ᖹᡂ 20 ᖺ 4 ᭶ ࡼࡾ㑇ఏᏊデ⒪㒊㛗වົᖹᡂ 27 ᖺ 3 ᭶༓ⴥ኱Ꮫᩍᤵࢆᐃᖺ㏥௵

ᖹᡂ 27 ᖺ 4 ᭶ ~༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫᐤ௜◊✲㒊㛛 ≉௵ᩍᤵබ┈㈈ᅋἲேࡕࡤ┴Ẹಖ೺ண㜵㈈ᅋ Ꮫ⾡㢳ၥ

́́

L-3
ḟୡ௦ࣉࣟࢸ࣑࢜ࢡࢫࢆ⏝࠸ࡓࡀࢇ≉ᛶࡢゎ᫂୰ᒣᩗ୍஑ᕞ኱Ꮫ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ศᏊ་⛉Ꮫศ㔝࣭ࣄࢺࣉࣟࢸ࣮࣒࢜◊✲ࢭࣥࢱ࣮Next-generation proteomics unveils a global landscape of cancer
Keiichi Nakayama
Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu
Universityࣄࢺࢤࣀ࣒ィ⏬ࡀ⤊஢ࡋ࡚࡯ࡰ 10 ᖺࡀ⤒࡜࠺࡜ࡋ࡚࠸ࡿࡀࠊ⏕࿨ࡢᇶᮏసືཎ⌮࡟ࡣᮏ㉁ⓗ࡟ᮍゎ᫂ࡢ㒊ศࡀከࡃṧࡉࢀ࡚࠸ࡿࠋࡑࢀࡣ⣽⬊άືࡢᐇ⾜㒊㝲ࡀࢱࣥࣃࢡ㉁࡛࠶ࡿ࠿ࡽ࡛࠶
ࡿࠋ⏕࿨࡜࠸࠺ࢿࢵࢺ࣮࣡ࢡࢩࢫࢸ࣒ࢆ⌮ゎࡍࡿୖ࡛ࠊࢱࣥࣃࢡ㉁ࡢ᫬㛫࣭✵㛫࣭㔞࡜࠸࠺⥙⨶ⓗ᝟ሗࡀ࡞࠸㝈ࡾࠊಶࠎࡢࣀ࣮ࢻࡀ」㞧࡟㐃⤖ࡍࡿࢿࢵࢺ࣮࣡ࢡࢆ⌮ゎࡍࡿࡇ࡜ࡣ୙ྍ⬟࡛࠶ࢁ࠺ࠋࡑࡇ࡛ࢃࢀࢃࢀࡣࣄࢺ඲ࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞࡜࠸࠺ክࡢࣉࣟࢪ࢙ࢡࢺ㸦ࣄࢺࣉࣟࢸ
࣮࣒࢜ィ⏬㸧࡟ᣮᡓࡋ࡚࠸ࡿࠋࡲࡓ඲࡚ࡢࢱࣥࣃࢡ㉁ࢆ⤯ᑐᐃ㔞ࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊ⢭ᐦ࡞ᩘ⌮⛉Ꮫⓗ࡞ゎᯒࡢᑟධࢆ┠ᣦࡋ࡚࠸ࡿࠋ
ࢃࢀࢃࢀࡣ 16 ྎࡢ㉁㔞ศᯒィࢆᑟධࡋࠊࣉࣟࢸ࣮࣒࢜ィ ࡢ㣕㌍ⓗ࡞ࢫ࣮ࣝࣉࢵࢺᣑ኱࡟ດ
ࡵ࡚࠸ࡿࠋྠ᫬࡟ࣄࢺࡢ඲ࣜࢥࣥࣅࢼࣥࢺࢱࣥࣃࢡ㉁ 25,000 ✀ࢆヨ㦂⟶ෆ࡛ྜᡂࡋࠊࡇࡢ᝟ሗ
ࢆᇶ࡟㧗㏿ MRM ࡛▷᫬㛫࡟ከᩘࡢࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞ࢆྍ⬟࡟ࡍࡿᢏ⾡㸦in vitro
proteome-assisted MRM for Protein Absolute QuanTification: iMPAQT㸧࡜࠸࠺᪉ἲࢆⓎ᫂ࡋࡓ㸦≉チ➨ 5468073 ྕ㸧ࠋࡇࡢ iMPAQT ἲࡣࠊᢠయࢆ౑⏝ࡏࡎ࡟ᩘ୓✀㢮ࡢࢱࣥࣃࢡ㉁ࢆ㉸㧗ឤᗘ࡛⤯ᑐᐃ㔞ࡍࡿࡇ࡜ࡀྍ⬟࡛࠶ࡿࠋࡇࡢ iMPAQT ἲࢆ⏝࠸࡚ከࡃࡢࢱࣥࣃࢡ㉁ࡢ⤯ᑐᐃ㔞ࢆ⾜ࡗࡓࠋ≉࡟ṇᖖ⣽⬊࡜ࡀࢇ⣽⬊࡟ࡘ࠸࡚ࠊࡑࡢ௦ㅰ≧ែࡢኚ໬ࢆࡶࡓࡽࡍ࣮࢟㓝⣲ࢆ᥈⣴ࡋࡓࠋ⣙ 90 ᖺ๓࡟ࢻ࢖ࢶࡢ⏕⌮Ꮫ⪅ Otto Warburg ࡟ࡼࡗ࡚Ⓨぢࡉࢀࡓࡀࢇ࡟࠾ࡅࡿ௦ㅰࢩࣇࢺ
ࠕ࣮࣡ࣝࣈࣝࢢຠᯝࠖࡣࠊࡀࢇ⣽⬊ࡀዲẼⓗ᮲௳ୗ࡟࠾࠸࡚ࡶ᎘Ẽⓗ௦ㅰࢆ⾜࠺࡜࠸࠺୍ぢወጁ࡞᣺ࡿ⯙࠸ࢆࡍࡿ⌧㇟࡛࠶ࡿࡀࠊከࡃࡢࡀࢇ⣽⬊ࡀࡇࡢᡓ␎ࢆ᥇ࡿ⌮⏤ࡣ⌧ᅾ࡛ࡶ᫂ࡽ࠿࡛ࡣ࡞
࠸ࠋࢃࢀࢃࢀࡣ࣮࣡ࣝࣈࣝࢢຠᯝࡢᮏ㉁ࢆゎ᫂ࡍࡿࡓࡵࠊiMPAQT ἲ࡟ࡼࡗ࡚ṇᖖ⣽⬊࡜ࡀࢇ⣽⬊࡟࠾࠸࡚ࠊ඲࡚ࡢ௦ㅰ㓝⣲㸦⣙ 1000 ✀㢮㸧࠾ࡼࡧ௦ㅰ⏘≀ࢆ⤯ᑐᐃ㔞ࡋࠊࢩࢫࢸ࣒⏕≀Ꮫⓗᡭἲࢆྲྀࡾධࢀ࡞ࡀࡽࠊ࣮࣡ࣝࣈࣝࢢຠᯝࡢ࣮࢟㓝⣲ࢆྠᐃࡋࡓࠋࡇࡢ⤖ᯝࠊࡀࢇ࡟࠾ࡅࡿ௦
ㅰࢩࣇࢺࡣࠊ࣮࢝࣎ࣥࢯ࣮ࢫ฼⏝ࢆ࢚ࢿࣝࢠ࣮⏘⏕࠿ࡽ㧗ศᏊ໬ྜ≀ྜᡂ࡬ࣜࣔࢹࣜࣥࢢࡍࡿ
㐺ᛂᡓ␎࡛࠶ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ௒ᚋࡣ iMPAQT ἲ࡟ࡼࡗ࡚ከࡃࡢศ㔝ࡢ◊✲ࢆ㠉᪂ⓗ࡟㐍Ṍࡉࡏࡿ࡜ྠ᫬࡟ࠊ⮫ᗋ᳨ᰝ࡬ࡢᛂ⏝ࡸࣂ࢖࣐࣮࣮࢜࢝᥈⣴࡞࡝ࠊ་Ꮫ⏕≀Ꮫ࡟㛗㊊ࡢ㐍Ṍࢆࡶࡓࡽࡍࡇ࡜ࡀᮇᚅࡉࢀࡿࠋ
ࡇࡢࡼ࠺࡟ṇᖖ࡜⑌ᝈ࡟࠾ࡅࡿࢿࢵࢺ࣮࣡ࢡᵓ㐀ࡢᕪ␗ࡀ᫂ࡽ࠿࡟࡞ࢀࡤࠊ⑌ᝈࢿࢵࢺ࣮࣡
ࢡ࡟࠾ࡅࡿࣁࣈศᏊࢆ✺ࡁṆࡵࠊࡑࢀࢆᶆⓗ࡜ࡋࡓ๰⸆ࡀྍ⬟࡟࡞ࡿࠋࢃࢀࢃࢀࡣࡇࡢ⪃࠼᪉ࢆࠕࢿࢵࢺ࣮࣡ࢡᶆⓗ๰⸆ࠖࢆ࿧ࡧࠊᚑ᮶ࡢศᏊᶆⓗ๰⸆࡜ࡣ୍⥺ࢆ⏬ࡋ࡚⪃࠼࡚࠸ࡿࠋࢿࢵ
ࢺ࣮࣡ࢡᶆⓗ๰⸆ࢆྍ⬟࡟ࡍࡿࡓࡵ࡟ࡣࠊ⢭ᐦ࡞ᐃ㔞ィ ࡜㧗ᗘ࡞᝟ሗᩘ⌮⛉Ꮫࡢ㐃ᦠࡀᚲせ࡛࠶ࡾࠊ⌧ᅾୖグࡢࡀࢇ࡟࠾ࡅࡿ௦ㅰࢩࣇࢺࢆࣃ࢖ࣟࢵࢺࢣ࣮ࢫ࡜ࡋ࡚ᐇド◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋ

́́

Ӑ␎

Ṕӑ

1980 ᖺ 3 ᭶ 㸸⚄ዉᕝ┴❧•༡㧗➼Ꮫᰯ ༞ᴗ
1980 ᖺ 4 ᭶ 㸸ᮾி་⛉ṑ⛉኱Ꮫ་Ꮫ㒊་Ꮫ⛉ ධᏛ
1986 ᖺ 3 ᭶ 㸸ྠ ༞ᴗ
1986 ᖺ 4 ᭶ 㸸㡰ኳᇽ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ ධᏛ㸦ච␿Ꮫᑓᨷ㸧
1990 ᖺ 3 ᭶ 㸸ྠ ༞ᴗ

1990 ᖺ 4 ᭶ 㸸⌮໬Ꮫ◊✲ᡤ ࣇࣟࣥࢸ࢕࢔◊✲ဨ
1990 ᖺ 12 ᭶ 㸸࣡ࢩࣥࢺࣥ኱Ꮫ་Ꮫ㒊 ࣏ࢫࢺࢻࢡࢺࣛࣝࣇ࢙࣮ࣟ
1992 ᖺ 3 ᭶ 㸸࣡ࢩࣥࢺࣥ኱Ꮫࣁ࣮࣡ࢻࣄ࣮ࣗࢬ◊✲ᡤ ༤ኈ◊✲ဨ
1995 ᖺ 7 ᭶ 㸸᪥ᮏࣟࢩࣗ◊✲ᡤ⏕≀Ꮫ㒊 ୺ᖿ◊✲ဨ
1996 ᖺ 10 ᭶ 㸸஑ᕞ኱Ꮫ⏕య㜵ᚚ་Ꮫ◊✲ᡤ⣽⬊Ꮫ㒊㛛 ᩍᤵ
⌧ᅾ࡟⮳ࡿ

́́

ㅮ₇せ᪨
㸦S1㹼S4㸸ࢩ࣏ࣥࢪ࣒࢘㸧

́́

S1-1
ࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ⾜࠺㝧ᛶ౛ࡢホ౯࡜ᑐᛂ❑⏣ ‶ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮⥲ྜデ⒪㒊

How should consultant doctors evaluate and respond to MS/MS positive results?
Mitsuru Kubota
Department of General Pediatrics & Interdisciplinary Medicine, National Center for Child Healthand Development࠙ࡣࡌࡵ࡟ࠚ ⌧ᅾࠊ᪥ᮏ඲ᅜ࡛⏕ࡲࢀࡿࡍ࡭࡚ࡢ᪂⏕ඣ࡟ᑐࡋࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜ
ࢽࣥࢢ㸦௨ୗ TMS㸧ࡀᐇ᪋ࡉࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊᐇ᪋୺య࡛࠶ࡿ 67 㒔㐨ᗓ┴࣭ᨻ௧ᣦᐃ㒔ᕷࡍ࡭࡚࡟ TMS ࢆᑓ㛛࡜ࡋ࡚࠸ࡿ་ᖌࡀ࠸ࡿࢃࡅ࡛ࡣ࡞ࡃࠊࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀඛኳᛶ
⏥≧⭢ᶵ⬟పୗ⑕࡞࡝ࡢෆศἪ⑌ᝈࢆᑓ㛛࡜ࡋ࡚࠾ࡾࠊTMS ࡢᑓ㛛ᐙ࡛ࡣ࡞࠸ࡇ࡜ࡶከ࠸ࠋ
࠙෌᳨ᰝࠚ෌᳨ᰝࡢุ᩿ࡣᇶᮏⓗ࡟ TMS ᢸᙜࡢᢏ⾡⪅ࡀ⾜ࡗ࡚࠸ࡿࠋ
TMS ஦ᴗࡢ୍㒊࡛࠶ࡾࠊࡲࡔࠕ་⒪࡛ࠖࡣ࡞࠸ࠋ⢭ᐦ᳨ᰝ࡟ࡍࡿ࠿ࠊ෌᳨ᰝ࡟ࡍࡿ࠿ࡢุ᩿ࡣ༢⣧࡞ࡶࡢ࡛ࡣ࡞ࡃࠊ
ඣࡢ့ங≧ἣࠊᢠ⳦⸆౑⏝ࡢ᭷↓ࠊ࿘⏘ᮇࡢ≧ែ࡞࡝ࡶຍ࿡ࡋ࡚Ỵᐃࡋ࡚࠸ࡿࠋTMS ᢏ⾡⪅࡟ࡣࠊṇ☜࡞ࢹ࣮ࢱࢆ᪥ࠎࡢᴗົ࡛ฟࡋ⥆ࡅࡿࡇ࡜ࡢࡳ࡞ࡽࡎࠊࡇࡢࠕุ᩿ࠖࡀせồࡉࢀࠊࢥࣥࢧࣝࢱࣥࢺ་ᖌࡣᑓ㛛ᐙ࡜ඹ࡟ࡑࡢᣦᑟࢆ⾜࠺ᚲせࡀ࠶ࡿࠋ࠙⢭ᐦ᳨ᰝࠚ ࡇࡇ࠿ࡽࡀࢥࣥࢧࣝࢱࣥࢺ་ᖌࡀ┤᥋ᢸᙜࡍࡿࠕ་⒪࡛ࠖ࠶ࡿࠋTMS ࡟ࡼࡗ࡚ࠊ
⣙ 10,000 ே࡟୍ேࡢᝈ⪅ࡀⓎぢࡉࢀ࡚࠸ࡿࠋࡑࡢ⣙ 3 ಸࡢேᩘࡀ TMS 㝧ᛶࡢ⢭ᰝᑐ㇟⪅࡜⪃࠼ࡽࢀࠊ⢭ᰝ་⒪ᶵ㛵࡟ᣦᐃࡉࢀࢀࡤࠊ୍ᐃࡢᩘࡢ⢭ᰝࢆ⾜࠺ᚲせࡀ࡛࡚ࡃࡿࠋࡑࡢࡓ
ࡵࠊᑓ㛛ᐙ࡛࡞ࡃ࡚ࡶデ⒪࡛ࡁࡿࡼ࠺࡟ࠊ᪥ᮏඛኳ௦ㅰ␗ᖖᏛ఍ࡣࠊTMS ᑐ㇟⑌ᝈ࡟㛵ࡍࡿデ⒪࢞࢖ࢻࣛ࢖ࣥࢆసᡂࡋࡓࠋࡋ࠿ࡋࠊ࢞࢖ࢻࣛ࢖ࣥࡀᏑᅾࡋ࡚࠸࡚ࡶࠊࡑࢀࡔࡅ࡛デ⒪࡛ࡁࡿࢃࡅ࡛ࡣ࡞࠸ࠋᑓ㛛ᐙ࡟ࢥࣥࢧࣝࢺ࡛ࡁࡿࢩࢫࢸ࣒ࡀᚲせ࡛࠶ࡾࠊNPO ἲேࢱࣥࢹ࣒
࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢᬑཬ༠఍࡛ࡣࠊࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࣭ࢥࣥࢧࣝࢸ࣮ࢩࣙ
ࣥࢭࣥࢱ࣮ࢆタ⨨ࡋ࡚࠸ࡿࠋࡋ࠿ࡋࠊface to face ࡢࢥࣥࢧࣝࢸ࣮ࢩࣙࣥࡶ㔜せ࡛࠶ࡾࠊ₇⪅ࡣ」ᩘࡢ⮬἞య࡜ዎ⣙ࡋࠊࢥࣥࢧࣝࢺᴗົࢆ⾜ࡗ࡚࠸ࡿࠋࡲࡓࠊ᫖ᖺ࠿ࡽ㛵ᮾᆅ༊࡛ࠊ
ࠕ㛵ᮾࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࣭ࣇ࢛࣮࣒ࣛࠖࢆ㛤ദࡋ࡚࠸ࡿࠋ
࠙་⒪ୖࡢၥ㢟Ⅼࠚ ๓㏙ࡢࢩࢫࢸ࣒࡛⢭ᰝ᪉㔪ࡀỴࡲࡗ࡚ࡶࠊ☜ᐃデ᩿ࡢࡓࡵ࡟ᚲせ࡞᳨ᰝࡢ୰࡛ࠊಖ㝤཰㍕ࡉࢀ࡚࠸ࡿ᳨ᰝࡣഹ࠿࡛࠶ࡿࡇ࡜ࡀၥ㢟࡛࠶ࡿࠋࠕಖ㝤་⒪ᶵ㛵ෆ࡛ࡢ᳨ᰝࠖ࡜࠸࠺ไ⣙ࡀ࠶ࡿ㡯┠ࡶ࠶ࡾࠊᮍࡔⰋ࠸デ⒪యไ࡟࡞ࡗ࡚࠸࡞࠸ࠋ
࠙ࡲ࡜ࡵࠚ ఱࡼࡾࡶ㔜せ࡞ࡇ࡜ࡣࠊᆅᇦࡢࢥࣥࢧࣝࢱࣥࢺ་ᖌࢆᨭ࠼ࡿࢩࢫࢸ࣒ࡢᵓ⠏࡛
࠶ࡿࠋTMS ࡢᑓ㛛ᐙࡣࠊ་ᖌ࡛࠶ࡗ࡚ࡶᢏ⾡⪅࡛࠶ࡗ࡚ࡶࠊ✚ᴟⓗ࡟ࢥࣥࢧࣝࢱࣥࢺ་ᖌ࡟
㛵ࢃࡾࠊࡼࡾⰋ࠸ TMS ࢆᐇ⌧࡛ࡁࡿࡼ࠺࡟ດຊࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ

́́

S1-2
ࠕ඲ᅜ⮬἞య࡛஦ᴗ໬ࡉࢀࡓࢱࣥࢹ࣒࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ࡬ࡢᑐᛂࠖ
⢭ᐦ᳨ᰝ࡬ࡢᑐᛂࡢ⌧ἣ㛗㇂ᕝ᭷⣖ 11ᓥ᰿኱Ꮫ་Ꮫ㒊ᑠඣ⛉Management of second-tier tests in newborn screening using tandem mass
spectrometry in Shimane University
Yuki Omura-Hasegawa1
1
Department of Pediatrics, Shimane University School of Medicineࢱࣥࢹ࣒࣐ࢫ㉁㔞ศᯒィ㸦MS/MS㸧ࢆ⏝࠸ࡓ᪂ࡋ࠸᪂⏕ඣ࣐ࢫ࣭ࢫࢡ࣮ࣜࢽࣥࢢ㸦NBS㸧ࡣ≉࡟⬡⫫㓟࣭᭷ᶵ㓟௦ㅰ␗ᖖ⑕ࡢデ᩿࡟᭷⏝ࡔࡀࠊඣࡢ᪩ᮇ἞⒪ࡸ㞀ᐖண㜵࡟ᙺ❧࡚ࡿࡓࡵ࡟ࡣࠊ⢭ᐦ᳨ᰝ࡬ࡢᑐᛂࡸデ᩿ᚋࡢࣇ࢛࣮ࣟ࡜࠸ࡗࡓࢩࢫࢸ࣒ᵓ⠏ࡀ㔜せ࡛࠶ࡿࠋ☜ᐃデ᩿࡟ࡣ MS/MS ࡟ࡼࡿ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒ࡟ຍ࠼࡚ࠊ࢞ࢫࢡ࣐ࣟࢺࢢࣛࣇ㉁㔞ศᯒィ㸦GC/MS㸧ࢆ⏝࠸ࡓᒀ୰᭷ᶵ㓟ศᯒࡸ㑇ఏᏊゎᯒࠊ㓝⣲άᛶ ᐃ࡞࡝ࡢ᳨ᰝࡀᚲせࡔࡀࠊࡇࢀࡽࡢ஧ḟ᳨ᰝࢆᐇ᪋࡛ࡁࡿ᪋タࡣ㝈ࡽࢀ࡚࠸ࡿࡢࡀ⌧≧࡛࠶ࡿࠋᓥ᰿኱Ꮫ࡛ࡣ 1995 ᖺ࠿ࡽᒀ୰᭷ᶵ㓟ศᯒࢆࠊ2003 ᖺ࠿ࡽࡣ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒࢆ
㛤ጞࡋࡓࠋ2014 ᖺ 12 ᭶ࡲ࡛࡟ࠊNBS ࢆ㝖࠸ࡓࡢ࡭ศᯒ᳨యᩘࡣᒀ୰᭷ᶵ㓟ศᯒࡀ 23,496
᳨యࠊ࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒ 20,255 ᳨యࠊ㑇ఏᏊゎᯒ 532 ᳨యࠊ㓝⣲άᛶ/immunoblotting
884 ᳨య࡜ࠊᅜෆእ࠿ࡽከᩘࡢࣁ࢖ࣜࢫࢡඣࡢデ᩿౫㢗࡟ᑐᛂࡋࠊ⤒㦂ࢆ㔜ࡡ࡚ࡁࡓࠋ
ᓥ᰿኱Ꮫ࡛ NBS ࢆ⾜ࡗࡓ⑕౛࡟ࡘ࠸࡚ࡣࠊ2005 ᖺ 4 ᭶࠿ࡽ 2014 ᖺ 12 ᭶ࡲ࡛ࡢศᯒᩘࡀ
ィ 224,352 ᳨య࡛ࠊ࠺ࡕ⢭ᐦ᳨ᰝ࡜࡞ࡗࡓ⑕౛ࡀ 199 ౛㸦0.09%㸧
ࠊࡉࡽ࡞ࡿ᳨ᰝࢆ⾜ࡗࡓ⑕౛㸦␲㝧ᛶ౛㸧ࡣ 77 ౛㸦0.03㸣㸧࡛ࠊ᭱⤊ⓗ࡟௦ㅰ␗ᖖ࡜デ᩿ࡉࢀࡓࡢࡣ 32 ౛㸦0.01%㸧
࡛࠶ࡗࡓࠋ⑌ᝈࡣࣇ࢙ࢽࣝࢣࢺࣥᒀ⑕㸦PKU㸧5 ౛ࠊ㍍⑕ࢆྵࡴࣉࣟࣆ࢜ࣥ㓟⾑⑕࡜ᴟ㛗㙐࢔ࢩࣝ CoA ⬺Ỉ⣲㓝⣲㸦VLCAD㸧Ḟᦆ⑕ࡀࡑࢀࡒࢀ 4 ౛ࠊ࣓ࢳ࣐ࣝࣟࣥ㓟⾑⑕ࠊ୰㙐࢔ࢩࣝCoA ⬺Ỉ⣲㓝⣲㸦MCAD㸧Ḟᦆ⑕࡞࡝ࡀ 2 ౛ࡎࡘⓎぢࡉࢀࡓࠋඛኳᛶ⑌ᝈ௨እ࡟ࡶࣅࢱ࣑ࣥ
12 ୙㊊࡟ࡼࡿ࡜ᛮࢃࢀࡿ୍㐣ᛶࡢ࣓ࢳ࣐ࣝࣟࣥ㓟⾑⑕ 12 ౛ࠊࣅ࢜ࢳࣥḞஈ 1 ౛࡞࡝ࡶデ᩿ࡋ࠼ࡓࠋࡉࡽ࡟⾑Ύ࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒ࡛㍍ᗘࡢ␗ᖖࡀ⥆ࡃ⑕౛࡟ᑐࡋ࡚ࡣࠊ㑇ఏᏊゎᯒࡸ㓝⣲άᛶ ᐃࢆ⾜࠸ࠊィ 7 ౛ࡀ VLCAD Ḟᦆ⑕ࡸ MCAD Ḟᦆ⑕ࡢಖᅉ⪅࡜デ᩿ࡉࢀࡓࠋ
ࡇࡢࡼ࠺࡟ NBS ࠿ࡽデ᩿☜ᐃࡲ࡛ࡢࢩࢫࢸ࣒ࡀ☜❧ࡋ࡚࠸ࢀࡤࠊ
⢭ᐦ᳨ᰝࡢᚲせ࡞⑕౛࡟⣲᪩ࡃᑐᛂ࡛ࡁࡿࡔࡅ࡛࡞ࡃࠊ⑕౛ࡈ࡜࡟ࢹ࣮ࢱࢆヲ⣽࡟ゎᯒ࡛ࡁࠊ⢭ᐦ᳨ᰝ⋡ࢆ୍ᐃ࡟ಖࡕ࡞ࡀࡽぢ㏨ࡋ౛ࢆῶࡽࡍࡓࡵࡢࡼࡾ㐺ษ࡞ᣦᶆࡢ᳨ウ࡟ࡶᙺ❧ࡘࠋデ᩿⤒㦂ࢆά࠿ࡋࠊ஧
ḟ᳨ᰝ᪋タࢆᣢࡓ࡞࠸⮬἞య࡛ࡶࡼࡾ㎿㏿࡞デ᩿ࡀ࡛ࡁࡿࡼ࠺ࠊNPO ἲேࢱࣥࢹ࣒࣐ࢫᬑཬ༠఍ࢆタ❧ࡋデ᩿ᨭ᥼ࡢ㐃ᦠࢆᅗࡗ࡚࠾ࡾࠊࡇࢀࡽࢆྵࡵࡓᑐᛂࡢ⌧≧ࢆ࠾ヰࡋࡍࡿࠋ

́́

S1-3
ṇᖖ᳨య࡜ᝈ⪅ࢹ࣮ࢱ᝟ሗ཰㞟࡟ࡼࡿࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢ⢭ᗘ⟶⌮ⰼ஭₶ᖌ 1, ⚟ኈ ຾ 2, ▼ẟಙஅ 3, ⏣ᓮ㝯஧ 41
ᮐᖠᕷ⾨⏕◊✲ᡤ, 2 ᮐᖠ࢖࣒ࣀࢲ࢖࢔ࢢࣀࢫࢸ࢕ࢵࢡࣛ࣎ࣛࢺ࣮ࣜ, 3(බ㈈)ᮾி㒔ண㜵་Ꮫ༠఍, 4(୍㈈)໬Ꮫཬ⾑Ύ⒪ἲ◊✲ᡤ

Quality control utilizing screening data from the normal babies and the patients innewborn screening using tandem mass spectrometry
Junji Hanai1, Masaru Fukushi2, Nobuyuki Ishige3, Ryuji Tasaki4
1
Sapporo City Institute of Public Health, 2Sapporo Immuno diagnostic laboratory, 3Tokyo HealthService Association, 4The Chemo Sero-Therapeutic Research Institute࠙┠ⓗࠚࢱࣥࢹ࣒㉁㔞ศᯒィࢆ⏝࠸ࡿ᪂⏕ඣ௦ㅰ␗ᖖ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ(௨ୗࠊࢱࣥࢹ࣒࣭
࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ㸸TMS)ࡣ඲ᅜࡢ⮬἞య࡛ᐇ᪋ࡉࢀ࡚࠾ࡾࠊ᳨ᰝ᪋タࡣ 38 ࠿ᡤ࡜࡞ࡗ࡚
࠸ࡿࠋTMS ࡣከᣦᶆ࡟ࡼࡿከ✀㢮ࡢ⑌ᝈࡢࢫࢡ࣮ࣜࢽࣥࢢ࡛࠶ࡿࡇ࡜࠿ࡽࠊྛ⑌ᝈ࡟ᛂࡌ
ࡓ㐺ษ࡞࢝ࢵࢺ࢜ࣇ್ࡢタᐃࡀᚲせ࡛࠶ࡾࠊ඲ᅜᆒ㉁࡞⢭ᗘࡢ㧗࠸ࢫࢡ࣮ࣜࢽࣥࢢࢆ┠ᣦࡍୖ࠿ࡽࡶࠊ᪋タ㛫ᕪࡢゎᾘࡣ㔜せ࡞ㄢ㢟࡛࠶ࡿࠋࡑࡇ࡛ࠊࢫࢡ࣮ࣜࢽࣥࢢ⢭ᗘࡢᨵၿ࡜᪋タ㛫ᕪࡢゎᾘࢆᅗࡿࡓࡵࠊTMS ࡢ⢭ᗘྥୖ࡟ᡂᯝࢆୖࡆ࡚࠸ࡿ࢔࣓ࣜ࢝ࠕThe Region 4 Stork
collaborative projectࠖ(௨ୗࠊR4S)ࡢゎᯒࢩࢫࢸ࣒ࢆཧ⪃࡟ࠊྛᣦᶆࡢṇᖖ್ศᕸ࡜࢝ࢵࢺ࢜
ࣇ್ࡢㄪᰝ⤖ᯝ࡟ຍ࠼࡚ࠊ
ࢫࢡ࣮ࣜࢽࣥࢢⓎぢ౛࠾ࡼࡧഇ㝧ᛶ౛ࡢ᳨ᰝࢹ࣮ࢱࢆ฼⏝ࡋࡓ᪥ᮏ∧ R4S ࢆ᝿ᐃࡋࡓ TMS Web ゎᯒࢩࢫࢸ࣒ࡢᵓ⠏ࢆ᳨ウࡋࡓࠋ࠙᪉ἲࠚᖹᡂ 26 ᖺ 9 ᭶࠿ࡽ 12 ࠿᭶ࠊ᪥ᮏ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢᏛ఍ᢏ⾡㒊఍ࡀసᡂࡋࡓෆ㒊⢭ᗘ⟶⌮ࢶ࣮ࣝࢆ⏝࠸࡚ࠊTMS ࢫࢡ࣮ࣜࢽࣥࢢ᪋タ࡟ṇᖖ್ศᕸㄪᰝࢆ⾜ࡗࡓࠋࡲࡓࠊཌ
ປ⛉◊◊✲⌜ࠕ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ⢭ᗘྥୖ࡟㛵ࡍࡿ◊✲ࠖ㸦◊✲௦⾲⪅㸸ᓥ᰿኱Ꮫ་
Ꮫ㒊ᑠඣ⛉ᩍᤵᒣཱྀΎḟ㸧ࡢ୍⎔࡜ࡋ࡚ TMS Ⓨぢᝈ⪅ㄪᰝࢆᐇ᪋ࡋࠊࢫࢡ࣮ࣜࢽࣥࢢ᫬ࡢ
TMS ࢹ࣮ࢱࢆ཰㞟ࡋࡓࠋ
࠙⤖ᯝࠚR4S ࡢ Analyte Comparison ゎᯒࢆཧ⪃࡟ EXCEL ࡛సᡂࡋࡓෆ㒊⢭ᗘ⟶⌮ࢶ࣮ࣝ࡟ࡼࡾྛ᪋タࡢṇᖖ್ศᕸࠊ࢝ࢵࢺ࢜ࣇ್ࠊᝈ⪅ࢹ࣮ࢱ࡞࡝ࢆ⟽ࡦࡆᅗ࡛⾲♧࡛ࡁࡿࡼ࠺ࡋ
ࡓࠋࡇࡢゎᯒࢶ࣮ࣝࢆⓎᒎࡉࡏࠊࢡࣛ࢘ࢻࢧ࣮ࣂ࣮ୖ࡟ TMS ᑓ⏝ࡢ Web ゎᯒࢩࢫࢸ࣒ࢆᵓ
⠏ࡍࡿࡇ࡜࡟ࡼࡾࠊྛ᳨ᰝ᪋タ࡛ࡣᐃᮇⓗ࡟ࡲࡓࡣ㝶᫬ࠊṇᖖ್ศᕸ㞟ィ⤖ᯝࡸᝈ⪅ࢹ࣮ࢱࢆ᭦᪂ࡋࠊᚲせ࡞᫬࡟ṇᖖ್ศᕸࡢ᪋タ㛫ᕪࡸ࢝ࢵࢺ࢜ࣇ್ࡢጇᙜᛶࢆ᳨ド࡛ࡁࡿࠋ࠙⪃ᐹࠚᡃࡀᅜࡢ TMS ࡣᖺ㛫᳨యᩘࡀ 2 ୓௳࡟‶ࡓ࡞࠸᪋タࡀ⣙༙ᩘ࠶ࡾࠊ඲ᅜᆒ㉁࡞ࢫ
ࢡ࣮ࣜࢽࣥࢢ⢭ᗘࡢ☜ಖࡀ㔜せ࡞ㄢ㢟࡛࠶ࡿࡀࠊWeb ゎᯒࢩࢫࢸ࣒ࢆ⏝࠸ࡿࡇ࡜࡛ࠊ඲ᅜ
ࡢ᳨ᰝ᪋タࡀࠊᚲせ࡞᫬࡟࠸ࡘ࡛ࡶࠊ
᳨ᰝࢹ࣮ࢱࡢ᪋タ㛫ᕪࡸ࢝ࢵࢺ࢜ࣇ್ࡢጇᙜᛶࢆ᳨ドࠊゎᯒ࡛ࡁࡿࡇ࡜࠿ࡽࠊTMS ࡟࠾ࡅࡿ᳨ᰝ⢭ᗘࡢࡉࡽ࡞ࡿྥୖ࡟㈉⊩ࡍࡿࡇ࡜ࡀᮇᚅࡉࢀࡿࠋ

́́

S1-4
LC-MS/MS ࡟ࡼࡿ஧ḟ᳨ᰝἲࡢ㛤Ⓨ㔜ᯇ㝧௓ 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 31⚟஭኱Ꮫ་Ꮫ㒊೺ᗣ⛉Ꮫ, 2 ⚟஭኱Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫ
ࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ

Development of second-tier tests using LC-MS/MS for newborn screening
Yosuke Shigematsu1, Ikue Hata2, Hideki Nakajima3
1
Department of Health Science, University of Fukui
2
Department of Pediatrics, University of Fukui
3
Mass screening laboratory, National Research Institute for Child Health and Development࠙┠ⓗࠚ ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢࡢ࢔ࢩࣝ࢝ࣝࢽࢳ࣭ࣥ࢔࣑ࣀ㓟 flow-injection
ESI-MS/MS ศᯒ࡛ࡣࠊ␗ᛶయࡢศูᐃ㔞ࡀᅔ㞴࡛࠶ࡾࠊࢫࢡ࣮ࣜࢽࣥࢢᣦᶆ≀㉁ࡢデ᩿≉␗ᛶࡀప࠸ࡓࡵഇ㝧ᛶࡀከࡃⓎ⏕ࡍࡿࠋ୍᪉ࠊℐ⣬⾑୰࡟ࡣ㏻ᖖࡢᣦᶆ≀㉁௨እ࡟デ᩿≉␗ⓗ࡞௦ㅰ≀ࡀྵࡲࢀ࡚࠸ࡿࡢ࡛ࠊࡑࡢᐃ㔞ࢆ┠ⓗ࡜ࡋࡓ LC-MS/MS ἲࢆ㛤Ⓨࡋࡓࠋ
࠙᪉ἲࠚAB Sciex ♫〇 API4000 MS/MS system ࡟ᓥὠ〇సᡤ〇 LC system ࢆ᥋⥆ࡋ࡚ LC-MS/MSศᯒࢆ⾜ࡗࡓࠋLC ࣒࢝ࣛࡣ Imtakt ♫〇࣐ࣝࢳ࣮ࣔࢻࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮࣒࢝ࣛ Scherzo
SS-C18 (3.0㹶150 mm)ࢆ౑⏝ࡋࡓࠋ࠙⤖ᯝࠚ ࢔࣑ࣀ㓟࡜࢔ࢩࣝ࢝ࣝࢽࢳࣥࡣࢫࢡ࣮ࣜࢽࣥࢢ⏝ࡢᢳฟᾮࢆ஝ᾲࡋ 2%ࢠ㓟࡟෌⁐ゎࡋ࡚ศᯒྍ⬟࡛࠶ࡾࠊ࢔ࢩࣝࢢࣜࢩࣥࡣᏳᐃྠ఩యᶆ㆑యࢆู㏵ຍ࠼ࡿࡇ࡜࡛ࠊྠ᫬࡟
ศᯒྍ⬟࡛࠶ࡗࡓࡀࠊ㧗ឤᗘ࡛▷᫬㛫࡟ศᯒࡍࡿ࡟ࡣࠊᑐ㇟⑌ᝈࡈ࡜ࡢศᯒ࣓ࢯࢵࢻࢆ౑
⏝ࡍࡿᚲせࡀ࠶ࡗࡓࠋ᭷ᶵ㓟௦ㅰ␗ᖖ⑕࡛デ᩿࡟฼⏝ࡉࢀࡿ᭷ᶵ㓟࡜ࡋ࡚ࠊ࣓ࢳ࣐ࣝࣟࣥ
㓟ࠊ3-ࣄࢻࣟ࢟ࢩࣉࣟࣆ࢜ࣥ㓟ࠊࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩ-3࣓ࢳࣝࢢࣝࢱࣝ㓟ࠊ3-ࣄࢻࣟ࢟ࢩ࢖ࢯྜྷⲡ㓟ࡀ stable-isotope dilution ἲ࡛ℐ⣬⾑ 1 ࣃࣥࢳࢆ⏝࠸࡚ᐃ㔞ฟ᮶ࡓࡀࠊ⁐ゎᾮࡸ⛣ື┦࡟ᕤኵࡀᚲせ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚ ཝ᱁࡞ẕஙᰤ㣴୺⩏࡟ࡼࡾ㔜ᗘࡢ㣚㣹≧ែ࡟㝗ࡗ࡚࠸ࡿ᪂⏕ඣ࡛ࡣ␗໬ஹ㐍࡟ࡼࡾᑐ㇟⑌ᝈࡢഇ㝧ᛶ࡜࡞ࡿࡇ࡜ࡀከࠎ࠶ࡾࠊ᪩ᮇࡢ᳨ᰝ࡛㐺ษ࡟≧ែホ౯⾜࠺ࡇ࡜ࡣ㔜せ࡛࠶ࡿࠋ࣓࣮ࣉࣝࢩࣟࢵࣉᒀ⑕ࡣ allo-isoleucine ࡢቑຍ࡛໬Ꮫデ᩿ࡀྍ⬟࡛࠶ࡾࠊ㣚㣹࡟ࡼࡿ␗໬ஹ㐍≧ែ࡜༊ูฟ᮶ࡿࠋ࣓ࢳ࣐ࣝࣟࣥ㓟⾑⑕࣭ࣉࣟࣆ࢜ࣥ㓟⾑⑕ࡢഇ㝧ᛶࡶ㉳ࡇࡾ࠺ࡿࡀࠊࡇࢀࡶ࣓ࢳ࣐ࣝࣟࣥ㓟⃰ᗘᐃ㔞࡛໬Ꮫデ᩿ࡀྍ⬟࡛࠶ࡿࠋ୰㛗㙐࢔ࢩࣝ࢝ࣝࢽࢳ
ࣥࡢቑຍ࡟ࡼࡿ⬡⫫㓟㓟໬␗ᖖ⑕ࡢഇ㝧ᛶ࡟ࡘ࠸࡚ࡣࠊ௒ᅇࡢ͆஧ḟ᳨ᰝ͇࡛㚷ูࡍࡿࡢࡣ㞴ࡋ࠸ࡢ࡛ࠊูࡢ࢔ࣝࢦࣜࢬ࣒࡛ᑐᛂࡍࡿࡇ࡜࡟࡞ࢁ࠺ࠋྠ᫬࡟ቑຍࡍࡿ C5-DC ࢝ࣝࢽࢳࣥ࡟ᑐࡋ࡚ࡣ 3-ࣄࢻࣟ࢟ࢩࢢࣝࢱࣝ㓟࡞࡝ࡢ᭷ᶵ㓟ᐃ㔞ࡀ໬Ꮫデ᩿࡟᭷⏝࡛࠶ࡿࠋࡇࡢ
ࡼ࠺࡞ LC-MS/MS ἲࡀࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ᪋タ࡟ࢫ࣒࣮ࢬ࡟ᑟධฟ᮶ࡿయไࢆࡘࡃࡿࡇ࡜
ࡀồࡵࡽࢀ࡚࠸ࡿࠋ

́́

S2-1
࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟࠾ࡅࡿ㧗ឤᗘ࡜ᡭἲ᭱㐺໬

ᐃࡢࡓࡵࡢ஧ẁ㝵࣐ࢺࣜࢵࢡࢫ౪⤥ἲ᪂㛫⚽୍ 11኱㜰኱Ꮫ኱Ꮫ㝔ᕤᏛ◊✲⛉Methodology of two-step matrix application procedure for imaging mass
spectrometry
Shuichi Shimma1
1
Osaka University Graduate School of Engineering
IMS 䛿䚸㏆ᖺ䚸๰⸆◊✲䛻䛚䛡䜛⏕యෆ⸆≀ືែ䛾ホ౯䜔ẘᛶホ౯䛾䛯䜑䛾⸆≀௦ㅰ≀䜲䝯䞊䝆䞁䜾䛺䛹䛻ᑟධ䛥䜜䛴䛴䛒䜛㐣Ώᮇ䛷䛒䜛䛸䛔䛘䜛䚹௒ᚋ䠈་⸆ရ䛾 IMS 䛜┿䛻౑䛘䜛ᢏ⾡䛸䛺䜛䛯䜑䛻䛿ከ᪋タ䛷䛾ホ౯䛜ྍ⬟䛺ᶆ‽ᡭ㡰䜢䛿䛨䜑䛸䛩䜛ホ౯ᇶ‽䛜ᚲせ䛷䛒䜛䛸⪃䛘䛶䛔䜛䚹䛧䛛䛧䛺䛜䜙䚸⌧᫬Ⅼ䛷䛾་⸆ရ䛻䛚䛡䜛 IMS 䛷䛿䛂┠ⓗ䛾⸆≀⏤᮶䝅䜾䝘䝹䛜ぢ䛘䛺䛔䛃䚸䛂་⸆ရ䛾⏕యෆศᕸ䜢ぢ䜛䛻䛿⸆ຠホ౯䛷䛾ᢞ୚㔞䛷䛿ឤᗘ୙༑ศ䛃䛸䛔䛳䛯ึṌⓗ䛷䛒䜛䛜ゎỴ䛜㠀ᖖ䛻㞴䛧䛔ၥ㢟䛻┤㠃䛩䜛䛣䛸䛜䛒䜛䚹䛧䛯䛜䛳䛶䚸ỗ⏝ⓗᢏ⾡䛸䛧䛶ᡂ⇍䛩䜛䛻䛿䜎䛰䜎䛰ᵝ䚻䛺㞀ቨ䜢஌䜚㉺䛘䜛ᚲせ䛜䛒䜛䚹㞀ቨ䛾୍䛴䛾せᅉ䛸䛧䛶䚸⸆≀䜢ྍど໬䛩䜛䛯䜑䛻⾜䛖ヨᩱ๓ฎ⌮ἲ䛾୙༑ศ䛥䚸୙㐺ษ䛥䛜ᣲ䛢䜙䜜䜛䚹་⸆ရ䛾 IMS 䛻䛚䛔䛶䛿䚸㐣ཤ䛻ሗ࿌䛥䜜䛶䛔䜛䝸䞁⬡㉁ྍど໬䛾䛯䜑䛾๓ฎ⌮ἲ䛸䛿඲䛟ู䛾᮲௳タᐃ䛜ᚲせ䛷䛒䜛䛜䚸䛹䛾䜘䛖䛺ᡓ␎䛷๓ฎ⌮ἲ䜢㛤Ⓨ䛩䜛䛣䛸䛜ᮃ䜎䛧䛔䛛᫂☜䛷䛿䛺䛔䚹
IMS ๓ฎ⌮᫬䛻䛚䛡䜛䝟䝷䝯䞊䝍䞊䛿䝬䝖䝸䝑䜽䝇౪⤥ἲ䛻㝈䛳䛶䜒ᩘከ䛟Ꮡᅾ䛩䜛䚹᝿ᐃ䛥䜜䜛䝟䝷䝯䞊䝍䞊䛜᭱⤊⤖ᯝ䛻䛹䛾⛬ᗘ䛾ᙳ㡪䜢୚䛘䜛䛛䚸䛸䛔䛖᝟ሗ䜢ಖ᭷䛧䛶䛔䜛䛛ಖ᭷䛧䛶䛔䛺䛔䛛䛿䝯䝋䝑䝗㛤Ⓨ䜢⾜䛖ୖ䛷㠀ᖖ䛻㔜せ䛷䛒䜛䛸⪃䛘䛶䛔䜛䚹ᮏⓎ⾲䛷䛿䚸䜲䝯䞊䝆䞁䜾㉁㔞ศᯒ䛾㧗ឤᗘᐃ⏝䛻㛤Ⓨ䛥䜜䛯஧ẁ㝵䝬䝖䝸䝑䜽䝇౪⤥ᡭἲ䛾ᴫせ䛻䛴䛔䛶ㄝ᫂䛧䚸ᮏᡭἲ䜢ᐇ᪋䛩䜛䛻䛒䛯䜚᝿ᐃ䛥䜜䜛ᵝ䚻䛺䝟䝷䝯䞊䝍䞊䛻䛴䛔䛶ᩚ⌮䛩䜛䚹䜎䛯䚸ᥦ♧䛧䛯䝟䝷䝯䞊䝍䞊䛜ᐇ㝿䛻⤌⧊ୖ䛛䜙ᚓ䜙䜜䜛䝬䝇䝇䝨䜽䝖䝹䛻䚸䛹䛾䜘䛖䛺ᙳ㡪䜢୚䛘䛶䛔䜛䛛䛻䛴䛔䛶౛䜢䛒䛢䛶⪃ᐹ䛧
䛯䛔䚹

́́

S2-2
࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟ࡼࡿ᳜≀ྵ᭷ᡂศࡢゎᯒᖹ ಟ 1, ➃ᓮ㔛ᕹ 1, ∦㔝 ⫕ 1, 㔠Ꮚ኱స 2, ୰す㇏ᩥ 31⚟஭┴❧኱Ꮫ⏕≀㈨※Ꮫ㒊ࠊ2 ஑ᕞᕤᴗ኱Ꮫࠊ3 ኱㜰་⛉኱Ꮫ

Nano-PALDI MS for Plant hormone
Shu TAIRA1, Riho HASHIZAKI1, Hajime KATANO1, Daisaku KANEKO2, Toyofumi NAKANISHI2
1
Fukui Prefectural University Department of Bioscience,
2
Kyushu Institute of Technology,
3
Osaka Medical College, Faculty of Medicine࠙┠ⓗࠚ᭱㏆ࡣࠊ࢖࣓࣮ࢪࣥࢢ MS ࡶ་⸆௨እࡢศ㔝ࠊ㎰ࠊᕤศ㔝࡟ࡶ✚ᴟⓗ࡟ᛂ⏝ࡉࢀ࡚࠸ࡿ࡜
ᛮ࠸ࡲࡍࠋ₇⪅ࡣࠊ㎰Ꮫ㒊ࡢ❧ሙ࠿ࡽ㣗ရ㸦᳜≀㸧࡟↔Ⅼࢆᙜ࡚࡚≀㉁ࡢᒁᅾࢆ᫂ࡽ࠿࡟
ࡋ࡚࠸ࡲࡍࠋ௒ᅇࠊ
1. ࢺ࢘࢞ࣛࢩࡢ࢝ࣉࢧ࢖ࢩࣥࡢᒁᅾ㸦ᅗ㸯㸧1
2. ࢟ࣗ࢘ࣜࡢࣅࢱ࣑ࣥ C ࡜౑⏝ࡍࡿ㎰⸆ࡢᒁᅾ 2
3. ⏕⸆㸦኱㯤㸧࡟ྵࡲࢀࡿࢭࣥࣀࢩࢻ㢮ࡢᒁᅾ࡞࡝࡟ࡘ࠸࡚ࡈ⤂௓ࡋࠊⓙᵝ࡜㆟ㄽࡋࠊⓙᵝࡢ◊✲ࡢ୍ຓ࡜࡞ࢀࢀࡤ࡜ᛮࡗ࡚࠾ࡾࡲࡍࠋ
࠙᪉ἲࠚྛࢧࣥࣉࣝࡢ෾⤖ษ∦ࢆసᡂᚋࠊ࢖࢜ࣥ໬ᨭ᥼๣ࢆሬᕸࡋࠊ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆ⾜ࡗࡓࠋ⏝࠸ࡓ࢖࢜ࣥ໬ᨭ᥼๣ࡣࠊCHCAࠊDHBࠊࢼࣀᚤ⢏Ꮚ࡛࠶ࡿࠋ࠙⤖ᯝࠚ
1. ࢝ࣉࢧ࢖ࢩࣥࡣ✀Ꮚ࡟ከ࠸࡜ࡉࢀࡿࡀᐇ㝿ࡣ⫾ᗙ࡜ࡼࡤࢀࡿⰺࡢ⾲㠃࡟ᒁᅾࡋ࡚࠸ࡿࠋ
2. ࣅࢱ࣑ࣥ C ࡣ࢟ࣗ࢘ࣜࡢእ࡜ⰺ࡟ᒁᅾࡋ࡚࠾ࡾࠊ㎰⸆ࡣ᫬஦้ࠎෆ㒊࡟ᾐ㏱ࡋ࡚࠸ࡓࠋ
3. ࢭࣥࣀࢩࢻ㢮ࡣ㧊㒊࡟ᒁᅾࡋ࡚࠸ࡓࠋࡇࢀࡣྂ᮶ࡼࡾࠊ㧊㒊ࡢࡳࢆ౑⏝ࡍࡿ࡜࠸࠺ಟ἞
ຍᕤἲ࡟⛉Ꮫⓗ᰿ᣐࢆ୚࠼ࡓࠋ࠙⪃ᐹࠚ᳜≀ࡢᶵ⬟ᛶᡂศ࡞࡝ࢆྍど໬ࡍࡿࡇ࡜ࡣࠊ⏕⌮Ꮫⓗ࡟ព⩏ࡢ࠶ࡿࡇ࡜࡛ࡶ࠶ࡿࡀࠊ㣗ရ࡜ࡋ࡚ぢࡓሙྜࠊရ㉁ࢆド᫂ࡍࡿࢹ࣮ࢱ࡜ࡋ࡚⌮ゎࡋࡸࡍ࠸ࠋࡲࡓࠊṧ␃㎰⸆ࡢ༴㝤ᛶࢆどぬⓗ࡟♧ࡍ஦ࡶ㣗ရ⾨⏕Ꮫⓗ࡟౯್ࡢ࠶ࡿࡇ࡜࡛࠶ࡿࠋ
࠙ㅰ㎡ࠚ
ࡇࡢᡂᯝࡣ NEDO ⱝᡭࢢࣛࣥࢺ㸦Project ID: 11B16002d㸧ࡢᨭ᥼࡟ࡼࡗ࡚ᚓࡽࢀࡲࡋࡓࠋ

࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------1. S. Taira, et al. ” Mass spectrometry imaging of the capsaicin localization in the capsicum fruits” International
Journal of Biotechnology for Wellness Industries 1, 61-65 (2012)
2. S. Taira, et al. ‘Mass Spectrometry Imaging Analysis of Location of Procymidone in Cucumber Sample’ Journal of
Agricultural and Food Chemistry 63, 6109-6112 (2015)

́́

S2-3
⤫ྜኻㄪ⑕἞⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ࡟ࡼࡿ⚄⤒ẘᛶⓎ⌧ᶵᵓࡢゎᯒ㸸㉁㔞࢖࣓࣮ࢪࣥࢢᡭἲ࡟ࡼࡿ⬻ෆࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢྍど໬ྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ㸱, ஬༑ᔒ୍㞝㸲
1㏆␥኱Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 ኱㜰་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 ኱㜰኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ,4୍⯡♫ᅋἲே་⸆ศᯒ༠఍

Brain distribution studies of the neurotoxic pyridinium metabolite (HPP+) of
haloperidol with MALDI mass spectrometry imaging
Motonari Yoshida1, Toyofumi Nakanishi2, Kana Sugimoto3 , Kazuo Igarashi4
Department of Legal Medicine, Faculty of Medicine, Kinki University, 2Department of Clinical and3
Laboratory Medicine, Osaka Medical College, Department of Legal Medicine, Osaka University
4
Graduate School of Medicine, Department of Research Development, Association of Medicinal
Analysis1⸆≀ࡢయෆศᕸ◊✲࡟࠾࠸࡚ࠊᚑ᮶ࡢᨺᑕᛶᶆ㆑యࢆ⏝࠸ࡿ࣮࢜ࢺࣛࢪ࢜ࢢࣛࣇ࢕࣮࡜
ࡣ␗࡞ࡗ࡚ࠊ㉁㔞ศᯒ࡟ࡼࡾ⤌⧊ษ∦ୖࡢ⸆≀ศᕸ≧ែࢆ

ᐃ࡛ࡁࡿ㉁㔞࢖࣓࣮ࢪࣥࢢἲ

ࡢ฼⏝ࡋࡓሗ࿌ࡀ㏆ᖺᑡࡋࡎࡘቑຍࡋ࡚࠸ࡿࠋࡇࡢ᪉ἲࡣࠊᨺᑕᛶᶆ㆑యࢆᚲせ࡜ࡋ࡞࠸ࡇ࡜ࠊ㉁㔞ศᯒࡢ≉ᛶࢆ฼⏝ࡋࠊ⸆≀ࡸࡑࡢ௦ㅰ≀ࡢศᕸ≧ἣࢆ㑅ᢥⓗ࡟ྍど໬࡛ࡁࡿ฼
Ⅼࢆ᭷ࡋ࡚࠸ࡿࠋ௒ᚋࠊ⸆≀ࡢయෆศᕸ◊✲ศ㔝࡬ࡢᛂ⏝ࡀࡲࡍࡲࡍᮇᚅࡉࢀࡿࠋ
⤫ྜኻㄪ⑕἞⒪⸆࡛࠶ࡿࣁࣟ࣌ࣜࢻ࣮ࣝ㸦HP㸧ࡣࠊ➨୍ୡ௦ࡢᢠ⢭⚄⑓⸆࡛࠶ࡿࡀࠊ⤫ྜኻㄪ⑕ࡢ୰࡛ࡶᗁ⫈ࡸዶ᝿࡞࡝ࡢ⑕≧ᨵၿࡢࡓࡵ࡟௒࡞࠾ᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋ୍᪉ࠊ
ࡇࡢ἞⒪⸆ࡢ㛗ᮇ౑⏝࡟ࡼࡾࠊ๪స⏝࡜ࡋ࡚⸆๣ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒ࡀㄏᑟࡉࢀࡿࡇ࡜ࡶ
▱ࡽࢀ࡚࠸ࡿࠋࡇࡢ HP ࡟ࡼࡿ⸆๣ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒Ⓨ⌧ࡢせᅉ࡜ࡋ࡚ࠊHP ࡟ࡼࡿ⚄⤒ẘᛶ௦ㅰ≀ࣆࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ㛵୚ࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡇࡢ௦ㅰ≀ HPP+ࡣ໬Ꮫᵓ㐀ⓗ࡟ࠊ⚄⤒ẘᛶㄏⓎ≀㉁ MPTP ࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ MPP+࡟㢮ఝࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊ㢮ఝࡋࡓ⬻⚄⤒ẘᛶࢆ᭷ࡍࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋḟ࡟ HP ᢞ୚ᚋࡢయෆືែ࡜ࡋ࡚ࠊࡲࡎ⫢⮚ CYP3A ࡟ࡼࠊࡾࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡀ⏕ᡂࡉࢀࠊ⬻ෆ࡟㍺㏦ࡉࢀࡿࡇ࡜ࡀࠊIgarashi ➼㸦1998㸧
Crowley ➼㸦2013㸧࡟ࡼࡾሗ࿌ࡉࢀ࡚࠸ࡿࠋࡲࡓ Igarashi ➼㸦2002㸧ࡣ HP ᢞ୚ື≀ࡢ⬻⤌⧊࡟࠾ࡅࡿࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+⃰ᗘࡀᢞ୚ᅇᩘ࡟౫Ꮡࡋ࡚ቑຍࡍࡿഴྥ࡟࠶ࡿࡇ࡜ࡶ
ሗ࿌ࡋ࡚࠸ࡿࠋ
ࡇࢀࡽࡢሗ࿌ࡼࡾࠊ⤫ྜኻㄪ⑕἞⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ HP ᢞ୚࡟⏤᮶ࡍࡿ⸆๣ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒Ⓨ⌧ᶵᵓࢆゎ᫂ࡍࡿࡓࡵ࡟ࠊ㉁㔞࢖࣓࣮ࢪࣥࢢᡭἲࢆ฼⏝ࡋࡓ⚄⤒ẘᛶ௦ㅰ≀ࣆࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ⬻ෆศᕸ㒊఩࡟㛵ࡍࡿྍど໬ࢆ᳨ウࡋࡓࠋ

́́

S2-4
࢔ࣝࢶࣁ࢖࣐࣮⑓⬻◊✲ࡢࡓࡵࡢ㉁㔞࢖࣓࣮ࢪࣥࢢゎᯒụᕝ㞞ဢ 1, ᐑᆏ▱ᏹ 1, ゅ⏣ఙே 1, ᒾᓮ஢ᩍ 2, 㡞⃝ ᓫ 2, 㝮ⶶ኱ᖾ 3, ᮧᒣ⦾㞝 3,஭ཎᗣኵ 41ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊, 2 ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫओ, 3 ᮾி㒔೺ᗣ㛗ᑑ་⒪ࢭࣥࢱ࣮◊✲ᡤ㧗㱋⪅ࣈࣞ࢖ࣥࣂࣥࢡ, 4 ྠᚿ♫኱Ꮫ⬻⛉Ꮫ◊✲⛉Imaging Mass Spectroscopy for the study of Alzheimer’s disease (AD) Brain
Masaya Ikegawa1, Tomohiro Miyasaka1, Nobuto Kakuda1, Noriyuki Iwasaki2, Takashi Nirasawa2,
Hiroyuki Sumikura3, Shigeo Murayama3, Yasuo Ihara4
1
Doshisha University Faculty of Life and Medical Sciences
2
Bruker Daltonics K.K.
3
The Brain Bank for Aging Research, Tokyo Metropolitan Geriatric Hospital and Institute ofGerontology
4
Doshisha University, Graduate School of Brain Science࢔ࣝࢶࣁ࢖࣐࣮⑓ࡢᝈ⪅⬻࡛ࡣࠊ⪁ேᩬ࡜࿧ࡤࢀࡿ࢔࣑ࣟ࢖ࢻE (AE)ࢆ୺ᡂศ࡜ࡍࡿ␗ᖖ
ᵓ㐀≀ࡢỿ╔ࡀ⑓ែࡢ୰ᚰⓗᙺ๭ࢆᯝࡓࡍ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋࡇࡢᵓ㐀≀ࡢᵓᡂᡂศࡣࠊ
ࡇࢀࡲ࡛㉁㔞ᩘ 4000 ࠿ࡽ 5000 ࡢ AE࣌ࣉࢳࢻ⩌࡛ࠊ࢔࣑ࣟ࢖ࢻ๓㥑యࢱࣥࣃࢡ㉁ (amyloid
precursor protein: APP) ࡟⏤᮶ࡍࡿࡇ࡜ࡀ᫂ࡽ࠿࡜ࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊㄆ▱⑕⬻࡟࠾࠸࡚⚄⤒ཎ⥺⥔ኚ໬࡜ࡋ࡚▱ࡽࢀࡿ⣽⬊ෆจ㞟యࡢᵓᡂᡂศ࡛࠶ࡿࢱ࢘ࢱࣥࣃࢡ㉁ࡣࠊࡑࡢจ㞟㐣⛬࡛ࢩࢼࣉࢫᾘኻࠊ⚄⤒⣽⬊Ṛ࡟ࡼࡗ࡚⬻ᶵ⬟పୗࢆᘬࡁ㉳ࡇࡍ࡜ࡉࢀࠊ࢔ࣝࢶࣁ࢖࣐
࣮⑓⬻ࡢ◊✲࡟⬻ࢱࣥࣃࢡ㉁⪁໬ࡢほⅬ࠿ࡽ࠾ࡇ࡞࠺ࣉࣟࢸ࣮࣒࢜ゎᯒࡢᯝࡓࡍᙺ๭ࡣ኱
ࡁ࠸࡜ᮇᚅࡉࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊAD ࣐࢘ࢫࣔࢹࣝ࡜ࡋ࡚☜❧ࡉࢀ࡚࠸ࡿ APP23 ࢺࣛࣥࢫࢪ࢙ࢽࢵࢡ࣐࢘ࢫ⬻ࢆᑐ㇟࡜ࡋ࡚ MALDI-TOF MS ࡸ FT-MS ࢆ⏝࠸ࡓࣉࣟࢸ࣮࣒࢜ࣞ
࣋ࣝࡢ㉁㔞࢖࣓࣮ࢪࣥࢢゎᯒࢆヨࡳࡓࠋࡇࡢࣔࢹࣝࡣࠊAPP 㑇ఏᏊ࡟ࢫ࢙࣮࢘ࢹࣥᆺኚ␗
ࢆධࢀࡓࢺࣛࣥࢫࢪ࢙ࢽࢵࢡ࣐࢘ࢫ࡛ࠊ㢧ⴭ࡞ࣉ࣮ࣛࢡ⵳✚ࡀච␿⤌⧊Ꮫⓗ᪉ἲ࡟ࡼࡗ࡚
☜ㄆࡉࢀ࡚࠸ࡿࠋࡑࡢ⤖ᯝࠊ㐌㱋ࢆྜࢃࡏࡓࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫ࡟ࡣㄆࡵࡽࢀ࡞࠸ AE࣌ࣉࢳࢻ⩌ࡢ⬻ෆศᕸࡀ࠶ࡁࡽ࠿࡟࡞ࡗࡓࠋࡉࡽ࡟ࠊࣄࢺ AD ⬻ࢆᑐ㇟࡜ࡋࡓ⮫ᗋ⑓⌮Ꮫⓗゎᯒ࡬ࡢᛂ⏝࡟ࡘ࠸࡚ࡶ㉁㔞࢖࣓࣮ࢪࣥࢢゎᯒࡢ⌧≧࡜ㄢ㢟࡟ࡘ࠸࡚ⱝᖸࡢ⪃ᐹࢆヨࡳࡓࠋ

́́

S3-1
ࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒ࡟ࡼࡿ࢖ࣥࢫࣜࣥ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡࡢ෌ᵓ⠏ᰆᮌඞஅ 1, ஂಖ⏣ᾈ⾜ 2, 3, 㯮⏣┿ஓ 1, 4
1ᮾி኱Ꮫ኱Ꮫ㝔⌮Ꮫ⣔◊✲⛉࣭⏕≀⛉Ꮫᑓᨷ, 2 ஑ᕞ኱Ꮫ࣭⏕య㜵ᚚ་Ꮫ◊✲ᡤ࣭ࢺࣛࣥࢫ
࣑࢜ࢡࢫ་Ꮫ◊✲ࢭࣥࢱ࣮࣭⤫ྜ࣑࢜ࢡࢫศ㔝, 3 JST ࡉࡁࡀࡅ, 4JST CREST

Reconstruction of insulin signal flow in global phosphorylation and metabolic
network
Katsuyuki Yugi1, Hiroyuki Kubota 2,3, Shinya Kuroda1,4
1

University of Tokyo, 2Kyushu University, 3JST PRESTO, 4JST CREST࠙┠ⓗࠚ࢖ࣥࢫࣜࣥస⏝ࡢศᏊࢿࢵࢺ࣮࣡ࢡࡣ」ᩘࡢ࣑࢜ࢡࢫ㝵ᒙ࡟ࡲࡓࡀࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࡀࠊࡑࡢ඲ㇺࡣᮍࡔ᫂ࡽ࠿࡟࡞ࡗ࡚࠸࡞࠸ࠋ
࠙᪉ἲࠚᡃࠎࡣࠊࣜࣥ㓟໬ࣉࣟࢸ࣮࣒࢜࡜࣓ࢱ࣮࣒࣎ࣟࡢ 2 ࡘࡢ࣑࢜ࢡࢫ㝵ᒙ࡟ࡲࡓࡀࡿࢿࢵࢺ
࣮࣡ࢡࢆ෌ᵓ⠏ࡍࡿ᪉ἲㄽࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࠖࢆ☜❧ࡋࠊ࢖ࣥࢫࣜࣥస⏝࡟ᛂ⏝ࡋࡓࠋᮏゎᯒࡢ᭱኱ࡢ≉Ⰽࡣࠊ่⃭࡟ᛂ⟅ࡋ࡚⃰ᗘࡀ᭷ព࡟ኚືࡋࡓ௦ㅰ≀ࢆ㉳Ⅼ࡟ࠊࡑࡢኚືࡢ᰿ᮏⓗཎᅉ࡛࠶ࡿ่⃭࡬࡜ࢩࢢࢼࣝࡢ㏻ࡾ㐨ࢆࡉ࠿ࡢࡰࡿࡇ࡜࡛ከ㝵ᒙ௦ㅰไᚚࢿ
ࢵࢺ࣮࣡ࢡࢆ෌ᵓ⠏ࡍࡿ࡜ࡇࢁ࡟࠶ࡿࠋ
࠙⤖ᯝࠚྠ୍᮲௳ୗ࡛ㄪ〇ࡋࡓࣛࢵࢺ⫢ࡀࢇ⏤᮶ Fao ⣽⬊࠿ࡽᚓࡽࢀࡓ࣑࢜ࢡࢫࢹ࣮ࢱ
࠿ࡽࠊ࢖ࣥࢫ่⃭ࣜࣥᚋ 60 ศ௨ෆ࡟ᛂ⟅ࡍࡿከ㝵ᒙ௦ㅰไᚚࢿ
ࢵࢺ࣮࣡ࢡࢆ෌ᵓ⠏ࡍࡿࡇ࡜࡟ᡂຌࡋࡓ
[1, ྑᅗ]ࠋ

ᅗ ࠕࢺ࣑ࣛࣥ࢜ࢡࢫゎᯒࠖ࡟ࡼࡾ෌ᵓ⠏ࡋࡓ࢖ࣥࢫࣜࣥ࡟ࡼࡿ
ከ㝵ᒙ௦ㅰไᚚࢿࢵࢺ࣮࣡ࢡ [1]ࠋ࠙⪃ᐹࠚ෌ᵓ⠏ࡉࢀࡓ࢖ࣥࢫࣜࣥస⏝ࡢࢿࢵࢺ࣮࣡ࢡࡣࠊಶูศᏊゎᯒࡢࣃࢵࢳ࣮࣡ࢡ࡜ࡋ࡚▱ࡽࢀ࡚࠸ࡓ⤒㊰௨እ࡟ࡶከᩘࡢ᪂つ⤒㊰ࢆྵࡳࠊ࢖ࣥࢫࣜࣥࢩࢢࢼࣝࡀᚑ᮶▱ࡽࢀ࡚࠸ࡿ
ࡼࡾࡶࡣࡿ࠿࡟ᗈ࠸⠊ᅖ࡟ఏ㐩ࡉࢀ࡚࠸ࡿࡇ࡜ࢆ♧၀ࡍࡿࠋ
Reference
1) Yugi et al. Cell Reports 8, 1171–1183 (2014).

́́

S3-2
⬡㉁ࢡ࢜ࣜࢸ࢕࠿ࡽゎࡁ᫂࠿ࡍ⑓ែ࣭ࣂ࢖࢜ࣟࢪ࣮◊✲᭷⏣ ㄔ 1,2
1⌮໬Ꮫ◊✲ᡤ⤫ྜ⏕࿨་⛉Ꮫ◊✲ࢭࣥࢱ࣮࣭࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒2ᶓ὾ᕷ❧኱Ꮫ኱Ꮫ㝔⏕࿨་⛉Ꮫ◊✲⛉

Quality of lipids in health and disease
Makoto Arita1, 2
1
Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences2
Graduate School of Medical Life Science, Yokohama City Universityᚑ᮶ࡢ⏕࿨⛉Ꮫ࡟࠾ࡅࡿ⬡㉁◊✲ࡣࠊ⬡㉁ࡢࠕ㔞ࠖࢆ㔜どࡋ࡚⾜ࢃࢀ࡚ࡁࡓࡀࠊ⬡㉁࡟
ࡣከࡃࡢ✀㢮ࠊࡍ࡞ࢃࡕࠕ㉁ࠖࡢ㐪࠸ࡀᏑᅾࡍࡿࠋ⏕యෆ࡟ࡣከᵝ࡞⬡⫫㓟ศᏊ✀ࡀᏑᅾ
ࡋࠊࡑࡢ㉁ࡢ㐪࠸ࡸ௦ㅰࣂࣛࣥࢫࡢኚ໬ࡀࠊᵝࠎ࡞⅖⑕࣭௦ㅰᛶ⑌ᝈ࡟㛵ࢃࡿࡇ࡜ࡀ♧၀ࡉࢀ࡚࠸ࡿࠋࡇࢀࡽ⬡㉁ศᏊࡢᵓ㐀ⓗ࡞≉㉁ࢆࠕ⬡㉁ࢡ࢜ࣜࢸ࢕ࠖ࡜ᤊ࠼ࠊ⬡㉁ࢡ࢜ࣜࢸ
࢕ࡢከᵝᛶࡀᯝࡓࡍ⏕≀Ꮫⓗព⩏࡟ࡘ࠸࡚⪃࠼ࡿᚲせࡀ࠶ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ⬡㉁ࢡ࢜ࣜ
ࢸ࢕ࢆ⥙⨶ⓗ࠿ࡘ᫂☜࡟༊ูࡍࡿゎᯒᢏ⾡ࡣᮍࡔⓎᒎ㏵ୖ࡟࠶ࡾࠊࡲࡓ⬡㉁ࢡ࢜ࣜࢸ࢕ࢆ
ไᚚ࣭㆑ูࡍࡿศᏊᶵᵓࡸࡑࡢ⏕≀Ꮫⓗព⩏࡟㛵ࡍࡿ⌮ゎࡣⴌⱆⓗ࡞ẁ㝵࡟࠶ࡿࠋ⬡㉁ࢡ࢜ࣜࢸ࢕ࡢኚ໬ࡀࡶࡓࡽࡍᵝࠎ࡞⾲⌧ᆺ࡟ࡘ࠸࡚ࠊࡑࡢ⌮ゎࢆ㐍ࡵࡿୖ࡛㔜せ࡞ࡶࡢࡢ୍ࡘࡀࠊ⬡㉁ศᏊࡢᵓ㐀ⓗ࡞≉㉁ࢆᗈ⠊ᅖ࠿ࡘ᫂☜࡟༊ู࡛ࡁࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒࡛࠶ࡿࠋᡃࠎࡣࡇࢀࡲ࡛࡟ࠊ⬡⫫㓟௦ㅰ≀ࢆໟᣓⓗ࡟ゎᯒࡍࡿࡓࡵࡢ࣓ࢱ࣮࣎ࣟ
࣒ゎᯒࢩࢫࢸ࣒ࢆ☜❧ࡋࠊ⅖⑕ࡢไᚚ࡟࠾࠸࡚⬡⫫㓟௦ㅰࡢ㉁ⓗኚ໬ࡀ㛵୚ࡍࡿྍ⬟ᛶࢆぢ࠸ࡔࡋ࡚ࡁࡓࠋࡉࡽ࡟ࠊ≉ᐃࡢ⬡㉁ศᏊ✀ࢆ㑅ᢥⓗ࡟ᐃࡍࡿᚑ᮶ᆺࡢࢱ࣮ࢤࢵࢺゎᯒ࡟ຍ࠼ࠊศᏊ✀ࢆ≉ᐃࡋ࡞࠸ࣀࣥࢱ࣮ࢤࢵࢺゎᯒࢆᐇ⌧ࡍࡿࡇ࡜࡛ࠊඛධほࡢ࡞࠸᥈⣴⠊ᅖࡢᣑ኱࠾ࡼࡧゎᯒࢹ࣮ࢱࡢ㉁ࡢྥୖࢆ┠ᣦࡋ࡚࠸ࡿࠋᡃࠎࡣࠊྛ✀⬡⫫㓟ࡢྜᡂ࣭௦ㅰ
㓝⣲ࡢ㑇ఏᏊᨵኚື≀ࠊ࠶ࡿ࠸ࡣ␗࡞ࡿ⬡⫫㓟ࢆྵࡴᰤ㣴せᅉ࡟ࡼࡗ࡚⬡⫫㓟௦ㅰࣂࣛࣥ
ࢫࡀኚ໬ࡋࡓ≧ἣࢆ㐀ࡾฟࡋࠊࡇࢀࡽࡢ࣓ࢱ࣮࣒࣎ࣟゎᯒࡸ㑇ఏᏊⓎ⌧ゎᯒ࡞࡝ࢆ⤌ࡳྜࢃࡏࡿࡇ࡜࡟ࡼࡾࠊᵝࠎ࡞⏕࿨⌧㇟࡟㛵ࢃࡿศᏊ࣓࢝ࢽࢬ࣒ࢆ⬡⫫㓟௦ㅰࡢ㉁ࡢ㐪࠸࡜࠸࠺ほⅬ࠿ࡽ᫂ࡽ࠿࡟ࡋࠊࡉࡽ࡟⬡㉁ࢡ࢜ࣜࢸ࢕ࡢ㐪࠸ࢆᶵ⬟ⓗ࡟཯ᫎࡍࡿ⏕⌮άᛶ⬡㉁ࡢ
ྠᐃࢆ┠ᣦࡋ࡚࠸ࡿࠋ

́́

S3-3
௦ㅰࣇࣛࢵࢡࢫゎᯒ࡜୰ᚰ௦ㅰࡢࢺࣛࣥࢫ࣑࢜ࢡࢫ
ᯇ⏣ྐ⏕ 1, ΎỈ ᾈ 11኱㜰኱Ꮫ኱Ꮫ㝔᝟ሗ⛉Ꮫ◊✲⛉Trans-omics analysis of central metabolism using metabolic flux information
Fumio Matsuda1, Hiroshi Shimizu1
1
Graduate school of information science and technologies, Osaka University⣽⬊ෆ௦ㅰ⤒㊰ࢆὶࢀࡿ໬ྜ≀ὶ㔞㸦௦ㅰࣇࣛࢵࢡࢫ㸧ࡣ┤᥋ィ ࡍࡿࡇ࡜ࡀ࡛ࡁ࡞࠸ࠋ
ࡑࡇ࡛ 13C ௦ㅰࣇࣛࢵࢡࢫゎᯒ (13C-MFA)࡜࿧ࡤࢀࡿィἲࡀᚤ⏕≀௦ㅰᕤᏛศ㔝࡛Ⓨᒎࡋ࡚ࡁࡓࠋィ ᑐ㇟ࡢ⣽⬊ᰴࢆ 13C ᶆ㆑Ⅳ⣲※㸦[1-13C]ࢢࣝࢥ࣮ࢫࠊ[1-13C]ࢢࣝࢱ࣑ࣥ࡞࡝㸧ࢆྵ᭷ࡍࡿᇵᆅ࡛ᶆ㆑ᇵ㣴ࡍࡿࠋ⣽⬊ෆ௦ㅰ≀㉁ࡢྠ఩యᶆ㆑ࣃࢱ࣮ࣥ࡟ࡣࠊ㏻㐣ࡋ࡚ࡁࡓ௦ㅰ⤒㊰ࡢ᝟ሗࡀ཯ᫎࡍࡿࠋࡇࢀࢆ㉁㔞ศᯒ⿦⨨࡛ ᐃࡋࠊࢹ࣮ࢱゎᯒࢆ⾜࡞࠺ࡇ࡜࡛ࠊ
௦ㅰࣇࣛࢵࢡࢫศᕸࢆ

ᐃࡍࡿࠋࢃࢀࢃࢀࡣ 13C-MFA ᑓ⏝ࢹ࣮ࢱゎᯒࢯࣇࢺ࢙࢘࢔

OpenMebius ࢆ㛤Ⓨࡋ (http://www-shimizu.ist.osaka-u.ac.jp/)ࠊ┿᰾ࣔࢹࣝ⏕≀ࡢฟⱆ㓝ẕ࠿ࡽື≀ᇵ㣴⣽⬊ࡲ࡛ゎᯒᑐ㇟ࡢᣑ኱ࢆ⾜࡞ࡗ࡚ࡁࡓࠋ13C-MFA ࠿ࡽࡣࠊNAD(P)H ࡸ ATP ࡢ཰ᨭࢆぢ✚ࡶࡿࡇ࡜ࡀ࡛ࡁࡿࡓࡵࠊ⣽⬊ෆࡢ㓟໬㑏ඖࠊ࢚ࢿࣝࢠ࣮≧ែࡀ᥎ᐃ࡛ࡁࡿࠋࡲࡓࠊ
ࡀࢇ≉␗ⓗ࡞௦ㅰࡢάᛶࢆ┤᥋᥎ᐃࡋࡓࡾࠊ࠶ࡿ௦ㅰ⤒㊰ࡢάᛶኚ໬ࢆㄪ࡭ࡿ࣐࣮࣮࢝࡜
ࡋ࡚฼⏝࡛ࡁࡿࠋࡉࡽ࡟௦ㅰࣇࣛࢵࢡࢫ᝟ሗࡣࠊ௦ㅰไᚚᶵᵓࡢࢩࢫࢸ࣒⏕≀Ꮫⓗゎᯒ࡟࠾࠸࡚㔜せ࡞ᙺ๭ࢆᯝࡓࡍ࡜ᮇᚅࡉࢀ࡚࠾ࡾࠊ⑌ᝈ࡜ࣂ࢖࣐࣮࣮࢜࢝࡜ࡢᅉᯝ㛵ಀࡢゎᯒ࡟ࡶ᭷⏝࡛࠶ࡿࠋ㉁㔞ศᯒᢏ⾡ࡢⓎᒎ࡟ࡼࡾࠊ௦ㅰ୰㛫యࡢ⃰ᗘࡸ㓝⣲ࢱࣥࣃࢡࡢ୍ᩧᐃ
㔞ࡀྍ⬟࡜࡞ࡾࠊࢺࣛࣥࢫ࣑࢜ࢡࢫࢹ࣮ࢱࢆࡶ࡜࡟௦ㅰไᚚࢆᐃ㔞ⓗ࡟⌮ゎࡍࡿ⣲ᆅࡀᩚ࠸ࡘࡘ࠶ࡿࠋࡑࡇ࡛ࠊ13C ௦ㅰࣇࣛࢵࢡࢫゎᯒἲࡢᴫせࢆ⤂௓ࡋࠊࡉࡽ࡟㓝ẕ୰ᚰ௦ㅰࡢࢺ
ࣛࣥࢫ࣑࢜ࢡࢫゎᯒ࠿ࡽぢ࠼࡚ࡁࡓ௦ㅰไᚚᶵᵓ࡟ࡘ࠸࡚㆟ㄽࡋࡓ࠸ࠋ

́́

S3-4
኱つᶍࢥ࣮࣍ࢺ࣑࢜ࢡࢫゎᯒ࡟ࡼࡿ⑌ᝈண㜵࣐࣮࣮࢝᥈⣴୕ᯞ኱㍜ 1,2
1ᮾ໭኱Ꮫᮾ໭࣓ࢹ࢕࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓ, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉Researching Predictive Biomarker in a Large Scale Cohort Study
Daisuke Saigusa1
1
Tohoku Medical Megabank Organization, Tohoku University
2
School of Medicine, Tohoku Universityḟୡ௦་⒪࡛ࡣࠊಶู໬ࡉࢀࡓ⑌ᝈࣜࢫࢡุᐃ࡟ᇶ࡙ࡃண㜵་⒪ࡀồࡵࡽࢀ࡚࠾ࡾࠊ᪂
ࡓ࡞⑌ᝈࣂ࢖࣐࣮࣮࢜࢝ࡢⓎぢ࡜ࡑࡢ⮫ᗋᛂ⏝ࡀᮇᚅࡉࢀ࡚࠸ࡿࠋࣂ࢖࣐࣮࣮࢜࢝᥈⣴࡟࠾࠸࡚ࡣࠊࢤࣀ࣒ࠊࢺࣛࣥࢫࢡࣜࣉࢺ࣮࣒ࠊࣉࣟࢸ࣮࣒࢜ཬࡧ࣓ࢱ࣮࣒࣎ࣟࢆከ㝵ᒙⓗ࡟ゎᯒࡍࡿᡭἲࠊ
ࠕࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࠖࡀ᭷ຠ࡞ᡭẁ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋ≉࡟ࠊ࣓ࢱ࣎ࣟ
࣮࣒ゎᯒࡣࠊࢤࣀ࣒࡜⎔ቃせᅉ࡜࡟ࡼࡾᙧᡂࡉࢀࡿಶேࡢ⾲⌧ᆺࢆ㔞ⓗᙧ㉁࡜ࡋ࡚グ㏙࣭ᐃ⩏ࡋ࠺ࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋ㏆ᖺࠊ㉁㔞ศᯒィ (MS) ࢆ⏝࠸ࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒᢏ⾡ࡀ኱ࡁࡃ㐍Ṍࡋࠊ୍ḟཬࡧ஧ḟ௦ㅰ≀ࢆᶆⓗ࡜ࡋࡓ Targeted Metabolomics (TMet) ࡀࠊ⑌ᝈࣂ࢖࣐࣮࣮࢜࢝᥈⣴ཬࡧⓎ⑕࣓࢝ࢽࢬ࣒ࡢゎ᫂࡟୍ᐃࡢᡂᯝࢆࡶࡓࡽࡋ࡚࠸ࡿࠋࡋ࠿ࡋ࡞
ࡀࡽࠊᶆⓗࢆ⤠ࡽࡎ࡟௦ㅰ≀ゎᯒࢆ⾜࠺ Global Metabolomics (GMet) ࡣࠊᮍ▱ࡢ⑌ᝈࣂ࢖
࣐࣮࣮࢜࢝ྠᐃ࡟࠾ࡅࡿ᭷⏝ᛶࡣホ౯ࡉࢀ࡚࠸ࡿࡶࡢࡢࠊ᳨య๓ฎ⌮ࡢࣁ࢖ࢫ࣮ࣝࣉࢵࢺ
໬ࠊMS

ᐃࡢ෌⌧ᛶࠊ໬ྜ≀ࡢྠᐃ⢭ᗘࠊࢹ࣮ࢱゎᯒࡢ↹㞧ࡉ࡟ㄢ㢟ࡀᣦ᦬ࡉࢀ࡚࠸ࡿࠋ

ࡉࡽ࡟ࠊ⮫ᗋ㡿ᇦ࡟ࡅࡿࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࡣࠊࢤࣀ࣒ࡸ⮫ᗋ᝟ሗ➼ࡢࣅࢵࢡࢹ࣮ࢱ࡟
ࡼࡿ┦㛵ゎᯒࢆᐇ᪋ࡍࡿࡇ࡜ࡀᚲせ࡛࠶ࡿⅭࠊᚓࡽࢀࡓゎᯒ⤖ᯝ࠿ࡽ᭷ព⩏࡞ᅉᏊࢆᢳฟ
ࡍࡿࡇ࡜ࡀᅔ㞴࡛࠶ࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋᚑࡗ࡚ࠊࡇࢀࡽࡢㄢ㢟ࢆゎỴࡍࡿᇶ┙ᢏ⾡ཬࡧ࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫゎᯒᇶ┙ࡢᵓ⠏ࡀồࡵࡽࢀ࡚࠸ࡿࠋᡃࠎ ࡣࠊጞࡵ ࡟⮫ᗋ᳨యࡢ ࣁ࢖ࢫࣝ ࣮ࣉࢵࢺ࡞඲ ⮬ື๓ฎ ⌮ࢩࢫࢸ࣒ࢆ ᵓ⠏ࡋ ࠊ
UPLC-Q-TOF/MS ཬࡧ LC-Q-FT/MS ࡟ࡼࡿ GMet ゎᯒࣉࣟࢺࢥࣝࢆᵓ⠏ࡋࡓࠋࡲࡓࠊLC-MS/MSࢆ⏝࠸࡚ 300 ໬ྜ≀⛬ᗘࡢᐃࢆྍ⬟࡜ࡍࡿ TMetᐃᡭἲࢆᵓ⠏ࡋࡓࠋḟ࡟ࠊᵓ⠏ࡋࡓ

GMet ཬࡧ TMet ゎᯒᡭἲ࡟ࡼࡿ⮫ᗋ᳨యࡢᑠつᶍゎᯒཬࡧఫẸࢥ࣮࣍ࢺ᳨య㸦500 ே㸧ࡢゎᯒࢆᐇ᪋ࡋࡓࠋ⌧ᅾࠊᚓࡽࢀࡓゎᯒ⤖ᯝࢆ⏝࠸ࡿࢺࣛࣥࢫ࣑࢜ࢡࢫゎᯒࢆᐇ᪋ࡋ࡚࠾ࡾࠊ
ࣂ࢖࢜࢖ࣥࣇ࢛࣐ࢸ࢕ࢡࢫゎᯒࢆ㥑౑ࡋࡓ᪂つ⑌ᝈࣂ࢖࣐࣮࣮࢜࢝ೃ⿵໬ྜ≀ࡢᢳฟࢆヨ
ࡳ࡚࠸ࡿࠋ

́́

S4-1
⌧ሙ࡛᥇ྲྀྍ⬟࡞ᚤ㔞ࡢ⾑ᾮࠊၚᾮཬࡧờ࠿ࡽࡢ⸆≀᳨ᰝ᱓ᒣ೺ḟ⛉Ꮫ㆙ᐹ◊✲ᡤDrug test using blood, saliva, and sweat collected on site
Kenji Kuwayama
National Research Institute of Police Science࠙◊✲ࡢ⫼ᬒࠚ༴㝤ࢻࣛࢵࢢᑐ⟇ࡢᙉ໬ࡢࡓࡵࠊᣦᐃ⸆≀ࡢ౑⏝ࡀつไࡉࢀࡓࡇ࡜࡟క࠸ࠊ
ᦤྲྀ⸆≀ࡢ≉ᐃࡀࡲࡍࡲࡍ㔜せ࡜࡞ࡗ࡚࠸ࡿࠋ⸆≀ᦤྲྀࡢド᫂࡟ࡣᒀࡀ୍⯡ⓗ࡟⏝࠸ࡽࢀ
ࡿࡀࠊ㏿ࡸ࠿࡟௦ㅰࡉࢀࠊᒀ࠿ࡽᮍኚ໬యࡀ᳨ฟࡉࢀ࡞࠸⸆≀ࡀᏑᅾࡍࡿࠋࡲࡓࠊ㢮ఝᵓ㐀≀ࡀඹ㏻ࡢ௦ㅰ≀ࢆ⏕ᡂࡍࡿྍ⬟ᛶࡀ࠶ࡿࡓࡵࠊᦤྲྀ⸆≀ࡢ≉ᐃࡀᅔ㞴࡞ሙྜࡀ࠶ࡿࠋ
⸆≀ᦤྲྀ࠿ࡽᩘ᫬㛫௨ෆ࡟⾑ᾮࢆ᥇ྲྀ࡛ࡁࢀࡤࠊᮍኚ໬యࢆ᳨ฟ࡛ࡁࡿྍ⬟ᛶࡀ㧗ࡲࡿࡀࠊ⿕␲⪅➼ࢆ☜ಖࡋࡓ⌧ሙ࡛ᤚᰝဨࡀᙉไⓗ࡟⾑ᾮࢆ᥇ྲྀࡍࡿࡇ࡜ࡣ࡛ࡁ࡞࠸ࠋ⿢ุࡢドᣐ࡟࡞ࡾᚓࡿ㈨ᩱࡢ㐺ṇ࡞᥇ྲྀࡢࡓࡵࠊἲⓗ࡞ᡭ⥆ࡁࡸ་ົᐊ࡬ࡢ⛣ື➼࡟᫬㛫ࡀ࠿࠿ࡾࠊ
ࡑࡢ㛫࡟ࡶయෆࡢ⸆≀ࡣ௦ㅰ࣭᤼ἥࡉࢀࡿࠋ⌧ሙ࡛⾑ᾮࢆ᥇ྲྀࡍࡿ࡟ࡣࠊ⿕␲⪅➼࠿ࡽࡢྠពࢆᚓࡓୖ࡛ࠊ་⒪⏝✸่ჾࢆ⏝࠸࡚⿕␲⪅➼ࡀ⮬ࡽࡢయ࡟യࢆ௜ࡅ࡚ᚤ㔞ࡢ⾑ᾮࢆᥦ౪ࡍࡿࡋ࠿࡞࠸ࠋ୍᪉ࠊᦤྲྀࡋࡓ⸆≀ࡢ୍㒊ࡀၚᾮࡸờ࡟ࡶศἪࡉࢀࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾࠊၚᾮࡸờࡣ⾑ᾮ࡟ẚ࡭࡚ࠊ≉ู࡞ᢏ⾡ࡸ᪋タࢆᚲせ࡜ࡏࡎ࡟᥇ྲྀ࡛ࡁࡿࡓࡵࠊ௦᭰㈨ᩱ࡜ࡋ࡚᭷ຠ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ࠸ࡎࢀ࡟ࡋ࡚ࡶࠊ⌧ሙ࡛⏕య㈨ᩱࢆ᥇ྲྀࡍࡿ࡟ࡣࠊ⿕␲⪅➼࠿ࡽ㈨ᩱᥦ౪ࡢྠពࢆᚓ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࡀࠊࡇࡢࡼ࠺࡞ไ⣙ࡀ࠶ࡗ࡚ࡶ࡞࠾ࠊ⏕య㈨ᩱࢆ㎿㏿࡟᥇ྲྀࡍࡿࡇ࡜ࡀᦤྲྀࡋࡓ⸆≀ࡢ≉ᐃ࡟㔜せ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ
࠙⌧ሙ࡛ࡢ⏕య㈨ᩱ᥇ྲྀἲࠚ㈨ᩱᥦ౪⪅ࠊ㈨ᩱ᥇ྲྀ⪅ࠊ⸆≀᳨ᰝ⪅ࡑࢀࡒࢀࡢ❧ሙࠊ᥇ྲྀࡸ
ศᯒ๓ฎ⌮ࡢ⡆౽ᛶࠊ㎿㏿ᛶࠊ⤒῭ᛶ➼ࢆ⪃៖ࡋࠊྛ㈨ᩱࡢ᥇ྲྀἲࢆ㑅ᐃࡋࡓࠋࡲࡓࠊࡑ
ࡢ᪉ἲ࡛᥇ྲྀࡋࡓ⾑ᾮཬࡧၚᾮ࠿ࡽ༴㝤ࢻࣛࢵࢢ➼ࢆ᳨ฟࡍࡿࡓࡵ࡟ᚲせ࡞⸆≀⃰ᗘࢆぢ✚ࡶࡗࡓࠋ⌧ሙ࡛᥇ྲྀ࡛ࡁࡿ⾑ᾮࡣᚤ㔞࡛࠶ࡿࡓࡵࠊẚ㍑ⓗ㧗⃰ᗘࡢ⸆≀࡛࡞ࡅࢀࡤࠊࡑ
ࡢ᳨ฟࡀᅔ㞴࡛࠶ࡿࠋၚᾮࡣ኱㔞࡟᥇ྲྀ࡛ࡁࡿࡓࡵࠊ⾑ᾮ୰ࡼࡾࡶప࠸⃰ᗘࡢ⸆≀ࢆ᳨ฟ࡛ࡁࡿࡀࠊ⥥Წ➼ࡢ᥇ྲྀჾල࡟྾╔ࡋࡸࡍ࠸⸆≀ࡀ࠶ࡿࡓࡵࠊ᥇ྲྀἲࡸᢳฟἲ࡟ὀពࡀᚲ
せ࡛࠶ࡿࠋ࠙ྛ⏕య㈨ᩱࡢ᭷⏝ᛶࠚ⸆≀ᢞ୚ᚋࠊᒀࠊ⾑ᾮࠊၚᾮཬࡧờࢆ᥇ྲྀࡋࠊ⸆≀᳨ᰝ࡟࠾ࡅࡿྛ㈨ᩱࡢ᭷⏝ᛶࢆホ౯ࡋࡓࠋ᥇ྲྀࡢᐜ᫆ࡉࠊ᥇ྲྀ㔞ࠊ⸆≀⃰ᗘࠊ⸆≀ࡢ᳨ฟྍ⬟࡞ᮇ㛫➼ࢆẚ㍑ࡍࡿ࡜ࠊ࠸ࡎࢀࡢ㈨ᩱ࡟ࡶ᭷⏝࡞Ⅼࡀ࠶ࡗࡓࠋᒀࢆ⏝࠸ࡓ⸆≀᳨ᰝࢆᇶᮏ࡜ࡋ࡚ࠊᒀ
ࡢ᥇ྲྀ๓࡟⌧ሙ࡛ࡇࢀࡽࡢ⏕య㈨ᩱࡶ᥇ྲྀ࡛ࡁࢀࡤࠊᦤྲྀ⸆≀ࡢ≉ᐃࡢྍ⬟ᛶࡀ㧗ࡲࡿ࡜⪃࠼ࡽࢀࡿࠋ

́́

S4-2
࢝ࢳࣀࣥ⣔༴㝤ࢻࣛࢵࢢࡢ௦ㅰ

㸫໬Ꮫᵓ㐀ࡀ௦ㅰ࡟ཬࡰࡍᙳ㡪࡟ࡘ࠸࡚㸫ᚿᦶ඾᫂ 1, 㙊⏣ᐶᜨ 1, ᯇ⏣㥴ኴᮁ 1, ᥃ᶫ⚽┤ 1, ୕ᮌ᫛ᏹ 1, ∦ᮌ᐀ᘯ 1, ᅵᶫ ᆒ 21኱㜰ᗓ㆙⛉Ꮫᤚᰝ◊✲ᡤ, 2 ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉Metabolism of cathinone-derived drugs of abuse̿Influences of the chemical
structures on the metabolism̿
Noriaki Shima1, Hiroe Kamata1, Shuntaro Matsuta1, Hidenao Kakehashi1, Akihiro Miki1, Munehiro
Katagi1, Hitoshi Tsuchihashi2
1
Forensic Science Laboratory, Osaka Prefectural Police Headquarters, Osaka
2
Nagoya University Graduate School of Medicineࠕ༴㝤ࢻࣛࢵࢢࠖ࡜ࡋ࡚ὶ㏻ࡍࡿ࢝ࢳࣀࣥ⣔⸆≀ࡣࠊྜᡂ࢝ࣥࢼࣅࣀ࢖ࢻ⣔⸆≀࡜ඹ࡟ࡑ
ࡢὶ㏻ࡣ㝿❧ࡗ࡚ከࡃࠊᦤྲྀド᫂ࡀồࡵࡽࢀࡿ஦౛ࡀ඲ᅜⓗ࡟ከⓎࡋ࡚࠸ࡿࠋ2015 ᖺ 5 ᭶࡟ࡣ➨୕ᅇໟᣓつไ㸦࢝ࢳࣀࣥ㢮ࡀᑐ㇟㸧ࡀ᪋⾜ࡉࢀࠊ1300 ✀௨ୖࡢ࢝ࢳࣀࣥ⣔⸆≀ࡀࠊ㯞⸆࠶ࡿ࠸ࡣ་⸆ရ་⒪ᶵჾ➼ἲ㸦ᪧ⸆஦ἲ㸧ࡢᣦᐃ⸆≀࡜ࡋ࡚つไࡉࢀ࡚࠸ࡿࡢࡀ⌧≧࡛࠶ࡿࠋ࢝ࢳࣀࣥ⣔⸆≀ࡣࠊぬ㓰๣➼࡜ẚ㍑ࡋ࡚௦ㅰࡀ㏿࠸ࡇ࡜ࡀ♧၀ࡉࢀ࡚࠾ࡾࠊ⏕యヨᩱࢆᑐ㇟࡜ࡋࡓศᯒ࡛ࡣࠊᮍኚ໬య࡜ඹ࡟௦ㅰ≀ࢆ᥈⣴ࡍࡿࡇ࡜ࡀ㔜せ࡜࡞ࡿࠋ࢝ࢳࣀࣥ⣔⸆≀ࡢ௦ㅰࡣࠊࡑࡢඹ㏻ࡢ㦵᱁࡛࠶ࡿ࢝ࣝ࣎ࢽࣝᇶࡢ㑏ඖࡀᇶᮏ࡜࡞ࡿࠋከ
ࡃࡢ⸆≀࡟࠾࠸࡚ࡑࡢ㑏ඖయ㸦ࢪ࢔ࢫࢸ࣐࣮ࣞ࢜㸧ࡀ☜ㄆࡉࢀ࡚࠾ࡾ 1-3)ࠊᦤྲྀド᫂ࡢᣦᶆ࡜ࡋ࡚᭷⏝࡞௦ㅰ≀࡜࡞ࡿࠋ୍᪉ࠊ࢝ࣝ࣎ࢽࣝ㑏ඖ௨እࡢ௦ㅰ⤒㊰࡟㛵ࡋ࡚ࡣࠊ࢔࣑ࣀᇶࠊ
࣋ࣥࢮࣥ⎔ୖࡢ⨨᥮ᇶ࠶ࡿ࠸ࡣ࢔ࣝ࢟ࣝ㙐㸦୺㙐㸧ࡢ㛗ࡉ࡟ࡼࡗ࡚␗࡞ࡾࠊ୺せ࡜࡞ࡿ௦ㅰ⤒㊰ࡶࡑࡢᵓ㐀࡟౫Ꮡࡍࡿࡇ࡜ࡀ♧၀ࡉࢀ࡚࠸ࡿࠋࡍ࡞ࢃࡕࠊN-࢔ࣝ࢟ࣝ࢔࣑ࣀᇶࢆ᭷
ࡍࡿ໬ྜ≀࡛ࡣ N-⬺࢔ࣝ࢟ࣝ໬ࡀ㐍ࡴ୍᪉ࠊࣆࣟࣜࢪࣥ⎔ࢆ᭷ࡍࡿ Į-PVP ࡸ Į-PBP ➼ࡣࠊࣆࣟࣜࢪࣥ⎔ࡢ㓟໬࡟ࡼࡾ࢜࢟ࢯయ࡬࡜௦ㅰࡉࢀࡿࡇ࡜ࡀ♧ࡉࢀ࡚࠸ࡿ 1,2)ࠋࡲࡓࠊ࣋ࣥࢮࣥ⎔ࡢ࣓ࢺ࢟ࢩᇶ⨨᥮య࡛ࡣࠊO-⬺࣓ࢳࣝ໬ࡉࢀࡿ⤒㊰ࡀ୺࡜࡞ࡾࠊ࢔ࣝ࢟ࣝ㙐㸦୺㙐㸧ࡢ㛗࠸໬ྜ≀࡛ࡣࠊȦ-1 ఩ཬࡧ Ȧ ఩ࡢ㓟໬ࡀ୺௦ㅰ⤒㊰࡟࡞ࡿࡇ࡜ࡀ♧၀ࡉࢀ࡚࠸ࡿ 3)ࠋࡇࡢࡼ࠺
࡞௦ㅰ⤒㊰ࡢண ࡣࠊ᪂つ⸆≀ࢆᑐ㇟࡜ࡋࡓศᯒ࡛ࡣᚲせ୙ྍḞ࡜࡞ࡿࠋ
ᮏⓎ⾲࡛ࡣࠊࣆࣟࣜࢪࣥ⎔ࢆ᭷ࡍࡿ࢝ࢳࣀࣥ⣔⸆≀ࢆ୰ᚰ࡟ࠊ㉁㔞ศᯒ࡟ࡼࡿᮍኚ໬య
ཬࡧ௦ㅰ≀ࡢᵓ㐀᥎ᐃ౛ࢆ♧ࡍ࡜ඹ࡟ࠊ࢔ࣝ࢟ࣝ㙐㸦୺㙐㸧ࡢ㛗ࡉࡸ࣋ࣥࢮࣥ⎔⨨᥮ᇶ➼ࠊᵓ㐀ࡢ㐪࠸ࡀ௦ㅰ⤒㊰࡟ཬࡰࡍᙳ㡪࡟ࡘ࠸࡚⤂௓ࡍࡿࠋ࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------1. Shima, N., et al., Forensic Toxicol., 32, 59-67 (2014).
2. Matsuta, S., et al., Forensic Sci. Int., 249, 181-188 (2015).
3. Shima, N., et al., Forensic Toxicol., 33, 279-294 (2015).

́́

S4-3
༴㝤ࢻࣛࢵࢢὶ㏻ᐇែㄪᰝ࡟࠾ࡅࡿ㉁㔞ศᯒࡢᙺ๭
ⰼᑼ㸦ᮌ಴㸧⍠⌮ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤMass spectrometry for a survey of the prevalence of new psychoactive substances
in Japan
Ruri Kikura-Hanajiri
National Institute of Health Sciences༴㝤ࢻࣛࢵࢢࡣࠊ㯞⸆ࡸぬࡏ࠸๣ࡢࡼ࠺࡟ἲつไࡉࢀ࡚࠸࡞࠸ࡀࠊࡑࢀࡽ࡜㢮ఝࡢ᭷ᐖᛶࢆ᭷ࡍࡿࡇ࡜ࡀ␲ࢃࢀࡿ໬ྜ≀࡛࠶ࡾࠊ஘⏝┠ⓗ࡛〇㐀ࠊ㈍኎ࡉࢀࡿࡶࡢࢆ♧ࡍࠋࡇࢀࡽ໬ྜ≀ࢆྵࡴ〇ရࡢὶ㏻ࡣࠊᖹᡂ 10 ᖺ㡭ࡼࡾ㢧ᅾ໬ࡋࠊᅛᙧࠊ⢊ᮎࠊᾮయࠊ࢝ࣉࢭࣝ➼ࠊᵝࠎ࡞ᙧែ࡛㈍኎ࡉࢀࡓࠋᖹᡂ 18 ᖺ࡟ࠊ⸆஦ἲ㸦⌧་⸆ရ་⒪ᶵჾ➼ἲ㸧ࡀᨵṇࡉࢀࠊᣦᐃ⸆≀ไᗘࡀᑟධࡉࢀࡓᚋࡣࠊ୍᫬ᮇࠊࡑࡢ㈍኎ᩘࡀῶᑡࡋࡓࠋࡋ࠿ࡋࠊᖹᡂ 24 ᖺ๓ᚋ࠿ࡽࠊ࢝ࣥࢼࣅࣀ࢖ࢻཷᐜయ࡟ᙉ࠸άᛶࢆ♧ࡍ໬ྜ≀⩌㸦ྜᡂ࢝ࣥࢼࣅࣀ࢖ࢻ㢮㸧ࢆ஝⇱᳜≀⣽∦࡟ΰྜࡋࡓࠕ⬺ἲࣁ࣮ࣈࠖࡸࠊࠕ࢔࣐ࣟࣜ࢟ࢵࢻࠖ㸦ᾮయ㸧➼࡜ࡋ࡚㈍኎ࡉࢀࡿ⯆ዧᛶ࢔࣑ࣥ㢮㸦࢝ࢳࣀࣥ㢮㸧ྵ᭷〇ရ࡟ࡼࡿ೺ᗣ⿕ᐖࡀᛴቑࡋࠊ῝้࡞♫఍ၥ㢟࡜࡞ࡗࡓࠋ
ᅜ❧⾨◊࡛ࡣ༴㝤ࢻࣛࢵࢢ〇ရࡢὶ㏻ᐇែኚ໬ࢆᢕᥱࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࠊᖹᡂ 14 ᖺᗘࡼࡾ༴㝤ࢻࣛࢵࢢ〇ရࡢྵ᭷ᡂศㄪᰝࢆᐇ᪋ࡋ࡚࠸ࡿࠋᖹᡂ 26 ᖺᗘࡲ࡛࡟ᅜ❧⾨◊ࡀㄪᰝࡋࡓ༴㝤ࢻࣛࢵࢢ〇ရࡣ⣙ 3500 ✀㢮࡟ࡶ࠾ࡼࡪࠋ༴㝤ࢻࣛࢵࢢ〇ရศᯒ࡛ࡣࠊGC-MSࠊ
LC-PDA-MSࠊDART-Orbitrap ➼࡟ࡼࡾࢫࢡ࣮ࣜࢽࣥࢢศᯒࢆ⾜࠸ࠊ᪂つὶ㏻໬ྜ≀ࡀ᳨ฟࡉࢀࡓሙྜࡣࠊLC-QTOF ཬࡧ NMR ศᯒ࡟ࡼࡾᵓ㐀ࢆྠᐃࡋ࡚࠸ࡿࠋ୍᪉ࠊ༴㝤ࢻࣛࢵࢢࡀ
㛵୚ࡋࡓᩆᛴᦙ㏦࣭Ṛஸ஦౛➼࡟࠾࠸࡚ࡣࠊLC-QTOF ཬࡧ LC-MS/MS ࡢ୧ᡭἲࢆ⏝࠸࡚ࠊ⾑ᾮࠊᒀࠊẟ㧥➼ࡢ⏕యヨᩱ୰⸆≀ࡢࢫࢡ࣮ࣜࢽࣥࢢศᯒ࣭ᐃ㔞ศᯒࢆ⾜ࡗ࡚࠸ࡿࠋ࡞࠾ࠊ
ḟ࠿ࡽḟ࡬࡜᪂つὶ㏻໬ྜ≀ࡀฟ⌧ࡍࡿ༴㝤ࢻࣛࢵࢢ࡟࠾࠸࡚ࡣࠊᅜෆእࡢ◊✲ᶵ㛵㛫࡟࠾ࡅࡿ᝟ሗࡢඹ᭷໬ࡀ㔜せ࡜࡞ࡿࠋᅜ❧⾨◊࡛ࡣࠊᖹᡂ 26 ᖺ 3 ᭶࠿ࡽࠕ㐪ἲࢻࣛࢵࢢࢹ࣮
ࢱ㜀ぴࢩࢫࢸ࣒ࠖ
㸦http://npsdb.nihs.go.jp/Search/㸧࡟࠾࠸࡚ࠊ༴㝤ࢻࣛࢵࢢ࡟㛵ࡍࡿ ᐃࢹ࣮ࢱ➼ࡢ᝟ሗࢆබ㛤ࡋ࡚࠸ࡿࠋᖹᡂ 27 ᖺ 3 ᭶ᮎ᫬Ⅼ࡛ࠊ656 ໬ྜ≀ࠊ1980 〇ရࡢ᝟ሗࡀ཰㍕ࡉࢀ࡚࠾ࡾࠊᅜ㐃➼ࡢᅜ㝿ᶵ㛵ࢆྵࡴ⣙ 310 ᶵ㛵㸦㒊⨫㸧ࡀⓏ㘓ࢆࡋ࡚࠸ࡿࠋ
ᖹᡂ 26 ᖺᗘᚋ༙௨㝆ࠊ༴㝤ࢻࣛࢵࢢ࡟ᑐࡍࡿつไཬࡧྲྀ⥾ࡾᙉ໬ࡀᐇ᪋ࡉࢀࠊᖹᡂ 27
ᖺ 7 ᭶࡟ࡣ㈍኎ᗑ⯒ᩘࡣࡘ࠸࡟ࢮࣟ࡟࡞ࡗࡓࠋࡋ࠿ࡋࠊ༴㝤ࢻࣛࢵࢢ࠿ࡽ㏨ࢀࡽࢀ࡞࠸஘
⏝⪅ࡶᮍࡔከᩘᏑᅾࡋ࡚࠸ࡿࡇ࡜ࡀ᥎

ࡉࢀࠊண᩿ࢆチࡉ࡞࠸≧ἣୗ࡟࠶ࡿࠋᮏࢩ࣏ࣥࢪ

࣒࡛࢘ࡣࠊ༴㝤ࢻࣛࢵࢢ࡟ࡘ࠸࡚ࠊࡇࡢ 10 ᖺ㛫ࡢὶ㏻ࡢኚ໬ࢆゎㄝࡍࡿ࡜ඹ࡟ࠊ༴㝤ࢻࣛ
ࢵࢢὶ㏻ᐇែㄪᰝ㸦⏕యヨᩱ୰⸆≀ศᯒࢆྵࡴ㸧࡟࠾ࡅࡿ㉁㔞ศᯒࡢᙺ๭࡟ࡘ࠸࡚ㄽࡌࡿࠋ

́́

ㅮ₇せ᪨
㸦P1㹼P62㸸࣏ࢫࢱ࣮Ⓨ⾲㸧

́́

P-1
HILIC-MS/MS ἲ࡟ࡼࡿࣄࢺయᾮ୰ tegafur ཬࡧ 5-fluorouracil ࡢ㧗ឤᗘศᯒἲ
ᑠῲᚊᏊ 1,2, ᮤ ᬡ㭉 1, ⇃⃝Ṋᚿ 1, ᘅ⃝ᵞᏊ 2, 㛗㇂ᕝᬛ⳹ 3, ධᡞ㔝᫴ 1, 㧗ᶫ᫓⏨ 2,బ⸨ၨ㐀 1
1 ᫛࿴኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ
2 ᫛࿴኱Ꮫ་Ꮫ㒊║⛉Ꮫㅮᗙ
3 ᮾ㑥኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ

High sensitive analysis of tegafur and 5-fluorouracil in human body fluids by
HILIC-MS/MS
Ritsuko Obuchi1,2, Xiao-Pen Lee1, Takeshi Kumazawa1, Makiko Hirosawa2, Chika Hasegawa3, Susumu Nittono1, Haruo Takahashi2, Keizo Sato1
1
Department of Legal Medicine, Showa University School of Medicine
2
Department of Ophthalmology, Showa University School of Medicine
3 Department of Legal Medicine, Toho University School of Medicine࠙┠ⓗࠚ⤒ཱྀᢠࡀࢇ๣ࢸ࢕࣮࢚ࢫ࣡ࣥ®ࡣࠊ୺ᡂศࡀࢸ࢞ࣇ࣮ࣝ㸸5-fluoro-1-[(2RS)- tetrahydrofuran-2-yl] uracil (FT)࡛࠶ࡾࠊ5-fluorouracil㸦5-FU㸧ࡣ FT ࡢ௦ㅰయ࡛࠶ࡿࠋFT ࠾ࡼࡧ 5-FUࡣࠊࢸ࢕࣮࢚ࢫ࣡ࣥ®ᢞ୚ᝈ⪅ࡢゅ⭷㞀ᐖࠊᾦ㐨㞀ᐖ࡞࡝║ྜే⑕࡬ࡢ㛵୚ࡀᣦ᦬ࡉࢀ࡚࠸
ࡿࠋ௒ᅇᡃࠎࡣࠊ㡰┦࣒࢝ࣛࢆ⏝࠸ࡓ㉸㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮㸦UFLC㸧íࢱࣥࢹ࣒㉁㔞ศᯒ㸦MS/MS㸧࡟ࡼࡿࣄࢺᾦᾮ࠾ࡼࡧ⾑₢୰ FT ࡜ 5-FU ࡢ⡆౽࠿ࡘ㧗ឤᗘ࡞ศᯒ᮲௳ࢆタᐃࡋࡓࡢ࡛ሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚᮏศᯒࢩࢫࢸ࣒࡟ࡣ Prominence UFLC ⿦⨨㸦ᓥὠ〇సᡤ㸧࠾ࡼࡧࢺࣜࣉࣝᅄ㔜ᴟ࡜ࣜࢽ࢔࢖࢜ࣥࢺࣛࢵࣉᶵ⬟ࢆᦚ㍕ࡋࡓ API4000 Q Trap MS/MS ⿦⨨㸦AB SCIEX㸧ࢆ⏝࠸ࡓࠋ
ࡲࡓࠊᕷ㈍Ⅼ║⸆ࢸ࢕࢔࣮ࣞ W®㸦࢜ࣇࢸࢡࢫ〇㸧ࢆேᕤᾦᾮ࡜ࡋ࡚⏝࠸ࡓࠋ⸆≀ῧຍᾦᾮࡣࠊࣄࢺᾦᾮࡲࡓࡣேᕤᾦᾮ 10 μL ࡟ FTࠊ5-FU ࠾ࡼࡧ 5-chlorouracil (IS) ࢆῧຍࡋࡓᚋࠊ2M
㓑㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮ 40 μLࠊ2%ࢠ㓟࢔ࢭࢺࢽࢺࣜࣝ 250 μL ࢆຍ࠼࡚ㄪ〇ࡋࡓࠋヨᩱᾮࡣࠊ㐲ᚰศ㞳ࡋࡓᚋࠊࡑࡢୖΎ 15 μL ࢆศᯒࢩࢫࢸ࣒࡟࢔ࣉࣛ࢖ࡋࡓࠋࡲࡓࠊ⸆≀ῧຍࣄࢺ⾑₢
ࡣࠊ20 μL ࡟ྛ⸆≀ࢆῧຍࡋࡓᚋࠊ2M 㓑㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮ 80 μLࠊ2%ࢠ㓟࢔ࢭࢺࢽࢺࣜ
ࣝ 500 μL ࢆຍ࠼࡚ㄪ〇ࡋࡓࠋヨᩱᾮࡣࠊ㐲ᚰศ㞳ࡋࡓᚋࠊࡑࡢୖΎ 15 μL ࢆศᯒࢩࢫࢸ࣒
࡟࢔ࣉࣛ࢖ࡋࡓࠋHILIC-MS/MS ศᯒࡢศ㞳࣒࢝ࣛ࡟ࡣ Imtakt ♫〇ࡢ㡰┦࣒࢝ࣛ UK-Amino㸦㛗ࡉ 50 mmࠊෆᚄ 3 mmࠊ⢏ᚄ 3 μm㸧ࢆ౑⏝ࡋࠊ⛣ື┦ࡣ࢔ࢭࢺࢽࢺࣜࣝࢆ࣮࣋ࢫ࡟ࡋࡓ
10 mM 㓑㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮࡢࣜࢽ࢔ࢢࣛࢪ࢚ࣥࢺࢆ⏝࠸ࡓࠋ࠙⤖ᯝࠚ኱Ẽᅽ໬Ꮫ࢖࢜ࣥ໬ἲ㸦APCI㸧ࢆ⏝࠸ࡓ SRM

ᐃ࡟ࡼࡾࠊFT ࠾ࡼࡧ 5-FU ࡣࠊᾦᾮ࠾ࡼࡧ⾑₢࠿ࡽ 1 ศ௨ෆ࡟ឤᗘࡼࡃ᳨ฟࡉࢀࡓࠋࡲࡓࠊFT ࡜ 5-FU ࡢᅇ཰⋡ࡣᾦᾮ࡛87-104 %ࠊ
⾑₢࡛ 94-106 %࡛࠶ࡗࡓࠋ
᳨㔞⥺ࡣᾦᾮ࡛ 0.08㹼4.0 μg/mLࠊ⾑₢࡛ 0.1㹼4.0 μg/mLࡢ⠊ᅖ࡛୧⪅࡜ࡶ࡟Ⰻዲ࡞┤⥺ᛶࡀᚓࡽࢀࡓࠋ᳨ฟ㝈⏺㸦LOD㸧ࡣᾦᾮࡀ 0.04 μg/mLࠊ⾑₢ࡀ 0.02-0.04 μg/mL ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚᮏ◊✲࡛ࡣࠊ10 μL ᾦᾮࡲࡓࡣ 20 μL ⾑₢࡜࠸࠺ᚤ㔞ࡢ⏕యヨᩱ࠿ࡽ FT ࠾ࡼࡧ 5-FUࢆ⡆౽࠿ࡘ㧗ឤᗘ࡟ศᯒ࡛ࡁࡓࠋᮏἲࡣᚤ㔞࡞⏕యヨᩱ࡟࠾ࡅࡿᚤ㔞ࡢ⸆≀ᡂศࢆᑐ㇟࡜
ࡍࡿ㧗ឤᗘࣁ࢖ࢫ࣮ࣝࣉࢵࢺศᯒ࡟᭷⏝࡛࠶ࡾࠊ║⛉㡿ᇦࢆጞࡵ࡜ࡍࡿ⮫ᗋ㡿ᇦ࠾ࡼࡧἲ
་Ꮫ㡿ᇦ࡟࠾ࡅࡿ⸆≀࠾ࡼࡧ௦ㅰ≀ࡢᚤ㔞ศᯒ࡟ጾຊࢆⓎ᥹ࡍࡿࡶࡢ࡜ᛮࢃࢀࡿࠋ

́́

P-2
⤌⧊ษ∦୰ࢪࣇ࢙ࢽࢪࣥࡢ MALDI-MS(/MS)࡟ࡼࡿ┤᥋ศᯒ༡᪉࠿ࡼᏊ 1, 㕥ᮌ㞞Ꮚ 2, 㔝⃝⚽ᶞ 1, ᒣᓊ ᱁ 1, 㛗㇂ᕝᘯኴ㑻 1, 㜿Ẹ໚᪥௚ 1,ᶒᏲ㑥ኵ 1, Ώ㒊ຍዉᏊ 1, 㕥ᮌ ಟ 11὾ᯇ་⛉኱Ꮫ኱Ꮫἲ་Ꮫ, 2 ὾ᯇ་⛉኱Ꮫᐇ㦂ᐇ⩦ࢭࣥࢱ࣮Direct MALDI mass spectrometric analysis of diphenidine in several tissues
Kayoko Minakata1, Masako Suzuki2, Hideki Nozawa1, Itaru Yamagishi1, Koutaro Hasegawa1, Amin
Wurita1, Kunio Gonmori1, Kanako Watanabe1, Osamu Suzuki1
1
Department of Legal Medicine, Hamamatsu University School of Medicine
2
Research Equipment Center, Hamamatsu University School of Medicine࠙┠ⓗࠚ㏆ᖺ, ྜᡂ࢝ࣥࢼࣅࣀ࢖ࢻ㢮ࡸ࢝ࢳࣀࣥ㢮ࡢ༴㝤ࢻࣛࢵࢢࡀ⶝ᘏࡋࡓࡓࡵࠊࡑࢀࡽࡣໟᣓつไࡉࢀࡓࠋࡑࡢࡓࡵ࠿ࡑࢀࡽ࡟ᒓࡉ࡞࠸⸆≀ࡀ᳨ฟࡉࢀጞࡵࡓࠋࢪࣇ࢙ࢽࢪࣥࡶࡑ
࠺ࡋࡓ⸆≀ࡢ 1 ࡘ࡛࠶ࡾ, 2014 ᖺ࠿ࡽሗ࿌ࡉࢀጞࡵ, ᙜᩍᐊ࡛ࡶࢪࣇ࢙ࢽࢪࣥ୰ẘ࡜⪃࠼ࡽࢀࡿゎ๗౛࡟㐼㐝ࡋࡓࠋ⤌⧊ษ∦ࢆ⏝࠸ࡓࢪࣇ࢙ࢽࢪࣥࡢ MALDI-M(/MS) ࡟ࡼࡿ┤᥋ศᯒ࡟ࡘ࠸࡚ࡢሗ࿌ࡣࡲࡔ࡞ࡉࢀ࡚࠸࡞࠸ࠋ௒ᅇࡣࢪࣇ࢙ࢽࢪࣥ ᐃࡢ᭱㐺᮲௳ࡢ᳨ウࢆ⾜࠸,௒ᚋࡢ⤌⧊ษ∦࠿ࡽࡢ௚ࡢ⸆≀᳨ฟ࡬ࡢ㐺⏝ࢆ┠ⓗ࡜ࡍࡿࠋ࠙᪉ἲࠚゎ๗᫬࡟᦬ฟࡉࢀࡓ✀ࠎࡢ⤌⧊࠿ࡽᚄ 5mm ⛬ᗘࡢ⤌⧊ሢࢆ᥇ྲྀࡋ, -80 ᗘ࡛෾⤖ಖ
ᏑࡋࡓࠋMSᐃ࡟㝿ࡋ, ࡑࡢሢ࠿ࡽ 20 Pm ཌࡢ෾⤖ษ∦ࢆసᡂࡋ, MALDI-MSᐃ⏝ࡢࢫࢸࣥࣞࢫࣉ࣮ࣞࢺୖ࡟ 20 ᯛ⛬ࡢࡏ, ᥋╔ࡉࡏࡓࠋࡑࢀࢆࢩࣜ࢝ࢤࣝධࡾࡢࣃࢵࢡ࡟ᐦ㛢ࡋ,ᐊ ࡟ 1 ᬌᨺ⨨ࡋࡓࠋෆ㒊ᶆ‽(imipramine) ࡣ⤌⧊ษ∦ࢆࡢࡏࡿ๓࡟ࣉ࣮ࣞࢺୖ࡟ῧ௜ࡋࡓࠋ
ḟ࡟⤌⧊⾲㠃࡟ matrix ⁐ᾮࢆ࢚࢔ࣈࣛࢩ࡛ሬᕸࡋࡓࠋ஝⇱ᚋ reflector type-TOF-MS, QSTAR
Eliet Hybrid (AB SCIEX) ࡟࡚ MS ࡜ MS/MS ࢆ ᐃࡋࡓࠋ⿦⨨ࡢ mass resolution ࡣ 15,000,
mass accuracy ࡣ 5 ppm ࡛࠶ࡿࠋ355-nm Nd:YAG laser ࢆ power level 10.6 PJ, 1000 Hz, 20 cycle࡛↷ᑕࡋࡓࠋྖἲゎ๗࡟కࡗࡓ⤌⧊୰ࡢ⸆≀᳨ฟࡣබⓗ࡟せㄳࡉࢀ࡚࠸ࡿࠋ
࠙⤖ᯝࠚ⸆≀᳨ฟࡢሙྜ, ⤌⧊ษ∦ࡢᚄࡣࡑࢀ࡯࡝኱ࡁ࠸ᚲせࡣ࡞࠸ࡀ, ᚄ 3mm ௨ୗ࡛ࡣษ∦ࢆࣉ࣮ࣞࢺୖ࣊⛣ືࡉࡏࡿࡢࡀᅔ㞴࡛࠶ࡗࡓࡢ࡛, ᚄࡣ 5mm ⛬ᗘ࡜ࡋࡓࠋmatrix ๣࡜ࡋ࡚ Į-cyano-4-hydroxy cinnamic acid (CHCA)ࢆ⏝࠸ࡓሙྜ, CHCA 10mg ࢆ࢔ࢭࢺࢽࢺࣜࣝ㸸Ỉ (1 ml : 0.2 ml) ࡟⁐ゎࡋࡓ⁐ᾮࡀ㐺ᙜ࡛࠶ࡗࡓࠋ⬡⫫୰ࡢࢪࣇ࢙ࢽࢪࣥࡣ௚⮚ჾࡼࡾࡶ㠀ᖖ࡟㧗⃰ᗘ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚ⤌⧊࡟ࡼࡿ ion suppression ࡣ኱ࡁࡃ, ࡲࡓ⤌⧊㸦㒊఩㸧࡟ࡼࡗ࡚␗࡞ࡿࡢ࡛, ᮏἲ࡟ࡼࡿ⢭ᐦ࡞ᐃ㔞ࡣᅔ㞴࡜ᛮࢃࢀࡿࠋࡋ࠿ࡋ⸆≀⃰ᗘࡀ࣮࢜ࢲ࣮ⓗ࡟ṇࡋࡃᐃྍ⬟࡛࠶ࢀࡤ୰ẘࡸ⮴Ṛࡢุ᩿ᮦᩱ࡜࡞ࡾᚓࡿࡢ࡛, ἲ་Ꮫศ㔝࡟࠾ࡅࡿ⸆ẘ≀ࡢ㎿㏿࡞ุู࡟฼
⏝࡛ࡁࡿ᭷ຊ࡞᪉ἲ࡛࠶ࡿ࡜ᛮࢃࢀࡿࠋ

́́

P-3
ḟளሷ⣲㓟࡟ࡼࡾ㓟໬ࡉࢀࡓ࣍ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥࡢ LC/QTOF-MS ࢆ⏝࠸ࡓศᯒᫍᒸభ⨾ 1, Ᏻ㒊ᐶᏊ 1, ▮ᓥ኱௓ 1, ᒾ℩༤ኴ㑻 1,2
1༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᮾி኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ

Analysis of hypochlorite-oxidized phosphatidylcholines using LC/QTOF-MS
Yumi Hoshioka1, Hiroko Abe1, Daisuke Yajima1, Hirotaro Iwase1, 2
1
Department of Legal Medicine, Graduate School of Medicine, Chiba University
2
Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo࠙⫼ᬒ࣭┠ⓗࠚዲ୰⌫ෆࡢ㓝⣲ࡢ୍ࡘ࡛࠶ࡿ࣑࢚ࣟ࣌ࣝ࢜࢟ࢩࢲ࣮ࢮ(MPO)ࡣࠊ⣽⳦➼ࡢ␗≀㈎㣗ࢆࡁࡗ࠿ࡅ࡟⏘⏕ࡉࢀࡓ㐣㓟໬Ỉ⣲࠿ࡽḟளሷ⣲㓟ࢆ⏘⏕ࡍࡿ཯ᛂࢆゐ፹ࡍࡿ࡜ࡉ
ࢀࡿࠋ⏘⏕ࡉࢀࡓḟளሷ⣲㓟ࡣࠊ㈎㣗ࡉࢀࡓ⣽⳦➼ࡢ⬡㉁ࡸ⺮ⓑ㉁ࠊDNA ➼ࢆ㓟໬യᐖࡋẅ⳦࡟㛵୚ࡍࡿ࡜ゝࢃࢀ࡚࠸ࡿࠋࡇࡢస⏝ࡣࠊᚰ➽᱾ሰᕢ࡞࡝␗≀ฎ⌮ࡀ⾜ࢃࢀࡿቯṚᕢ
ࡸࠊ⅖⑕࣭ಟ᚟ࡢ࣓࢝ࢽࢬ࣒ࡀ㛵୚ࡍࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿື⬦◳໬ᕢ࡟࠾࠸࡚ࡶാ࠸࡚࠸
ࡿ࡜⪃࠼ࡽࢀࡿࠋᮏ◊✲ࡣࠊዲ୰⌫ MPO ࡟ࡼࡿ␗≀ฎ⌮ࡢ࣓࢝ࢽࢬ࣒ࡢ࠺ࡕ⏕య⭷ࡢ⬡㉁㓟໬࡟ὀ┠ࡋࠊࡑࡢศᯒࢆ⾜࠺ࡇ࡜࡛⏕య⭷࡟࠾ࡅࡿ⬡㉁㓟໬ࡢᐇែゎ᫂ࢆ┠ⓗ࡜ࡍࡿࠋ௒ᅇࡣࠊ࣍ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥ(PC)ᶆ‽ရ࡟ḟளሷ⣲㓟ࢆຍ࠼ࠊ཯ᛂࡋࡓ PC ࢆ LC/QTOF-MS࡛ศᯒࡋࠊ࡝ࡢࡼ࠺࡞ PC 㓟໬≀ࡀ⏘⏕ࡉࢀࡿ࠿᳨ウࡋࡓࠋ࠙᪉ἲࠚPC ᶆ‽ရࢆ 0.14mol/l NaCl ࣜࣥ㓟⦆⾪ᾮ(pH 6.9)ࢆ⏝࠸࡚ㄪᩚࡋࠊࡇࢀ࡟ḟளሷ⣲㓟ࢼࢺ࣒ࣜ࢘(NaOCl)Ỉ⁐ᾮࢆῧຍࡋࡓࠋ37Υ࡛཯ᛂᚋࠊࢡ࣒ࣟࣟ࣍ࣝ/࣓ࢱࣀ࣮ࣝ(2:1, v/v)
ࢆຍ࠼࡚཯ᛂࢆ೵Ṇࡉࡏࠊࢡ࣒ࣟࣟ࣍ࣝᒙࢆศྲྀࡋࡓࠋศྲྀ⁐ᾮࢆヨᩱ࡜ࡋ࡚ LC (Nexera
system㸸ᓥὠ〇సᡤ) / QTOF-MS (TripleTOF5600+㸸AB SCIEX)࡛ศᯒࡋࡓࠋ࣒࢝ࣛࡣ Acquity
HSS T3 C18 ȝPmm×100mm) (Waters)ࢆ౑⏝ࡋࠊ⛣ື┦ࡣ A ᾮ㸸10mM 㓑㓟࢔ࣥࣔࢽ࣒࢘, 0.2%㓑㓟, 50%࣓ࢱࣀ࣮ࣝỈ⁐ᾮࠊB ᾮ㸸2-ࣉࣟࣃࣀ࣮ࣝ:࢔ࢭࢺࣥ=1:1ࠊὶ㏿ 0.35ȝl/min࡜ࡋࡓࠋ ῧຍࡍࡿ NaOCl ࡢ⃰ᗘཬࡧ཯ᛂ᫬㛫ࢆኚ໬ࡉࡏ᳨ウࡋࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚ୙㣬࿴⬡⫫㓟ᇶࢆࡶࡘ PC ࡟࠾࠸࡚ࡣࠊࣔࣀࢡࣟࣟࣄࢻࣜࣥయ(+OH+Cl)ࠊሷ
⣲⨨᥮య(+Cl-H)ࠊ㓟⣲௜ຍయ(+O, +2O)➼ࡀ⏘⏕ࡉࢀࡓࠋ୙㣬࿴⬡⫫㓟ᇶࢆࡶࡓ࡞࠸ PC ࡟࠾࠸࡚ࡣࡇࢀࡽࡢ⏘⏕≀ࡣㄆࡵ࡞࠿ࡗࡓࠋḟளሷ⣲㓟ࡢ⃰ᗘࡀ㧗ࡃ࡞ࡿ࡟ࡘࢀࠊࣔࣀࢡࣟ
ࣟࣄࢻࣜࣥయཬࡧሷ⣲⨨᥮యࡢ㔞ࡣቑຍࡋࡓࡀࠊ+O ࡟ࡘ࠸࡚ࡣࣉࣛࢺ࣮࡜࡞ࡾࠊ+2O ࡟ࡘ࠸࡚ࡣప⃰ᗘᇦ୍࡛ᗘቑຍࡋࡓᚋῶᑡࡋࡓࠋPC+2O ࠿ࡽ PC+O ࡬ࡢ཯ᛂࡀᏑᅾࡍࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋࡑࡢ௚ヲ⣽ࡣᙜ᪥ሗ࿌ࡍࡿࠋ
௒ᚋࡣἲ་ゎ๗࡟࠾࠸࡚ᚓࡽࢀࡿࠊᚰ➽᱾ሰᕢ➼ࣄࢺ⏤᮶ࡢヨᩱ࠿ࡽ⬡㉁ࢆᢳฟࡋࠊ᳨
ウࢆ㐍ࡵࡿணᐃ࡛࠶ࡿࠋ

́́

P-4
ἲ་ヨᩱ࡟࠾ࡅࡿ⸆≀୰ẘࡢࣂ࢖࣐࣮࣮࢜࢝᥈⣴ (2)Ᏻ㒊ᐶᏊ 1, ᫍᒸభ⨾ 1, ᑠᲚဴ㞝 2, ዉⰋ᫂ዉ 1, Ọ⃝᫂ె 1, ▮ᓥ኱௓ 1, ᒾ℩༤ኴ㑻 1,3
1༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔 ἲ་Ꮫᩍᐊ, 2 ᰴᘧ఍♫࢚࣮ࣅ࣮ࢧ࢖࢚ࢵࢡࢫ
3ᮾி኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ ἲ་Ꮫᩍᐊ

Search for biomarkers of drug intoxication cases of postmortem (2)Hiroko Abe1, Yumi Hoshioka1, Tetsuo Kokaji2, Akina Nara1, Sayaka Nagasawa1, Daisuke Yajima1,
Hirotaro Iwase1,3
1
Department of Legal Medicine, Graduate School of Medicine, Chiba University
2
AB SCIEX
3
Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo࠙┠ⓗࠚἲ་ศ㔝࡟࠾࠸࡚ࠊ⸆≀㛵㐃Ṛࡢぢᴟࡵࡢࡓࡵ࡟ࡶ⸆≀ศᯒࡣᚲ㡲ࡢศᯒ࡛࠶ࡿࠋ
ࡋ࠿ࡋࠊἲ་ヨᩱࡣ⭉ᩋࡢᙳ㡪ࡸ⸆≀ࡢṚᚋ෌ศᕸ࡜࠸ࡗࡓᙳ㡪ࢆᙉࡃཷࡅ࡚࠸ࡿࡇ࡜࠿ࡽࠊ
⸆≀⾑୰⃰ᗘࡣཧ⪃್⛬ᗘ࡟ࡋ࠿࡞ࡽ࡞࠸ࠋࡑࡇ࡛ࠊᡃࠎࡣ⾑୰⃰ᗘ࡟ຍ࠼࡚⭉ᩋࡸṚᚋ෌ศᕸࡢᙳ㡪ࢆཷࡅ࡞࠸⸆≀୰ẘᣦᶆ≀㉁ࡢ᥈⣴ࢆ㐍ࡵ࡚࠸ࡿࠋ➨ 39 ᅇ་⏝࣐ࢫࢫ࣌ࢡࢺࣝ
Ꮫ఍ᖺ఍࡟࠾࠸࡚ࡣࠊぬࡏ࠸๣ᡂศ࡟↔Ⅼࢆ⤠ࡾࠊぬࡏ࠸๣ࡀ᳨ฟࡉࢀࡓヨᩱ୰࡟ぬࡏ࠸๣ᡂศ௨እࡢ࣐࣮࣮࢝࡜࡞ࡾ࠺ࡿ≉ᚩⓗ࡞≀㉁ࡀ᳨ฟࡉࢀࡿ᪨ሗ࿌ࡋࡓࡀࠊ
ࡑࡢ≀㉁ࡢྠᐃࡲ
࡛࡟ࡣ⮳ࡽ࡞࠿ࡗࡓࠋ௒ᅇࠊྠᵝࡢ⑕౛࡟࠾࠸࡚ࠊ᭦࡟⬡㉁ࡶศᯒᑐ㇟࡜ࡋ࡚ホ౯ࢆ⾜ࡗࡓࡢ࡛ሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚ༓ⴥ኱Ꮫἲ་Ꮫᩍᐊ࡟࠾࠸࡚ࠊ㐣ཤぬࡏ࠸๣ࡀ᳨ฟࡉࢀࡓ⾑ᾮヨᩱ㸦MP ⩌㸧ࠊᑐ↷⩌࡜ࡋ࡚་⸆ရ㸦୺࡟ྥ⢭⚄⸆㸧ࡀ᳨ฟࡉࢀࡓ⾑ᾮヨᩱ㸦PC ⩌㸧ࠊ⸆≀ࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ
࡟ࡼࡗ࡚⸆≀ࡀ᳨ฟࡉࢀ࡞࠿ࡗࡓ⾑ᾮヨᩱ㸦NG ⩌㸧ࢆ⏝࠸ࡓࠋࡲࡓ࠶ࡿ✀ࡢ⸆≀࡛ࡣ㧗࣑࢜ࢢࣟࣅࣥ⾑⑕ࢆⓎ⑕ࡍࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾࠊ
᥈⣴࣐࣮࣮࢝ࡀ࣑࢜ࢢࣟࣅࣥ⏤᮶࡛࠶ࡿ࠿
ྰ࠿ࢆุ᩿ࡍࡿࡓࡵࠊ⸆≀࡜㛵㐃ࡏࡎ࣑࢜ࢢࣟࣅࣥࡀ㧗್ࢆ♧ࡋࡓ⾑ᾮヨᩱ㸦HG ⩌㸧ࡶ௒ᅇᑐ↷ヨᩱ࡜ࡋ࡚㏣ຍࡋࡓࠋBligh & Dyer ἲ࡟࡚ྛ⾑ᾮ୰ࡢᡂศࢆᢳฟࡋࠊࢡ࣒ࣟࣟ࣍ࣝᒙࢆ ศ ྲྀ ࠋ ࡑ ࢀ ࡽ ࢆ ศ ᯒ ヨ ᩱ ࡜ ࡋ LC 㸦 Nexera system 㸸 ᓥ ὠ 〇 స ᡤ 㸧 /QTOF-MS
㸦TripleTOF5600+㸸AB SCIEX)࡛ศᯒࡋࠊከኚ㔞ゎᯒ㸦MarkerView㸸AB SCIEX㸧ࢆ⾜ࡗࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚPCA ゎᯒࡢ⤖ᯝࠊMP ⩌ࠊHG ⩌ࠊPC ⩌+NG ⩌ࡢ 3 ⩌࡟ศ㞳ࡉࢀࠊࡑࢀࡒࢀ
ࡢ⩌࡟≉ᚩⓗ࡞≀㉁ࡀᏑᅾࡋࡓࠋ໬ྜ≀ྠᐃࡢ⤖ᯝࠊࡇࢀࡽࡢ≀㉁ࡣ⸆๣ᡂศ࠾ࡼࡧ⸆๣
ᡂศ௦ㅰ≀⏤᮶࡛ࡣ࡞࠸࡜⪃࠼ࡽࢀࠊ⏕యෆ௦ㅰ⏘≀࡛࠶ࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ≉࡟ HG⩌࡜ MP ⩌ࡀศ㞳ࡋࡓࡇ࡜࠿ࡽࠊMP ⩌࡟≉ᚩⓗ࡞≀㉁ࡣ࣑࢜ࢢࣟࣅࣥ⏤᮶࡛ࡣ࡞࠸ྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ௒ᚋࡇࢀࡽ≀㉁ࡢྠᐃࢆ㐍ࡵ࡚࠸ࡁࠊ≉ᐃࡢ⸆≀୰ẘ࡟≉␗ⓗ࡞≀㉁࡛࠶
ࡿ࠿ྰ࠿ࠊ᳨ウࢆ㐍ࡵࡿࠋ

́́

P-5
HSD10 ⑓ࡢ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥศᯒ࡟ࡼࡿ໬Ꮫデ᩿㔜ᯇ㝧௓ 1, ⏿ 㑳Ụ 2, ୰ᓥⱥつ 3, ణ㤿 ๛ 4, ▼ẟಙஅ 51⚟஭኱Ꮫ་Ꮫ㒊೺ᗣ⛉Ꮫ, 2 ⚟஭኱Ꮫ་Ꮫ㒊ᑠඣ⛉Ꮫ, 3 ᅜ❧ᡂ⫱་⒪◊✲ࢭࣥࢱ࣮࣭࣐ࢫ
ࢫࢡ࣮ࣜࢽࣥࢢ◊✲ᐊ, 4 ᗈᓥ኱Ꮫ኱Ꮫ㝔ᑠඣ⛉Ꮫ◊✲ᐊ, 5 ᮾி㒔ண㜵་Ꮫ༠఍ᑠඣࢫࢡࣜ
࣮ࢽࣥࢢ⛉Chemical diagnosis of HSD10 disease by LC-MS/MS analysis of acylcarnitines inblood
Yosuke Shigematsu1, Ikue Hata2, Hideki Nakajima3, Go Tajima4, Nobuyuki Ishige5
1
Department of Health Science, University of Fukui
2
Department of Pediatrics, University of Fukui
3
Mass screening laboratory, National Research Institute for Child Health and Development
4
Department of Pediatrics, Hiroshima University
5
Tokyo Health Service Association࠙┠ⓗࠚHSD10 ⑓࡜șࢣࢺࢳ࣮࢜ࣛࢮḞᦆ⑕ࡢ㓝⣲␗ᖖ㒊఩ࡣ㏆᥋ࡋ࡚࠾ࡾࠊࡑࡢ㚷ูデ᩿
ࡣ㏻ᖖ GC/MS ᒀ᭷ᶵ㓟ศᯒ࡛࣓ࢳࣝ࢔ࢭࢺ㓑㓟ࡀ␗ᖖ᤼ἥࡉࢀ࡚࠸ࡿ࠿ྰ࠿࡟ࡼࡾ⾜ࢃࢀࡿࠋᒀ୰࣓ࢳࣝ࢔ࢭࢺ㓑㓟ࡣಖᏑ࡟ࡼࡾ᳨ฟࡉࢀ࡟ࡃࡃ࡞ࡿࡇ࡜ࡸࠊᒀࡀ᥇ྲྀࡉࢀ࡚࠾ࡽࡎ
⾑ᾮℐ⣬ࡀ၏୍ࡢ᳨ᰝᮦᩱ࡛࠶ࡿࡇ࡜ࡶ࠶ࡿࡓࡵࠊLC-MS/MS ࡟ࡼࡿ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥ
ศᯒࢆヨࡳࡓࠋ
࠙᪉ἲࠚHSD10 ⑓࠾ࡼࡧșࢣࢺࢳ࣮࢜ࣛࢮḞᦆ⑕࡜㑇ఏᏊゎᯒ࡛☜ᐃデ᩿ࡉࢀࡓᝈ⪅ࡢℐ⣬
⾑࠶ࡿ࠸ࡣ⾑Ύ㸦෭෾ᗜಖᏑ㸧ࢆศᯒࡋࡓࠋAB Sciex ♫〇 API4000 MS/MS system ࡟ᓥὠ〇సᡤ〇 LC system ࢆ᥋⥆ࡋ࡚ LC-MS/MS ศᯒࢆ⾜ࡗࡓࠋLC ࣒࢝ࣛࡣ Imtakt ♫〇࣐ࣝࢳ࣮ࣔ
ࢻࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮࣒࢝ࣛ Scherzo SS-C18 (3.0㹶150 mm)ࢆ౑⏝ࡋࡓࠋᐃ㔞ࡢࡓࡵࡢෆ
㒊ᶆ‽≀㉁࡜ࡋ࡚ d9-3-hydroxyisovalerylcarnitine ࢆ౑⏝ࡋࡓࠋ࠙ ⤖ ᯝ ࠚ 2-methyl-3-hydroxybutyrylcarnitine (MHBC) ࠾ ࡼ ࡧ 2-methylacetoacetylcarnitine㸦MAAC㸧ࡢᶆရࡣධᡭฟ᮶࡞࠿ࡗࡓࡀࠊ[M+H]+ཬࡧࡑࡢ product ion ࡢศᯒ࠿ࡽ
ࡇࢀࡽ࡜᥎ᐃࡉࢀࡿ࢔ࢩࣝ࢝ࣝࢽࢳࣥࢆ᳨ฟ࡛ࡁࡓࠋࡇࢀࡽࢆ[M+H]+㸼85 ࡢࢺࣛࣥࢪࢩࣙ
ࣥࢆ⏝࠸࡚ MRM ศᯒࡋࡓ࡜ࡇࢁࠊșࢣࢺࢳ࣮࢜ࣛࢮḞᦆ⑕࡛ࡣ MHBC ࡜ MAAC ࡀቑຍࡋ࡚࠾
ࡾࠊHSD10 ⑓࡛ࡣ MHBC ࡢࡳቑຍࡋ࡚࠸ࡓࠋ
࠙⪃ᐹࠚ⾑୰࢔ࢩࣝ࢝ࣝࢽࢳࣥ⃰ᗘࡣᴟࡵ࡚ప࠸ࡶࡢࡢࠊ≉ᚩⓗ࡞ CID product ion m/z 85 ࡀ
ඹ㏻ࡋ࡚ࡳࡽࢀࡿࡢ࡛ࠊdioylcarnitine ࡛࡞ࡅࢀࡤࠊᶆရࡀධᡭฟ᮶࡞࠸࢔ࢩࣝ࢝ࣝࢽࢳ࡛ࣥ
ࡶ MRM ศᯒ࡛⌧ᐇⓗ࡞⃰ᗘホ౯ࡀྍ⬟࡛࠶ࡿࠋ୧⑌ᝈ࡜ࡶ㔜⑕ᗘࡢᖜࡀ኱ࡁࡃࠊ㍍⑕౛࡛
ࡢ MAAC ࡣࠊ≉࡟↓⑕≧ࡢ㛫Ḟᮇ࡟ࡣࠊᑐ㇟⪅ࡢ⃰ᗘᇦ࡟పୗࡍࡿࡇ࡜ࡀ࠶ࡿࡢ࡛ࠊࡑࡢ᭷
⏝ᛶ࡟ࡘ࠸࡚ࡣ᭦࡟᳨ウࡀᚲせ࡛࠶ࡿࠋ୍᪉⾑୰ࡢ᭷ᶵ㓟࡟ࡘ࠸࡚ࡣࠊ࢔ࢩࣝ࢝ࣝࢽࢳࣥ
࡜␗࡞ࡾ CID product ion ࡀ୍ᐃࡋ࡚࠸࡞࠸ࡢ࡛ࠊᶆရࡀᚓࡽࢀ࡞࠸࣓ࢳࣝ࢔ࢭࢺ㓑㓟ࡢศᯒࡣᅔ㞴࡛࠶ࡗࡓࠋ

́́

P-6
㉁㔞ศᯒ࡟ࡼࡿ௦ㅰ␗ᖖ⑕࡜⸆≀௦ㅰࡢ㚷ูᙇ ᫓ⰼ, ᮤ ወ, ㉿ ᑀ, 㔠 ᫂ጲ, 㜲 ᐀ᾏ࣑ࣝࢫ࢖ࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊

Distinguishing of metabolic disorder or drug metabolism by mass spectrometry
analysis
Chunhua Zhang, Qi Li, Ning Zhao, Mingji Jin and Zonghai Ruan
Department of research & development of MILS International࠙┠ⓗࠚ㉁㔞ศᯒ࡟ࡼࡿ௦ㅰࣉࣟࣇ࢓࢖ࣝゎᯒࡣࠊࣜ࢔ࣝ࡟᳨య᥇ྲྀ᫬ࡢయෆ௦ㅰືែࢆ཯
ᫎࡋࠊ⑓ែゎᯒࢶ࣮ࣝ࡜ࡋ࡚௦ㅰ␗ᖖ⑕ࡢ໬Ꮫデ᩿࡟ࡶ㛵ࢃࡽࡎࠊ⸆≀௦ㅰࠊ㓟໬ࢫࢺࣞࢫホ౯ࠊ⒴᳨デ࡟ࡶᛂ⏝ࡉࢀ࡚࠸ࡿࠋࢃࢀࢃࢀࡣࠊ௦ㅰ␗ᖖ⑕ࢆ␲࠺ᝈ⪅ࡢ௦ㅰ⑓ែゎᯒࢆᐇ᪋ࡋ࡚࠸ࡿ࡞࠿ࠊᗄࡘ࠿ࡢ་※ᛶ⸆≀ࡢ౑⏝࡟ࡼࡿ௦ㅰࣉࣟࣇ࢕ࣝࡢኚ໬ࡣ௦ㅰ␗ᖖ
⑕࡜ㄗㄆࡍࡿྍ⬟ᛶࡸ඾ᆺⓗ࡞௦ㅰ␗ᖖ⑕ࡢ≉ᚩⓗ࡞ኚ໬ࢆぢ࠼࡞ࡃ⑌ᝈࡢデ᩿ࢆぢⴠ࡜ࡍᜍࢀࡶࡋࡤࡋࡤ㐼㐝ࡋࠊ┿ࡢඛኳᛶ௦ㅰ␗ᖖ⑕ࡢ⑓ែゎᯒ࡟ᝨࢃࡏࡿࡇ࡜ࡀከ࠿ࡗࡓࠋ
௒ᅇࡇࢀࡽࡢ⸆≀⏤᮶௦ㅰࣉࣟࣇ࢕ࣝࡢ≉ᚩࢆศᯒࡋࠊᗄࡘ࠿ΰ஘ࡋࡸࡍ࠸⑌ᝈࡢゎᯒ࡟㓄៖ࡍ࡭ࡁⅬࡀぢࡘࡅࡓࠋࡇࡢ⤒㦂ࢆ⏕࠿ࡋࡓ᪂ࡋ࠸ᢞ⸆᝟ሗ࡜⮫ᗋ⑓ែࢆ㓄៖ࡋࡓ௦ㅰ
␗ᖖ⑕ࡢࣉࣟࣇ࢕ࣝゎᯒࢆᥦၐࡍࡿࠋ
࠙᪉ἲࠚ㐣ཤ௦ㅰ␗ᖖ⑕ࡢཷク᳨ᰝࡋ࡚ࡁࡓᝈ⪅ࡢ௦ㅰ⑓ែゎᯒࡢ࠺ࡕࠊ඾ᆺⓗ࡞௦ㅰ␗ᖖ
⑕ࣉࣟࣇ࢕ࣝࢆ஋㞳ࡋࡓኚ໬ࢆ࿊ࡋࡓ⑕౛ࡢ⮫ᗋ᝟ሗ࡜ྜࢃࡏ࡚෌᳨ウࡋࡓࠋୗグ 4 ✀ࡢ⸆≀㛵୚ࡍࡿ௦ㅰࣉࣟࣇ࢕ࣝࡢኚ໬ࢆ෌ゎᯒࡋࠊࡑࡢ≉ᚩࢆ⧳ࡵࡓࠋձ⮫ᗋデ᩿ࡢࡓࡵࡢ
࢔ࣝࢠࢽࣥ㈇Ⲵᝈ⪅࡜἞⒪ࡢࡓࡵࡢ࢔ࣝࢠࢽࣥᢞ୚ࡋࡓࢩࢺࣝࣜࣥ⾑⑕ᝈ⪅ࡢᒀ࡜⾑ᾮ㸹ղᒀ㓟್ࢆୗࡆࡿࡓࡵࡢ࢔ࣟࣉࣜࣀ࣮ࣝᢞ⸆ᝈ⪅ࡢᒀ࡜⾑ᾮ㸹ճࡃࡿ⑓ண㜵἞⒪ࡍࡿࡓࡵࡢ㨶⫢Ἔ౑⏝୰ᝈ⪅ࡢᒀ࡜⾑ᾮ㸹մ㛗ᮇ࡟ࢺ࣓ࣜࢳࣝࢢࣜࢩࣥᢞ୚୰ࡢ࣓ࢳ࣐ࣝࣟࣥ㓟⾑⑕ᝈ⪅ࡢᒀࠋ
࠙⤖ᯝࠚ࢔ࣝࢠࢽࣥᢞ୚࡟ࡼࡿ࢜ࣝࢽࢳࣥ࡜⎔≧໬ࢩࢺࣝࣜࣥ㢮ఝᡂศࡢᒀ୰᤼ἥቑຍࠊ࢔
ࣟࣉࣜࣀ࣮ࣝᢞ⸆࡟ࡼࡿ࢟ࢧࣥࢳࣥᒀ⑕ᵝ௦ㅰኚ໬ࠊ㨶⫢Ἔ౑⏝࡟ࡼࡿ⾑୰㛗㙐ࣄࢻࣟ࢟ࢩ࢔ࢩࣝ-CoA ⬺Ỉ⣲㓝⣲Ḟᦆ⑕ᵝ࢔ࢩࣝ࢝ࣝࢽࢳࣥࡢኚ໬ࠊࢺ࣓ࣜࢳࣝࢢࣜࢩࣥᢞ୚࡟ࡼ
ࡿ࣓ࢳ࣐ࣝࣟࣥ㓟⾑⑕ᝈ⪅ࡢᒀ୰ࢨࣝࢥࢩࣥࡢୖ᪼࡞࡝ࢆุ᫂ࡋࡓࠋ
࠙⪃ᐹࠚ᪤ሗࡋࡓ࢚ࢳࣞࣥࢢࣜࢥ࣮ࣝㄗ㣧࡟ࡼࡿ㧗ⶃ㓟ᒀ⑕ᵝ௦ㅰࣉࣟࣇ࢕ࣝࡢฟ⌧࡟ࠊୖグ 4 ✀ࡢ⸆≀ᢞ୚᫬ࡢ௦ㅰኚ໬ࡣࡑࢀࡒࢀ┦ᛂࡍࡿ✀ࡢ௦ㅰ␗ᖖ⑕࡟㢮ఝࡍࡿࡇ࡜ࢆ᫂ࡽ
࠿࡟ࡋࡓࠋࡇࢀࡽࡢ⤒㦂ࢆά࠿ࡋ࡚ࡉࡽ࡟ࡉࡲࡊࡲ࡞⸆ရᢞ୚࡟ࡼࡿ௦ㅰࣉࣟࣇ࢕ࣝࡢኚ໬ࢆ᳨ドࡋࠊࡼࡾヲ⣽࡞ୟࡘṇ☜࡞⑓ែゎᯒ࡟⧅ࡀࢀࠊ᳨య᥇ྲྀ᫬ࡢᢞ⸆ࡸ⮫ᗋ⑓ែࢆ㓄៖ࡋࡓ௒ᚋࡢ௦ㅰࣉࣟࣇ࢕ࣝゎᯒࡢ⮫ᗋᛂ⏝࡬㐍ࡵ࡚ࡺࡁࡓ࠸ࠋ

́́

P-7
GC/MS ศᯒ࡟ࡼࡿࢩࢺࣝࣜࣥ⾑⑕ᝈ⪅ᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢ⮫ᗋព⩏㜲 ᐀ᾏ, ᮤ ወ, 㔠 ᫂ጲ, ᙇ ᫓ⰼ࣑ࣝࢫ࢖ࣥࢱ࣮ࢼࢩࣙࢼࣝ ◊✲㛤Ⓨ㒊

Study on clinical significance of urinary ornithine in citrullinemia patients by
GC/MS
Zonghai Ruan, Qi Li, Mingji Jin and Chunhua Zhang
Department of research & development of MILS International
࠙┠ⓗࠚGC/MS ศᯒ࡟ࡼࡿᒀ୰࢘ࣛࢩࣝ࡜࢜ࣟࢵࢺ㓟ࡢ␗ᖖ㧗᤼ἥࡀᒀ⣲ᅇ㊰⣔␗ᖖࡢ໬Ꮫ
デ᩿ࡢࣂ࢖࣐࣮࣮࢜࢝࡜ࡋ࡚ྂࡃ࠿ࡽ౑ࢃࢀ࡚࠸ࡿࠋࢃࢀࢃࢀࡣࠊᒀ⣲ᅇ㊰࣓ࣥࣂ࣮࢔࣑
ࣀ㓟ࡢ࢜ࣝࢽࢳࣥࡸ࢔ࣝࢠࢽࣥ⇕ศゎ⏘≀ࡢྠ᫬᳨ฟ࡟ࡼࡾࠊ᭦࡟ᒀ⣲ᅇ㊰⣔␗ᖖࡢヲ⣽デ᩿࡟㈉⊩࡛ࡁࡿ◊✲⤖ᯝࢆ 2000 ᖺࡢᮏᏛ఍࡛ሗ࿌ࡋࡓࠋ௒ᅇᒀ୰ࡢ⎔≧໬ࢩࢺࣝࣜࣥᡂ
ศࡢ᳨ฟ≧ἣࢆຍ࠼ࠊࢩࢺࣝࣜࣥ⾑⑕ᝈ⪅ࡢᒀ୰࢜ࣝࢽࢳ᳨ࣥฟࡢព⩏ࢆ෌᳨ウࡋࡓࡢ࡛ሗ࿌ࡍࡿࠋ࠙᪉ἲࠚඛኳᛶ௦ㅰ␗ᖖ⑕ࡢࢫࢡ࣮ࣜࢽࣥࢢ࡛ᙜ᪋タ࡟౫㢗ࡋ࡚ࡁࡓ୰ᅜேᝈ⪅ 7 ྡ㸦⏨ඣ2 ౛ࠊዪඣ 5 ౛㸧ࡢᒀ࡜ℐ⣬⾑࡟ࡘ࠸࡚ศᯒࡋࡓࠋᒀ᳨య࡟ࡘ࠸࡚ࠊ᪤ሗࡢ࢘ࣞ࢔࣮ࢮฎ⌮ἲ࡟ࡼࡿ๓ฎ⌮ࡋࡓᚋࠊGC/MS ศᯒࢆ⾜ࡗࡓࠋGC/MS ศᯒࡣࠊJEOL ♫ࡢ JMS-K9 ࡛⾜ࡗࡓࠋℐ⣬⾑᳨య࡟ࡘ࠸࡚ࠊࢱࣥࢹ࣒࣐ࢫศᯒࡼࡾ⾑୰࢔࣑ࣀ㓟࡜࢔ࢩࣝ࢝ࣝࢽࢳࣥࢆศᯒࡋࡓࠋ
ࢱࣥࢹ࣒࣐ࢫࡣᓥὠ♫ࡢ LCMS-8040 ࢆ౑⏝ࡋࡓࠋᒀ࡜ℐ⣬⾑ࡢศᯒ⤖ᯝࢆྜࢃࡏ࡚ࠊᙜ᪋タࡢ௦ㅰ␗ᖖ⑕ゎᯒࣉࣟࢢ࣒࡛ࣛ⑓ែゎᯒࡋࡓࠋ࠙⤖ᯝࠚୖグ 7 ౛࠸ࡎࢀࡶᒀ୰࢘ࣛࢩࣝ࡜࢜ࣟࢵࢺ㓟ࡢ␗ᖖቑຍࢆㄆࡵࡓࠋࡑࡢ࠺ࡕ 6 ౛ᒀ୰࢜ࣝࢽࢳࣥࡶ᳨ฟࡉࢀࡲࡋࡓࠋྠ᫬࡟࢜ࣝࢽࢳ᳨ࣥฟࡉࢀࡓᝈ⪅ࡢ࠺ࡕࡢ 3 ౛ࡀ⎔≧໬ࢩࢺࣝࣜࣥᡂศࡶ᳨ฟࡉࢀࡓࠋణࡋࠊ࠺ࡕ 1 ౛ࡢ෌᳨᫬࡟ᒀ୰࢜ࣜࢽࢳࣥࡢࣆ࣮ࢡࡀᾘኻ
ࡋࠊ௦ࡾ࡟⎔≧໬ࢩࢺࣝࣜࣥᡂศࢆ኱ࡁࡃ᳨ฟࡉࢀࡓወጁ࡞⌧㇟ࡀぢࡽࢀࡓࠋ⾑୰ࡢ࢔࣑ࣀ㓟ศᯒ࡛ࡣࡍ࡭࡚ࡢ⑕౛ࡢࢩࢺࣝࣜࣥࡢୖ᪼ࢆ☜ㄆ࡛ࡁࡓࡢ࡛ࠊᒀ⣲ᅇ㊰⣔␗ᖖࡢࢩࢺ
ࣝࣜࣥ⾑⑕࡜໬Ꮫデ᩿ࡋࡲࡋࡓࠋ
࠙⥲ᣓࠚୖ㏙ࡢ⤖ᯝࡼࡾࠊᒀ୰࢘ࣛࢩࣝ࡜࢜ࣟࢵࢺ㓟ࡢቑຍ࡟క࠸ࠊ࢜ࣝࢽࢳࣥࡢ㧗᤼ἥࢆㄆࡵࡓ௦ㅰࣉࣟࣇ࢕ࣝࡣࠊࢩࢺࣝࣜࣥ⾑⑕ࡢ໬Ꮫデ᩿ࡢ≉ᚩ࡛࠶ࡿࡢࡣ௨๓ࡢሗ࿌࡜୍⮴ࡋࡓࠋ⎔≧໬ࢩࢺࣝࣜࣥᡂศࡀࠊ୍㒊ศࡢࢩࢺࣝࣜࣥ⾑⑕ᝈ⪅࠿ࡽ᳨ฟࡉࢀࡓࠋࡇࡢᡂศ
ࡢ໬Ꮫᵓ㐀ࡣࡲࡔ୙᫂ࡀࠊ࢜ࣜࢽࢳࣥࡢᾘኻ࡟ฟ⌧ࡍࡿ⌧㇟࠿ࡽࠊ࢜ࣝࢽࢳࣥࡢศゎ⏘≀࡛ࡣ࡞࠸࠿࡜᥎ ࡍࡿࠋࡇࢀࡲ࡛⎔≧໬ࢩࢺࣝࣜࣥᡂศࡀࢩࢺࣝࣜࣥ⾑⑕࡜࢔ࣝࢠࢽࣥࢥ
ࣁࢡ㓟⾑⑕ࡢデ᩿࣐࣮࣮࢝࡜ࡋ࡚ሗ࿌ࡉࢀ࡚࠸ࡓࡀࠊ⎔≧໬ࢩࢺࣝࣜࣥᡂศࡢ᳨ฟࡣ୙Ᏻ
ᐃ࡛࠶ࡾࠊ࢜ࣝࢽࢳࣥ࡜ࡢ┦㛵ᛶࡀ࠶ࡿࡓࡵࠊᒀ୰࢜ࣝࢽࢳࣥࡢ᳨ฟࡀᒀ⣲ᅇ㊰⣔␗ᖖࡢヲ⣽デ᩿࡟ಙ㢗࡛ࡁࡿ࣐࣮࣮࢝࡜ࡋ࡚෌ㄆ㆑ࡋࡓࠋ௒ᚋ⎔≧໬ࢩࢺࣝࣜࣥᡂศ࡜࢜ࣝࢽࢳ
ࣥࡢ┦㛵ᛶ࡟ࡘ࠸࡚ࡉࡽ࡟◊✲㐍ࡵ࡚ࡺࡁࡓ࠸ࠋ

́́

P-8
GCMS ࡟ࡼࡿ⣅౽୰⭉ᩋ⏘≀ࡢᐃⅲ⹒ཧ୹, ⚟ཎ⨾௦Ꮚ, ஂ⏣㈗⩏ᰴᘧ఍♫ࢸࢡࣀࢫ࣭ࣝ࢞ࣛ࣎

Determination of phenols and indoles in feces using GCMS
Olansandan, Miyoko Fukuhara, Takayoshi Hisada
TechnoSruga Laboratory Co.,Ltd.
࠙┠ⓗࠚ㏆ᖺࠊ⭠ෆ⣽⳦ࡢᵝࠎ࡞௦ㅰ≀ࡀᐟ୺ࡢ೺ᗣ࡟ᙳ㡪ࢆཬࡰࡍࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋ
ࡑࢀࡽࡢ㛵ಀࢆヲ⣽࡟᳨ウࡍࡿୖ࡛ࠊ⭠ෆ⣽⳦ྀࡢゎᯒࡀᗈࡃ⾜ࢃࢀ࡚࠸ࡿࠋࡲࡓࠊ⭠ෆ⣽⳦௦ㅰ≀࡜ࡢ⥲ྜⓗ࡞ゎᯒࡶ㠀ᖖ࡟㔜せ࡛࠶ࡾࠊ௦ㅰ≀ࢆ⢭ᗘࡼࡃࠊ࠿ࡘ㎿㏿࡟ᐃ㔞࡛ࡁࡿศᯒἲࡢᵓ⠏ࡀồࡵࡽࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊ⭠ෆ⎔ቃᝏ໬ࢆホ౯ࡍࡿᣦᶆ࡜ࡋ࡚▱ࡽࢀ࡚࠸ࡿ⣅౽୰ࣇ࢙ࣀ࣮ࣝ㢮ࡸ࢖ࣥࢻ࣮ࣝࠊࢫ࢝ࢺ࣮ࣝ࡞࡝⭉ᩋ⏘≀࡟㛵ࡍࡿ GCMS ࢆ⏝࠸ࡓศᯒἲࢆ☜❧ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋࢧࣥࣉࣝࡢಖᏑ࡟㛵ࡋ࡚ࡶ᳨ウࡋࡓࡢ࡛ేࡏ࡚
ሗ࿌ࡍࡿࠋ࠙᪉ἲࠚ᳨యࡢ๓ฎ⌮ࡣࠊΰ⦎ࡋࡓࢧࣥࣉࣝࡼࡾ⣙ 0.2 g ࢆ⛗㔞ࡋࠊෆ㒊ᶆ‽ྵ᭷ࣜࣥ㓟ࣂࣇ࢓࣮࡛ᠱ⃮ࡋࠊ85Υ࡟࡚ 15 ศ㛫⇕ฎ⌮ࡋࡓࠋ෭༷ᚋ࢔ࢭࢺࢽࢺࣜࣝࢆ⏝࠸࡚ᢳฟࢆ⾜࠸ࠊ
PSA-30 ࡟ࡼࡾ⢭〇ࡋ࡚ GCMS ࡟౪ࡋࡓࠋ೺ᖖே 4 ྡࡢ୍ᅇࡢ⣅౽ࢆࡑࢀࡒࢀ᥇㞟ΰ⦎ࡋ࡚ࠊ
4 ಶ࡟ᑠศࡋ࡚í30Υ࡛෾⤖ಖᏑࡋࠊ0 ᪥ࠊ14 ᪥ࠊ28 ᪥(n=3)࡟࠾࠸࡚ ᐃࢆ⾜ࡗࡓࠋ࠙⤖ᯝࠚ೺ᖖே 4 ྡࡢ⣅౽࠿ࡽࣇ࢙ࣀ࣮ࣝ 0.89~2.2 ȝJJࠊp-ࢡࣞࢰ࣮ࣝ 4.2~143 ȝJJࠊ࢖ࣥࢻ࣮ࣝ 2.0~56 ȝJJࠊࢫ࢝ࢺ࣮ࣝ 0.16~20 ȝJJ ࠾ࡼࡧ 4-࢚ࢳࣝࣇ࢙ࣀ࣮ࣝ 0.63~4.6 ȝJJ ࡢ⠊ᅖ᳨࡛ฟࡉࢀࠊಶேᕪࡀ኱ࡁ࠿ࡗࡓࠋᮏἲ࡟ࡼࡿࣄࢺ⣅౽࡬ࡢΰྜᶆ‽ᾮῧຍᅇ཰⋡ᐇ㦂࡛ࡣࠊప⃰ᗘ(0.04 ȝJJ)࡛ 74.1~115%ࠊ㧗⃰ᗘ(1.0 ȝJJ) ࡛ࡣ 86.1~122%࡛࠶ࡗࡓࠋᐇヨᩱ࡟࠾ࡅࡿ⧞ࡾ㏉ࡋ

ᐃ(n=7)ࡋࡓ᫬ࡢ┦ᑐᶆ‽೫ᕪ(RSDr)ࡣ 0.26~4.3%࡜Ⰻዲ࡞⢭ᗘࡀ☜ㄆࡉࢀࡓࠋᮏἲࡢᐃ㔞ୗ㝈ࡣ ȝJJ ࡛࠶ࡗࡓࠋ
࠙⥲ᣓࠚᮏἲࡣࠊࣄࢺࡢ⣅౽ࡔࡅ࡛ࡣ࡞ࡃࣛࢵࢺࠊ࣐࢘ࢫࠊ࣐࢘ࠊࣄࢶࢪࠊ࢖ࢾ࡞࡝ࡢ⣅౽୰⭉ᩋ⏘≀ࡢศᯒἲ࡜ࡋ࡚ࡢ฼⏝ࡶᮇᚅ࡛ࡁࡿࠋ

́́

P-9
LC-MS/MS ἲ࡟ࡼࡿࣄࢺᒀ୰࡟࠾ࡅࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟ࠊ࣍ࣔࣂࢽࣜࣥ㓟ࠊ࣓ࢱࢿࣇࣜࣥࠊࣀ࣓ࣝࢱࢿࣇࣜࣥ࠾ࡼࡧࢡࣞ࢔ࢳࢽࣥࡢྠ᫬ᐃ㔞ἲࡢ᳨ウሷᕝுኴ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼஭࿴ኵ 1
1ᮥᯘ኱Ꮫಖ೺Ꮫ㒊, 2 ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊Simultaneous determination of vanillylmandelic acid, homovanillic
metanephrine, normetanephrine and creatinine in human urine

acid,

Ryota Shiokawa1, Kaori Hosoda1, Hiromi Shibasaki2, Akitomo Yokokawa2, Kazuo Ishii1
1
Kyorin University Faculty of Health Sciences
2
Tokyo University of Pharmacy and Life Sciences School of Pharmacy࠙┠ⓗࠚ⚄⤒ⱆ⣽⬊⭘ࡣⓑ⾑⑓࡟ḟ࠸࡛ᑠඣ࡟ከ࠸ࡀࢇ࡛࠶ࡿࠋࡇࡢ⑌ᝈ࡛ࡣࠊᝈ⪅ࡢᒀ୰࡟࢝ࢸࢥ࣮ࣝ࢔࣑ࣥࡢ᭱⤊௦ㅰ⏘≀࡛࠶ࡿࣂࢽ࣐ࣜࣝࣥࢹࣝ㓟 (VMA) ࡜࣍ࣔࣂࢽࣜࣥ㓟(HVA) ࡀከࡃ᤼ἥࡉࢀࡿࠋࡑࡢࡓࡵࠊࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ࡟ࡣࢡࣞ࢔ࢳࢽࣥ (Cr) ⿵ṇࡋࡓᒀ୰ VMAࠊHVA ್ࡀ⏝࠸ࡽࢀ࡚࠸ࡓࡀࠊⰋᛶ⭘⒆࡜ࡢ༊ูࡀᅔ㞴࡛࠶ࡿࡇ࡜࠿ࡽ⌧ᅾఇṆࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊ〓Ⰽ⣽⬊⭘ࡶ࢝ࢸࢥ࣮ࣝ࢔࣑ࣥ⏘⏕⭘⒆࡛࠶ࡾࠊࢫࢡ࣮ࣜࢽࣥࢢ᳨
ᰝ࡟ࡣ Cr ⿵ṇࡋࡓᒀ୰࣓ࢱࢿࣇࣜࣥ (MN) ್࡜ࣀ࣓ࣝࢱࢿࣇࣜࣥ (NMN) ್ࢆ฼⏝ࡍࡿࠋ
VMAࠊHVAࠊCr ࡢࡳ࡞ࡽࡎ MN ࡜ NMN ࡶྠ᫬࡟ᐃࡍࡿࡇ࡜࡟ࡼࡾࠊ⚄⤒ⱆ⣽⬊⭘ࢫࢡ࣮ࣜࢽࣥࢢࡢデ᩿ࡢ⢭ᗘࡢྥୖࡸࠊヲ⣽࡞〓Ⰽ⣽⬊⭘ࡢ᳨ᰝࡢ୍ຓ࡟࡞ࡿࡇ࡜ࡀᮇᚅࡉ
ࢀࡿࠋࡉࡽ࡟ࠊ2 ⭘⒆ࡢྜే⑕౛ࡀ࠶ࡿⅬ࠿ࡽࡶ 5 ✀ࢆྠ᫬࡟ศᯒࡍࡿࡇ࡜ࡣ㠀ᖖ࡟᭷⏝࡛࠶ࡿࠋᮏ◊✲࡛ࡣࠊ໬Ꮫⓗᛶ㉁ࡀ኱ࡁࡃ␗࡞ࡿ VMAࠊHVAࠊMNࠊNMN ࡜ Cr ࡢ LC-MS/MS࡟ࡼࡿ▷᫬㛫ྠ᫬ศᯒἲࢆ᳨ウࡋࡓࠋ࠙᪉ἲࠚ࣒࢝ࣛࡣ YMC Triart-C18 (150 × 2.0 mm, 3 Pm; YMC)ࠊ⛣ື┦࡟ 10 mM 㓑㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮ࡜࢔ࢭࢺࢽࢺࣜࣝ㸦ࢢࣛࢪ࢚ࣥࢺἲ㸧ࢆ⏝࠸ࡓࠋᒀ 10 ml ࡟ᑐࡋ 6N ሷ㓟ࢆ 100 Plຍ࠼ࡓࡶࡢࢆ 10 ಸᕼ㔘ࡋࠊ඲㔞ࢆ 100 Pl ࡟ㄪ〇ࡋࡓᚋࠊ2 Pl ࢆ ᐃࡋࡓࠋ࡞࠾ࠊෆᶆ‽≀㉁ࡣ㔜Ỉ⣲࡛ᶆ㆑ࡉࢀࡓ VMA-d3ࠊHVA-d3ࠊMN-d3ࠊNMN-d3 ࠾ࡼࡧ Cr-d3 ࢆ⏝࠸ࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚVMAࠊHVAࠊMNࠊNMNࠊCr ࠾ࡼࡧෆᶆ‽≀㉁ࡣ 7 ศ௨ෆ࡟ศᯒྍ⬟࡛࠶ࡗࡓࠋ೺ᖖேᒀ࡟࠾ࡅࡿᇶ‽್ࡢ⠊ᅖ࡟࠾࠸᳨࡚㔞⥺ࢆసᡂࡋࡓ࡜ࡇࢁࠊ┦㛵ಀᩘ 0.9951
㹼0.9997 ࡢⰋዲ࡞┤⥺ᛶࡀᚓࡽࢀࡓࠋ᳨㔞⥺ࡢ⠊ᅖෆ 3 ⃰ᗘ࡟࠾࠸࡚ῧຍᅇ཰ヨ㦂ࢆ⾜ࡗࡓ⤖ᯝࠊCr ࡣ࠸ࡎࢀࡶ CV 3.6% ௨ୗ࡛࠶ࡗࡓࡀࠊ௚ࡢ 4 ✀ࡣ༑ศ࡞⢭ᗘࡀᚓࡽࢀ࡞࠿ࡗࡓ
ࡓࡵࠊᘬࡁ⥆ࡁศᯒἲࡢ᳨ウࢆຍ࠼ࡿࠋLC-MS/MS ἲ࡟ࡼࡿ 5 ✀ࡢྠ᫬ศᯒࡣࠊ᳨య᳨ᰝ
ࡢ▷᫬㛫໬ࡢほⅬ࠿ࡽ᭷⏝࡜⪃࠼ࡿࠋ⌧ᅾࠊ⡆౽࡞ᅛ┦ᢳฟἲࡶど㔝࡟ධࢀ᳨ウࢆ㐍ࡵ࡚࠾ࡾࠊ⢭ᗘ෌⌧ᛶࡢ㧗࠸ศᯒἲࢆ☜❧ࡍࡿணᐃ࡛࠶ࡿࠋ

́́

P-10
LC-MS/MS ࡟ࡼࡿᒀ୰ࢥࣝࢳࢰ࣮ࣝཬࡧࢥࣝࢳࢰࣥࡢ Į- / ȕ-Ỉ㓟໬௦ㅰ≀ࡢศ㞳ᐃ㔞ἲᶓᕝᙲ᭸ 1, ඵ㒓㞞ᘯ 1, ᖹ㔝Ⰻᖹ 1, ⣽⏣㤶⧊ 2, ▼஭࿴ኵ 2, ྂ⏣ 㝯 1, ᰘᓮᾈ⨾ 11ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊, 2 ᮥᯘ኱Ꮫಖ೺Ꮫ㒊

Separation and quantitative determination of Į- and ȕ-hydroxylated metabolitesof cortisol and cortisone in human urine by LC-MS/MS
Akitomo Yokokawa1, Masahiro Hachigo1, Ryohei Hirano1, Kaori Hosoda2, Kazuo Ishii2,
Takashi Furuta1, and Hiromi Shibasaki1
1School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
2
Faculty of Health Sciences, Kyorin University࠙┠ⓗࠚࢥࣝࢳࢰ࣮ࣝࡣࠊCYP3A ࡟ࡼࡾ ȕ-ࣄࢻࣟ࢟ࢩࢥࣝࢳࢰ࣮ࣝ ȕ-OHF) ࡜❧య␗ᛶయ Į-OHF ࡟௦ㅰࡉࢀࡿࠋ₇⪅ࡽࡣࠊ⾑୰ࢥࣝࢳࢰ࣮ࣝ⃰ᗘ-᫬㛫᭤⥺ୗ㠃✚࡜ᒀ୰ ȕ-OHF
᤼ἥ㔞࠿ࡽ⟬ฟࡉࢀࡿࢥࣝࢳࢰ࣮ࣝ ȕ-Ỉ㓟໬௦ㅰࢡࣜ࢔ࣛࣥࢫ (CLP ȕ F) ࢆᣦᶆ࡜ࡋࡓCYP3A άᛶホ౯ἲࢆ㛤Ⓨࡋࡓࠋࡉࡽ࡟ࠊHPLC-UV ࡛ ȕ-OHF ࡜ Į-OHF ࢆศ㞳ᐃ㔞ࡋࠊ
CLP Į ) ࡀ CLP ȕ ) ࡢ⣙ 1/10 ࡛࠶ࡿࡇ࡜ࢆ᫂ࡽ࠿࡜ࡋࡓࠋ୍᪉ࠊࢥࣝࢳࢰ࣮ࣝࡣ 1ȕ-HSD ࡟ࡼࡾࢥࣝࢳࢰࣥ࡜┦஫ኚ᥮ࡍࡿࡓࡵࠊCYP3A άᛶホ౯࡟ࡣ ȕ-ࣄࢻࣟ࢟ࢩࢥࣝࢳࢰࣥ
ȕ-OHE)ࡶ⪃៖ࡍ࡭ࡁ࡜ࡢሗ࿌ࡀ࠶ࡿࡀࠊĮ-OHE ࡬ࡢゝཬࡣ࡞࠸ࠋᮏ◊✲࡛ࡣࠊࢥࣝࢳࢰ
࣮ࣝ 6 ఩Ỉ㓟໬௦ㅰ࡟ᇶ࡙ࡃ CYP3A άᛶホ౯࡬ࡢྛ 6 ఩Ỉ㓟໬௦ㅰ≀ࡢᐤ୚ࡢ᳨ウࢆ┠ⓗ࡟ࠊLC-MS/MS ࡟ࡼࡿᒀ୰ Į-OHF, ȕ-OHF, Į-OHE, ȕ-OHE ࡢศ㞳ศᯒἲࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚLC-MS/MS ࡣ TSQ Quantum Ultra (Thermo Fisher Scientific) ࢆ⏝࠸ࡓࠋ࣒࢝ࣛࡣ Kinetex
C8 (phenomenex; 75×3.0 mm I.D.,  ȝP  ࡜ࡋࠊෆᶆ‽≀㉁࡟ࡣ ȕ-OHF-2H4 ࡜ Į-OHF-2H4
ࢆ⏝࠸ࡓࠋ⛣ື┦࡟ࡣ 0.2%ࢠ㓟+10 mM 㓑㓟࢔ࣥࣔࢽ࣒࢘Ỉ⁐ᾮ࡜࣓ࢱࣀ㸫ࣝࢆ⏝࠸ࠊࢢࣛࢪ࢚ࣥࢺἲ࡛ ᐃࡋࡓࠋESI (negative-ion mode) ἲ࡛ࡣࠊȕ-OHF ࡜ Į-OHF ࡢ precursor
ion ࡜ product ion (ࢠ㓟௜ຍయ) ࡜ࡋ࡚ m/z 423 ࡜ m/z 347 ࢆタᐃࡋࠊȕ-OHE ࡜ Į-OHE ࡛ࡣ m/z 421 ࡜ m/z 345 ࢆタᐃࡋࡓࠋᒀࡢᢳฟ࡟ࡣ Sep-Pak C18 Plus ࢆ⏝࠸ࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚࢢࣛࢪ࢚ࣥࢺἲ࡟ࡼࡿࢥ࢔ࢩ࢙࣒ࣝ࢝ࣛ C8 ࡛❧య␗ᛶయࢆศ㞳ࡋࡓࠋȕ-OHF
࡜ Į-OHF ࡢಖᣢ᫬㛫ࡣ 4.1, 4.7 min (Rs=2.5)ࠊ
ȕ-OHE ࡜ Į-OHE ࡛ࡣ 6.4, 7.1 min (Rs=3.1) ࡛࠶ࡗࡓࠋࡇࢀࡲ࡛ᒀ୰ Į-OHE ศᯒࡢሗ࿌ࡣ࡞࠸ࡀࠊ❧య␗ᛶయ ȕ-OHE ࡢ 1/10 ⛬ᗘ࡟┦ᙜࡍࡿࣆ࣮ࢡࢆ☜ㄆࡋࡓࠋᮏἲࡢ⢭ᗘ࣭෌⌧ᛶࡣࠊȕ-OHFࠊĮ-OHF ࡛ࡣ┦ᑐㄗᕪࡀ 7.3%
௨ෆࠊኚືಀᩘࡀ 2.0%௨ෆ࡜Ⰻዲ࡛࠶ࡗࡓࠋȕ-OHF-2H4 ࢆෆᶆ‽≀㉁࡜ࡋࡓࠊȕ-OHE ࡜Į-OHE ࡢᐃ㔞࡛ࡣ┦ᑐㄗᕪࡀ኱ࡁࡃࠊ⌧ᅾࠊᑐᛂࡍࡿᏳᐃྠ఩యᶆ㆑యࢆྜᡂ୰࡛࠶ࡿࠋ

́́

P-11
Dried Blood Spot(DBS)࡜ᒀ୰ࡢከ⢾㢮ࢹ࢟ࢫࢺࣛࣥཬࡧࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ
࣮ࢳࡢศᯒᑠᓥ㯞ᐇ 1, ᒸ㔝㞞ே 1, ᅵ⫧⨾ᬛᏊ 2, 㝜ᒣಙ஧ 11ᰴᘧ఍♫ LSI ࣓ࢹ࢕࢚ࣥࢫ ࢔ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ
2ᅜ❧ࢫ࣏࣮ࢶ⛉Ꮫࢭࣥࢱ࣮ ࣓ࢹ࢕࢝ࣝࢭࣥࢱ࣮

Analysis of polysaccharides dextran and hydroxyethylstarch in dried blood spot
and urine
Asami Kojima1, Masato Okano1, Michiko Dohi 2, Shinji Kageyama1
1Anti-Doping Laboratory, LSI Medience Corporation
2
Medical Centre, Japan Institute of Sports Sciences࠙┠ⓗࠚ㏆ᖺࠊᣢஂຊྥୖࢆពᅗ࡟࢚ࣜࢫ࣏࢚ࣟࢳࣥࡢ౑⏝ࡸ㍺⾑࡟ࡼࡾ㉥⾑⌫ࢆቑຍࡉࡏ
ࡿࢻ࣮ࣆࣥࢢࡀ➇ᢏࢫ࣏࣮ࢶ࡟࠾࠸࡚኱ࡁ࡞ၥ㢟࡜࡞ࡗ࡚࠸ࡿࠋࡇࡢࡼ࠺࡞⾑ᾮࢻ࣮ࣆࣥ
ࢢ࡟ᑐࡋ࡚ࠊ➇ᢏ⪅ಶேࡢ࣊ࣔࢢࣟࣅࣥ㔞࡞࡝ࡢ⾑ᾮࣃ࣓࣮ࣛࢱ࣮ࢆ⥅⥆ⓗ࡟ᐃࡋࠊࡑࡢኚ໬࠿ࡽࢻ࣮ࣆࣥࢢࢆ᳨▱ࡍࡿᡭἲ㸸Athlete Biological Passport (ABP)᳨ᰝࡀᐇ᪋ࡉࢀ࡚࠸
ࡿࠋࡲࡓࠊ⾑ᅽࡢ⥔ᣢࡸᾋ⭘ࡢ἞⒪࡟౑⏝ࡉࢀࡿ⾑₢ቑ㔞๣࡛࠶ࡿࣄࢻࣟ࢟ࢩ࢚ࢳࣝࢫࢱ
࣮ࢳ (HES)ཬࡧࢹ࢟ࢫࢺࣛࣥ(DEX)ࡣࠊ⾑ᾮࡢᕼ㔘ຠᯝࡀ࠶ࡿࡓࡵࠊ⾑ᾮࢻ࣮ࣆࣥࢢࡢ㞃ⶸ๣࡜ࡋ࡚⚗Ṇ⸆≀࡟ᣦᐃࡉࢀ࡚࠸ࡿࠋ⌧ᅾࠊࡇࢀࡽࡢ⾑₢ቑ㔞๣ࡣࠊᒀヨᩱ࡟ࡼࡿࢻ࣮ࣆ
ࣥࢢ᳨ᰝ࡟ࡼࡾ᳨ฟࡋ࡚࠸ࡿࡀࠊABP ᳨ᰝ࡟࠾࠸࡚ࡣࠊ᥇ᒀࢆకࢃ࡞࠸ࡇ࡜ࡀከ࠸ࠋࡑࡢ
ࡓࡵࠊ⾑ᾮヨᩱ࠿ࡽࡶ⾑₢ቑ㔞๣ࡀ᳨ฟ࡛ࡁࡿࡇ࡜ࡀᮃࡲࢀࡿࠋ᫖ᖺࠊᡃࠎࡣࠊ஝⇱⾑ᾮࢫ࣏ࢵࢺ㸦Dried Blood Spot: DBS㸧ࡢ฼⏝ࡀ⯆ዧ๣ࡢࢻ࣮ࣆࣥࢢ᳨ᰝ࡟࠾࠸࡚᭷⏝࡛࠶ࡿ࡜ሗ࿌ࡋࡓࠋࡑࡇ࡛௒ᅇࡣࠊHES ཬࡧ DEX ࡟࠾࠸࡚ࡶ DBS ࢆ౑⏝ࡋࡓศᯒἲࢆ㐺⏝ࡍࡿ஦ࢆ᳨ウࡋࡓࠋᮏⓎ⾲࡛ࡣࠊྛ⸆๣ࡢᢞ୚ࡀ ABP ࡟୚࠼ࡿᙳ㡪࡟ࡘ࠸࡚ࡶሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚDBS㸸⾑ᾮ ȝ/ ࢆ DMPK-C IND ࣮࢝ࢻ࡟ࢫ࣏ࢵࢺࡋࠊᐊ ஝ᅛᚋࠊ࣐࢖ࢡࣟࣃࣥ
ࢳ࡛ᢤࡁྲྀࡾࠊෆ㒊ᶆ‽⁐ᾮ㸦ȕ-cyclodextrin㸧200 ȝ/ ࢆῧຍࡋࠊᨩᢾࡋࡓࠋࡑࡢᚋࠊ㉸㡢Ἴᢳฟࢆ⾜ࡗࡓࠋᒀ᳨య㸸ᒀ᳨య 10 ȝ/ ࡟ࠊෆ㒊ᶆ‽⁐ᾮ 190 ȝ/ ࢆῧຍࡋࠊᨩᢾࡋࡓࠋ࠸ࡎ
ࢀࡢࢧࣥࣉࣝࡶ㉸㐲ᚰศ㞳ࢆ⾜࠸ࠊୖΎ 2 ȝ/ ࢆ UPLC/MS/MS (Waters) ࡟ὀධࡋࡓࠋ
࠙⤖ᯝ࣭⪃ᐹࠚDBS ࢆ⏝࠸ࡓ⾑ᾮヨᩱ࡟ࡼࡿࠊHES ཬࡧ DEX ࡢศᯒ᪉ἲࢆ☜❧ࡋࡓࠋᒀヨᩱ࡜ẚ㍑ࡋ࡚ࡶศᯒ⢭ᗘ᳨࣭ฟឤᗘࡶⰋዲ࡛࠶ࡗࡓࠋᢞ୚ヨ㦂࡛᥇ྲྀࡋࡓ⾑ᾮヨᩱ࠿ࡽࡣᢞ୚ᚋ 48 ᫬㛫ࡲ࡛ࡢ᳨ฟࡀྍ⬟࡛࠶ࡾࠊ⾑ᾮࣃ࣓࣮ࣛࢱ࣮࡟ᙳ㡪ࢆཬࡰࡍ᫬㛫ᖏ࡟࠾࠸࡚
Ⰻዲ࡟᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋ௒ᚋࠊ᥇ᒀࢆᐇ᪋ࡋ࡞࠸ ABP ᳨ᰝ࡟࠾࠸࡚ࡶࠊ⾑ᾮヨᩱ㸦DBS㸧ࢆࣃ࣓࣮ࣛࢱ࣮ኚືࡢ㞃ⶸࢆ┠ⓗ࡜ࡋࡓ⾑₢ቑ㔞๣ࡢ᳨ฟ࡟㐺⏝ࡍࡿࡇ࡜ࡀྍ⬟࡜࡞ࡿࠋ

́́

P-12
ℐ⣬⾑ࢆ⏝࠸ࡓ᪂⏕ඣࡢࢡࣞ࢔ࢳࢽࣥࢫࢡ࣮ࣜࢽࣥࢢ᳨ᰝ◊✲୰㔝 ඃ 1, ୖᮧ ἞ 2, ୰ᓥⴥᏊ 3, ఀ⸨ဴဢ 3, ᮏ⏣㞞ᩗ 4, 㰻⸨ఙ἞ 11ྡྂᒇᕷ❧኱Ꮫᑠඣ⛉, 2 ࠶࠸ࡕᑠඣಖ೺་⒪⥲ྜࢭࣥࢱ࣮⭈⮚⛉, 3 ⸨⏣ಖ೺⾨⏕኱Ꮫᑠඣ⛉, 4 ᮾி㒔❧ᑠඣಖ೺་⒪ࢭࣥࢱ࣮

Newborn mass screening using liquid chromatography-tandem mass spectrometry
for congenital abnormalies of kidney and urinary tract.
Masaru Nakano1, Osamu Uemura 2, Yoko Nakajima3, Tetsuya Ito3, Masataka Honda4, Shinji Saitoh1,
1
Department of Neonatology and Pediatrics, Nagoya City University Graduate School of Medical
Sciences2
Pediatric Nephrology Aichi Children's Health and Medical Center3
Department of pediatrics, Fujita Health University
4
Tokyo Metropolitan Children's Medical Center࠙┠ⓗࠚඛኳᛶ⭈ᒀ㊰⑌ᝈ(congenital anomalies of kidney and urinary tract:௨ୗ CAKUT)
ࡣ඲ዷፎࡢ 0.5%࡟ㄆࡵࡽࢀࠊᑠඣ៏ᛶ⭈୙඲ࡢཎᅉ࡜ࡋ࡚᭱ࡶከ࠸ࠋࡋ࠿ࡋ CAKUT ࡛ࡣ㏆
఩ᒀ⣽⟶࡟࠾ࡅࡿ෌྾཰㞀ᐖ࡟ࡼࡿᕼ㔘ᒀࢆ࿊ࡍࡿࡇ࡜ࡀከࡃࠊ⌧ᅾ⾜ࢃࢀ࡚࠸ࡿࢸ࣮ࣉἲ࡛ࡢⓎぢࡣᅔ㞴࡛࠶ࡿࠋ௒ᅇᡃࠎࡣࢱࣥࢹ࣒࣐ࢫἲࢆ⏝࠸ࡓ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ
࡜ྠࡌᡭἲ࡛ℐ⣬⾑࠿ࡽࢡࣞ࢔ࢳࢽࣥ㸦Cr㸧ࢆᐃ㔞ࡋࠊ᪂⏕ඣ࡟࠾ࡅࡿℐ⣬⾑ Cr ್ࡢᇶ‽್సᡂࢆ⾜࠺ࡇ࡜࡜ࡋࡓࠋ
࠙᪉ἲࠚࢁ⣬࠿ࡽࡢᢳฟ࡞࡝

ᐃ࡟㛵ࢃࡿᡭᢏࡣ᪂⏕ඣࢱࣥࢹ࣒࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ࡟‽ࡌ࡚タᐃࡋࡓࠋℐ⣬⾑࠿ࡽࡢ Cr ್㸦ℐ⣬⾑ Cr ್㸧࡜㏻ᖖࡢ⾑Ύ Cr ್࡜ࡢ┦㛵ࢆぢࡿࡓࡵࠊᑠඣ 100 ேࡢ᳨య࡛ℐ⣬⾑ Cr ್࡜⾑Ύ Cr ್࡜ࢆẚ㍑ࡋࡓࠋࡇࡢ┦㛵ࢆ☜ㄆࡋࡓᚋࠊᐇ㝿࡟᪂⏕ඣ᳨య 177 ᳨య㸦⏨ඣ 92 ᳨యࠊዪඣ 85 ᳨య㸧࡛ࡢ ᐃࢆ⾜ࡗࡓࠋᮏ◊✲ࡣྡྂᒇᕷ❧኱Ꮫ೔⌮ጤဨ఍࡛ᢎㄆࢆཷࡅ࡚࠸ࡿࠋ࠙⤖ᯝࠚᑠඣ 100 ேࡢ᳨య࡛ℐ⣬⾑ Cr ್࡜⾑Ύ Cr ್࡜ࢆẚ㍑ࡋࡓ࡜ࡇࢁࠊ
ℐ⣬⾑ Cr ್=0.56
⾑Ύ Cr ್㸦R㸰=0.87㸧࡜Ⰻ࠸┦㛵ࡀᚓࡽࢀࡓࠋ᪂⏕ඣℐ⣬⾑ Cr ್ࢆ ᐃࡋࡓ࡜ࡇࢁ㠀ṇつศᕸ࡛୰ኸ್ 0.221mg/dL㸦0.191,0.268㸧࡛࠶ࡗࡓࠋ⏨ዪᕪࡣㄆࡵ࡞࠿ࡗࡓࠋ
࠙⪃ᐹࠚℐ⣬⾑ࡢ Cr ࢫࢡ࣮ࣜࢽࣥࢢࡣ᪂⏕ඣᮇ࡟ CAKUT ࢆⓎぢࡍࡿࢫࢡ࣮ࣜࢽࣥࢢ᪉ἲ࡜
ࡋ࡚౑⏝ྍ⬟࡛࠶ࡿ࡜⪃࠼ࡓࠋࡉࡽ࡟᳨యᩘࢆ㔜ࡡ⤫ィᏛⓗ᳨ウࢆຍ࠼ࡿ஦࡛ࠊ⢭ᗘࡢ㧗࠸࢝ࢵࢺ࢜ࣇ್ࢆసᡂࡋ࡚ࠊࢫࢡ࣮ࣜࢽࣥࢢᑟධࢆ᳨ウࡋࡓ࠸ࠋ

́́

P-13
኱⭠⒴ᝈ⪅∎୰ගᏛ␗ᛶయ௦ㅰ≀ࡢศᯒすᑿඃử, 㛬 ಇဴ, ㎘ᮌሀ୍㑻, Ỉ㔝 ึ, ㇏ᒸ฼ṇ㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊

Analysis of the chiral metabolites in fingernail of colorectal cancer patients
Yuta Nishio, Jun Zhe Min, Kenichiro Todoroki, Hajime Mizuno, Toshimasa Toyo’oka
School of pharmaceutical Sciences, University of Shiuoka࠙┠ⓗࠚ኱⭠⒴ࡣࠊ᪩ᮇⓎぢ࡟ࡼࡿ⏕Ꮡ⋡ࡀᴟࡵ࡚㧗ࡃࠊⓎ⑕๓ࡢ᪩ᮇⓎぢཬࡧࡑࡢデ᩿ἲࡀᙉࡃồࡵࡽࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊᚑ᮶ࡢ኱⭠⒴ࡢࣂ࢖࣐࣮࣮࢜࢝ࡣ᪩ᮇデ᩿ࡀᅔ㞴࡛࠶ࡿࡇ࡜ࡀၥ㢟どࡉࢀ࡚࠸ࡿࠋ୍᪉ࠊ㏆ᖺࣄࢺ⾑୰࣓ࢱ࣮࣒࣎ࣟゎᯒ࠿ࡽ኱⭠⒴࡟᪩ᮇ཯ᛂࢆ♧ࡍ᪂つࣂ࢖࣐࣮࣮࢜࢝ೃ⿵≀࡜ࡋ࡚ 2-Hydroxy butyrate (D-HB)ࠊAspartic acid (Asp)ࠊ
Kynurenine (Kyn)ࠊCystamine (Cys)ࡀⓎぢࡉࢀࠊࡑࡢ᭷⏝ᛶࡀ♧၀ࡉࢀࡓ[1]ࠋࡇࢀࡽࡢ᪂つࣂ࢖࣐࣮࣮࢜࢝ೃ⿵≀ࡣ࢟ࣛࣝ୰ᚰࢆᣢࡘ໬ྜ≀ࡶ࠶ࡿࡀࠊࡑࡢගᏛ␗ᛶయࡢ᭷⏝ᛶ࡟ࡘ࠸࡚ࡣࡲࡔ୙࡛᫂࠶ࡿࠋࡑࡇ࡛ᡃࠎࡣࠊࡇࢀࡽࡢ࢟ࣛࣝ୰ᚰࢆᣢࡘ᪂つࣂ࢖࣐࣮࣮࢜࢝ೃ⿵
≀࡟╔┠ࡋࡓࠋ௒ᅇ⏝࠸ࡿࣄࢺ∎ࡣࠊỗ⏝ࡢ⾑ᾮࡸᒀ࡜␗࡞ࡾࠊ㠀౵くⓗ࡟᥇ྲྀཬࡧಖᏑ
ࡀᐜ࡛᫆࠶ࡾࠊ㛗ᮇ㛫ࡢ⏕య᝟ሗࢆ཯ᫎࡍࡿࡇ࡜ࡀ࡛ࡁࠊ៏ᛶ⑌ᝈデ᩿⏝ࡢ᪂つ⏕యヨᩱ࡜ࡋ࡚ὀ┠ࡉࢀ࡚࠸ࡿ[2]ࠋࡑࡇ࡛ᡃࠎࡣ LC-ESI-MS/MS ࢆ⏝࠸࡚ࠊ኱⭠⒴ᝈ⪅∎୰ࡢ࢟ࣛࣝ
௦ㅰ≀ࡢ୍ᩧศᯒࢆヨࡳࡓࠋ࠙᪉ἲࠚㄏᑟయ໬ヨ⸆࡜ࡋ࡚ (S)-DBD-Pro-COCl ࢆ⏝࠸ࠊD-HBࠊAspࠊKynࠊCys ࢆᶆ㆑ࡋࠊ
LC-ESI-MS/MS ୍࡛ᩧศᯒࢆ⾜ࡗࡓࠋ᥇ྲྀࡋࡓࣄࢺ∎ࡣࠊὙίᚋ⢊○⛗㔞ࡋࠊ௦ㅰ≀ࢆᢳฟࡋࠊㄏᑟయ໬䜢⾜䛳䛯䚹LC ⿦⨨࡟ࡣᓥὠ〇సᡤ〇ࡢ Nexera X2 ࢆ⏝࠸ࠊ࣒࢝ࣛࡣ Imtakt ♫〇ࡢ Cadenza CD-C18 HT (3 Pm, 150×3 mm I.D.) ࠊ⛣ື┦ࡣ 10 mM HCOONH4 ྵ᭷ H2O ཬࡧ
0.1% HCOOH ྵ᭷ CH3CN ࢆ⏝࠸ࡓࠋ㉁㔞ศᯒィ࡟ࡣࠊᓥὠ〇సᡤ〇ࡢ LCMS-8040 ࢆ⏝࠸ࠊ࢖࢜ࣥ໬ἲࡣ ESI+࢖࢜ࣥ໬ἲ࡛ࠊMRM ࣮ࣔࢻ࡟࡚ ᐃࢆ⾜ࡗࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚ㸲✀ࡢ௦ㅰ≀ࢆ(S)-DBD-Pro-COClࢆ⏝࠸ࠊ᭱㐺࡞ㄏᑟయ໬཯ᛂ

ᗘࠊ཯ᛂ᫬㛫࡛ㄏᑟయ໬ࢆ⾜࠺ࡇ࡜࡛࢟ࣛࣝ୰ᚰࢆ᭷ࡍࡿD-HBࠊAspࠊKyn ࢆࢪ࢔ࢫࢸ࣐࣮ࣞ࢜య࡟ᙧᡂࡉࡏࠊC18 ࣒࡛࢝ࣛගᏛ␗ᛶయࢆ 20 min ௨ෆ࡟Ⰻዲ࡞ศ㞳 (Rs>1.57)ࢆ㐩ᡂࡍࡿࡇ࡜ࡀ࡛
ࡁࡓࠋᢳฟ⁐፹࡜ࡋ࡚࣓ࢱࣀ࣮ࣝࠊࢺ࢚ࣜࢳࣝ࢔࣑ࣥΰྜ⁐ᾮࢆ⏝࠸ࠊ∎୰࠿ࡽึࡵ࡚ Asp
࡜D-HB ࡢගᏛ␗ᛶయࢆᢳฟࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋ᪥ෆཬࡧ᪥㛫ኚືࡣ 4.54%௨ୗ࡛࠶ࡾࠊῧ
ຍᅇ཰⋡ࡣ 81.12-113.84%࡛࠶ࡗࡓࠋ೺ᖖே 20 ேࠊ኱⭠⒴ᝈ⪅ 23 ேࡢ∎ࢆศᯒࡋࡓ࡜ࡇࢁࠊ኱⭠⒴ᝈ⪅ࡢ AspࠊD-HB ࡢᐃ㔞್ࠊࣆ࣮ࢡ㠃✚ࡢ D/L ẚࡣඹ࡟ୖ᪼ഴྥࡀ♧ࡉࢀࡓࠋࡑࡢ
᭷ពᕪ࡟ࡘ࠸࡚ࡶ௒ᅇሗ࿌ࡍࡿணᐃ࡛࠶ࡿࠋ

࠙ཧ⪃ᩥ⊩ࠚ -----------------------------------------------------------------------------------------------------------[1] Shin Nishiumi et al., PLoS ONE , (2012) 7, e40459.
[2] J.Z. Min et al., J. Chromatogr. B, (2011) 879, 3220-3228.

́́

P-14
UPLC-MS/MS ࡟ࡼࡿࣆ࣑ࣜࢪࣥሷᇶ௦ㅰ≀ࡢᐃ㔞࡟ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖ⑕
ࢫࢡ࣮ࣜࢽࣥࢢ
๓⏣ᗣ༤ 1, ⓙᕝ┿㔛 1, ୰ᓥⴥᏊ 2, ᚋ⸨ెዉ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ⩏ᾈ 1, ఀ⸨ဴဢ 2, ᮌᮧ࿴ဴ 1,31ྡྂᒇᕷ❧኱Ꮫ ኱Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ⸨⏣ಖ೺⾨⏕኱Ꮫ ་Ꮫ㒊 ᑠඣ⛉
3ྡྂᒇᕷ❧኱Ꮫ ኱Ꮫ㝔་Ꮫ◊✲⛉Determination of pyrimidine metabolites for inborn error of pirimidine
metabolism by UPLC-MS/MS
Yasuhiro Maeda1, Mari Minagawa1, Yoko Nakajima2, Kana Gotoh1, Yuji Hotta1, Tomoya Kataoka3,
Yoshihiro Kawade1, Tetsuya Ito2, Kazunori Kimura1,3
1
Graduate School of Pharmaceutical Sciences, Nagoya City University, 2 School of medicine, Fujita
Health University, 3 Graduate School of Medical Sciences, Nagoya City University࠙┠ⓗࠚ᰾㓟ሷᇶ࡛࠶ࡿ uracil ࠾ࡼࡧ thymine ࡣ dihydropyrimidine dehydrogenase (DPDase),
dihydropirimidinase (DHPase), ureidopropionase (UPase)ࡢྛ㓝⣲࡟ࡼࡾ㸱ẁ㝵࡟␗໬௦ㅰࡉࢀ㸪
ȕ-Alanine (BAL) ࠾ࡼࡧ ȕ-Aminoisobutyrate (BAIB)ࢆ⏕ᡂࡍࡿࠋྛ㓝⣲ࡢḞᦆ⑕ࡢࢫࢡ࣮ࣜ
ࢽࣥࢢࡢࡓࡵ㸪ᣦᶆ࡜࡞ࡿ㓝⣲ࡢᇶ㉁ࢆ UPLC-MS/MS ࡛ศᯒࡍࡿᡭἲࢆ☜❧ࡋ㸪ᒀ୰௦ㅰ≀ࢆศᯒࡋࡓࠋ
࠙᪉ἲࠚࢥࣥࢺ࣮ࣟࣝ࠾ࡼࡧ UPase Ḟᦆ⑕ᝈ⪅ࡢᒀࢆ㸪ෆ㒊ᶆ‽≀㉁ࢆྵࡴỈ࡛ 50%࡟ᕼ㔘ᚋ 㸪 UPLC-MS/MS (Waters) ࡟ ᑟ ධ ࡋ 㸪 uracil ࡜ ࡑ ࡢ ௦ ㅰ ≀ ࡛ ࠶ ࡿ dihydrouracil (DHU),
ȕ-ureidopropionate (UP), BAL ࠾ࡼࡧ thymine ࡜ࡑࡢ௦ㅰ≀࡛࠶ࡿ dihydrothymine (DHT),
ȕ-ureidoisobutyrate (UIB), BAIB ࢆ୍ᩧ࡟ᐃ㔞ࡋࡓࠋࡉࡽ࡟㸪ᒀ୰௦ㅰ⏘≀⃰ᗘࡢᇶ‽࡜࡞ࡿ
creatinine (cre)ࢆྠ᫬࡟ ᐃࡋࡓࠋUPLC ࣒࢝ࣛ࡟ Acquity UPLC HSS T3㸦2.0 × 150 mm,
Waters㸧ࢆ⏝࠸㸪⛣ື┦ࢆ 0.1%ࢠ㓟Ỉ⁐ᾮ 100% ࠿ࡽ࢔ࢭࢺࢽࢺ࡛ࣜࣝ gradient ศᯒࡋࡓࠋ
࠙⤖ᯝࠚࢥࣥࢺ࣮ࣟࣝ (n = 50) ࡟࠾࠸࡚ࡣ uracil, DHU, UP, BAL ࡣ 4.8-8.5 ± 5.5-7.1 (ave, ± SD)
μmol/mmol·cre, thymine, DHT, UIB ࡣ 1.1-1.3 ± 1.3-2.7 μmol/mmol·cre ࡛࠶ࡗࡓࡀ㸪BAIB 418 ±620 μmol/mmol·cre,࡜ಶேᕪࡀ㠀ᖖ࡟኱ࡁ࠿ࡗࡓࠋUPase Ḟᦆ⑕ᝈ⪅ (n= 3)ࡢᒀ࠿ࡽࡣ㸪
UPase ࡢᇶ㉁࡛࠶ࡿ UP ࡜ UIB ࡀࢥࣥࢺ࣮ࣟࣝࡢ 200 ಸ௨ୖ᳨ฟࡉࢀࡓࠋ୍᪉ UPase ࡢ௦ㅰ≀ ࡛ ࠶ ࡿ BAL ࡣ ࢥ ࣥ ࢺ ࣟ ࣮ ࣝ ࡜ ᕪ ࡣ ぢ ࡽ ࢀ ࡞ ࠿ ࡗ ࡓ ࠋ BAIB ࡟ ࡘ ࠸ ࡚ ࡣ 1.0-3.0μmol/mmol·cre ࡜పୗഴྥ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚUPLC-MS/MS ࡟ࡼࡿࣆ࣑ࣜࢪࣥ௦ㅰ␗ᖖ⑕ࡢࢫࢡ࣮ࣜࢽࣥࢢࡣ㸪᳨యࡢᒀࢆ↹㞧࡞๓ฎ⌮ࢆࡏࡎ㸪ᐜ᫆࡟⾜࠺ࡇ࡜ࡀྍ⬟࡛࠶ࡿࠋUPase Ḟᦆ⑕࡛ࡣᇶ㉁࡛࠶ࡿ UP, UIB ࡀ㧗⃰ᗘ᳨࡛ฟࡉࢀデ᩿࡟᭷⏝࡛࠶ࡗࡓࠋࡲࡓ㸪⏕ᡂ≀ࡢ BAIB ࡀపୗഴྥ࡛࠶ࡿࡇ࡜ࡀ⚄⤒⑕≧ࢆ࿊ࡍࡿ୍ᅉ࡛࠶ࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ

́́

P-15
࢖ࣥࢻ࢟ࢩࣝ◲㓟ࡣṧᏑ⭈ᶵ⬟ࡢపୗ࡜࡜ࡶ࡟⾑୰࡟⵳✚ࡋ࣑࢘ࣞࢵࢡࢧࣝࢥ
࣌ࢽ࢔࡟㛵ಀࡍࡿ
బ⸨ᜨ⨾Ꮚ 1,2, ᳃ ᘓᩥ 1, 㕥ᮌள㔛Ἃ 1, Ⳣཎ┿ᜨ 1, ಴⃝ዉ✑ 1, ୕ᯞ኱㍜ 3, ኱ሙ㑳Ꮚ 1,Ọ἟⤮⌮ 1, బ⸨ ༤ 1,2, ୹⩚฼඘ 4, ఀ⸨㈆჆ 11ᮾ໭኱Ꮫ኱Ꮫ㝔 ་Ꮫ⣔◊✲⛉, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔 ⸆Ꮫ◊✲⛉, 3 ᮾ໭࣓ࢹ࢕࣭࣓࢝ࣝ࢞ࣂ
ࣥࢡᶵᵓ, 4 ಟᩥ኱Ꮫ೺ᗣᰤ㣴Ꮫ㒊

Indoxyl sulfate accumulates in blood as residual renal function decreases, and isrelated to uremic sarcopenia
Emiko Sato1,2, Takefumi Mori1, Arisa Suzuki1, Sanae Sugawara1, Nao Kurasawa1, Daisuke Saigusa3,
Ikuko Oba1, Eri Naganuma1, Hiroshi Sato1,2, Toshimitsu Niwa4, Sadayoshi Ito1
1
Division of Clinical Pharmacology and Therapeutics, Graduate School of Pharmaceutical Science,
Tohoku University, 2Division of Nephrology, endocrinology and Vascular Medicine, Graduate
School of Medicine, Tohoku University, 3Tohoku Medical Megabank Organization, Tohoku
University, 4Faculty of Health and Nutrition, Shubun University࠙┠ⓗࠚ៏ᛶ⭈⮚⑓࡟࠾࠸࡚(chronic kidney disease; CKD)࡟࠾࠸࡚ࠊ⭈ᶵ⬟ࡢపୗ࡟క࠸యෆ
࡟⵳✚ࡋࡓᒀẘ⑕≀㉁ࡀཎᅉ࡜࡞ࡾࠊ➽ῶᙅ⑕㸦ࢧࣝࢥ࣌ࢽ࢔㸧ࢆⓎ⑕ࡍࡿ࣑࢘ࣞࢵࢡࢧ
ࣝࢥ࣌ࢽ࢔ࡀ╔┠ࡉࢀ࡚࠸ࡿࠋCKD ࡟࠾࠸࡚ࢧࣝࢥ࣌ࢽ࢔ࡣ⏕Ꮡ⋡࡟ᙉ࠸ᙳ㡪ࢆ୚࠼ࡿࡇ
࡜࠿ࡽண㜵ࡀ㔜せ࡛࠶ࡾࠊࡑࡢⓎ⑕ᶵᗎࢆゎ᫂ࡍࡿࡇ࡜ࡀᚲ㡲࡛࠶ࡿࠋᮏ◊✲ࡣ MS ࢆ⏝࠸࡚࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽ࢔Ⓨ⑕ᶵᗎࢆゎ᫂ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚࠸ࡿࠋ
࠙᪉ἲࠚ⭡⭷㏱ᯒᝈ⪅ࢆᑐ㇟࡜ࡋ⭡⭷ᖹ⾮ヨ㦂᫬ࡢ⾑₢࡜⭡⭷㏱ᯒ᤼ᾮࢆᅇ཰ࡋࠊ16 ✀㢮ࡢᒀẘ⑕≀㉁ࡢࢱ࣮ࢤࢵࢺ࣓ࢱ࣑࣎ࣟࢡࢫࢆ⾜࠸ࠊ⮫ᗋࣃ࣓࣮ࣛࢱ࣭యᡂศศᯒ⿦⨨ࢹ࣮ࢱ࡜ࡢ㛵㐃࠾ࡼࡧᒀẘ⑕≀㉁ࡢ⭡⭷㏱㐣ᛶࡢ᳨ウࢆ⾜ࡗࡓࠋࡉࡽ࡟➽ⱆ⣽⬊ᰴ C2C12 ࢆ⏝࠸ࠊᒀẘ⑕≀㉁ࡢ㦵᱁➽࡟ᑐࡍࡿᙳ㡪ࢆ࣓ࢱ࣑࣎ࣟࢡࢫࡢどⅬ࠿ࡽ᳨ウࢆ⾜ࡗࡓࠋ࠙⤖ᯝࠚࢱ࣮ࢵࢤࢵࢺ࡜ࡋࡓᒀẘ⑕≀㉁ࡢ࠺ࡕࠊ4 ✀㢮ࡢᒀẘ⑕≀㉁ࡀ᭷ព࡟⾑ᾮ୰࡛ቑຍ
ࡋ࡚࠸ࡓࠋࡇࢀࡽࡢ≀㉁ࡢ࠺ࡕ࢖ࣥࢻ࢟ࢩࣝ◲㓟ࠊ࣓ࢳࣝࢢ࢔ࢽࢪࣥࠊࢢ࢔ࢽࢪࣀࢥࣁࢡ
㓟ࡀṧᏑᶵ⬟ࡢపୗ࡟క࠸యෆ࡟⵳✚ࡋ࡚࠸ࡓࠋࡇࡢ࠺ࡕ⾑୰࢖ࣥࢻ࢟ࢩࣝ◲㓟࠾ࡼࡧ࣓ࢳࣝࢢ࢔ࢽࢪࣥ⃰ᗘ࡟యෆࡢ㦵᱁➽㔞࡜ࡢ㛵㐃ࡀ࠶ࡿࡇ࡜ࡀㄆࡵࡽࢀࡓࠋC2C12 ࢆ⏝࠸ࡓ⣽⬊ቑṪヨ㦂ࡢ⤖ᯝ࠿ࡽࠊ࢖ࣥࢻ࢟ࢩࣝ◲㓟ࡢࡳቑṪᢚไస⏝ࡀㄆࡵࡽࢀࡓࠋࡉࡽ࡟࢖ࣥ
ࢻ࢟ࢩࣝ◲㓟Ꮡᅾୗ࡟࠾ࡅࡿ C2C12 ࡢ࣓ࢱ࣑࣎ࣟࢡࢫࢆ⾜ࡗࡓ⤖ᯝࠊ࢖ࣥࢻ࢟ࢩࣝ◲㓟ࡢ
C2C12 ෆ࡬ࡢྲྀࡾ㎸ࡳࡀ☜ㄆࡉࢀࠊࡉࡽ࡟࢚ࢿࣝࢠ࣮⏘⏕࡟㛵㐃ࡍࡿ࢔࣑ࣀ㓟ࡢ᭷ព࡞ῶ
ᑡࡀㄆࡵࡽࢀࡓࠋ
࠙⪃ᐹࠚᮏ◊✲ࡣ MS ࢆ⏝࠸ࡓ࣓ࢱ࣑࣎ࣟࢡࢫ࡛ࠊ࢖ࣥࢻ࢟ࢩࣝ◲㓟ࡀ㦵᱁➽࡟࠾ࡅࡿ࢚ࢿ
ࣝࢠ࣮⏘⏕࡟ᙳ㡪ࢆ୚࠼࣑࢘ࣞࢵࢡࢧࣝࢥ࣌ࢽ࢔ࢆᘬࡁ㉳ࡇࡍࡇ࡜ࢆ♧၀ࡋࠊ࢖ࣥࢻ࢟ࢩ
ࣝ◲㓟ࡢ᪂ࡓ࡞୍㠃ࢆぢฟࡋࡓࠋ

́́

P-16
➽ࢪࢫࢺࣟࣇ࢕࣮ᝈ⪅ࡢᒀ୰ࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ࠾ࡼࡧ E2 ௦ㅰ≀ࡢኚື➉ෆᩔᏊ 1, ⿬ฟⰋ༤ 2, ᯇᑿ㞞ᩥ 31⚄ᡞ⸆⛉኱Ꮫ, 2 ⟃Ἴ኱Ꮫᅜ㝿⤫ྜ╧╀་⛉Ꮫ◊✲ᶵᵓ, 3 ⚄ᡞᏛ㝔኱Ꮫ⥲ྜࣜࣁࣅࣜࢸ࣮
ࢩࣙࣥᏛ㒊Fluctuations of urinary prostaglandin D2 and E2 metabolites in Duchenne
muscular dystrophy patients
Atsuko Takeuchi1, Yoshihiro Urade2, Masafumi Matsuo3
1
Kobe Pharmaceutical University
2
Tsukuba University, International Institute for Integrative Sleep Medicine
3
Kobe Gakuin University, The Faculty of Rehabilitation
࠙┠ⓗࠚDuchenne ᆺ➽ࢪࢫࢺࣟࣇ࢕࣮(Duchennne muscular dystrophy : DMD)ࡣ㐍⾜ᛶࡢ➽ⴎ⦰ࢆ࿊ࡋ㸪ᴟࡵ࡚㔜⠜࡞㑇ఏᛶ⑌ᝈ࡛࠶ࡿࠋᮏ⑌ᝈࡣ㸪ཎᅉ㑇ఏᏊ࡛࠶ࡿࢪࢫࢺࣟࣇ࢕
ࣥ㑇ఏᏊࡢ࢚ࢡࢯࣥḞኻ࠾ࡼࡧ㔜」➼ࡢኚ␗࡟ࡼࡾ㸪➽ࡢ⣽⬊⭷ᙧᡂ࡟㛵୚ࡍࡿࢪࢫࢺࣟ
ࣇ࢕ࣥࢱࣥࣃࢡ㉁ࡀḞᦆࡍࡿ㑇ఏᛶ➽⑌ᝈ࡛࠶ࡿࠋே✀࡟㛵ಀ࡞ࡃฟ⏕⏨Ꮚ⣙ 3,500 ே࡟ 1ேࡢ๭ྜ࡛Ⓨ⑕ࡍࡿࠋᡃࠎࡣ௨๓࡟ࠊDMD ᝈ⪅ࡢ➽⫗࡛ࡣ⅖⑕ࡸ࢔ࣞࣝࢠ࣮࡞࡝࡟㛵୚ࡍࡿࣉࣟࢫࢱࢢࣛࣥࢪࣥ D2 ྜᡂ㓝⣲ࡢⓎ⌧ࡀஹ㐍ࡋ࡚࠾ࡾࠊDMD ࡢ⑓≧デ᩿࡟ PGD2 ࡢᒀ୰௦ㅰ
≀㸦PGDM㸧⃰ᗘࡀ᭷ຠ࡛࠶ࡿࡇ࡜ࢆሗ࿌ࡋࡓࠋ௒ᅇࡣࠊPGD2 ࡜ྠᵝࡢ COX ࡢస⏝࠾ࡼࡧ PGE2ྜᡂ㓝⣲࡟ࡼࡾ⏕ᡂࡍࡿ PGE㸰࡟ὀ┠ࡋࠊDMD ᝈ⪅ࡢᒀ୰ PGDM ࡜ඹ࡟ PGE2 ௦ㅰ≀㸦PGEM㸧ࢆᐃ㔞ࡋࠊኚືࢆㄪ࡭ࡓࠋ
࠙᪉ἲࠚDMD ᝈ⪅࠾ࡼࡧ೺ᖖ⪅ࡢᒀ 0.4ml ࡟ PGDM-d6ࠊPGEM-d6 ࢆຍ࠼ࠊᅛ┦ᢳฟ࣒࢝ࣛ
ࢆ⏝࠸࡚ PG ௦ㅰ≀ࢆᢳฟࡋࠊᢳฟᾮࢆ⃰⦰஝ᅛ࣭෌⁐ゎࡋ࡚ ᐃ⏝ヨᩱ࡜ࡋࡓࠋᶆ‽ヨᩱ࣭ᐃ⏝ヨᩱࢆ API3000 LC-MS/MS system ࡟㐺⏝ࡋࠊ᭱㐺᮲௳ࡢࣉ࣮ࣜ࢝ࢧ࣮࠾ࡼࡧࣉࣟࢲ
ࢡࢺ࢖࢜ࣥࢆ㑅ࡧࠊSRM㸦Selected Reaction Monitoring㸧ἲ࡛ ᐃࡋࡓࠋPGDM ࡲࡓࡣ PGEM
࡜ࡑࢀࡒࢀࡢෆᶆ‽≀㉁࡜ࡢࣆ࣮ࢡ㠃✚ẚࢆ⏝࠸࡚ᐃ㔞್ࢆ⟬ฟࡋࡓࠋࡲࡓࠊࢡࣞ࢔ࢳࢽ
ࣥࢆᐃ㔞ࡋࠊ⿵ṇࡋࡓࠋ࠙⤖ᯝ/⪃ᐹࠚLC-MS/MS ࡟ࡼࡾࠊPGDM ࠾ࡼࡧ PGEM ࡣྠ᫬ศ㞳ᐃ㔞ࡀྍ⬟࡛࠶ࡗࡓࠋ᳨
㔞⥺ࡶⰋዲ࡞┤⥺ᛶࢆ♧ࡋࠊಙ㢗ᛶࡢ㧗࠸ᐃ㔞ࡀ࡛ࡁࡓ࡜⪃࠼ࡽࢀࡓࠋᒀ୰ PGDM ⃰ᗘ࠾ࡼࡧᒀ୰ PGEM ⃰ᗘࢆ DMD ᝈ⪅࡜೺ᖖ⪅࡛ẚ㍑ࡋࡓ࡜ࡁࠊDMD ᝈ⪅ࡢ᪉ࡀ࡜ࡶ࡟ᩘ್ࡀ
㧗࠿ࡗࡓࠋࡋ࠿ࡋ࡞ࡀࡽࠊᒀ୰ PGDM ⃰ᗘ࡜ࡣ␗࡞ࡾࠊᒀ୰ PGEM ⃰ᗘࡣ DMD ࡢデ᩿࡟᭷ຠ࡛࠶ࡿ࡜᩿ᐃࡍࡿࡇ࡜ࡣ㞴ࡋࡃࠊ௒ᚋࡶ᳨ウࡋ࡚࠸ࡃᚲせࡀ࠶ࡿ࡜⪃࠼ࡽࢀࡓࠋ

́́

P-17
᥈㔪࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ/ࢱࣥࢹ࣒㉁㔞ศᯒ(PESI/MS/MS)࡟ࡼࡿ࣐࢘ࢫ⫢⮚ෆࡢ࣓ࢱ࣮࣒࣎ࣟ┤᥋ศᯒἲ㸦࢖ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࡢᵓ⠏ᯘ ⏤⨾ 1,2, ㈈ὠ ᱇ 1,2, ᮧ⏣ ໷ 3, ኱ཎ೔⨾ 1, ୰ษ೺ኴ 1, ⲡ㔝㯞⾰Ꮚ 1, 㑣㡲ẸỤ 4,୰ᓥᏹᶞ 3, ▼ᕝဴஓ 1, ᅵᶫ ᆒ 1, ▼஭ ᫭ 1
1ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 2 ྡྂᒇ኱Ꮫ㧗➼◊✲㝔, 3 ᓥὠ〇సᡤ, 4 ୰㒊኱Ꮫ⏕࿨೺ᗣ⛉Ꮫ㒊

Development of an intact metabolome analytical method of mouse hepatic tissue by
probe electrospray ionization-tandem mass spectrometry (PESI/MS/MS)
Yumi Hayashi1,2, Kei Zaitsu1,2, Tasuku Murata3, Tomomi Ohara1, Kenta Nakagiri1, Maiko Kusano1,
Tamie Nakajima4, Hiroki Nakajima3, Tetsuya Ishikawa1, Hitoshi Tsuchihashi1, Akira Ishii1
1
Nagoya University Graduate School of Medicine, 2Institute for Advanced Research, Nagoya
University, 3Shimadzu Corporation, 4College of Life and Health Sciences, Chubu University࠙┠ⓗࠚෆᅉᛶ௦ㅰ≀㸦࣓ࢱ࣮࣒࣎ࣟ㸧ゎᯒ࡟࠾࠸࡚ࡣࠊ๓ฎ⌮ࡸࢧࣥࣉࣜࣥࢢ᫬࡟࠾ࡅࡿ
ࣂ࢖࢔ࢫࢆ᏶඲࡟㝖እࡍࡿࡇ࡜ࡣ㞴ࡋࡃࠊ⏕యෆࡢ࣓ࢱ࣮࣒࣎ࣟࡢኚືࢆṇ☜࡟⿵㊊ࡍࡿࡓࡵ࡟ࡣࠊ࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒἲࡢᵓ⠏ࡀ୙ྍḞ࡛࠶ࡿࠋ᪂つ࢖࢜ࣥ໬ἲ࡛࠶ࡿ᥈㔪࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ࢖࢜ࣥ໬ἲ(PESI)ࡣࠊࢧࣥࣉࣝࡢ๓ฎ⌮ࡀࠕ୙せ࡛ࠖ࠶ࡾࠊ⏕యヨᩱ୰ࡢ࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒࡀྍ⬟࡛࠶ࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊPESI/MS/MS ࡟ࡼࡿ⏕య⤌⧊୰࣓ࢱ࣮࣒࣎ࣟࡢ┤᥋ศᯒἲ㸦࢖ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟศᯒἲ㸧ࢆᵓ⠏ࡋࡓࠋࡉࡽ࡟ᮏἲࢆࠕCCl4 ㄏᑟᛶᛴᛶ⫢㞀ᐖࣔࢹ࣐ࣝ࢘ࢫࠖࡢ࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ᛂ⏝ࡋࠊ᭷⏝ᛶࢆ᳨ドࡋࡓࠋ࠙᪉ἲࠚື≀ᐇ㦂: 6 㐌㱋 C57/BL6J ࣐࢘ࢫ࡟ CCl4 ࣮࢜ࣜࣈ࢜࢖ࣝ⁐ᾮ(0.5 ml/kg)ࡲࡓࡣ࢜ࣜ
࣮ࣈ࢜࢖ࣝࢆ⭡⭍ෆᢞ୚ࡋࡓ(n=5)ࠋ24 ᫬㛫ࡢ⤯㣗ᚋࠊ⫢⮚ࢆ᥇ྲྀࡋࠊᛴ㏿෾⤖ࡋࡓࠋ⿦⨨㸸ᓥὠ〇సᡤ〇 PESI ࢖࢜ࣥ※࠾ࡼࡧ LCMS-8040 ࢱࣥࢹ࣒ᆺ㉁㔞ศᯒィࢆ⏝࠸ࡓࠋヨᩱㄪ〇㸸⣙ 3 mm ゅࡢ⫢⮚ษ∦࡟ 50% EtOH Ỉ⁐ᾮࢆ㐺㔞ῧຍࡋࠊࢧࣥࣉࣝࣉ࣮ࣞࢺ࡟ࢭࢵࢺࡋࡓࠋ
ศᯒ᮲௳: ࣉࣟࢲࢡࢺ࢖࢜ࣥࢫ࢟ࣕࣥ࠾ࡼࡧ SRM ࣮ࣔࢻ࡛ ᐃࢆ⾜ࡗࡓࠋᚓࡽࢀࡓ⤖ᯝࡣ
SIMCA-P+࡟ࡼࡿከኚ㔞ゎᯒ࠾ࡼࡧ R ࡟ࡼࡿ᭷ពᕪ᳨ᐃࢆ⾜ࡗࡓࠋ ᐃἲࡢ᳨ド: GC/MS/MS㸦⿦⨨:ᓥὠ〇సᡤ〇 GCMS-TQ8040㸧ࢆ⏝࠸࡚࣓ࢱ࣮࣒࣎ࣟゎᯒࢆ⾜࠸ࠊ⤖ᯝࢆ᳨ドࡋࡓࠋ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚPESI/MS/MS ࡟ࡼࡾ 27 ✀ࡢ௦ㅰ≀ࢆྠᐃࡋࡓࠋSRM ࢺࣛࣥࢪࢩࣙࣥ࠾
ࡼࡧᐃ᫬㛫➼ࢆ᭱㐺໬ࡋࡓᚋࠊ⫢㞀ᐖࣔࢹࣝ࠾ࡼࡧࢥࣥࢺ࣮ࣟࣝ⩌࡟ࡘ࠸࡚⫢⮚ヨᩱࡢ࢖ࣥࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒࢆ⾜ࡗࡓࠋPCA ࢫࢥ࢔ࣉࣟࢵࢺ࡟࠾࠸࡚ 2 ⩌ࡣⰋዲ࡟ศ㞳ࡋࠊ≉ᐃࡢᡂศ࡟࠾࠸࡚᭷ព࡞ኚືࡀㄆࡵࡽࢀࡓࠋGC/MS/MS ࢆ⏝࠸࡚ᮏ⤖ᯝࢆ᳨ドࡋࡓ࡜ࡇࢁࠊPESI/MS/MS ࡛ᚓࡽࢀࡓ⤖ᯝ࡜᭷ព࡞┦㛵ࡀㄆࡵࡽࢀࡓࠋ௨ୖࡢ⤖ᯝࠊᮏἲࡣ࢖ࣥ
ࢱࢡࢺ࣭࣓ࢱ࣮࣒࣎ࣟゎᯒࢆྍ⬟࡜ࡍࡿ᪂つศᯒἲ࡜ࡋ࡚᭷⏝࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋ

́́

P-18
㧗⬡⫫㣗ᦤྲྀࡀᘬࡁ㉳ࡇࡍ⭠ෆ⎔ቃࡢኚ໬࡟ᑐࡍࡿ࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ࡼࡿホ౯すᾏ ಙ 1, ྜྷ⏣ ඃ 1,2
1⚄ᡞ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉, 2 ᅜ❧◊✲㛤Ⓨἲே᪥ᮏ་⒪◊✲㛤Ⓨᶵᵓ, AMED-CREST

Evaluation of high-fat diet-induced alterations in the intestinal environment by
metabolome analysis
Shin Nishiumi1, Masaru Yoshida1, 2
1
Kobe University Graduate School of Medicine
2
AMED-CREST, Japan Agency for Medical Research and Development࠙┠ⓗࠚ⭠⟶⑌ᝈ࡛࠶ࡿ኱⭠ࡀࢇࡣࠊࡑࡢⓎ⑕せᅉࡢࡦ࡜ࡘࡀ⎔ቃᅉᏊࡢኚ໬࡜ࡉࢀ࡚࠸ࡿࠋ
᪥ᮏ࡛ࡶࠊ㏆ᖺࠊ㧗⬡⫫㣗ࡸ㧗࣮࢝ࣟࣜ㣗࡜࠸ࡗࡓ㣗⏕άࡢḢ⡿໬ࡀ㐍ࢇ࡛࠾ࡾࠊࡑࡢ⤖ᯝ࡜ࡋ࡚ࠊ኱⭠ࡀࢇࡢᝈ⪅ᩘࡀቑຍࡋ࡚ࡁࡓྍ⬟ᛶࡀ␲ࢃࢀ࡚࠸ࡿࠋࡲࡓࠊ᭱㏆࡛ࡣࠊ⬡⫫ྵ㔞ࡢከ࠸㣗஦ࡢᦤྲྀࡀࠊ⭠ෆ⣽⳦ྀ࡟ᙳ㡪ࢆ୚࠼ࡿࡇ࡜ࢆ♧ࡍሗ࿌ࡀ࡞ࡉࢀ࡚࠸ࡿࠋ
ᮏ◊✲࡛ࡣࠊ኱⭠ࡀࢇ࣐࢘ࢫࣔࢹࣝࢆ⏝࠸࡚ࠊ࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ࡼࡾࠊ㧗⬡⫫㣗ᦤྲྀ࡟ࡼࡿ⭠ෆ⎔ቃࡢኚ໬ࢆࠊపศᏊ௦ㅰ≀࡛ࣞ࣋ࣝホ౯ࡋࡓࠋ࠙᪉ἲࠚᮏ◊✲ࡣࠊ኱⭠ࡀࢇࣔࢹࣝ࡜ࡋ࡚ᗈࡃ౑⏝ࡉࢀ࡚࠸ࡿ APCmin/+࣐࢘ࢫࢆ⏝࠸࡚ᐇ㦂ࢆᐇ᪋ࡋࡓࠋAPCmin/+࣐࢘ࢫ࡟ࠊ㧗⬡⫫㣗ࠊ࠶ࡿ࠸ࡣࠊᑐ↷㏻ᖖ㣗ࢆᦤྲྀࡉࡏࠊ⥆ࡅ࡚ࠊ⭠⟶࣏࣮ࣜࣉⓎ⏕ᩘࢆィࡋࡓࠋࡲࡓࠊ኱⭠ෆᐜ≀୰ࡢపศᏊ௦ㅰ≀ࢆࠊ࢞ࢫࢡ࣐ࣟࢺࢢࣛ

ࣇ㉁㔞ศᯒィࢆ⏝࠸࡚ศᯒࡋࡓࠋ
࠙⤖ᯝࠚAPCmin/+࣐࢘ࢫ࡟㧗⬡⫫㣗ࢆᦤྲྀࡉࡏࡿࡇ࡜࡛ࠊ㏻ᖖ㣗ᦤྲྀ࡜ẚ㍑ࡋ࡚ࠊ⭠⟶࣏࣮ࣜࣉࡀከࡃⓎ⏕ࡍࡿࡇ࡜ࡀ☜ㄆ࡛ࡁࡓࠋࡲࡓࠊ㧗⬡⫫㣗ᦤྲྀ࡟ࡼࡾࠊ኱⭠ෆ࡟࠾ࡅࡿపศ
Ꮚ௦ㅰ≀ࣉࣟࣇ࢓࢖ࣝࡀ␗࡞ࡿࠊࡍ࡞ࢃࡕࠊపศᏊ௦ㅰ≀࡟ᇶ࡙࠸ࡓ⭠ෆ⎔ቃࡀኚ໬ࡍࡿ
ࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ
࠙⪃ᐹࠚᮏ◊✲ࢆᐇ᪋ࡍࡿࡇ࡜࡛ࠊ㧗⬡⫫㣗ᦤྲྀࢆ⥅⥆ⓗ࡟ᦤྲྀࡍࡿࡇ࡜ࡀࠊపศᏊ௦ㅰ≀࡟ᇶ࡙࠸ࡓ⭠ෆ⎔ቃࡢኚ໬࡟ࡘ࡞ࡀࡿ࡜࠸࠺ࡇ࡜ࢆ☜ㄆ࡛ࡁࡓࠋ㧗⬡⫫㣗ᦤྲྀ࡟ࡼࡾࠊ⭠⟶࣏࣮ࣜࣉᩘࡢቑຍࡶ☜ㄆ࡛ࡁࡓࡇ࡜࠿ࡽࠊ㧗⬡⫫ᦤྲྀ࡟ᇶ࡙ࡃ⭠ෆ⎔ቃࡢኚ໬ࡀࠊ⭠⟶࣏࣮ࣜࣉᩘቑຍ࡟㉳ᅉࡍࡿྍ⬟ᛶࡀ♧၀ࡉࢀࡓࠋ௒ᚋࠊ࡝ࡢࡼ࠺࡞⭠ෆ⎔ቃࡀࠊࡍ࡞ࢃࡕࠊ
࡝ࡢࡼ࠺࡞௦ㅰ≀ࡀࠊ⭠⟶࣏࣮ࣜࣉࠊࡉࡽ࡟ࡣࠊ኱⭠ࡀࢇࡢⓎ⏕࡟㛵ಀࡋ࡚࠸ࡿࡢ࠿ࢆ᫂
ࡽ࠿࡟ࡋ࡚࠸ࡃᚲせࡀ࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ

́́

P-19
⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈ࡟ࡼࡿ࣐࢘ࢫ⫢⮚⅖⑕㒊࡟࠾ࡅࡿ GC-MS/MS ௦ㅰࣉࣟࣇ࢓࢖ࣜࣥࢢゎᯒᕤ⸨ᜤᙪ, ୰す ㇦, ᕝྡಟ୍, ᆏ஭೺ᮁ, ᒣཱྀ ு, ➉ෆ ྖ, ᑿᓥ඾⾜ᰴᘧ఍♫ᓥὠ〇సᡤ

GC-MS/MS metabolic profiling analysis of the inflamed mouse liver by dosing
fluorescent imaging probe
Yukihiko Kudo, Takeshi Nakanishi, Shuichi Kawana, Takero Sakai, Ryo Yamaguchi, Tsukasa Takeuchi,
Noriyuki Ojima
Shimadzu Corporation࠙┠ⓗࠚ⮬ᐙ⺯ගࡢᙳ㡪ࡸගᩓ஘ࡀᑡ࡞ࡃ㧗⢭⣽ᗘࡢ⏬ീࡀᚓࡽࢀࡿࡇ࡜࠿ࡽࠊᚑ᮶⏝࠸ࡽࢀ࡚࠸ࡿ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ᭦࡟㛗࠸ NIR-ϩ(1000nm ௨ୖ)㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆㉥እ⺯ග࢖࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆ㛤Ⓨࡋ࡚࠸ࡿࠋᮏ࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡣࠊ㧗⢭⣽࡞⏬
ീࡀᚓࡽࢀࡿ཯㠃ࠊ⫢⮚࡬ࡢ㢧ⴭ࡞㞟✚࡜⅖⑕ࡀぢࡽࢀࡿࡓࡵࠊࡇࡢⅬࢆᨵၿࡋ࡚࠸ࡃᚲ
せࡀ࠶ࡿࠋᮏ◊✲࡛ࡣࠊ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚࡬ࡢ㞟✚ࡀ࣐࢘ࢫ࡟࡝ࡢࡼ࠺࡞
ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿ࠿ࢆ☜ㄆࡍࡿࡓࡵ࡟ࠊ⫢⮚࡟࠾ࡅࡿ௦ㅰ≀ኚືࢆ㧗ศ㞳ࠊ㧗ឤᗘ࡞ศᯒࡀྍ⬟࡞ GC-MS/MS ࢆ⏝࠸࡚ Scan ศᯒࠊMRM ศᯒ࡟ࡼࡾホ౯ࡋࡓࠋ࠙᪉ἲࠚScan ཬࡧ MRM ࡣ GCMS-TQ8040(ओᓥὠ〇సᡤ)ࠊศ㞳࣒࢝ࣛࡣ BPX-5 30m ×0.25mm I.D. df=0.25ȣm(SGE)࡛⾜ࡗࡓࠋSmart Metabolites Database (ओᓥὠ〇సᡤ)࡟ᦚ㍕ࡉ
ࢀࡓศᯒ࣓ࢯࢵࢻࢆ౑⏝ࡋࠊศᯒ᫬㛫 23 ศ࡛ 475TMS ㄏᑟయ໬௦ㅰ≀ࢆᑐ㇟࡟ ᐃࢆ⾜ࡗࡓࠋࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫࠊ࠾ࡼࡧ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈ 100ȣL(100mg/mL)ࢆᑿ㟼⬦ᢞ
୚ࡋ࡚ 48 ᫬㛫ᚋ࡟῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏࡓ࣐࢘ࢫࡢ⫢⮚ࢆ෾⤖⢊○ࡋࠊ㝖ࢱࣥࣃࢡฎ⌮ᚋࡢୖΎࢆ┿✵஝⇱࣭෌⁐ゎᚋ࡟࣓ࢺ࢟ࢩ࣒-TMS ㄏᑟయ໬ࢆ⾜࠸ศᯒヨᩱ࡜ࡋࡓࠋ
࠙⤖ᯝࠚࢥࣥࢺ࣮ࣟࣝཬࡧࣉ࣮ࣟࣈᢞ୚ࡋࡓ࣐࢘ࢫ⫢⮚࠿ࡽᚓࡽࢀࡓヨᩱࢆ Scan ཬࡧ MRM࡛ᐃࡋࡓ⤖ᯝࠊScan ࡛ࡣࢥࣥࢺ࣮ࣟࣝ:101 ᡂศࠊᢞ୚᭷:113 ᡂศࠊMRM ࡛ࡣࢥࣥࢺ࣮ࣟ

ࣝ:198 ᡂศࠊᢞ୚᭷:230 ᡂศࡢ௦ㅰ≀ࡀ᳨ฟ࡛ࡁࡓࠋࣉ࣮ࣟࣈᢞ୚ࡢ᭷↓࡟ࡼࡿ⫢⮚ࡢ௦ㅰ≀ࢆ OPLS-DA ゎᯒࡋࡓ⤖ᯝࠊScan ࡛ࡣࣉ࣮ࣟࣈᢞ୚࡟ࡼࡿ⅖⑕ࢆ཯ᫎࡍࡿ࡜᥎ᐃࡉࢀࡿ
ࣂ࢖࣐࣮࣮࢜࢝ೃ⿵ 47 ᡂศࠊMRM ࡛ࡣ 94 ᡂศࢆᢳฟࡋࡓࠋMRM ࡛ᢳฟࡉࢀࡓᡂศ࡟ࡣ
TCA ࢧ࢖ࢡࣝ(Citric acidࠊcis-Aconitic acid ➼)ࠊࣆ࣑ࣜࢪࣥࢾࢡࣞ࢜ࢳࢻศゎ(UridineࠊDihydrouracil ➼)➼ࡢ௦ㅰ⤒㊰࡟㛵㐃ࡍࡿᡂศࡀྵࡲࢀࡿࠋ
࠙⪃ᐹࠚMRM ࢆ⏝࠸࡚࣐࢘ࢫ⫢⮚ࡢ௦ㅰ≀ࢆ ᐃࡍࡿࡇ࡜࡟ࡼࡾࠊጉᐖᡂศࡀ㝖ཤࡉࢀᐇ㉁ⓗ࡞ឤᗘࡀྥୖࡋࡓ⤖ᯝࠊScan ࡼࡾከࡃࡢ௦ㅰ≀ࡀ᳨ฟ࡛ࡁࡓࠋࡇࡢࡇ࡜ࡣࠊMRM ࡣ
Scan ࡼࡾከࡃࡢࣂ࢖࣐࣮࣮࢜࢝ೃ⿵ࡀ᳨ฟ࡛ࡁࡿࡇ࡜ࢆ♧၀ࡋࠊ࣐࣮࣮࢝᥈⣴࡟࠾࠸࡚᭷
⏝࡛࠶ࡿࡇ࡜ࢆ⾲ࡋ࡚࠸ࡿࠋࡲࡓࠊࣂ࢖࣐࣮࣮࢜࢝ೃ⿵ࡢከࡃࡀ⅖⑕࡟ࡼࡾቑຍࡋࡓࡇ࡜
࠿ࡽࠊᗈ⠊࡞௦ㅰ⤒㊰࡟ᑐࡋ࡚㐣๫࡞௦ㅰ཯ᛂ࡞࡝ࡢ␗ᖖࡀ⏕ࡌ࡚࠸ࡿࡇ࡜ࡀ♧၀ࡉࢀࡿࠋ

́́

P-20
UPLC/MS/MS ࡟ࡼࡿ᪥ᮏேࣉࣟࣆ࢜ࣥ㓟⾑⑕ᝈ⪅ࡢࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ
࣮ࣛࢮάᛶ ᐃᚋ⸨ెዉ 1, ๓⏣ᗣ༤ 1, ୰ᓥⴥᏊ 2, ఀ⸨ဴဢ 2, ๓⏣㝧Ꮚ 1, ᇼ⏣♸ᚿ 1, ∦ᒸᬛဢ 3, ᕝฟ⩏ᾈ 1, ᮡᒣᡂྖ 4, ᮌᮧ࿴ဴ 1,31ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉ , 2 ⸨⏣ಖ೺⾨⏕኱Ꮫᑠඣ⛉, 3 ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉, 4 ឡ▱Ꮫ㝔኱Ꮫ⸆Ꮫ㒊An assay of propionyl-CoA carboxylase activity by UPLC/MS/MS in patients withpropionic acidemia in Japan
Kana Gotoh1, Yasuhiro Maeda1, Yoko Nakajima2, Tetsuya Ito2, Yoko Maeda1, Yuji Hotta1, Tomoya
Kataoka3, Yoshihiro Kawade1, Naruji Sugiyama4, Kazunori Kimura1,3
1
Graduate School of Pharmaceutical Sciences, Nagoya City University, 2Department of Pediatrics,
Fujita Health University, 3Graduate School of Medical Sciences, Nagoya City University, 4School of
Pharmacy, Aichi-Gakuin University࠙┠ⓗࠚࣉࣟࣆ࢜ࣥ㓟⾑⑕(PA)ࡣࠊࣉࣟࣆ࢜ࢽࣝ-CoA ࢝ࣝ࣎࢟ࢩ࣮ࣛࢮ(PCC)Ḟᦆࢆཎᅉ࡜
ࡍࡿ㑇ఏᛶ௦ㅰ⑌ᝈ࡛࠶ࡿࠋࡑࡢ⮫ᗋ⑕≧ࡣࠊ᪂⏕ඣᮇ࡟Ⓨ⑕ࡍࡿ㔜⠜࡞ࡶࡢ࠿ࡽࠊ᪂⏕ඣࢫࢡ࣮ࣜࢽࣥࢢ᳨࡛ฟࡉࢀࡿ↓⑕≧ࡢࡶࡢࡲ࡛ᵝࠎ࡛࠶ࡿࠋPCC άᛶࢆ▱ࡿࡇ࡜ࡣ㸪⑌ᝈࡢ⛬ᗘࢆண ࡍࡿୖ࡛㔜せ࡞ᡭࡀ࠿ࡾ࡜࡞ࡿࠋᡃࠎࡣࠊPA ᝈ⪅ࡢࣜࣥࣃ⌫ࢆ⏝࠸ࡓ㓝⣲཯ᛂࢆ⾜࠸ࠊUPLC/MS/MS ࡟ࡼࡾ PCC άᛶࢆ ᐃࡍࡿ᪉ἲࢆ㛤Ⓨࡋࡓࠋ࠙᪉ἲࠚPA ᝈ⪅ࡲࡓࡣ೺ᖖேࡢࣜࣥࣃ⌫ࢆ㉸㡢Ἴ࡛◚ቯࡋᠱ⃮ᾮ࡜ࡋࡓࠋࡇࢀ࡟ࣉࣟࣆ࢜ࢽ
ࣝ-CoAࠊATPࠊMgCl2 ࢆຍ࠼ࠊࡇࡢΰྜᠱ⃮ᾮࢆ 37 Υ࡛ 30 ศ࢖࣮ࣥ࢟ࣗ࣋ࢺࡋࡓࠋࡇࡢ
཯ᛂ࡛⏕ᡂࡋࡓ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࢆ UPLC/MS/MS ࢆ⏝࠸࡚ᐃ㔞ࡋࡓࠋUPLC/MS/MS ࡟ࡼࡿ ᐃ࡟ࡣࠊAcquity UPLC BEH C18 culumn (2.0x150 mm)ࢆ⏝࠸ࠊ⛣ື┦࡟ 400 mmol/L
HCOONH4 (pH 7.4)࡜࢔ࢭࢺࢽࢺࣜࣝࢆ౑⏝ࡋࡓࠋ࠙⤖ᯝࠚ㔜⑕ࡢ PA ᝈ⪅࡛ࡣ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࡣ⏕ᡂࡏࡎ PCC άᛶࡣࢮ࡛ࣟ࠶ࡗࡓࠋ୍
᪉ࠊ㍍⑕ࡲࡓࡣ↓⑕≧ࡢ PA ᝈ⪅࡛ࡣ೺ᖖே࡜ẚ㍑ࡋ࡚ 2-20%ࡢ࣓ࢳ࣐ࣝࣟࢽࣝ-CoA ࡀ⏕ᡂࡋࡓࠋ࠙⪃ᐹࠚᡃࠎࡢ㓝⣲άᛶ ᐃἲ࡛ࡣࠊ㍍⑕࣭↓⑕≧ PA ᝈ⪅࡛ࡢ PCC ṧᏑάᛶࢆṇ☜࡟ ᐃࡍࡿࡇ࡜ࡀ࡛ࡁࠊPA ᝈ⪅࡟࠾ࡅࡿ⑌ᝈࡢ⛬ᗘࢆุ᩿ࡍࡿࡇ࡜ࡀྍ⬟࡜࡞ࡗࡓࠋ㍍⑕ PA ᝈ⪅ࡢከࡃࡣ PCCB 㑇ఏᏊ࡟ Y435C ኚ␗ࢆᣢࡗ࡚࠾ࡾࠊ᪥ᮏ࡛ࡣࢥࣔࣥኚ␗࡜ࡋ࡚▱ࡽࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊY435C ኚ␗ࢆᣢࡘ PA ᝈ⪅ࡢ PCC άᛶࡣ೺ᖖேࡢ⣙ 10%࡛࠶ࡗࡓࠋ
Phenotype ࡜㓝⣲άᛶ࡜ࡢ㛵ಀࢆ᫂ࡽ࠿࡜ࡍࡿࡓࡵࠊ᭦࡞ࡿ◊✲ࡀᚲせࡔ࡜⪃࠼ࡽࢀࡿࠋ

́́

P-21
ᐇ ࡟ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࣛ࢖ࣈ࣮ࣛࣜࢆ⏝࠸ࡓ㓟໬ࣜࣥ⬡㉁ࡢໟᣓⓗ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡢ☜❧㟷ᰗⰋᖹ 1,2, ụ⏣࿴㈗ 1,2, ᭷⏣ ㄔ 1,2
1 ⌮໬Ꮫ◊✲ᡤ⤫ྜ⏕࿨་⛉Ꮫࢭࣥࢱ࣮࣓ࢱ࣮࣒࣎ࣟ◊✲ࢳ࣮࣒
2 ᶓ὾ᕷ❧኱Ꮫ⏕࿨་⛉Ꮫ◊✲⛉ศᏊ࢚ࣆࢤࣀ࣒⛉Ꮫ◊✲ᐊ

Comprehensive metabolomics of oxidized phospholipids using a measured MS/MS
spectra library
Ryohei Aoyagi1,2, Kazutaka Ikeda1,2, Makoto Arita1,21
Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences (IMS)
2
Cellular and Molecular Epigenetics Laboratory, Graduate School of Medical Life Science,
Yokohama City University࠙┠ⓗࠚ㓟໬ࣜࣥ⬡㉁ࡣࠊࣜࣥ⬡㉁ࡢ⬡⫫㓟㙐ࡀάᛶ㓟⣲✀ࡸ௦ㅰ㓝⣲࡛㓟໬ࡉࢀࡿࡇ࡜࡞
࡝࡟ࡼࡾ⏕ᡂࡍࡿࠋࡇࢀࡽ㓟໬ࣜࣥ⬡㉁ࡣࠊື⬦◳໬ࢆࡣࡌࡵ࡜ࡍࡿᵝࠎ࡞⑌ᝈࡢⓎ⑕ࡸ㐍⾜࡟㛵ࢃࡗ࡚࠸ࡿྍ⬟ᛶࡀᣦ᦬ࡉࢀ࡚࠸ࡿࡀࠊ⏕యෆ࡟࠾ࡅࡿศᕸࡸືែࠊ௦ㅰไᚚࠊ
࠾ࡼࡧ⏕⌮ᶵ⬟࡟ࡘ࠸࡚ࡣᮍࡔ୙᫂࡞Ⅼࡀከ࠸ࠋࡑࡢ⌮⏤ࡢ୍ࡘ࡜ࡋ࡚ࠊධᡭྍ⬟࡞ᶆ‽≀㉁ࡀ㝈ࡽࢀ࡚࠾ࡾࠊໟᣓⓗ࡞࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡀ☜❧ฟ᮶࡚࠸࡞࠸ࡇ࡜ࡀᣲࡆ
ࡽࢀࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊᇵ㣴⣽⬊࡟㓟໬⬡⫫㓟ࢆῧຍࡍࡿࡇ࡜࡟ࡼࡾ⏕ᡂࡍࡿ㓟໬ࣜࣥ⬡㉁ࢆ⏝࠸ࡿࡇ࡜࡛ᐇ ࡟ᇶ࡙ࡃ MS/MS ࢫ࣌ࢡࢺࣝࡢ཰㞟ࢆ⾜࠸ࠊࡇࡢ᝟ሗࢆ⏝࠸ࡓ㓟໬ࣜࣥ⬡㉁ࡢໟᣓⓗ࣓ࢱ࣮࣒࣎ࣟゎᯒࢩࢫࢸ࣒ࡢᵓ⠏ࢆ┠ᣦࡋࡓࠋ
࠙᪉ἲࠚHEK293 ⣽⬊࡟㓟໬⬡⫫㓟ࢆῧຍࡋࠊࡑࡢ⤖ᯝ⏕ᡂࡋࡓ㓟໬ࣜࣥ⬡㉁ࢆᅛ┦ᢳฟ
㸦Monospin C18: GL science)࡛ㄪ〇ࡋࡓࠋḟ࡟ UPLC/Triple TOF-MS (Waters/SCIEX)ࢆ⏝࠸࡚
Information dependent acquisition (IDA) ࣮ࣔࢻ࡛ࣀࣥࢱ࣮ࢤࢵࢺゎᯒࢆ⾜࠸ࠊMS/MS ࢫ࣌ࢡࢺࣝ࡟ࡼࡿ㓟໬ࣜࣥ⬡㉁ࡢໟᣓⓗ࡞ྠᐃ࠾ࡼࡧᵓ㐀ゎᯒࢆ⾜ࡗࡓࠋ࠙⤖ᯝ࡜⪃ᐹࠚ㓟໬⬡⫫㓟ࡢῧຍ࡟ࡼࡾ⏕ᡂࡋࡓ㓟໬ࣜࣥ⬡㉁ࡢᵓ㐀ゎᯒ࡟ࡼࡾࠊࡇࢀࡲ࡛
࡟⣙ 300 ✀㢮ࡢ㓟໬ࣜࣥ⬡㉁ศᏊ✀ࡢ MS/MS ࢫ࣌ࢡࢺࣝࢆ཰㞟ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋࡇࢀࡽ
ࡢ᝟ሗࢆࡶ࡜࡟ࠊ୕㐃ᅄ㔜ᴟᆺ MS ࢆ⏝࠸ࡓࢱ࣮ࢤࢵࢺゎᯒ࠿ࡽ㧗ឤᗘ࠿ࡘᐃ㔞ⓗ࡞ ᐃ⣔ࢆᵓ⠏ࡋࡓࠋ⏕యヨᩱࢆ⏝࠸ࡓ㓟໬ࣜࣥ⬡㉁ࡢ᳨ฟ࠾ࡼࡧᐃ㔞ศᯒ࡟ᛂ⏝ࡋࡓ౛࡟ࡘ࠸࡚
ࡶ⤂௓ࡋࡓ࠸ࠋ

́́

P-22
ࢫࢸࣟ࢖ࢻ᳨ᰝヨᩱ࡜ࡋ࡚ࡢ∎ࡢホ౯㸸ᕥྑࡢᡭࡢ∎୰ࢫࢸࣟ࢖ࢻࡢྵ㔞ᕪᑠᕝ⚈஧㑻 1, ຍ⸨⏤㑣 1, 㧗㔝 㤶 1, ୰␁ຬኴ㑻 1, ᒣᙧ᠇୍㑻 1, 㛬 ಇဴ 2, ᮾ 㐩ஓ 11ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊, 2㟼ᒸ┴❧኱Ꮫ⸆Ꮫ㒊

Evaluation of the utility of fingernail clipping as sample for steroid test:
Differences in fingernail steroid contents between right and left hands
Shoujiro Ogawa 1, Yuina Kato 1, Kaori Takano 1, Yutaro Nakaaze 1, Kenichiro Yamagata 1,Jun Zhe Min 2,
Tatsuya Higashi 1
1
Faculty of Pharmaceutical Sciences, Tokyo University of Science2
School of Pharmaceutical Sciences, University of Shizuoka䛆┠ⓗ䛇 ∎ࡣ↓③ࠊ↓౵くⓗ࡟᥇ྲྀྍ⬟࡛࠶ࡿࡇ࡜࡟ຍ࠼ࠊ୰㛗ᮇ㛫ࡢ⏕య᝟ሗࢆಖᏑࡋ࡚
࠸ࡿࡇ࡜࠿ࡽࠊ៏ᛶ⑌ᝈࡢ᪂ࡋ࠸᳨ᰝヨᩱ࡜ࡋ࡚ᮇᚅࡉࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊ⌧᫬Ⅼ࡛ࡣࢫࢸࣟ࢖ࢻࢆᣦᶆ࡜ࡍࡿෆศἪ᳨ᰝ࡟ᑐࡋࠊヨᩱ࡜ࡋ࡚ࡢ∎࡟㛵ࡍࡿ᝟ሗࡣᴟࡵ࡚ஈࡋ࠸ࠋ
౛࠼ࡤᕥྑࡢᡭࡢ∎୰ࢫࢸࣟ࢖ࢻࡢྵ㔞ᕪ࡞࡝ࡣ୙࡛᫂࠶ࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣ
LC/ESI-MS/MS࡟ࡼࡿ∎୰testosterone (T) ࡜cortisol (F) ࡢྠ᫬ᐃ㔞ἲࠊglycochenodeoxycholicacid(GCDCA) ࡜ taurochenodeoxycholic acid

(TCDCA) ࡢ ྠ ᫬ ᐃ 㔞 ἲ ࠊ ཬ ࡧdehydroepiandrosterone sulfate (DHEAS) ᐃ㔞ἲࢆ㛤Ⓨࡋࠊ᳨ᰝヨᩱ࡜ࡋ࡚ࡢ∎ࡢホ౯ࡢ୍ࡘ࡜ࡋ࡚ࠊࡇࢀࡽ5✀ࡢࢫࢸࣟ࢖ࢻࡢᕥྑࡢᡭࡢ∎୰ྵ㔞ᕪࢆゎᯒࡋࡓࠋ䛆ᐇ㦂䛇 ೺ᖖ࣎ࣛࣥࢸ࢕࢔ (⏨ዪྛn = 10) ࠿ࡽ᥇ྲྀࡋࡓ∎ (➨1ᣦཬࡧ➨2ᣦ) ࢆ1 mmゅ௨ୗ࡟⣽᩿ࡋࠊ஝⇱ (45oCࠊ3 h) ࡋ࡚ಖᏑࡋࡓࠋ∎ヨᩱ (10 mg) ࡣෆᶆ‽≀㉁ (ྛࢫࢸࣟ࢖ࢻ
ࡢ2Hᶆ㆑య) ࢆྵࡴ50% EtOH࠶ࡿ࠸ࡣ70% MeOH (300 ȝL) ୰࡟ᨺ⨨ (60oCࠊ2 h) ᚋࠊ㉸㡢Ἴฎ⌮ (15 min) ࡋࡓࠋୖΎࢆᅛ┦ᢳฟ࣮࢝ࢺࣜࢵࢪ࡛⢭〇ࡋࠊLC/ESI-MS/MS࡟௜ࡋࡓࠋ
䛆⤖ᯝ䛇 ྛ䝇䝔䝻䜲䝗䛻䛴䛔䛶ᕥྑ䛾ᡭࡢ∎୰ࢫࢸࣟ࢖ࢻྵ㔞 (LཬࡧR) ࡢẚ (L/R) ࢆ⟬ฟࡋࡓ࡜ࡇࢁࠊGCDCA࡛0.40㸫2.03ࠊTCDCA࡛0.82㸫2.10ࠊDHEAS࡛0.44㸫2.13࡜࡞ࡾࠊࡇࢀࡽ
ࡢࢫࢸࣟ࢖ࢻ࡛ࡣR࡜Lࡢ࡝ࡕࡽࡢ⤖ᯝࢆ⏝࠸ࡿ࠿࡟ࡼࡗ࡚ࠊ⏘⏕࣭ศἪ≧ែࡢホ౯ࡀ኱ࡁࡃ␗࡞ࡿࡇ࡜ࡀ♧၀ࡉࢀࡓࠋ୍᪉ࠊTཬࡧF࡛ࡣL/Rࡀࡑࢀࡒࢀ0.84㸫1.24ཬࡧ0.83㸫1.27࡛࠶
ࡗࡓࠋ໬ྜ≀ࡢlogD࡜ࢣࣛࢳࣥ࡟ᑐࡍࡿぶ࿴ᛶ࡟ࡣṇࡢ┦㛵ࡀ࠶ࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊ
TࡸF࡞࡝ࡢ␯Ỉᛶࡢ㧗࠸ࢫࢸࣟ࢖ࢻࡣ∎࣐ࢺࣜࢡࢫ࡟ྲྀࡾ㎸ࡲࢀࡓᚋࠊ᪥ᖖάື (ᡭὙ࠸㸪ධᾎ࡞࡝) ࡟࠾ࡅࡿ⁐ኻࡀᑡ࡞ࡃࠊL࡜R࡟ᕪࡀ⏕ࡌ࡟ࡃ࠸ࡶࡢ࡜᥎ᐹࡉࢀࡓࠋࡲࡓࠊ∎୰Tྵ㔞࡟᫂ࡽ࠿࡞ᛶᕪ (⏨ᛶ㸸2.07 ± 0.64 ng/g㸪ዪᛶ㸸0.58 ± 0.33 ng/g) ࡀほᐹࡉࢀࡿ୍᪉࡛ࠊ
Fྵ㔞 (⏨ᛶ㸸5.23 ± 1.62 ng/g㸪ዪᛶ㸸4.49 ± 1.38 ng/g) ࡟ࡣࡑࢀࡀㄆࡵࡽࢀ࡞࠿ࡗࡓ㸬௨ୖࢆ⥲ྜࡍࡿ࡜ࠊ∎ࢆ⏝࠸࡚ྛಶேࡢTࡸFࡢ⏘⏕࣭ศἪ≧ែࡀホ౯࡛ࡁࡿࡶࡢ࡜⪃࠼ࡽࢀࡓࠋ

́́

P-23
⬡⫫⣽⬊ࡢ⬡⫫⁲࡟࠾ࡅࡿ㐣㓟໬ࢺࣜࢢࣜࢭࣜࢻࡢศᯒ᝴ ῄⴍ 1, ⦾ᐩ㸦ᰩᯘ㸧㤶⧊ 1, ᑠᯘ ᝆ 1, ༓ⴥோᚿ 11໭ᾏ㐨኱Ꮫ ኱Ꮫ㝔ಖ೺⛉Ꮫ◊✲㝔

Analysis of triglyceride hydroperoxides in lipid droplets from adipocyte
Shu-Ping Hui1, Kaori Kuribayashi-Shigetomi1, Yu kobayashi1, Hitoshi Chiba1,
1
Faculty of heath science, Hokkaido University࠙⫼ᬒ࣭┠ⓗࠚ⫧‶࣭⢾ᒀ⑓࣭㧗⾑ᅽ࣭ື⬦◳໬ࢆࡣࡌࡵ࡜ࡋࡓ⏕ά⩦័⑓ࡢⓎ⑕ࡣࠊෆ⮚⬡⫫ࡢ㐣๫⵳✚ࡀ୺せᅉࡔ࡜ゝࢃࢀ࡚࠸ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊ࡝ࡢࡼ࠺࡞࣓࢝ࢽࢬ࣒࡛ෆ⮚⬡⫫⵳✚ࢆᘬࡁ㉳ࡇࡍࡢ࠿ࠊࡲࡓࠊ⵳✚ࡉࢀࡓ⬡⫫ࡣ࡝ࡢࡼ࠺࡞ᡂศ࡞ࡢ࠿࡞࡝ᮍࡔ࡟୙
᫂࡞Ⅼࡀከ࠸ࠋ㏆ᖺࠊ࢞ࣛࢫ࢟ࣕࣆ࣮ࣛࣜࢆ⏝࠸࡚⏕య⤌⧊ࡸ⣽⬊ෆࡢపศᏊ࡟㛵ࡍࡿ㉁㔞ศᯒἲࡢ◊✲ࡀሗ࿌ࡉࢀࡓ㸦Nakajima K., et al Analy Sci. 2003; Mizuno H., et al,
J Mass Spectrom, 2008㸹 Tsuyama N., et al, Anal Sci, 2008㸧.

ᮏ◊✲ᐊ࡛☜❧ࡉࢀࡓ୍⣽⬊ෆ⬡⫫⁲ࡢ㓟໬ホ౯⣔㸦㉁㔞ศᯒἲ㸧ࢆ⏝࠸࡚ࠊ⬡⫫⣽⬊࡟⵳࠼ࡽࢀ࡚࠸ࡿ⬡⫫⁲ࡢࡳࢆ㑅ᢥⓗ࡟᥇ྲྀࡋࠊࢺࣜࢢࣜࢭࣜࢻ (TG) ཬࡧ㐣㓟໬ࢺࣜࢢࣜࢭࣜࢻ (TG-OOH) ࢆศᯒࡋࡓࠋ࠙᪉ἲࠚ⣽⬊ࡣࠊேࡢෆⶶ⬡⫫⤌⧊࡟୍␒㏆࠸࡜ゝࢃࢀ࡚࠸ࡿࣛࢵࢺࡢ⭠㛫⭷⬡⫫⣽⬊ࡼࡾ᥇ྲྀࡋࡓ stromal-vascular cells (SVCs)ࢆ౑⏝ࡋࡓ (Visceral Adipocyte Culture Kit
V-1; Cosmo Bio Co.Ltd., Japan)ࠋᮏ⣽⬊ࡣࠊ୍㐣ᛶࡢㄏᑟ่⃭ࡢ㝿࡟୍⯡ⓗ࡟⏝࠸ࡽࢀࡿࢹ࢟ࢧ࢖࣓ࢱࢰࣥཬࡧ࢖ࢯࣈࢳ࣓ࣝࢳࣝ࢟ࢧࣥࢳࣥࢆ౑⏝ࡍࡿࡇ࡜࡞ࡃࠊ୍㐌㛫࡯࡝࡛⬡⫫⣽⬊࡬࡜ศ໬ࡍࡿࡇ࡜ࡀྍ⬟࡛࠶ࡿ㸦Shimizu, Cell Biol Int, 2006㸧ࠋ⬡⫫⣽⬊࠿ࡽ
⬡⫫⁲ࢆ᥇ྲྀࡍࡿ๓࡟ࠊᇵᆅࢆ྾ᘬࡋࠊࣜࣥ㓟⦆⾪⏕⌮㣗ሷỈ(PBS)࡛ࡍࡍࡄࠋ⬡⫫⣽⬊࡟࠾ࡅࡿ⬡⫫⁲ࡣࠊ㢧ᚤ㙾(IX71, ࢜ࣜࣥࣃࢫ)ࡢୗ࡛ࠊ㔠࡛ࢥ࣮ࢸ࢕ࣥࢢࡉࢀࡓ⮬ᐙ〇࢟ࣕࣆ࣮ࣛࣜ㸦㔪㸧࠾ࡼࡧ࣐࢖ࢡࣟ࢖ࣥࢪ࢙ࢡࢱ࣮ (IM- 11-2 ࠊࢼࣜࢩࢤ)ࢆ⏝࠸࡚྾ᘬࡋࡓࠋ
ḟ࠸࡛ࠊ㔪࡟᭷ᶵ⁐፹ࢆῧຍࡋࠊࡑࡢࡲࡲ ESI-Orbitrap ㉁㔞ศᯒィ࡟ᑟධࡋࠊᐃᛶศᯒ
ࢆ⾜ࡗࡓࠋ࡞࠾ࠊᐃᛶศᯒ࡟ᚲせ࡞ࢺࣜ࢜ࣞ࢖ࣥ(TG 18:1/18:1/18:1)ཬࡧ㐣㓟໬ࢺࣜࢢࣜ
ࢭࣜࢻ(TG-OOH 16:0/18:2/16:0)ࡣ ᶆရ࡜ࡋ࡚໬Ꮫྜᡂࡉࢀࡓࠋ(Hui SP, et al. Lipids
2003, 38; Hui SP, et al. Anal Bioanal Chem 2013, 405)࠙⤖ᯝ࣭⪃ᐹࠚྜᡂࡉࢀࡓ TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࡣ୧᪉࡜ࡶ MS
ࢫ࣌ࢡࢺ࡛ࣝࡣ[M+Na]+࡜ࡋ࡚ほᐹࡉࢀࡓࠋࡲࡓࠊࡑࢀࡽࡢ MS2 ࢫ࣌ࢡࢺࣝࡀᚓࡽࢀࡓࠋ⏕ࡁ ࡓ ⬡ ⫫ ⣽ ⬊ ࠿ ࡽ ᥇ ྲྀ ࡋ ࡓ ⬡ ⫫ ⁲ ࠿ ࡽ ࡶ ྠ ࡌ ࡃ TG 18:1/18:1/18:1 ཬ ࡧ TG-OOH
16:0/18:2/16:0 ࡀ[M+Na]+࡜ࡋ࡚ほᐹࡉࢀࠊMS2 ࢫ࣌ࢡࢺࣝࡶᚓࡽࢀࡓࠋࡼࡗ࡚ࠊ⬡⫫⁲࡟
TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࡀᏑᅾࡋࡓࡇ࡜ࢆ☜ㄆࡋࡓࠋᮏ◊✲࡛ࡣࠊ
TG 18:1/18:1/18:1 ཬࡧ TG-OOH 16:0/18:2/16:0 ࢆྵࡵࠊ20 ✀㢮ࡢ TG ཬࡧ 15 ✀㢮ࡢ TG-OOH
ࢆ᳨ฟࡋࡓࠋ⬡⫫⣽⬊ෆࡢ⬡⫫⁲ࡣࠊ㓟໬ࡉࢀ࡚࠸ࡿࡇ࡜ࡀ᫂ࡽ࠿࡟࡞ࡗࡓࠋ

́́

P-24
LC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝̿ࣅࢱ࣑ࣥ D ௦ㅰ≀ᐃࢆᇶ┙࡟̿బ⸨ Ᏺ 1, ▼ẟᓫஅ 2, ᑠᕝ⚈஧㑻 3, すᮧ ᇶ 2,4, ᯇୗ୍அ 2,4, ᮾ 㐩ஓ 3, 㔝ᮧᩥኵ 1
1༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2 ༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔᳨ᰝ㒊, 3 ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊⮫ᗋศᯒ⛉Ꮫ◊✲ᐊ, 4 ༓ⴥ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔ศᏊ⑓ែゎᯒᏛClinical application of LC/MS/MS -focusing on vitamin D metabolites testingMamoru Satoh1, Takayuki Ishige2, Shoujiro Ogawa3, Motoi Nishimura2,4, Kazuyuki Matsushita2,4,
Tatsuya Higashi3, Fumio Nomura1
1
Division of Clinical Mass Spectrometry, Chiba University Hospital2
Clinical Laboratory, Chiba University Hospital
3
Faculty of Pharmaceutical Sciences, Tokyo University of Science
4
Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University࠙⫼ᬒ࡜┠ⓗࠚ⌧ᅾࡢ⮫ᗋ᳨ᰝᐊ࡛ࡣࠊྛ✀ࢫࢸࣟ࢖ࢻ࣭࣍ࣝࣔࣥࣅࢱ࣑ࣥ D ௦ㅰ≀࡞࡝ࡢపศᏊ໬ྜ≀ࡢศᯒ࡟ࡣᢠయ࡟ࡼࡿච␿Ꮫⓗ ᐃἲࡀ୺࡟⏝࠸ࡽࢀ࡚࠸ࡿࠋච␿Ꮫⓗ ᐃἲࡣ᳨యฎ⌮⬟ຊࡀ㧗ࡃࠊ⮫ᗋ᳨ᰝ࡟࠾࠸࡚ᚲ㡲࡛࠶ࡿ୍᪉ࠊ஺ᕪ཯ᛂࡢᏑᅾࡸ࢟ࢵࢺ㛫ᕪ࣭᪋タ㛫ᕪࡢၥ㢟ࡀᣦ᦬ࡉࢀ࡚࠸ࡿࠋపศᏊ໬ྜ≀ࡣഃ㙐ᵓ㐀࡞࡝ࡢᚤᑠ࡞㐪࠸࡟ࡼࡾ⏕≀Ꮫⓗάᛶࡀ኱ࡁࡃ␗࡞ࡿࡓࡵࠊ⢭ᐦ࡞௦ㅰືែࡢホ౯࡟ࡣࠊᚤᑠᵓ㐀ᕪࢆᘚูࡍࡿࡇ࡜ࡢ࡛ࡁࡿ
LC/MS/MS ࡛ࡢ ᐃࡀ㠀ᖖ࡟᭷⏝࡛࠶ࡿࠋᮏⓎ⾲࡛ࡣࠊLC/MS/MS ࡢ⮫ᗋ᳨ᰝᐊᑟධࡢ㸯౛࡜ࡋ࡚ࠊࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢศᯒࢆ⤂௓ࡍࡿࠋࣅࢱ࣑ࣥ D ࡣ࢝ࣝࢩ࣒࢘ࡢ௦ㅰㄪ⠇࡟ᚲせ࡞⬡⁐ᛶࣅࢱ࣑ࣥ࡜ࡋ࡚▱ࡽࢀ࡚࠾ࡾࠊ㏆ᖺ࡛ࡣࣅࢱ࣑ࣥ D ࡢ୙㊊ࡀከࡃࡢ⑌ᝈࡢⓎ⑕ࣜࢫࢡࢆ㧗ࡵࡿࡇ࡜ࡀሗ࿌ࡉࢀὀ┠ࡉࢀ࡚࠸ࡿࠋ⾑୰ࡢ୺ࡓࡿࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢ㸯ࡘ࡛࠶ࡿ
25(OH)ࣅࢱ࣑ࣥ D ࡣࣅࢱ࣑ࣥ D ࡢᰤ㣴≧ែࡢホ౯ࢆ୺࡜ࡋࡓ┠ⓗ࡛ ᐃࡉࢀ࡚࠸ࡿࠋࡲࡓ᭱
㏆ࠊ᪂⏕ඣ࡟࠾࠸࡚ 25(OH)D ࡢ␗ᛶయ࡛࠶ࡿ 3-epi-25(OH)D3 ࡀ 25(OH)D ࡢ 8㹼60㸣࡜ẚ㍑ⓗ࡟㧗⃰ᗘ࡛Ꮡᅾࡍࡿࡇ࡜ࡶሗ࿌ࡉࢀ࡚࠸ࡿࠋ3-epi-25(OH)D3 ࡣ⏕⌮άᛶࢆᣢࡓ࡞࠸ࡀࠊࡇ
ࢀࡀ᪂⏕ඣࡢ 25(OH)Dᐃ್ࢆㄗࡗ࡚㧗್࡟ࡋ࡚࠸ࡿྍ⬟ᛶࡀ࠶ࡾࠊಶࠎࡢࣅࢱ࣑ࣥ D ௦ㅰ≀ࢆṇ☜࡟ᐃ㔞࡛ࡁࡿࡇ࡜ࡀồࡵࡽࢀ࡚࠸ࡿࠋࡑࡇ࡛௒ᅇᡃࠎࡣࠊάᛶᆺࣅࢱ࣑ࣥ D ࡜ᐦ᥋࡞㛵ಀ࡟࠶ࡿ୙άᛶᆺࣅࢱ࣑ࣥ D㸦24,25(OH)2D3㸧ࡶྵࡵࡓ 4 ✀ࡢࣅࢱ࣑ࣥ D ௦ㅰ≀࡟ࡘ࠸᳨࡚ᰝᛂ⏝ࢆ┠ⓗ࡜ࡋ࡚ࠊ⮫ᗋ᳨ᰝࢆ⾜࠺㝿࡟⤯ᑐ࡟ồࡵࡽࢀࡿṇ☜ᗘ࣭෌⌧ᛶ࣭Ᏻᐃᛶ࣭
᭱ᑠᐃ㔞ឤᗘ࣭࣐ࢺࣜࢡࢫࡢᖸ΅࣭᥇⾑⟶✀ࡢᙳ㡪࣭ᚑ᮶ἲ࡜ࡢ┦㛵࡟ࡘ࠸࡚ヲ⣽࡟᳨ウࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚ࢖ࣥࣇ࢛࣮࣒ࢻࢥࣥࢭࣥࢺࡢᚓࡽࢀࡓ೺ᖖே⾑Ύ᳨యࢆ⏝࠸ࡓࠋ⾑Ύ 20PL ࡜ IS ࢆࢫࣃ࢖ࢡࡋࡓᢳฟᾮ 280PL ࢆΰ࿴ࡋࠊSLE (Supported Liquid extraction)ࢆ⾜ࡗࡓࠋᢳฟ⁐ᾮࢆ஝ᅛᚋ࡟ DAPTAD ㄏᑟయ໬ࢆᐊ ࡛ 1 ᫬㛫⾜࠸ SRM

ᐃࢆ⾜ࡗࡓࠋHPLC ࡣ NanoSpace SI-2

ࢆ⏝࠸ࠊ࢖࢜ࣥ໬ἲࡣ ESIࠊ㉁㔞ศᯒィ࡟ࡣ୕㐃ᅄ㔜ᴟ㉁㔞ศᯒィ TSQ vantage ࢆ⏝࠸ࡓࠋ
0.0202 ng/mLࠊ࠙⤖ᯝ࣭⪃ᐹࠚ
LOQ ࡣᕼ㔘┤⥺ᛶ࡜ CV10%௨ୗࡢࢡࣛ࢖ࢸࣜ࢔࠿ࡽ 0.0905 ng/mLࠊ
0.0241 ng/mLࠊ0.0127 ng/mL㸦ྛ 25(OH)D3ࠊ3-epi-25(OH)D3ࠊ24,25(OH)2D3ࠊ25(OH)D2㸧࡛࠶ࡗࡓࠋ೺ᖖே⾑Ύࢆ⏝࠸ࡓ⢭ᗘࡣྠ᫬෌⌧ᛶࡀࡑࢀࡒࢀ CV 0.9%ࠊCV 3.0%ࠊCV 3.8%ࠊCV 4.4%
࡛ 20 ᪥㛫ࡢ᪥ᕪ෌⌧ᛶࡀ CV 2.2%ࠊ
CV 3.4%ࠊ
CV 7.8%ࠊ
CV 4.4%㸦ྛ 25(OH)D3ࠊ
3-epi-25(OH)D3ࠊ
24,25(OH)2D3ࠊ
25(OH)D2㸧
࡛࠶ࡗࡓࠋ
NIST SRM972a ࢆ౑⏝ࡋࡓṇ☜ᗘࡣ Level2 ⾑Ύ࡛ 100.5%ࠊ
96.1%ࠊ99.3%㸦ྛ 25(OH)D3ࠊ3-epi-25(OH)D3ࠊ25(OH)D2㸧࡛࠶ࡾࠊNIST ࡢᣦᐃࡋࡓ⠊ᅖ࡟཰ࡲࡗ࡚࠾ࡾࠊ᪥ᖖ᳨ᰝ࡜ࡋ࡚༑ศ࡟౑⏝࡛ࡁࡿ࡜⪃࠼࡚࠸ࡿࠋ

́́

P-25
࣓ࢱ࣮࣒࣎ࣟゎᯒ࡟ࡼࡿዷፎ㧗⾑ᅽ⭈⑕἞⒪ᶆⓗศᏊࡢ᥈⣴ὠᅧ⏤ెᏊ 1, బ⸨ᜨ⨾Ꮚ 1,2, అ㛫ᬛྐ 1, బ⸨ ༤ 1,2, 㧗ᶫಙ⾜ 1,2, ୕ᯞ኱㍜ 2,31ᮾ໭኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉, 2 ᮾ໭኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 3 ᮾ໭኱Ꮫᮾ໭࣓ࢹ࢕࣭࢝ࣝ
࣓࢞ࣂࣥࢡᶵᵓ

Metabolomic screening for biomarkers of preeclampsia
Yukako Tsunokuni1, Emiko Sato1, 2, Tomofumi Fushima1, 2, Hiroshi Sato1,2, Nobuyuki Takahashi1,2,
Daisuke Saigusa2,31
Graduate School of Pharmaceutical Science, Tohoku University
2
School of Medicine, Tohoku University
3
Tohoku Medical Megabank Organization, Tohoku University࠙┠ⓗࠚዷፎ㧗⾑ᅽ⭈⑕ (Preeclampsia : PE) ࡣࠊዷፎ 20 㐌௨㝆࡟㧗⾑ᅽ࡜⺮ⓑᒀࢆ࿊ࡍࡿ⑓
ែ࡛࠶ࡾࠊ㔜⑕໬ࡍࡿࡇ࡜࡛ẕయⱝࡋࡃࡣᏊ࡟ᙳ㡪ࢆ୚࠼ࡿᜍࢀࡀ࠶ࡿ⑌ᝈ࡛࠶ࡿࠋ⌧ᅾ
ࡲ࡛࡟ࠊPE ࡢデ᩿࡟ࡣ⾑ᅽཬࡧࢱࣥࣃࢡᒀࡀ⏝࠸ࡽࢀ࡚࠸ࡿࡀࠊ᫂☜࡞⑓ែࡢኚ໬࡟ࡼࡿ
デ᩿ᇶ‽ࡀᐃ⩏ࡉࢀ࡚࠸࡞࠸ࠋᚑࡗ࡚ࠊPE ࡢ⑓ែࢆゎ᫂ࡋࠊ᪩ᮇⓎぢࢆྍ⬟࡜ࡍࡿ᪂つデ᩿࣐࣮࣮࢝ศᏊࡢྠᐃࡀồࡵࡽࢀ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࠊPE ࡢ⑓ែゎ᫂ࢆࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࠊࣔࢹ࣐ࣝ࢘ࢫࢆ⏝࠸ࡿ἞⒪ࢱ࣮ࢤࢵࢺศᏊཬࡧデ᩿࣐࣮࣮࢝ࡢ᥈⣴ࢆᐇ᪋ࡋࡓࠋ
࠙᪉ἲࠚึࡵ࡟ࠊICR ࣐࢘ࢫ (ዷፎ 8 㐌㱋) ࡟ࠊྍ⁐ᆺ VEGF ཷᐜయ 1 (sFlt-1)ࢆ㐣๫Ⓨ⌧ࡉࡏࡿ࢔ࢹࣀ࢘࢕ࣝࢫࢆᢞ୚ࡋࠊPE ࣔࢹ࣐ࣝ࢘ࢫࢆసᡂࡋࡓ (1)ࠋḟ࡟ࠊࣔࢹ࣐ࣝ࢘ࢫ࠿ࡽ⾑₢ࢆ᥇ྲྀࡋࠊglobal metabolomics (GMet) ゎᯒࢆᐇ᪋ࡋࡓࠋศᯒᇶ┙ࡣࠊLC ࡟ᅄ㔜ᴟ-ࣇ࣮ࣜ
࢚ኚ᥮ᆺ㉁㔞ศᯒィࢆ᥋⥆ࡋࡓ LC-Q-FT/MS ࢆ⏝࠸ࠊpositive (pos) ཬࡧ negative(neg)୧࢖࣮࢜ࣥࣔࢻ࡟࡚ ᐃࢆᐇ᪋ࡋࡓࠋࡲࡓࠊศᯒ࣒࢝ࣛ࡟ ZIC-pHILIC ࢆ㑅ᢥࡋࠊ10 mmol/L㔜Ⅳ㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮ (pH 9.2) ཬࡧ࢔ࢭࢺࢽࢺࣜࣝࢆ⏝࠸ࡿࢢࣛࢪ࢚ࣥࢺ⁐ฟ࡟࡚໬ྜ
≀ࢆ⁐ฟࡋࡓࠋᚓࡽࢀࡓࢹ࣮ࢱࡣࠊProgenesis QI ཬࡧ SIMCA-P ࢆ⏝࠸ࡿࡇ࡜࡟ࡼࡿ໬ྜ≀ྠᐃཬࡧከኚ㔞ゎᯒࢆᐇ᪋ࡋࠊࣔࢹ࣐ࣝ࢘ࢫ࡟࠾࠸࡚≉␗ⓗ࡟ኚືࡍࡿ໬ྜ≀ࢆᢳฟࡋࡓࠋ
ࡲࡓࠊ໬ྜ≀ࡣ LC-MS/MS ࢆ⏝࠸ࡿ targeted metabolomics (TMet) ࡟ࡼࡾࠊᐃ㔞ホ౯ࡋࡓࠋ࠙⤖ᯝཬࡧ⪃ᐹࠚGMet ࡟ࡼࡾᚓࡽࢀࡓ 1011 ✀ (pos) ཬࡧ 986 ✀ (neg) ࡢ໬ྜ≀ࢆ⏝࠸ࡿ
OPLS-DA ゎᯒࡢ⤖ᯝࠊPE ⩌࡟࠾࠸࡚ࠊ⾑₢୰ࡢ࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥཬࡧ㛗㙐࢔ࢩࣝ࢝ࣝࢽ
ࢳࣥࡀ sFlt-1 㠀ᢞ୚࣐࢘ࢫ࡜ẚ㍑ࡋ࡚᭷ព࡟ప್࡜࡞ࡗࡓ (P < 0.05)ࠋࡲࡓࠊྛ໬ྜ≀ࡣࠊ
TMet ࡢ⤖ᯝ࡟࠾࠸࡚ࡶྠᵝ࡟ప್࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋ࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥࡣࠊ࣑ࢺࢥ
ࣥࢻࣜ࢔ࡢ⬡⫫㓟㓟໬࡟㛵ࢃࡿࡇ࡜࠿ࡽࠊ௒ᚋ PE ࡟࠾ࡅࡿ࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥࡢືែ࡜⬡⫫㓟㓟໬ࡢ㛵㐃ࢆゎ᫂ࡋࠊࢱ࣮ࢤࢵࢺศᏊࡢ᭷⏝ᛶࢆホ౯ࡍࡿணᐃ࡛࠶ࡿࠋ
(1) Lu F et al. Am J Obstet Gynecol. 2007 Apr;196(4):396.

́́

P-26
⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ୚࣐࢘ࢫ⫢⤌⧊࡟ᑐࡍࡿ LC/MS ࢆ⏝࠸ࡓ௦ㅰ≀୍ᩧศᯒ୰す ㇦ 1, ᕤ⸨ᜤᙪ 1, ᕝྡಟ୍ 1, ᒣཱྀ ு 1, ➉ෆ ྖ 1, ᑿᓥ඾⾜ 1
1
ᓥὠ〇సᡤ

Simultaneous of primary metabolites by LC/MS for liver tissue from a mouse
dosed with fluorescent probes
Tsuyoshi Nakanishi1, Yukihiko Kudo1, Shuichi Kawana1, Ryo Yamaguchi1, Tsukasa Takeuchi1,
Noriyuki Ojima1
1
Shimadzu Corporation
࠙┠ⓗࠚ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ㛗࠸ NIR-ϩ㸦>1000 nm㸧㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆㉥እ⺯ග࢖࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆᓥὠ〇సᡤ࡛ࡣ㛤Ⓨࡋ࡚࠸ࡿࡀࠊᮏᢏ⾡࡟ࡼࡿ㧗⢭⣽࡞࢖࣓࣮ࢪࣥࢢ⏬ീࡀᚓࡽࢀࡿ཯㠃ࠊ⌧≧ࡢࣉ࣮ࣟࣈࡣ⫢⮚࡬ࡢ㢧ⴭ࡞㞟✚ࡀㄆࡵࡽࢀࡿࡓࡵࠊ
ࡇࡢⅬࢆᨵၿࡋ࡚࠸ࡃᚲせࡀ࠶ࡿࠋࡇࡇ࡛ࡣࠊ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚࡬ࡢ㞟✚ࡀ࣐࢘ࢫ࡟࡝ࡢࡼ࠺࡞ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿ࠿ࢆ☜ㄆࡍࡿࡓࡵ࡟ࠊ⫢⮚࡟࠾ࡅࡿ௦ㅰ≀ኚືࢆࢺࣜࣉࣝᅄ㔜ᴟᆺ LC/MS ࢆ౑ࡗ࡚ホ౯ࡋࡓࠋ࠙᪉ἲࠚ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆ 100 ȣ㹪(100 mg/ml㸧ࢆᑿ㟼⬦ᢞ୚ࡋࡓ BALB/c-nu ࣐࢘ࢫࢆᢞ୚ 48 ᫬㛫ᚋ࡟ࠊ῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏ⫢⤌⧊ࢆ᦬ฟࡋࡓࠋ᦬ฟࡋࡓ⫢⤌⧊ࡣ㏿ࡸ࠿࡟෾⤖ᚋࠊ࣓ࢱࣀ࣮ࣝ୰࡛◚○ࡋࡓࠋࢡ࣒࣭࣓ࣟࣟ࣍ࣝࢱࣀ࣮ࣝᢳฟἲ࡟ࡼࡿ⬡㉁࣭ࢱ
ࣥࣃࢡ㉁ࡢ㝖ཤࠊ5kDa cutoff ࣇ࢕ࣝࢱ࣮࡟ࡼࡿℐ㐣ࢆ⾜ࡗࡓࠋḟ࡟㐲ᚰ࢚ࣂ࣏࣮ࣞࢱ࡟ࡼ
ࡿ⃰⦰ᚋࠊ㉸⣧Ỉ࡛⁐ゎࡋ࡚㐺ᐅᕼ㔘ࡋࡓᚋࠊLC/MS ࡟ࡼࡿ௦ㅰ≀ࡢ୍ᩧศᯒࢆ⾜ࡗࡓࠋLC/MS ศᯒ࡛ࡣࠊ࢖࢜ࣥ࣌࢔ヨ⸆࡜ࡋ࡚ࢺࣜࣈࢳࣝ࢔࣑ࣥࢆ⛣ື┦࡟ຍ࠼ࡓ࢖࢜ࣥ࣌࢔ἲ
࡟ࡼࡿ୍ᩧศᯒ࡜ࠊPFPP ࣒࢝ࣛࢆ⏝࠸ࡓ㏻ᖖࡢ㏫┦⣔࡛ࡢศᯒࢆ⾜ࡗࡓࠋྛ௦ㅰ≀ࡢࣆ࣮ࢡ㠃✚ࢆෆ㒊ᶆ‽≀㉁ࡢ㠃✚್ࢆᇶ‽࡜ࡋࡓ㠃✚ẚࢆẚ㍑ࡍࡿࡇ࡜࡛ࠊ⺯ග࢖࣓࣮ࢪࣥࢢ
ࣉ࣮ࣟࣈᢞ୚࡟ࡼࡿ௦ㅰ≀ࡢኚືࢆẚ㍑ࡋࡓࠋ
࠙⤖ᯝࠚ࢖࢜ࣥ࣌࢔ἲ࡟ࡼࡿ୍ᩧศᯒ⤖ᯝ࠿ࡽࡣゎ⢾⣔ࢆ୰ᚰ࡜ࡋࡓ⢾ࣜࣥ㓟ࡸࢾࢡࣞ࢜ࢳ
ࢻ࡟௦⾲ࡉࢀࡿ௦ㅰ≀ࢆ᳨ฟࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋࡲࡓ PFPP ࣒࢝ࣛࢆ⏝࠸ࡓ㠀࢖࢜ࣥ࣌࢔ἲ
࡛ࡣࠊTCA ᅇ㊰࡟࠾ࡅࡿ᭷ᶵ㓟ࡸ Transsulfuration ⤒㊰௦ㅰ≀ࠊ࢔࣑ࣀ㓟ࠊࢾࢡࣞ࢜ࢩࢻ࡞
࡝ࢆ᳨ฟࡋࡓࠋ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢᮍᢞ୚㸭ᢞ୚㛫࡟࠾ࡅࡿ௦ㅰ≀ኚື࡜ࡋ࡚ࡣࠊ
ᢞ୚⩌࡟࠾࠸࡚ TCA ᅇ㊰ࡢ᭷ᶵ㓟࣭࢔࣑ࣀ㓟ࢆࡣࡌࡵ࡜ࡍࡿ௦ㅰ≀࡟࠾࠸࡚ⴭࡋ࠸ቑ኱ࠊ
⫹Ồ㓟࣭ATP ࡢపୗࡀㄆࡵࡽࢀࡓࠋ
࠙⪃ᐹࠚᢞ୚ࡉࢀࡓ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡀ⫢⤌⧊࡟⵳✚ࡍࡿࡇ࡜࡛⏕ࡌࡿ⫢㞀ᐖࠊ࣑ࢺࢥࣥࢻࣜ࢔ࡢᶵ⬟㞀ᐖࡸ⫹Ồ㓟ྜᡂ⬟ࡢపୗ࡟⏤᮶ࡍࡿ௦ㅰ≀ኚືࡀࠊࢺࣜࣉࣝᅄ㔜ᴟ
ᆺ㉁㔞ศᯒ⿦⨨㸦LC/MS㸧ࢆ⏝࠸ࡓ୍ᩧศᯒ࡟ࡼࡗ࡚♧၀ࡉࢀࡓࠋ

́́

P-27
࣐࢖ࢡࣟࣇ࣮ࣟLC/MS/MS ࡟ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻ୍ᩧศᯒἲ኱⏣ṇつ, బ⸨඘ᙪ, 㝜ᒣಙ஧, ᒸ㔝㞞ேᰴᘧ఍♫ LSI ࣓ࢹ࢕࢚ࣥࢫ ࢔ࣥࢳࢻ࣮ࣆࣥࢢࣛ࣎ࣛࢺ࣮ࣜ

Doping control analysis of small peptides in human urine by microfluidic
chromatography/tandem mass spectrometry
Masanori Ohta, Mitsuhiko Sato, Shinji Kageyama, Masato Okano,Anti-Doping Laboratory, LSI Medience Corporation
࠙┠ⓗࠚ㏆ᖺࠊ➇ᢏࢫ࣏࣮ࢶ࡟࠾࠸࡚ᡂ㛗࣍ࣝࣔࣥศἪ่⃭≀㉁㸦GHS㸧ࢆࡣࡌࡵ࡜ࡍࡿప
ศᏊ࣌ࣉࢳࢻࢆ⏝࠸ࡓࢻ࣮ࣆࣥࢢࡀ኱ࡁ࡞ၥ㢟࡜࡞ࡗ࡚࠸ࡿࠋࡇࢀࡽపศᏊ࣌ࣉࢳࢻࡢศ
ᯒ࡛ࡣࠊᒀ୰⃰ᗘ࡛ᩘ༑ pg/mL ࠿ࡽᩘⓒ pg/mL ࡜ప⃰ᗘ࡛ࡢ᳨ฟࡀྍ⬟࡞㧗ឤᗘศᯒࡀᚲ
せ࡛࠶ࡿࠋ㏻౛ࠊప⃰ᗘ≀㉁ࡢ㧗ឤᗘศᯒ࡟ࡣࢼࣀࣇ࣮࡛ࣟࡢ ESI ࢖࢜ࣥ໬࡟ࡼࡿ㧗ឤᗘ
LC/MS/MS ἲࡀ⏝࠸ࡽࢀࡿࡀࠊࢼࣀࣇ࣮ࣟศᯒࡣࢫࣉ࣮࣮ࣞࣖࡢㄪᩚ࡞࡝ྲྀᢅ࠸ࡀ㞴ࡋࡃࠊࡲࡓศᯒ᫬㛫ࡶ㛗ࡃࢫ࣮ࣝࣉࢵࢺࡀప࠸ࡇ࡜ࡀ㞴Ⅼ࡛࠶ࡿࠋWaters ♫ࡢ IonKey ࣔࢪ࣮ࣗࣝ
ࢆ⏝࠸ࡓ࣐࢖ࢡࣟࣇ࣮ࣟ࢖࢜ࣥ໬࡛ࡣࠊࢼࣀࣇ࣮ࣟ࡟ẚ࡭ὶ㏿ࡀ㏿ࡃࠊࡲࡓศᯒ࣒࢝ࣛ࡜
ࢫࣉ࣮࣮ࣞࣖࡀ୍య࡜࡞ࡗ࡚࠾ࡾࢫࣉ࣮࣮ࣞࣖࡢㄪᩚࡀ୙せ࡛࠶ࡿࡓࡵࠊࢫ࣮ࣝࣉࢵࢺ࠾
ࡼࡧỗ⏝ᛶࡢ㧗࠸㧗ឤᗘศᯒࡀྍ⬟࡛࠶ࡿࠋࡑࡇ࡛ࠊᡃࠎࡣࡇࡢ࣐࢖ࢡࣟࣇ࣮ࣟLC/MS/MS࡟ࡼࡾᒀ୰ࡢపศᏊ࣌ࣉࢳࢻࡢ㧗ឤᗘ㎿㏿୍ᩧศᯒἲࡢ㛤Ⓨࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚᒀ 1mL ࡟ෆ㒊ᶆ‽⁐ᾮ࠾ࡼࡧ 0.8 M ࣜࣥ㓟⦆⾪ᾮ (pH 7.4) ࢆῧຍࡋࠊ㏫┦࣑ࢵࢡࢫ࣮ࣔࢻᙅ㝧࢖࢜ࣥ஺᥮ᆺ࣒࢝ࣛ (Oasis WCXࠊWaters) ࡟ࡼࡿᅛ┦ᢳฟࢆ⾜ࡗࡓࠋᢳฟᾮ
ࢆ 45Υࠊῶᅽୗ࡛㐲ᚰ⃰⦰ࡋࠊṧࡉࢆ 0.1% HCOOH ࡛෌⁐ゎࡋࠊࢧࣥࣉࣝ⁐ᾮ࡜ࡋࡓࠋࡇ
ࡢࢧࣥࣉࣝ⁐ᾮࢆ࣐࢖ࢡࣟࣇ࣮ࣟLC/MS/MS ࢆ⏝࠸࡚ศᯒ࣭ ᐃࡋࡓࠋ⿦⨨ࡣ nanoACQUITYUPLC/Xevo TQ-S/ion Key (Waters)ࠊࢺࣛࢵࣉ࣒࢝ࣛ࡟ࡣ M-Class Trap Symmetry C18 100ύ (5ȝm 300 ȝm×50 mmࠊWaters)ࠊศᯒ࣒࢝ࣛ࡟ࡣ BEH C18 130ύ iKey (1.7 ȝm 150 ȝm×100 mmࠊ
Waters)ࢆ౑⏝ࡋࡓࠋ⛣ື┦࡟ࡣ 0.1% HCOOH ࠾ࡼࡧ 0.1% HCOOH in CH3CN ࢆ⏝࠸ࠊࢢࣛࢪ࢚ࣥࢺ⁐ฟࡋࡓࠋ࢖࢜ࣥ໬ࡣ ESI (+)࡜ࡋࠊ1 ᡂศ࠶ࡓࡾ 2 ࡘࡢ mass transition ࡟ࡼࡿ MRM
ᐃࢆ⾜ࡗࡓࠋ
࠙⤖ᯝ࣭⪃ᐹࠚ࣐࢖ࢡࣟࣇ࣮ࣟLC/MS/MS ࡟ࡼࡿᒀ୰పศᏊ࣌ࣉࢳࢻࡢ 31 ᡂศ୍ᩧศᯒἲࢆ
☜❧ࡋࡓࠋ᳨ฟឤᗘࡣࢼࣀࣇ࣮ࣟศᯒ࡜ᴫࡡྠ⛬ᗘࡢ㧗ឤᗘศᯒࡀྍ⬟࡛࠶ࡾࠊศᯒ᫬㛫ࡶ 1 ᳨య 15 ศ࡜㧗࠸ࢫ࣮ࣝࣉࢵࢺศᯒࢆྍ⬟࡜ࡋࡓࠋᮏἲࡢࢻ࣮ࣆࣥࢢ᳨ᰝ࡬ࡢ㐺⏝ᛶࢆ☜ㄆࡍࡿࡓࡵ࡟ࠊGHS 〇๣ࡢ୍ࡘ࡛࠶ࡿ GHRP-2 ࡢ᭹⏝⪅ࡢᒀヨᩱࢆᮏἲ࡟ࡼࡾศᯒࡋࡓ࡜
ࡇࢁⰋዲ࡞᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋᮏἲࡣࠊࢻ࣮ࣆࣥࢢ᳨ᰝ࡛ࡶヨᩱ࡜ࡋ࡚౑ࢃࢀጞࡵࡓ⾑Ύヨᩱ୰ࡢపศᏊ࣌ࣉࢳࢻศᯒ࡬ࡢ㐺⏝ࡶྍ⬟࡜࡞ࡿࡇ࡜ࡀᮇᚅ࡛ࡉࢀࡿࠋ

́́

P-28
nano LC/MS/MS ࢆ⏝࠸ࡓࣛࢵࢺ⫢⮚୰⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ὸ㔝཭⨾ 1,2, ㈈ὠ ᱇ 1, ℧೺ኴᮁ 1, ⲡ㔝㯞⾰Ꮚ 1, ໭᳃୍ဢ 2, ෆ⸨ஂ㞝 3,㑣㡲ẸỤ 4, ᅵᶫ ᆒ 1, ▼஭ ᫭ 1
1ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉, 2 㔠ᇛᏛ㝔኱Ꮫ⏕ά⎔ቃᏛ㒊, 3 ⸨⏣ಖ೺⾨⏕኱Ꮫ་Ꮫ㒊,4୰㒊኱Ꮫ⏕࿨೺ᗣ⛉Ꮫ㒊

Development of a simultaneous analytical method of bile acids in rat liver by nano
LC/MS/MS
Tomomi Asano1,2, Kei Zaitsu1, Kentaro Taki1, Maiko Kusano1, Kazuya Kitamori2, Hisao Naito3,
Tamie Nasu4, Hitoshi Tsuchihashi1, Akira Ishii1
1
Nagoya University Graduate School of Medicine, 2College of Human Life and Environment, Kinjo
Gakuin University, 3Fujita Health University School of Medicine, 4College of Life and Health
Sciences, Chubu University࠙┠ⓗࠚ⫹Ồ㓟㸦BA㸧ࡣ့ங㢮ࡢ⫹Ồ࡟Ꮡᅾࡍࡿࢫࢸࣟ࢖ࢻㄏᑟయࡢ⥲⛠࡛࠶ࡿࠋᡃࠎࡣࡇ
ࢀࡲ࡛࡟⏕యヨᩱ୰ BA ࡢ୍ᩧศᯒἲ࡜ࡋ࡚ࠊUPLC/MS/MS ࢆ⏝࠸ࡓᡭἲࢆᵓ⠏ࡋ࡚ࡁࡓࠋᮏ
ἲࡣከ᳨యࢆࣁ࢖ࢫ࣮ࣝࣉࢵࢺ࡛ฎ⌮ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓศᯒἲ࡛࠶ࡿࡀࠊ୍⯡࡟ BA ࡟ࡣከࡃࡢ␗ᛶయࡀᏑᅾࡍࡿࡓࡵࠊࡼࡾศ㞳ᛶ⬟ࡢ㧗࠸ศᯒἲࡶ୙ྍḞ࡛࠶ࡿࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊnano LC ࢆ⏝࠸ࡓ⫹Ồ㓟୍ᩧศᯒἲࡢᵓ⠏ࢆヨࡳࡓࠋࡉࡽ࡟ࠊࣛࢵࢺ⫢⮚࠿ࡽࡢBA ᢳฟ᮲௳࡟ࡘ࠸࡚ࡶ᳨ウࡋࠊࣛࢵࢺ⫢⮚ヨᩱ࠿ࡽࡢ⫹Ồ㓟୍ᩧศᯒἲࢆ᳨ウࡋࡓࠋ
࠙᪉ἲࠚBA㸦28 ✀㸧ࡣᕷ㈍ᶆ‽ရࢆ㉎ධࡋࡓࠋࡲࡓࠊෆ㒊ᶆ‽࡜ࡋ࡚ 4 ✀㢮ࡢ BA Ᏻᐃྠ఩యᶆ㆑໬ྜ≀ࢆ౑⏝ࡋࡓࠋ⿦⨨ࡣ nano LC ࢩࢫࢸ࣒ DiNa-2A㸦KYA Tech㸧࠾ࡼࡧ 4000 QTRAP㸦AB Sciex㸧ࢆ౑⏝ࡋࡓࠋศᯒ᮲௳ࡢ᳨ウ㸸0.1 ng/mL ࡲࡓࡣ 1 ng/mL ࡟ㄪᩚࡋࡓ BA ᶆ‽ရΰྜᾮศ㞳᮲௳ࢆ⏝࠸࡚ࠊSRM ᮲௳ࡢ᭱㐺໬࠾ࡼࡧ⿦⨨ឤᗘࡢ☜ㄆࢆ⾜ࡗࡓࠋࡲࡓࠊ⛣ື┦࡟㓑㓟࢔ࣥࣔࢽ࣒࢘Ỉ⁐ᾮࠊ࣓ࢱࣀ࣮ࣝ㸦MeOH㸧࠶ࡿ࠸ࡣ࢔ࢭࢺࢽࢺࣜࣝ㸦ACN㸧ࢆ⏝࠸࡚ศ㞳᮲௳ࢆ᳨ウࡋࡓࠋ࣍ࣔࢪࢼ࢖ࢬ᮲௳ࡢ᳨ウ㸸50% MeOHࠊMeOHࠊACN ࠶ࡿ࠸ࡣ MeOH࣭ACNΰᾮ㸦1:1, v/v㸧࡛ࣛࢵࢺ⫢ヨᩱࢆࡑࢀࡒࢀ࣍ࣔࢪࢼ࢖ࢬࡋࡓࠋ㐲ᚰศ㞳ᚋࡢୖΎࢆ⃰⦰஝ᅛࡋࠊ⛣ື┦࡟෌⁐ゎࡋࡓࡶࡢࢆศᯒヨᩱ࡜ࡋࡓࠋ
࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚ⛣ື┦࡟ ACN ࢆ⏝࠸ࡓሙྜࠊ୍㒊ࡢࣆ࣮ࢡࡀඹ⁐ฟࡋࠊศ㞳ࡀᅔ㞴࡛࠶
ࡗࡓࡀࠊMeOH ࢆ⏝࠸ࡓሙྜࡣྛࣆ࣮ࢡࢆⰋዲ࡟ศ㞳࡛ࡁࡓࠋᶆ‽ရࢆ⏝࠸ࡓ⿦⨨ឤᗘ࡜ࡋ࡚ࠊ
ᴫࡡ 0.1 ng/mL(SRM ࣮ࣔࢻ)ࡢ᳨ฟࡀྍ⬟࡛࠶ࡗࡓࠋ
ࡲࡓࠊ᪤ሗ࡟ᚑࡗ࡚⫢ヨᩱࢆ 50% MeOH
࡛࣍ࣔࢪࢼ࢖ࢬࡋࡓሙྜࠊࡑࡢᚋࡢ⬺ሷ࠾ࡼࡧ㝖ࢱࣥࣃࢡ᧯సࡀ↹㞧࡛࠶ࡿࡇ࡜࠿ࡽࠊ᭷
ᶵ⁐፹ࢆ⏝࠸ࡓ࣍ࣔࢪࢼ࢖ࢬἲ࡟ࡘ࠸᳨࡚ウࡋࡓࠋࡑࡢ⤖ᯝࠊMeOH࣭ACN ΰᾮࢆ⏝࠸ࡓ࣍ࣔࢪࢼ࢖ࢬἲ࡛ࡣࠊẚ㍑ⓗⰋዲ࡞ᅇ཰⋡ࡀᚓࡽࢀࠊ⫢ヨᩱ୰ࡢ⡆᫆ BA ᢳฟࡀྍ⬟࡜࡞ࡗࡓࠋ

́́

P-29
LC-MS/MS ἲ࡟ࡼࡿ኱㇋࢖ࢯࣇࣛ࣎ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝ࡜ࡑࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒἲࡢ᳨ウᮌୗ⍞㈗ 1, ⣽⏣㤶⧊ 1, ᰘᓮᾈ⨾ 2, ᶓᕝᙲ᭸ 2, ▼஭࿴ኵ 1
1ᮥᯘ኱Ꮫಖ೺Ꮫ㒊, 2 ᮾி⸆⛉኱Ꮫ⸆Ꮫ㒊Simultaneous analysis of daidzein, genistein, equol and their metabolites inhumans by liquid chromatography tandem mass spectrometry
Mizuki Kinoshita1, Kaori Hosoda1, Hiromi Shibasaki2, Akitomo Yokokawa2, Kazuo Ishii1
1
Kyorin University Faculty of Health Sciences
2
Tokyo University of Pharmacy and Life Sciences School of Pharmacy࠙┠ⓗࠚࢲ࢖ࢮ࢖ࣥࡸࢤࢽࢫࢸ࢖ࣥ࡟௦⾲ࡉࢀࡿ኱㇋࢖ࢯࣇࣛ࣎ࣥࡣࠊ࢚ࢫࢺࣟࢤࣥస⏝ࢆ᭷ࡍࡿࡓࡵࠊ࣍ࣝࣔࣥ౫Ꮡᛶ⑌ᝈࡢண㜵࡟᭷ຠ࡛࠶ࡿࠋ୍᪉ࠊ࢚ࢡ࣮࢜ࣝࡣࠊ⭠ෆ⣽⳦࡟ࡼࡾࢲ࢖ࢮ࢖ࣥ࠿ࡽ⏕ᡂࡉࢀࠊࡼࡾᙉຊ࡞࢚ࢫࢺࣟࢤࣥస⏝ࢆᣢࡘࡓࡵ࡟᭦ᖺᮇ⑕≧ࡢ⦆࿴ࢆᮇᚅࡋࡓ㣗ရᡂศ࡜ࡋ࡚ࡶὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋ࢚ࢫࢺࣟࢤࣥస⏝ࢆࡣࡌࡵ࡜ࡍࡿ኱㇋
࢖ࢯࣇࣛ࣎ࣥࡢ⏕యస⏝ࢆṇ☜࡟ホ౯ࡍࡿࡓࡵ࡟ࡣࠊ⾑୰࠾ࡼࡧᒀ୰ࡢࢲ࢖ࢮ࢖ࣥࡸࢤࢽ
ࢫࢸ࢖ࣥࡢࡳ࡞ࡽࡎ࢚ࢡ࣮࢜ࣝࡢ௦ㅰ࣭యෆືែࡢ⥙⨶ⓗ࡞ᢕᥱࡀᚲせ࡛࠶ࡿࠋᡃࠎࡣ᪤
࡟ HPLC ࢆ⏝࠸ࡓࢲ࢖ࢮ࢖ࣥ࡜ࢤࢽࢫࢸ࢖ࣥࡢᢪྜ௦ㅰ≀୍ᩧศᯒἲࢆሗ࿌ࡋࡓࠋ
ࡋ࠿ࡋࠊ࢚ࢡ࣮࢜ࣝ࡟㛵ࡋ࡚ࡣࠊᢪྜ௦ㅰ≀ࢆྵࡴ୍ᩧศᯒἲࡀ࡞࠸ࠋࡑࡇ࡛ LC-MS/MS ἲࢆ⏝࠸ࡿࢲ࢖ࢮ࢖ࣥࠊࢤࢽࢫࢸ࢖ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝ࡜ࡑࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒἲࢆ᳨ウࡋࡓࠋ
࠙᪉ἲࠚLC-MS/MS ࡣ TSQ Quantum Ultra (Thermo Fisher Scientific) ࢆ⏝࠸ࡓࠋࢲ࢖ࢮ࢖ࣥࠊ
ࢤࢽࢫࢸ࢖ࣥࠊ࢚ࢡ࣮࢜ࣝ࡜ࡑࢀࡽࡢᢪྜ௦ㅰ≀඲ 24 ✀ࢆศᯒᑐ㇟࡜ࡋࡓࠋྛᢪྜయࡢᶆ
ရࡣ໬ᏛྜᡂࡋࠊLC-MS ࡜ NMR ࡟࡚ᵓ㐀ࢆỴᐃࡋࡓࠋ࣒࢝ࣛ࡟ YMC-Triart C18 (100×2.0
mm I.D., 3 Pm; YMC)ࠊ⛣ື┦࡟㓑㓟࢔ࣥࣔࢽ࣒࢘⁐ᾮ࡜࢔ࢭࢺࢽࢺࣜࣝ㸦ࢢࣛࢪ࢚ࣥࢺἲ㸧ࢆ⏝࠸࡚ LC ศ㞳ࡋࡓᚋࠊᶆရࢆ⏝࠸࡚᭱㐺໬ࡋࡓ SRM ᳨ฟ᮲௳ୗ࡟࡚ 24 ✀ࢆศᯒࡋࡓࠋ
࠙⤖ᯝ࣭⪃ᐹࠚࡍ࡛࡟☜❧ࡋ࡚࠸ࡿ HPLC ࡟ࡼࡿࢲ࢖ࢮ࢖ࣥ࡜ࢤࢽࢫࢸ࢖ࣥࡢᢪྜ௦ㅰ≀ࡢ୍ᩧศᯒ᮲௳ࢆ㐺⏝ࡋࡓ࡜ࡇࢁࠊ24 ✀ࡣ 35 ศ௨ෆ࡟඲࡚⁐㞳ࡉࢀࡓࠋࢲ࢖ࢮ࢖ࣥ࡜ࢤࢽࢫ
ࢸ࢖ࣥ࡜ࡑࡢᢪྜ௦ㅰ≀ 14 ✀࠾ࡼࡧ࢚ࢡ࣮࢜ࣝ࡜ࡑࡢ஧㔜ᢪྜయ 3 ✀࡟ࡘ࠸࡚ࡣⰋዲ࡟ࣆ
࣮ࢡศ㞳ࡋࡓࠋࡋ࠿ࡋࠊ࢚ࢡ࣮࢜ࣝࡢࢢࣝࢡࣟࣥ㓟࠾ࡼࡧ◲㓟ࡢᢪྜ఩⨨␗ᛶయ 4 ✀ࡣ᏶඲࡟ศ㞳࡛ࡁࡎࠊLC ศ㞳᮲௳ࡢ᳨ウࢆ㐍ࡵ࡚࠸ࡿࠋศ㞳᮲௳ࡢ☜❧ᚋࡣࠊࡁ࡞⢊ (10 g) ࢆᦤྲྀࡋࡓ⿕㦂⪅࡟࠾ࡅࡿ⾑₢୰ࢲ࢖ࢮ࢖ࣥࠊࢤࢽࢫࢸ࢖ࣥ࠾ࡼࡧ࢚ࢡ࣮࢜ࣝ࡜ࡑࡢᢪྜ௦ㅰ≀ࡢᐃࢆ⾜࠺ணᐃ࡛࠶ࡿࠋ኱㇋࢖ࢯࣇࣛ࣎ࣥ࡜ࡑࡢᢪྜ௦ㅰ≀ࡢ௦ㅰ࣭యෆືែ◊✲ࡣࠊ኱㇋࢖ࢯࣇࣛ࣎ࣥࡢ⏕యస⏝ࡢṇ☜࡞ホ౯࡟᭷⏝࡞᝟ሗࢆᥦ౪ࡍࡿࡶࡢ࡜⪃࠼ࡿࠋ

́́

P-30
⮫ᗋ᳨ᰝࢆ┠ⓗ࡜ࡋࡓ LC-MS/MS ࡟ࡼࡿ⾑Ύ୰࢔ࢩࣝ࢝ࣝࢽࢳࣥࡢᐃ㔞ศᯒἲࡢ
㛤Ⓨᑠᯘᘯ඾ 1, ᒣ⏣೺἞ 1, ᆓ ு㍜ 1, 㛗㇂ᕝ᭷⣖ 1, ᒣཱྀΎḟ 1, ᇛୗ཭⩏ 2, ఀ⸨฼ᑗ 2,஭ᡭ㔝 ᫭ 2, ኱ཎ฼ᡂ 2
1ᓥ᰿኱Ꮫ་Ꮫ㒊ᑠඣ⛉, 2 ✚Ỉ࣓ࢹ࢕࢝ࣝᰴᘧ఍♫Development of method for acylcarnitines in serum using LC-MS/MS
Hironori Kobayashi1, Kenji Yamada1, Ryousuke Bo1, Yuki Hasegawa1, Seiji Yamaguchi1,
Tomoyoshi Shiroshita2, Toshimasa Ito2, Akira Ideno2, Toshinari Oh-hara2
1
Department of pediatrics, Shimane University Faculty of Medicine
2
SEKISUI MEDICAL Co., LTD.
࠙┠ⓗࠚLC-MS/MS ࢆ⏝࠸ࡿ᪂⏕ඣ࣐ࢫࢫࢡ࣮ࣜࢽࣥࢢ㸦NBS㸧ࡢᬑཬ࡟క࠸ࠊ୍⯡⮫ᗋ࡟࠾ࡅࡿ⾑Ύ୰࢔ࢩࣝ࢝ࣝࢽࢳࣥ㸦AC㸧ศᯒࡢ㟂せࡀ㧗ࡲࡗ࡚ࡁࡓࠋNBS ࡛⾜ࢃࢀࡿศᯒࡣ⾑ᾮࢁ⣬ࢆ⏝࠸ࠊ᪤▱⃰ᗘࡢෆ㒊ᶆ‽࡜┠ⓗ≀㉁ࠊ୧⪅ࡢ࢖࢜ࣥᙉᗘࢆẚ㍑ࡋࠊᐃ㔞ࡉࢀ࡚࠸ࡿࠋ
ࡇࡢ᪉ἲࡣపࢥࢫࢺ࡛኱㔞ศᯒࢆ⾜࠺࡟ࡣඃࢀ࡚࠸ࡿࡀࠊศᯒᶵჾ㛫࡛ᐃ㔞್ࡢᕪ㐪ࡀ⏕ࡌࡿࠊᐃ㔞ᛶࡀ༑ศ࡛࡞࠸࡞࡝ࠊ⮫ᗋ᳨ᰝ࡜ࡋ࡚౑⏝࡟ࡣㄢ㢟ࡶ࠶ࡿࠋࡑࡇ࡛ᡃࠎࡣ⮫ᗋ᳨ᰝ࡛ࡢ౑⏝ࢆᛕ㢌࡟ࠊ⾑Ύ୰ࡢ AC ᐃ㔞ἲࢆᵓ⠏ࡋࠊࣂࣜࢹ࣮ࢩࣙࣥヨ㦂ࢆᐇ᪋ࡋࡓࠋ
࠙᪉ἲࠚ㏱ᯒฎ⌮ࡋࡓࣄࢺ⾑Ύ࡟ࠊ᝿ᐃࡉࢀࡿ AC ⃰ᗘࢆ࢝ࣂ࣮ࡍࡿࡼ࠺࡟ 5 ⃰ᗘ࡟ㄪ〇ࡋࡓ15 ✀ࡢ AC ࢆྵࡴΰྜᶆ‽⁐ᾮ㸦1%ࢠ㓟ࢆྵࡴ࢚ࢱࣀ࣮ࣝ⁐ᾮ㸧ࢆῧຍࡋࠊ⢭ᗘ⟶⌮⏝㏵㸦QC
⾑Ύ㸧ࢆවࡡࡓ᳨㔞⥺సᡂ⏝ࡢᶆ‽⾑Ύ 5 ✀㢮ࢆㄪ〇ࡋࡓࠋㄪ〇ࡋࡓ QC ⾑Ύཬࡧᶆ‽⾑Ύ㸦ྜィ 7 ⃰ᗘ㸧࡟ࠊྛ AC ࡢᏳᐃྠ఩యࢆྵࡴෆ㒊ᶆ‽⁐ᾮࢆῧຍᚋࠊ࢚ࢱࣀ࣮ࣝࢆຍ࠼࡚⁐ᾮ㒊ศࢆᅇ཰ࡋࡓࠋᚓࡽࢀࡓ⁐ᾮࢆ❅⣲Ẽὶୗ࡛஝ᅛࡋࠊ஝ᅛࡋࡓヨᩱ࡟෌⁐ゎ⁐፹ࢆຍ࠼࡚෌⁐ゎࡋࠊ㐲ᚰศ㞳ᚋࡢୖΎࢆ ᐃ⏝ࢧࣥࣉࣝ࡜ࡋࡓࠋ
࡞࠾ࠊศᯒ࡟ࡣ LC-MS/MS㸦LC-20A㸸ᓥὠ〇సᡤཬࡧ API2000㸸AB Sciex㸧ࢆ⏝࠸࡚ HILIC࣮ࣔࢻࡢศᯒ࣒࡛࢝ࣛ ᐃࢆ⾜ࡗࡓࠋᵓ⠏ࡋࡓྛ AC ࡢᐃ㔞ศᯒἲ࡟ࡘ࠸࡚ࠊ᳨㔞⥺ࡢ┤⥺ᛶࠊ
୪ࡧ࡟ࠊQC ⾑Ύ ᐃ᫬ࡢ᪥ෆཬࡧ᪥㛫࡛ࡢ෌⌧ᛶཬࡧṇ☜ᛶ࡟ࡘ࠸࡚ࠊࡑࢀࡒࢀホ౯ࡋࡓࠋ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚᵓ⠏ࡋࡓࣄࢺ⾑Ύ୰ AC ࡢ⃰ᗘ ᐃἲࡣࠊࡑࢀࡒࢀࠊC0㸦2.0㹼200 ȝPRO/㸧
ࠊ
C2㸦1.0㹼100 ȝPRO/ࠊ௨ୗ༢఩┬␎㸧
ࠊC3㸦0.24㹼24㸧
ࠊC4㸦0.1㹼10㸧ࠊC5㸦0.06㹼6㸧
ࠊC5-OHࠊC6㸦0.05㹼5㸧ࠊC8㸦0.05㹼5㸧
ࠊC10㸦0.05㹼5㸧ࠊC12㸦0.05㹼5㸧ࠊ
㸦0.1㹼10㸧ࠊC5-DC㸦0.05㹼5㸧
C14㸦0.06㹼6㸧
ࠊC14:1㸦0.06㹼6㸧
ࠊC16㸦0.24㹼2.4㸧ཬࡧ C18㸦0.1㹼10㸧ࡢᐃ㔞⠊ᅖ࡛Ⰻዲ࡞
┤⥺ᛶࡀᚓࡽࢀࠊࡑࢀࡽࡢ᳨㔞⥺ࡢ┦㛵ಀᩘ㸦㹰㸧ࡣ 0.9942㹼0.9998 ࡛࠶ࡗࡓࠋ
ࡲࡓࠊᶆ‽⾑Ύ࡜ྠ᫬࡟ ᐃࡋࡓ QC ⾑Ύࡢ᪥ෆ࡛ࡢ෌⌧ᛶ㸦CV%㸧ཬࡧṇ☜ᛶ㸦RE%㸧
ࡣࠊ඲࡚ࡢ AC ࡟㛵ࡋ࡚ࠊCV% = 1.0㹼12.3%ཬࡧ RE% = -13.6㹼10.0%ࡢ⠊ᅖ࡛࠶ࡾࠊⰋዲ࡞
⤖ᯝࡀᚓࡽࢀࡓࠋࡲࡓࠊ 3 ᪥㛫ࡢ෌⌧ᛶཬࡧṇ☜ᛶࢆホ౯ࡋࡓ࡜ࡇࢁࠊࡑࢀࡒࢀ CV% = 2.4
㹼10.2%ཬࡧ RE% = -11.5㹼8.1%࡜Ⰻዲ࡛࠶ࡗࡓࠋ௒ᅇ☜❧ࡋࡓศᯒ᪉ἲ࡛ࡣ⢭ᗘ⟶⌮⏝᳨యࢆ᳨㔞⥺సᡂ⏝᳨య࡜ࡋ࡚౑⏝࡛ࡁࡿ⢭ᗘ࡟࠶ࡆࡿ஦࡛ᚑ᮶ࡣูࠎ࡟⾜ࢃࢀ࡚࠸ࡓᕤ⛬ࢆ༢⣧໬ࡋࡓࠋࡇࡢศᯒἲ࡟ࡼࡾ LC-MS/MS ࡟ࡼࡿ⾑Ύ AC ศᯒἲࡢᶆ‽໬ࡀྍ⬟࡛࠶ࡾࠊ⢭ᐦ᳨ᰝࡸࣇ࢛࣮ࣟ࢔ࢵࣉ᫬ࡢศᯒ࡟㈉⊩ࡍࡿ஦ࡀᮇᚅࡉࢀࡿࠋᮏⓎ⾲࡛ࡣࠊᮏ ᐃἲ࡟ࡼࡾ୍
⯡᳨యࢆ ᐃࡋࡓ⤖ᯝ࡟ࡘ࠸࡚ࡶሗ࿌ࢆ⾜࠺ணᐃ࡛࠶ࡿࠋ

́́

P-31
LC/ESI-MS/MS࡟ࡼࡿ⾑₢୰25-hydroxyvitamin D3ཬࡧࡑࡢ◲㓟ᢪྜయࡢྠ᫬
ᐃ㔞ἲࡢ㛤Ⓨᚋ⸨ᙬె1, ᶓ⏣㯞⾰1, ᑠᕝ⚈஧㑻1, ᑠᯇ㈼ྖ2, ᮡᾆᓫᾈ2, ᮾ 㐩ஓ11ᮾி⌮⛉኱Ꮫ⸆Ꮫ㒊, 2㟼ᒸ῭⏕఍⥲ྜ⑓㝔

Development of a method for simultaneous determination
25-hydroxyvitamin D3 and its 3-sulfate by LC/ESI-MS/MSofplasmaAyaka Goto1㸪Mai Yokota1㸪Shoujiro Ogawa1㸪Kenji Komatsu2㸪Takahiro Sugiura2㸪Tatsuya Higashi1
1Faculty of Pharmaceutical Sciences, Tokyo University of Science2
Shizuoka Saiseikai General Hospital䛆┠ⓗ䛇 ᭱㏆ࠊᑠඣ࡟࠾ࡅࡿࣅࢱ࣑ࣥ D ୙㊊ࡀࡃࡿ⑓࡞࡝ࡢ㦵⑌ᝈࡢࡳ࡞ࡽࡎࠊᑗ᮶ࡢ⢾ᒀ
⑓ࡸከⓎᛶ◳໬⑕࡞࡝ࡢ༴㝤ᅉᏊ࡜ࡶ࡞ࡿࡇ࡜ࡀሗ࿌ࡉࢀࠊὀ┠ࡉࢀ࡚࠸ࡿࠋ⌧ᅾࠊࣅࢱ࣑ࣥ D ࡢ౪⤥≧ែࡣ⾑୰ 25-hydroxyvitamin D3 [25(OH)D3] ⃰ᗘ࡟ᇶ࡙࠸࡚ホ౯ࡉࢀ࡚࠸ࡿ
ࡀࠊඛ࡟ᡃࠎࡣ⾑₢୰ 25(OH)D3 3-sulfate [25(OH)D3S] ࡢ LC/ESI-MS/MS ᐃ㔞ἲࢆ㛤Ⓨࡍࡿ࡜࡜ࡶ࡟ࠊஙඣ࡛ࡣ 25(OH)D3S ࡀ 25(OH)D3 ࡼࡾࡶ㧗⃰ᗘ࡛Ꮡᅾࡍࡿࡇ࡜ࠊࡲࡓࠊࡑࡢࣞ࣋
ࣝࡣṇᮇ⏘ඣࡼࡾࡶ᪩⏘ඣ࡛ప࠸ࡇ࡜ࢆ᫂ࡽ࠿࡜ࡋࡓ 1)ࠋ25(OH)D3S ࡣ㈓ⶶᆺࣅࢱ࣑ࣥ D࡜ࡋ࡚ാ࠸࡚࠸ࡿ࡜ࡶ⪃࠼ࡽࢀࠊஙඣࡢࣅࢱ࣑ࣥ D ౪⤥≧ែࢆࡼࡾṇ☜࡟ホ౯ࡍࡿ࡟ࡣࠊ
⾑୰ 25(OH)D3 ࡜ࡶ࡟ 25(OH)D3S ࢆྠ᫬࡟ᐃ㔞ࡍࡿࡇ࡜ࡀ㔜せ࡜⪃࠼ࡽࢀࡿࠋᚑ᮶ࡢ᪉ἲࡣ
25(OH)D3 䛸 25(OH)D3S 䜢ู䚻䛻ᐃ㔞 (䛭䜜䛮䜜ṇ䜲䜸䞁ཬ䜃㈇䜲䜸䞁᳨ฟ) 䛩䜛䜒䛾䛷䛒䛳䛯䛜䚸௒ᅇ䚸䝇䝹䞊䝥䝑䝖䛾ྥୖ䜢┠ᣦ䛧䚸୧䝡䝍䝭䞁 D ௦ㅰ≀䛾ྠ᫬ᐃ㔞ἲ䛾㛤Ⓨ䜢ヨ䜏䛯䚹䛆ᐇ㦂䛇 ⾑₢ ȝ/  ࢆ 2H3-25(OH)D3 ཬࡧ 2H6-25(OH)D3S (ෆᶆ‽≀㉁) ࢆྵࡴ MeCN ࡛㝖⺮ⓑᚋࠊOasis HLB ࣮࢝ࢺࣜࢵࢪ࡟࡚⢭〇ࡋࠊDAPTAD ࡟ࡼࡿㄏᑟయ໬཯ᛂ࡟௜ࡋࡓࠋࡇࢀ
ࢆ௨ୗࡢ᮲௳ࡢ LC/ESI-MS/MS ࡟௜ࡋࡓ [⿦⨨㸸Waters LC-2695 ࢆ Waters Quattro Premier XE࡟᥋⥆㸹࣒࢝ࣛ㸸YMC-3DFN3UR&56 ȝP㸪150 × 2.0 mm i.d.)㸹⛣ື┦㸸ࢢࣛࢪ࢚ࣥࢺ⁐ฟ㸪MeOH-0.05% HCOOH ྵ᭷ 10 mM HCOONH4 (4:1ࠊv/v) Ѝ MeCN-0.05% HCOOH ྵ᭷
10 mM HCOONH4 (9:1ࠊv/v)㸹ὶ㏿㸸0.2 mL/min㸹᳨ฟ㸸SRM]ࠋ
䛆⤖ᯝ䛇 DAPTAD ㄏᑟయ໬࡟ࡼࡾࠊṇ࢖࢜ࣥ ESI-MS/MS ࡟ࡼࡿ 25(OH)D3 ࡜ 25(OH)D3S ࡢྠ᫬ᐃ㔞ࡀྍ⬟࡜࡞ࡿ࡜࡜ࡶ࡟ࠊ25(OH)D3 ࡜ 3-epi-25(OH)D3 (୙άᛶ௦ㅰ≀) ࡢศ㞳ࡶ㐩ᡂࡉࢀࡓࠋ᳨㔞⥺ࡣ 25(OH)D3 ࡛ࡣ 1.0–50 ng/mLࠊ25(OH)D3S ࡛ࡣ 2.5–50 ng/mL ࡢ⠊ᅖ࡛ r2 Ӎ
0.994 ࡢ┤⥺ᛶࡀᚓࡽࢀࠊஙඣࣉ࣮ࣝ⾑₢ࢆ⏝࠸ࡓ෌⌧ᛶヨ㦂 (RSD㸸4.5%௨ୗ) ࡢ⤖ᯝࡶⰋዲ࡛࠶ࡗࡓࠋ⌧ᅾࠊ᪩⏘ඣࢆྵࡴஙඣ (⏕ᚋ 10 ᪥௨ෆ) ࡢ⾑₢୰୧௦ㅰ≀ࡢᐃ㔞ࢆ㐍ࡵ࡚࠾ࡾࠊࡇࡢ⤖ᯝ࡟ࡘ࠸࡚ࡶⓎ⾲ࡍࡿணᐃ࡛࠶ࡿࠋ

䛆ཧ⪃ᩥ⊩䛇-------------------------------------------------------------------------------------------------------------J. Chromatogr. B, 969, 230–234 (2014).

́́

P-32
LC-MS/MS ࡟ࡼࡿ⾑Ύ࢚ࢫࢺࣟࢤࣥ࠾ࡼࡧࣉࣟࢤࢫࢸࣟࣥࡢྠ᫬ᐃ㔞ᐑᯘభ⾰ 1, బ⸨ Ᏺ 2, ⁪⬥ṇ㈗ 2, すᮧ ᇶ 1, ᯇୗ୍அ 1, 㔝ᮧᩥኵ 2
1༓ⴥ኱Ꮫ኱Ꮫ㝔 ་Ꮫ◊✲㝔 ศᏊ⑓ែゎᯒᏛ
2༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ

Simultaneous measurement of estrogens and progesterone in serum by LC-MS/MS
Yui Miyabayashi1, Mamoru Satoh2, Masaki Takiwaki2, Motoi Nishimura1, Kazuyuki Matsushita1,
Fumio Nomura2
1
Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University
2
Division of Clinical Mass Spectrometry, Chiba University Hospital࠙┠ⓗࠚ⌧ᅾ⮫ᗋ᳨ᰝᐊ࡛ࡣ⾑୰ࡢ 17ș࢚ࢫࢺࣛࢪ࣮࢜ࣝ(E2)࣭ࣉࣟࢤࢫࢸࣟࣥ(P)ࡢ ᐃ࡟ච␿Ꮫⓗᐃἲࢆ⏝࠸࡚࠸ࡿࠋච␿Ꮫⓗᐃἲࡣࣁ࢖ࢫ࣮ࣝࣉࢵࢺ࡛࠶ࡾ᳨య᳨ᰝ࡟࠾࠸

࡚ᚲ㡲ࡢᢏ⾡࡛࠶ࡿࡀࠊ౑⏝ᢠయࡢ஺ᕪ཯ᛂ࡟ࡼࡾᵓ㐀␗ᛶయࡸ௦ㅰ⏘≀ࡢࡾ㎸ࡳࡀᣦ᦬ࡉࢀ࡚࠸ࡿࠋࡲࡓࠊE2 ࡣ㛢⤒ᚋࡢዪᛶࡸᑠඣࡢ᳨య࡛ࡣ ᐃឤᗘ௨ୗ࡜࡞ࡾࠊ⑓ែᢕᥱ࡟ᚲせ࡞ ᐃ್ࡀᚓࡽࢀ࡚࠸࡞࠸ࡢࡀ⌧≧࡛࠶ࡿࠋLC/MS/MS ࢆ⏝࠸ࡓ ᐃ࡛ࡣᚤ⣽࡞ᵓ㐀ኚ໬ࢆᘚูࡋ࡚

ᐃ࡛ࡁࡿࡇ࡜࡟ຍ࠼ࠊྠ᫬ከ㡯┠ࡢᐃࡀྍ⬟࡜࡞ࡿࠋᐇ㝿࡟⮫ᗋࢧ࢖ࢻ࠿ࡽ᳨ᰝᐊ࡟࣮࢜ࢲ࣮ࡉࢀࡿ㡯┠࡜ࡋ࡚ E2 ࡜ P ࡣࢭࢵࢺ࡛ฟࡉࢀࡿࡇ࡜ࡀከ࠸ࠋࡑࡇ࡛
௒ᅇࠊࡼࡾ㧗ឤᗘ࡛ࢫ࣮ࣝࣉࢵࢺࡢ㧗࠸࢚ࢫࢺࣟࢤࣥ࡜ࣉࣟࢤࢫࢸࣟࣥࡢྠ᫬

ᐃἲࡢᵓ⠏ࢆ┠ᣦࡋ᳨ウࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚ⾑Ύࡣ࢖ࣥࣇ࢛࣮࣒ࢻࢥࣥࢭࣥࢺࡢᚓࡽࢀࡓ೺ᖖேዪᛶࢆ౑⏝ࠋ⣧ရࡲࡓࡣ⾑ΎȝO ࢆ⵨␃Ỉ࡛ಸ࡟ᕼ㔘ࡋࠊ,6ȝO ࢆῧຍ࣭ΰ࿴ᚋ SLE (Supported Liquid extraction)ࢆ⾜ࡗࡓࠋSLE ࡣ 96well ࣇ࢛࣮࣐ࢵࢺࡢ ISOLUTE SLE+ࢆ౑⏝ࡋࡓࠋᢳฟᾮࡣ஝⇱ᚋ࡟ Dansyl
Chloride ࡟ࡼࡿㄏᑟయ໬ࢆ 60Υ࡛ 5 ศ㛫⾜࠸ SRM

ᐃࢆ⾜ࡗࡓࠋศ㞳࡟ࡣ UPLC(Bruker)ࢆ⏝࠸ࠊ࢖࢜ࣥ໬ἲࡣ ESI ἲࠊ㉁㔞ศᯒィࡣ୕㐃ᅄ㔜ᴟ㉁㔞ศᯒィ EVOQ Elite (Bruker)⏝࠸ࡓࠋ࠙⤖ᯝࠚ⣧ရࢆ౑⏝ࡋࡓྠ᫬෌⌧ᛶ%CV(n=5)ࡣ E1 5.84%ࠊE2 6.42%ࠊP 5.6%࡛࠶ࡗࡓࠋࡲࡓ
⣧ရ࡛ࡢ LOQ(SN=10)ࡣ E1 5pg/mlࠊE2 5pg/mlࠊP 50pg/ml ࡛࠶ࡗࡓࠋSLE ࢆ⏝࠸ࡓ๓ฎ⌮࡛ࡢᅇ཰⋡(n=5)ࡣ E1 92.7%ࠊE2 91.2%ࠊP 83.8%࡜Ⰻዲ࡞⤖ᯝ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚ᳨ウ᳨యᩘࡀ༑ศ࡛ࡣ࡞࠸ࡀࠊᚑ᮶⑓㝔᳨ᰝᐊ࡛౑ࢃࢀ࡚࠸ࡿ᪉ἲ࡜ྠ➼ࡢᐃ㔞ឤᗘࢆᚓࡿࡇ࡜ࡀ࡛ࡁࡓࠋ௒ᚋࠊNISTࠊBCR ࢆ⏝࠸ࡓṇ☜ᗘࠊ⢭ᗘࡢ᳨ウࢆ㐍ࡵࡿࠋࡲࡓࠊ
⌧ᅾ༓ⴥ኱Ꮫ⑓㝔࡛ࡣデᐹ๓᳨ᰝࢆ⾜ࡗ࡚࠾ࡾࠊ᳨యࢆཷ⌮ࡋ࡚࠿ࡽᐃ⤖ᯝࢆ⮫ᗋ࡟ሗ

࿌ࡍࡿࡲ࡛ࡢ᫬㛫ࡣ㸯᫬㛫௨ෆ࡛࠶ࡿࠋ௒ᅇࡢ ᐃ᪉ἲ࡛ࡣ๓ฎ⌮ࢆ⡆౽࡞ SLE ࢆ౑⏝ࡍࡿࡇ࡜࡛ ᐃ⤖ᯝࡀฟࡿࡲ࡛ࡢ᫬㛫ࡣ 30 ศ࡛࠶ࡿࠋ௒ᚋ๓ฎ⌮ࡢ⮬ື໬ࢆ⾜࠺ࡇ࡜࡛ࡉࡽ
࡞ࡿ㧗㏿໬ࠊᏳᐃ໬ࢆᅗࡾࡓ࠸࡜⪃࠼࡚࠸ࡿࠋ

́́

P-33
㔜Ỉ⣲໬ࣀࣅࣞࢳࣥࡢྜᡂ࡜ LC/MS/MS ࡟ࡼࡿࣀࣅࣞࢳࣥᐃ㔞࡬ࡢᛂ⏝ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ 1
1୰㒊኱Ꮫᛂ⏝⏕≀Ꮫ㒊, 㸰୰㒊኱Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ఍♫ Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮

Synthesis and application of deuterated nobiletin for determination of nobiletin by
LC/MS/MS
Shogo Hirano1, Takayuki Yonezawa2, Byung-Yoon cha2, Je-Tae Woo 1,2,3, Kaname Tsutsumiuchi1
1
College of Bioscience and Biotechnology, Chubu University
2
Research Institute for Biological Function, Chubu University
3
Okinawa research center Co., Ltd࠙┠ⓗࠚᒱ㜧⸆⛉኱Ꮫࡢబ἞ᮌࡽࡣࠊⓑ㔠Ⅳ⣲(Pt/C)ཬࡧࣃࣛࢪ࣒࢘Ⅳ⣲(Pd/C)ࢆ㔜Ỉ୰Ỉ⣲㞺ᅖẼୗ࡛⏝࠸ࡿࡇ࡜࡟ࡼࡾⰾ㤶⎔࠶ࡿ࠸ࡣ࢔ࣝ࢟ࣝᇶୖ࡛ H-D ஺᥮཯ᛂࡀ㐍⾜ࡍࡿࡇ࡜ᙜ◊✲ᐊ࡛ࡣ LC/MS/MSࢆぢฟࡋࡓ 1)ࠋᐃ࡞࡝࡟ࡼࡿᏳᐃྠ఩యヨᩱࡢ᭷⏝ᛶ࡟╔┠ࡋࠊࡇࡢ H-D ஺᥮཯ᛂࢆ⏝࠸࡚⏕⌮άᛶ≀㉁ࡢࢧࣟࢤ࣮ࢺ≀㉁ࢆྜᡂࡋࠊ⏕యヨᩱ୰ࡢ㧗ឤᗘศᯒ࡬฼⏝ࡋ࡚ࡁࡓ 2)ࠋᮏ◊✲࡛ࡣࠊࡇࡢ཯ᛂ࡟ࡼࡿ㔜Ỉ⣲໬≀ࡢྜᡂ࡜ࡑࡢ฼⏝ࡢ୍౛࡜ࡋ࡚ࠊ㏆ᖺᢠ⫧‶స⏝ࡸ࢖ࣥࢫࣜࣥ᢬ᢠᛶࡢᨵၿ࡞࡝ᵝࠎ࡞ຠ⬟ࡀⓎぢࡉࢀὀ┠ࡉࢀࡿࣀ
ࣅࣞࢳࣥ(NOB)3)ࡢ㔜Ỉ⣲໬࡜ࡑࢀࢆෆ㒊ᶆ‽࡟⏝࠸ࡓ LC/MS/MS ศᯒࡢ᳨ウࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚNOB ࡢ㔜Ỉ⣲໬཯ᛂࡣ࣑ࢽࣂ࣮࣒࢟ࣗࢳ࣮ࣗࣈ࡟ NOB 10 mg (25 mmol) ࠊ5%Pt/C 2.5
mgࠊD2O 2.0 mL ࢆຍ࠼ࠊỈ⣲㞺ᅖẼୗ 180Υ࡛ 24 ᫬㛫཯ᛂࢆ⾜ࡗࡓࠋᚓࡽࢀࡓ㔜Ỉ⣲໬ࣀࣅࣞࢳࣥ(NOB-d)ࡢᵓ㐀ࡣ NMR ཬࡧ LC/MS ࡛ホ౯ࡋࡓࠋ㔜Ỉ⣲໬཯ᛂ࡟ࡼࡾᚓࡽࢀࡓ
NOB-d ࢆ࣐࢘ࢫ⾑Ύ 10 ȝ/ ࡟୍ᐃ㔞ῧຍࡋࡓᚋࠊ࣓ࢱࣀ࣮ࣝ+ࢡ࣒ࣟࣟ࣍ࣝΰྜ⁐፹[1:1(v/v)]ࢆ 0.50 mL ຍ࠼࡚᧠ᢾࠊ㐲ᚰศ㞳ࡋୖ⃈ࡳࢆ஝⇱ࡉࡏࡓࠋࡑࡢᚋ 10 mmol/L ࢠ㓟Ỉ⁐
ᾮ+࢔ࢭࢺࢽࢺࣜࣝ[1:1 (v:v)]ΰྜ⁐፹ 200 ȝ/ ࡛෌⁐ゎࡋࠊLC/MS/MS ࢆ⏝࠸ࡓῧຍᅇ཰ᐇ
㦂ࢆ⾜ࡗࡓࠋࢡ࣐ࣟࢺࢢ࣒ࣛ࡟࠾ࡅࡿ NOB ࡜ NOB-d ࡜ࡢࣆ࣮ࢡ㠃✚ẚࢆẚ㍑ࡍࡿࡇ࡜࡟
ࡼࡗ࡚࣐࢘ࢫ⾑Ύ࡟ྵࡲࢀ࡚࠸ࡿ NOB ࡢᐃ㔞ࢆ⾜ࡗࡓࠋ࠙⤖ᯝ࡜⪃ᐹࠚH-D ஺᥮཯ᛂ࡛ࡣ㔜Ỉ⣲ࡀ 3 ಶ⨨᥮ࡋࡓ NOB-d (m/z 406)ࢆᚓࡓࠋࡲࡓࠊ㔜Ỉ⣲໬཯ᛂࡢ㐣⛬࡟࠾࠸࡚ 24 ᫬㛫ࡢ཯ᛂᚋࠊD2O ࡜ Pt/C ࢆධࢀ᭰࠼෌ᗘ཯ᛂࡉࡏࡿࡇ࡜࡟ࡼ
ࡗ࡚ᮍ཯ᛂࡢ NOB ࡟⏤᮶ࡍࡿ m/z 403 ࡢࣆ࣮ࢡࡀ኱ᖜ࡟ῶᑡࡍࡿࡇ࡜ࢆぢฟࡋࡓࠋ⾑Ύࢧࣥࣉࣝࢆ⏝࠸࡚ࠊῧຍᅇ཰ᐇ㦂ࢆ⾜ࡗࡓ⤖ᯝࠊNOB (m/z 403Ѝ373)ࡢࣆ࣮ࢡ㠃✚್࡛⤯ᑐ᳨㔞⥺ࢆసᡂࡋࡓሙྜ࡜ NOB-d (m/z 406Ѝ376)࡜ࡢࣆ࣮ࢡ㠃✚ẚ᳨࡛㔞⥺ࢆసᡂࡋࡓሙྜࡢ
ᅇ཰⋡ࢆẚ㍑ࡋࡓ࡜ࡇࢁࠊࣆ࣮ࢡ㠃✚್࡛ồࡵࡓሙྜࡢᅇ཰⋡ࡣ 90%ࡔࡗࡓࡀ㠃✚ẚ࡛ồࡵࡓሙྜࡣ 95%࡛࠶ࡾࠊ5%ࡢᨵၿࡀぢࡽࢀࡓࠋ
1) H. Sajiki et al., Bull. Chem. Soc. Jpn, 81, 278-286 (2008).
2) S. Hirano et al., JSBMS letters, 39, 110 (2014).
3) B.-Y. Cha et al., J. Nutr. Biochem., 24, 156–162 (2013).

́́

P-34
ࣄࢺ㠌ᖏ࡟࠾ࡅࡿࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥࡢゎᯒ㛗Ꮚᬕ⨾ 1, ཎ ఙṇ 1, ᪥ྜྷᓠ㯇 1, Ἑ㔝㏻ᛌ 2, ෆᑿ♸ྖ 2, ᅵᒇ⨾ຍᏊ 1ᓥ᰿኱Ꮫ ་Ꮫ㒊 1 ⏕໬Ꮫㅮᗙ, 2 ᩚᙧእ⛉Ꮫㅮᗙ

Analysis of GAG in human ligament
Harumi Osago1, Nobumasa Hara1, Mineyoshi Hiyoshi1, Michihaya Kono2, Yuji Uchio2,
Mikako Tsuchiya1
1
Department of Biochemistry, Shimane University, Faculty of Medicine
2
Department of Orthopedic Surgery, Shimane University, Faculty of Medicine࠙┠ⓗࠚࢢࣜࢥࢧ࣑ࣀࢢࣜ࢝ࣥ (GAG) ࡣ஧⢾ࡀ⧞ࡾ㏉ࡍᇶᮏ㦵᱁࡟✀ࠎ࡞⛬ᗘࡢ◲㓟໬ࡀ㉳ࡇࡗ࡚࠸ࡿ⢾㙐࡛࠶ࡾࠊࢥࣥࢻࣟ࢖ࢳࣥ/ࢹ࣐ࣝࢱࣥ◲㓟ࠊࣄ࢔ࣝࣟࣥ㓟ࠊ࣊ࣃࣛࣥ◲㓟࠾ࡼࡧࢣࣛࢱࣥ◲㓟ࡢ㸲ࢡࣛࢫ࡟ศ㢮ࡉࢀࡿࠋGAG ࡣ㛵⠇㌾㦵ࠊ㠌ᖏࠊ⓶⭵࡞࡝ࡢ⣽⬊እ
ᇶ㉁࡟ከࡃྵࡲࢀࡿࡀࠊࡑࡢ⤌ᡂࡢ㐪࠸ࡀࡑࢀࡒࢀࡢ⤌⧊ࡢᶵ⬟࡟㛵ಀࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋGAG ࡢヲ⣽࡞ゎᯒࢆ⾜࠺ࡓࡵ࡟ࠊࢃࢀࢃࢀࡣ㉁㔞ศᯒ࡟ࡼࡿ㧗ឤᗘࠊ≉␗ⓗ࠿ࡘ⥙⨶ⓗゎᯒἲࢆ㛤Ⓨࡋࠊࣈࢱࡢ㌾㦵࡜㠌ᖏ࡟࠾ࡅࡿ GAG ⤌ᡂࡢ㐪࠸ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ
ࣄࢺ࡛ࡣ㠌ᖏࡢኚᛶ࣭⫧ཌ࡟㌾㦵⤌⧊ࡢቑ⏕㸦㌾㦵໬ᡂ㸧ࡀక࠺ࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊ
GAG ࡢ㉁ⓗ࣭㔞ⓗኚ໬ࡀண᝿ࡉࢀࡿࠋࡇࢀࢆᐇドࡍࡿࡓࡵ࡟ࡣᚤ㔞ࡢࣄࢺ㠌ᖏ࠿ࡽࡢ GAG
ゎᯒࡀᚲせ࡟࡞ࡿࠋ௒ᅇࢃࢀࢃࢀࡢ㛤Ⓨࡋࡓ᪉ἲ࡛ṇᖖࣄࢺ㠌ᖏ࠿ࡽࡢ GAG ゎᯒࡀྍ⬟࡛࠶ࡿ࠿ࢆ᳨ウࡋࡓࠋ࠙᪉ἲࠚṇᖖࣄࢺ㠌ᖏ࠿ࡽᢳฟࠊ஧⢾໬ࡋࡓ GAG ࢆࠊከᏍᛶࢢࣛࣇ࢓࢖ࢺ࣮࣒࢝࣎ࣥ࢝ࣛ
㸦Hypercarb, Thermo Scientific ♫㸧ୖ࡛ศ㞳ࡋࡓᚋࠊESI-QqQ㸦Shimadzu, 8030㸧࡟ࡼࡗ࡚ࠊ㈇࢖࣮࢜ࣥࣔࢻ࡛ ᐃࡍࡿࠋ࠙⤖ᯝࠚ㔜㔞 4㹼8 mg ࡢࣄࢺ㠌ᖏ⤌⧊ࡼࡾࠊ2㹼5 Pg ࡢ GAG ࡀᚓࡽࢀࡓࠋ40㹼80 ng ࡢ GAGࢆ⏝࠸࡚㉁㔞ศᯒ࡟ࡼࡿゎᯒࢆ⾜ࡗࡓ⤖ᯝࠊࣄ࢔ࣝࣟࣥ㓟ࡣࢥࣥࢻࣟ࢖ࢳࣥ◲㓟ࡢ࠾ࡼࡑ 5ศࡢ㸯࡟ࡶ㐩ࡋࠊࢥࣥࢻࣟ࢖ࢳࣥ◲㓟ࡢ୰࡛ࡣ㸯◲㓟యࡀ 8 ๭ࢆ༨ࡵࠊ㠀◲㓟యࡼࡾ㸰◲㓟యࡢ᪉ࡀከ࠸ࡇ࡜ࡀ᫂ࡽ࠿࡟࡞ࡗࡓࠋ
࠙⪃ᐹࠚ㉁㔞ศᯒ࡟ࡼࡾ mg ༢఩ࡢࣄࢺṇᖖ㠌ᖏࢆ⏝࠸࡚ GAG ࡢヲ⣽ゎᯒࡀྍ⬟࡛࠶ࡿࡇ࡜ࠊࣄࢺࡢ㠌ᖏࡣࣈࢱࡢࡑࢀ࡜ఝࡓ⤌ᡂࢆ♧ࡍࡇ࡜ࡀࢃ࠿ࡗࡓࠋ௒ᚋࡇࡢ᪉ἲࢆ⏝࠸࡚ࣄࢺࡢኚᛶ࣭⫧ཌࡋࡓ㠌ᖏ⤌⧊ࢆྠᵝ࡟ゎᯒࡋࠊGAG ࡢ㉁ⓗ࣭㔞ⓗ࡞ኚ໬ࢆ᫂ࡽ࠿࡟ࡍࡿࡇ
࡜ࡣࠊ⑓ែࡢゎ᫂ࡸ἞⒪ἲࡢ㛤Ⓨ࡟ᐤ୚ࡍࡿ࡜⪃࠼ࡽࢀࡿࠋ

́́

P-35
㸰✀㢮ࡢᏳᐃྠ఩యᶆ㆑ἲࢆ⏝࠸ࡓ⭤⬔⒴ࡢ⾑୰ࣂ࢖࣐࣮࣮࢜࢝ࢱࣥࣃࢡ㉁ࡢ
᥈⣴ᖹ⏣ెஓ 1, 㐲⸨ඞஓ 1, ᩪ⸨㐩ஓ 1,2, ᕝᓥ♸௓ 2, ༡⏣ ㄽ 3, ᯇᮏ࿴ᑗ 3, ᒾᮧṇႹ 3,ᑠᑎ⩏⏨ 1,2
1໭㔛኱Ꮫ⌮Ꮫ㒊⏕≀≀⌮Ꮫ◊✲ᐊ, 2 ໭㔛኱Ꮫ⌮Ꮫ㒊㝃ᒓ⑌ᝈࣉࣟࢸ࣑࢜ࢡࢫࢭࣥࢱ࣮,3໭㔛኱Ꮫ་Ꮫ㒊Ἢᒀჾ⛉

Discovery of biomarker proteins in plasma of bladder cancer patients using two
types of stable-isotope labeling methods
Yoshiya Hirata1, Katsuya Endo1,Tatsuya Saito1, 2 , Yusuke Kawashima2,Satoru Minamida3,
Kazumasa Matsumoto3,Masatsugu Iwamura3,Yoshio Kodera1, 2
1
Laboratory of Biophysics, Department of Physics, Kitasato University School of Science2Center for Disease Proteomics, Kitasato University School of Science3
Department of Urology, Kitasato University School of Medicine࠙┠ⓗࠚ⾑ᾮࡣ⑌ᝈࡸ೺ᗣ≧ែࢆ཯ᫎࡍࡿ᝟ሗࢆྵࡳࠊ᥇ྲྀࡶᐜ᫆࡞ࡓࡵࠊ㔜せ࡞⮫ᗋ᳨య࡛࠶ࡿࠋࡋ࠿ࡋࠊヲ⣽࡞ࣉࣟࢸ࣮࣒࢜ゎᯒࡣࠊ⤌⧊ࡸ⣽⬊࡟ẚ࡭࡚ᅔ㞴࡞Ⅼࡀከࡃࠊ⮫ᗋᛂ⏝ྍ⬟࡞ࣂ࢖࣐࣮࣮࢜࢝ࡢ᥈⣴౛ࡣᴟࡵ࡚ᑡ࡞࠸ࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊ2 ✀㢮ࡢᏳᐃྠ఩
యᶆ㆑ἲࢆ⏝࠸ࡿࡇ࡜࡛ࠊ⭤⬔⒴デ᩿࣐࣮࣮࢝ೃ⿵ࢱࣥࣃࢡ㉁ࡢ᥈⣴ཬࡧ᳨ドࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚヨᩱㄪ〇ࡣࠊ⊂⮬ࡢ⾑Ύ࣭⾑₢ࢱࣥࣃࢡ㉁ศ⏬ἲ Serum/plasma fraction ἲ(SF ἲ)࡜
㧗Ꮡᅾ㔞ࢱࣥࣃࢡ㉁ 12 ✀㢮㝖ཤ࣒࢝ࣛࢆ⤌ࡳྜࢃࡏ࡚⾜ࡗࡓࠋ᥈⣴ࡢࡓࡵࡢẚ㍑ศᯒࡣࠊ
MS/MS ศᯒ࡟ࡼࡗ࡚ᮍྠᐃᡂศࢆࡶẚ㍑ศᯒ࡛ࡁࡿ Tandem Mass Tag ヨ⸆ ( TMT 6 plex,
Thermo Fisher Scientific)ࢆ⏝࠸ࡓࠋࡲࡓࠊࡇ࠺ࡋ࡚᥈⣴ࡋࡓ࣐࣮࣮࢝ೃ⿵ࢱࣥࣃࢡ㉁ࡢ᳨ドࡣࢪ࣓ࢳࣝᶆ㆑ἲࢆ⏝࠸࡚⾜ࡗࡓࠋ ᐃ࡟ࡣపὶ㏿ nano flow LC Easy-nLC 1000 (Thermo
Fisher Scientific)࡜࣋ࣥࢳࢺࢵࣉᆺࣇ࣮࢚ࣜኚ᥮㉁㔞ศᯒィ LC-MS/MS Q-Exactive (Thermo
Fisher Scientific) ⤌ࡳྜࢃࡏࡓ LC-MS ࢆ౑⏝ࡋࡓࠋ ᐃࢹ࣮ࢱࡢゎᯒ࡟ࡣྠᐃゎᯒ⏝ࢯࣇࢺ࢙࢘࢔ Proteome Discoverer 1.4 (Thermo Fisher Scientific)ࢆ⏝࠸ࡓࠋ࠙⤖ᯝ࣭⪃ᐹࠚ⭤⬔⒴ᝈ⪅⾑₢ 4 ᳨యࡎࡘࡢΰྜ⾑₢ 6 ヨᩱ (ᡭ⾡๓ 3 ヨᩱࠊᡭ⾡ᚋ 3 ヨᩱ)ࢆᑐ㇟࡜ࡋࡓ᥈⣴ᐇ㦂࡟࠾࠸࡚ࠊ269 ✀㢮ࡢࢱࣥࣃࢡ㉁࡟⏤᮶ࡍࡿ㓝⣲ᾘ໬࣌ࣉࢳࢻ 2,046✀㢮ࢆྵࡴ⣙ 20,000 ✀㢮ࡢ㓝⣲ᾘ໬࣌ࣉࢳࢻ㸦ᮍྠᐃ࣌ࣉࢳࢻࢆྵࡴ㸧ࡢ㧗⢭ᗘ࡞ẚ㍑ศ
ᯒࢆᐇ⌧ࡋࡓࠋࡑࡢ⤖ᯝࠊ⣙ 30 ✀㢮ࡢࢱࣥࣃࢡ㉁࡟⏤᮶ࡍࡿ⣙ 80 ࣌ࣉࢳࢻ࡟࠾࠸࡚ᡭ⾡࡟క࠺᭷ព࡞ቑῶࡀ☜ㄆࡉࢀࡓࠋࡉࡽ࡟ࠊᮍྠᐃ࣌ࣉࢳࢻ࡟࠾࠸࡚ࡶᡭ⾡๓ᚋࡢ࡝ࡕࡽ࠿
୍᪉࡟ࡋ࠿ほ ࡉࢀ࡞࠸࣌ࣉࢳࢻࢆྵࡴ⣙ 80 ✀㢮ࡢ࣐࣮࣮࢝ೃ⿵࣌ࣉࢳࢻࡢ᳨ฟ࡟ᡂຌࡋ
ࡓࠋⓎ⾲࡛ࡣࠊ᳨ドᐇ㦂ࡢ⤖ᯝ࡜࡜ࡶ࡟ሗ࿌ࡍࡿࠋ

́́

P-36
Abcd1 ࣀࢵࢡ࢔࢘ࢺ࣐࢘ࢫࡢ⬻ࡢࣜࣥ⬡㉁ゎᯒ℈ᘯኴ㑻 1, ⸨ཎඃᏊ 1, Ᏺ⏣㞞ᚿ 2, ௒୰ᖖ㞝 2, ୗ⃝ఙ⾜ 3, ᶓᒣ࿴᫂ 1
1ᖇி኱࣭⸆, 2 ᐩᒣ኱࣭⸆, 3 ᒱ㜧኱࣭⏕࿨⛉Ꮫ⥲ྜ◊✲ᨭ᥼ࢭࣥࢱ࣮

Phospholipid profile of Abcd1 knockout mouse brain
Kotaro Hama1, Yuko Fujiwara1,, Masashi Morita2,, Tsuneo Imanaka2, Nobuyuki Shimozawa3,
Kazuaki Yokoyama1
1
Teikyo University Faculty of Pharmaceutical Sciences
2
University of Toyama Graduate School of Medicine & Pharmaceutical Sciences
3
Gifu University Life Science Research Center࠙┠ⓗࠚ๪⭈ⓑ㉁ࢪࢫࢺࣟࣇ࢕࣮ (X-ALD) ࡣࠊ୺࡟Ⅳ⣲ᩘ 24 ௨ୖࡢᴟ㛗㙐⬡⫫㓟ࢆ࣌ࣝ࢜࢟ࢩࢯ࣮࣒ෆ࡬㍺㏦ࡍࡿ ABCD1 ⺮ⓑ㉁ࡢ␗ᖖࢆཎᅉ࡜ࡍࡿ㐍⾜ᛶࡢ⬺㧊⑌ᝈ࡛࠶ࡿࠋ
X-ALD ᝈ⪅యෆ࡛ࡣᴟ㛗㙐⬡⫫㓟ࡢ⵳✚ࡀ㢧ⴭ࡛࠶ࡿࡀࠊᴟ㛗㙐⬡⫫㓟ࡀయෆ࡛࡝ࡢࡼ࠺
࡞⬡㉁࡜ࡋ࡚Ꮡᅾࡍࡿ࠿ࡣ᫂ࡽ࠿࡛࡞࠸ࠋࡲࡓ⌧ᅾࡲ࡛࡟⾑₢࠶ࡿ࠸ࡣᇵ㣴⥺⥔ⱆ⣽⬊࡟࠾ࡅࡿ⬡㉁ゎᯒࡀ⾜ࢃࢀ࡚࠸ࡿࡀࠊ⮚ჾ࡛ࣞ࣋ࣝࡢᴟ㛗㙐⬡⫫㓟ྵ᭷⬡㉁ࣉࣟࣇ࢓࢖ࣝࡣ
୙࡛᫂࠶ࡿࠋࡋ࠿ࡋ࡞ࡀࡽᴟ㛗㙐⬡⫫㓟ྵ᭷⬡㉁ࡣඖࠎ⏕య࡟ᚤ㔞ࡋ࠿࡞࠸ࡓࡵࠊ⥙⨶ⓗ࡞ゎᯒࡣࡇࢀࡲ࡛ᅔ㞴࡛࠶ࡗࡓࠋࡑࡇ࡛ᮏ◊✲࡛ࡣࠊABCD1 ࡢᶵ⬟␗ᖖ࡟࡜ࡶ࡞࠺ከ✀ࡢᴟ㛗㙐⬡⫫㓟ྵ᭷ࣜࣥ⬡㉁ࡢኚືࢆᢕᥱࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊX-ALD ࣔࢹࣝື≀࡛࠶ࡿ
Abcd1 KO ࣐࢘ࢫࡢ⬻୰ࡢࣜࣥ⬡㉁࡟ࡘ࠸࡚ࠊከẁ㝵 MRM ࣮ࣔࢻࢆ⏝࠸ࡓ㧗ឤᗘᐃ㔞ศᯒ࡟ࡼࡾኚື⬡㉁ࢆຠ⋡Ⰻࡃぢฟࡋࠊࡑࢀࡽࡢᵓ㐀ࢆᐃᛶศᯒ࡟ࡼࡾ᫂ࡽ࠿࡟ࡋࡓࠋ
࠙᪉ἲࠚ࣐࢘ࢫ඲⬻࠿ࡽ Bligh & Dyer ἲ࡟࡚⬡㉁⏬ศࢆᢳฟࡋࠊ㏫┦࣒࢝ࣛࢆ⏝࠸࡚
LC/ESI-MS ࡟ࡼࡾ⬡㉁ࢆ ᐃࡋࡓࠋ࢔ࢩࣝ㙐 2 ᮏศࡢⅣ⣲ᩘࡀ 32 ࠿ࡽ 54ࠊ୙㣬࿴ᗘࡀ 0 ࠿
ࡽ 12 ࡲ࡛ࡢྛ✀ࣜࣥ⬡㉁࡟ࡘ࠸࡚ MRM ࣮ࣔࢻ࡟࡚ᐃ㔞 ᐃࡋࠊ㔝⏕ᆺ࣐࢘ࢫ࡜ Abcd1 KO࣐࢘ࢫ㛫࡛᭷ពᕪࡢぢࡽࢀࡓ⬡㉁ศᏊ✀࡟ࡘ࠸࡚ࠊࣇࣛࢢ࣓ࣥࢺゎᯒ࡟ࡼࡾศᏊᵓ㐀ࢆỴᐃࡋࡓࠋ࠙⤖ᯝࠚⅣ⣲ᩘ 24 ௨ୖࡢᴟ㛗㙐⬡⫫㓟ࡣ࣍ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥࠊ ࣍ࢫࣇ࢓ࢳࢪ࢚ࣝࢱࣀ࣮
ࣝ࢔࣑ࣥ࠾ࡼࡧࢫࣇ࢕ࣥࢦ࣑࢚ࣜࣥ࡟᳨ฟࡉࢀࡓࠋ᭱኱㙐㛗ࡣ 34ࠊ୙㣬࿴ᗘࡣ 0 ࠿ࡽ 6 ࡛࠶ࡗࡓࠋࣇࣛࢢ࣓ࣥࢺ࢖࢜ࣥゎᯒ࡟࠾࠸࡚ࠊࣜࣥ⬡㉁ࡢࣜࢰయ࡟┦ᙜࡍࡿࣇࣛࢢ࣓ࣥࢺ࢖
࢜ࣥࡣ୙㣬࿴ᗘࡀ 0 ࠶ࡿ࠸ࡣ 1 ࡛࠶ࡗࡓࡇ࡜࠿ࡽࠊ୙㣬࿴ᗘࡀ 0 ࠶ࡿ࠸ࡣ 1 ࡢᴟ㛗㙐⬡⫫㓟ࡣࣜࣥ⬡㉁ࡢࢢࣜࢭ࣮ࣟࣝ㦵᱁ࡢ sn-1 ఩࡟⤖ྜࡍࡿ࡜᥎ᐃࡉࢀࡓࠋࡲࡓⅣ⣲ᩘ 16 ࠿ࡽ 22ࡲ࡛ࡢ㛗㙐⬡⫫㓟࠿ࡽᵓᡂࡉࢀࡿ࣍ࢫࣇ࢓ࢳࢪࣝࢭࣜࣥࠊ࣍ࢫࣇ࢓ࢳࢪࣝ࢖ࣀࢩࢺ࣮ࣝ࠾
ࡼࡧ࣍ࢫࣇ࢓ࢳࢪࣝࢢࣜࢭ࣮ࣟࣝࡢྛศᏊ✀ࡢ࠺ࡕࠊ୍㒊ࡢศᏊ✀࡟ࡘ࠸࡚ࠊ㔝⏕ᆺ࡟ẚ࡭࡚ Abcd1 KO ࣐࢘ࢫ࡛ῶᑡࡍࡿഴྥࡀぢࡽࢀࡓࠋ࠙⪃ᐹࠚᮏ◊✲࡟ࡼࡾࢢࣜࢭ࣮ࣟࣝ㦵᱁ࡢ sn-1 ఩ࢆㄆ㆑ࡍࡿᶵᵓࡀᏑᅾࡍࡿࡇ࡜ࠊ࠾ࡼࡧ
Abcd1 ⺮ⓑ㉁ࡢ␗ᖖ࡟ࡼࡾࠊᴟ㛗㙐⬡⫫㓟ࡢࡳ࡞ࡽࡎ㛗㙐⬡⫫㓟௦ㅰࡶᙳ㡪ࢆཷࡅࡿࡇ࡜ࡀ
♧၀ࡉࢀࡓࠋ

́́

P-37Ᏻᐃྠ఩యᶆ㆑ἲࢆ⏝࠸ࡓࢫࢺࣞࢫ㞀ᐖࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࣮࣒࢜ኚື
ࡢゎᯒᑠ㧗㡴Ꮚ 1, ᑠᯘ༓἞ 1, ຍ⸨฼ె 1,2, 㧗ᶫᯞ㔛 1, ᩧ⸨㐩ஓ 1,2, ᕝᓥ♸௓ 2, ᯈ಴ ㄔ 3,ᒣ᳃᪩⧊ 3, Ọᒣ༤㏻ 3, 㣤⏣ㅍᐅ 4, ᐑᒸ ➼ 4, 㧗ᶫṇ㌟ 3, ᑠᑎ⩏⏨ 1,21໭㔛኱Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉⏕≀≀⌮Ꮫ◊✲ᐊ, 2 ໭㔛኱Ꮫ⌮Ꮫ㒊㝃ᒓ⑌ᝈࣉࣟࢸ࣑࢜ࢡࢫࢭ
ࣥࢱ࣮, 3 ໭㔛኱Ꮫ་Ꮫ㒊⏕໬Ꮫ◊✲ᐊ, 4 ໭㔛኱Ꮫ་Ꮫ㒊⢭⚄⛉

Hippocampus proteome analysis of stress disorder model mouse using stable
isotope labeling method
Shoko Odaka1, Chiharu Kobayashi1, Rika Kato1,2, Eri Takahashi1, Tatsuya Saito1,2,
Yusuke Kawashima2, Makoto Itakura3, Saori Yamamori3, Hiromichi Nagayama3, Yuuki Iida4,
Hitoshi Miyaoka4, Masami Takahashi3, Yoshio Kodera1,2
1
Laboratory of Biophysics, Department of Physics, Kitasato University School of Science2Center for Disease Proteomics, Kitasato University School of Science3
Department of Biochemistry, Kitasato University School of Medicine
4
Department of Psychiatry, Kitasato University School of Medicine࠙┠ⓗࠚࢫࢺࣞࢫ♫఍࡜ゝࢃࢀࡿ⌧௦࡟࠾࠸࡚ࠊᵝࠎ࡞ࢫࢺࣞࢫ㛵㐃㞀ᐖࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋ
ࡋ࠿ࡋࠊࡑࡢⓎ⑕ᶵᗎ࡞ࡽࡧ࡟ᐈほⓗ࡞デ᩿ἲࡣ☜❧ࡉࢀ࡚࠸࡞࠸ࠋࡑࡇ࡛ᡃࠎࡣࠊࣄࢺ
ࡢࢫࢺࣞࢫ㛵㐃㞀ᐖࡢ⑓ែࢆ⾑ᾮᡂศ࠿ࡽ᥎

ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋ࡚ࠊྛ✀ࢫࢺࣞࢫ㞀ᐖࣔࢹ࣐ࣝ࢘ࢫࢆᑐ㇟࡟⬻⤌⧊࡜⾑ᾮࡢ୧㠃࠿ࡽ◊✲ࢆ㐍ࡵ࡚࠸ࡿࠋᮏ◊✲࡛ࡣࡑࡢ୍⎔࡜ࡋ࡚ࠊࣆࣟ࢝ࣝࣆࣥᢞ୚࡟ࡼࡗ࡚ྍ㏫ⓗ࡞୙Ᏻᵝ⾜ືࢆ♧ࡍࣔࢹ࣐ࣝ࢘ࢫᾏ㤿ࡢࣉࣟࢸ࢜
࣮࣒ኚືࡢゎᯒࢆ⾜ࡗࡓࠋ࠙᪉ἲࠚࢥࣥࢺ࣮࣐ࣟࣝ࢘ࢫ㸦3 ༉㸧࡜ࠊࣆࣟ࢝ࣝࣆࣥࢆᢞ୚ࡋྍ㏫ⓗ࡞୙Ᏻᵝ⾜ືࢆ㉳ࡇࡉࡏࡓ࣐࢘ࢫ㸦8 ༉㸧ࡢᾏ㤿ࢆᑐ㇟࡜ࡋࠊྍ⁐ᛶᡂศ࡜㞴⁐ᛶᡂศࢆᢳฟࡋࡓࠋࡇࢀࡽࡢ㓝⣲ᾘ໬≀࡟Ᏻᐃྠ఩యᶆ㆑ヨ⸆㸦Isobaric Tag ヨ⸆㸹TMT 6plex,Thermo Fisher Scientific㸧ࢆᶆ㆑ࡋࠊnano-LC ࡜ᅄ㔜ᴟࣇ࣮࢚ࣜኚ᥮ࣁ࢖ࣈࣜࢵࢻ㉁㔞ศᯒィ㸦Q-Exactive,Thermo Fisher
Scientific㸧ࢆ⤌ࡳྜࢃࡏࡓ LC-MS/MS ࢆ⏝࠸࡚⥙⨶ᛶࡢ㧗࠸㧗⢭ᗘẚ㍑ศᯒἲࢆ☜❧ࡋࠊᛂ⏝ࡋࡓࠋ࠙⤖ᯝ࡜⪃ᐹࠚ11 ༉ࡢࣔࢹ࣐ࣝ࢘ࢫᾏ㤿୰ࡢࢱࣥࣃࢡ㉁ࢆศᯒࡋࡓ⤖ᯝࠊࢩࢼࣉࢫ㛵㐃ࢱࣥ
ࣃࢡ㉁ࡸཷᐜయࠊࢳࣕࣥࢿࣝࢱࣥࣃࢡ㉁ࠊࢢࣜ࢔⣽⬊ࡢ࣐࣮࣮࢝➼ࢆྵࡴ⣙ 4,000 ✀㢮ࡢࢱ
ࣥࣃࢡ㉁ࡀྠᐃࡉࢀࡓࠋึṌⓗ࡞ゎᯒ࡜ࡋ࡚⣙ 1,600 ✀㢮ࡢࢱࣥࣃࢡ㉁࡟⏤᮶ࡍࡿ⣙ 8,600✀㢮ࡢ㓝⣲ᾘ໬࣌ࣉࢳࢻࢆᑐ㇟࡟ẚ㍑ゎᯒࢆ⾜ࡗࡓࠋࡑࡢ⤖ᯝࠊHeat shock protein ࡸ DNA
damage-binding proteinࠊSynaptotagmin-1 ➼ࡢࢱࣥࣃࢡ㉁ࡀ୙Ᏻᵝ⾜ືࡢᣦᶆ㸦⛣ື㊥㞳ࡸ᫂ᡤᏑᅾẚ⋡㸧࡟┦㛵ࡋ࡚ኚືࡋ࡚࠸ࡓࠋ

́́

P-38
Effects of preanalytical variables on serum peptidome profiling for long-term
storage using matrix-assisted laser desorption/ionization time-of-flight mass
spectrometryᅵ⏣⚈ኸ1, బ⸨ Ᏺ1, ᱵᮧၨྐ2, ᭮ᕝ୍ᖾ3, ⁪⬥ṇ㈗1, ูᗓ⨾ዉᏊ4, すᮧ ᇶ4, ᑠᑎ⩏⏨5,
ᯇୗ୍அ4, 㔝ᮧᩥኵ11༓ⴥ኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ, 2ᒸᒣ኱Ꮫ኱Ꮫ㝔་ṑᏛ⥲ྜ◊✲⛉, 3㯞ᕸ኱Ꮫ⏕࿨⎔ቃ⛉Ꮫ㒊⮫ᗋ᳨ᰝᢏᖌᏛ⛉, 4༓ⴥ኱Ꮫ་Ꮫ㒊་Ꮫ◊✲㝔ศᏊ⑓ែゎᯒᏛ, 5໭㔛኱Ꮫ⌮Ꮫ㒊≀⌮Ꮫ⛉
Sachio Tsuchida1, Mamoru Satoh1, Hiroshi Umemura2, Kazuyuki Sogawa3, Masaki Takiwaki1,
Minako Beppu4, Motoi Nishimura4, Yoshio Kodera5, Kazuyuki Matsushita4, Fumio Nomura1
1
Division of Clinical Mass Spectrometry, Chiba University Hospital2
Departments of Dermatology, Okayama University Graduate School of Medicine, Dentistry andPharmaceutical Sciences3
Department of Biochemistry, School of Life and Environmental Science, Azabu University
4
Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University
5
Laboratory of Biomolecular Dynamics, Department of physics, School of Science, Kitasato
University
The peptidome profiling of human serum is a promising tool for identifying novel
disease-associated biomarkers. However, care must be taken while collecting samples and handlingprocedures that could have a profound impact on serum peptidome patterns. The effects ofpreanalytical variables on serum peptidome profiles for long-term storage have not yet been fully
clarified. In the present study, we tested the effects of preanalytical variables, including different
freezing temperatures and methods to thaw specimens, on MALDI-TOF MS-based serum peptidome
patterns for long-term storage.
We applied automation and robotics to the ClinProtTM system (Bruker Daltonics, Bremen,
Germany) and evaluated the effects of selected parameters on the MS patterns of serum peptides forlong-term storage (12 months). We evaluated the effects of different freezing temperatures; that is,
ZHIUR]HVHUXPVDPSOHVIURPVXEMHFWVDWHLWKHUíqC RUí& in freezers for long-term storage(12 months). The same experimental protocols as described above were also applied to serum
proteome analysis using SDS-PAGE with densitometry.
Our results showed that tKHLQWHQVLWLHVRIP]P]DQGP]SHDNVZHUHGHFUHDVHG
On the other hand, the intensity of P]SHDNZDVLQFUHDVHG'LIIHUHQWIUHH]LQJWHPSHUDWXUHV
dramatically affected the serum peptidome profiling. However, gel-based protein profiling was notapparently altered by the two different freezing temperatures. The effects of preanalytical variables
on both gel-based and gel-free serum proteome and peptidome patterns as evaluated in detail in thepresent study will enable us to standardize blood sampling and long-term storage conditions forinterlaboratory and multicenter studies for the validation of biomarker candidates.

́́

P-39
H-D ஺᥮཯ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢࢧࣟࢤ࣮ࢺ≀㉁ྜᡂ
ᶓᒣ⿱ኈ 1, ᖹ㔝ṇᝅ 1, ⡿⃝㈗அ 2, ㌴ Ⅸඔ 2, ⚷ ῭Ὀ 1,2,3, ሐෆ せ 1
1୰㒊኱Ꮫᛂ⏝⏕≀Ꮫ㒊, 㸰୰㒊኱Ꮫ⏕≀ᶵ⬟㛤Ⓨ◊✲ᡤ, 3 ᰴᘧ఍♫Ἀ⦖ࣜࢧ࣮ࢳࢭࣥࢱ࣮

Synthesis of Surrogate Compounds of Harmine by H-D Exchange Reaction
Yuji Yokoyama1, Shogo Hirano1, Takayuki Yonezawa2, Byung-Yoon cha2, Je-Tae Woo 1,2,3, Kaname
Tsutsumiuchi1
1
College of Bioscience and Biotechnology, Chubu University
2
Research Institute for Biological Function, Chubu University
3
Okinawa research center Co., Ltd࠙┠ⓗࠚᙜ◊✲ᐊ࡛ࡣࡇࢀࡲ࡛࡟ࠊLC/MS/MS ࡞࡝ࢆ⏝࠸ࡓᐃ㔞ศᯒ࡟࠾࠸࡚ෆ㒊ᶆ‽≀㉁࡜
ࡋ࡚ࡢᏳᐃྠ఩యヨᩱ(ࢧࣟࢤ࣮ࢺ≀㉁)ࡢ㔜せᛶ࡟╔┠ࡋࠊᒱ㜧⸆⛉኱Ꮫࡢబ෬ᮌࡽࡀ㛤Ⓨࡋࡓ୙ᆒ୍⣔ⓑ㔠᪘ゐ፹࡟ࡼࡿ㔜Ỉ⣲ᶆ㆑໬཯ᛂ 1)ࢆ⏝࠸ࡓ⏕⌮άᛶ≀㉁ࡢ H-D ஺᥮཯ᛂ࡜ࡑࢀࡽࢆ⏝࠸ࡓ⏕యヨᩱ୰ࡢᐃ㔞ศᯒࢆሗ࿌ࡋ࡚ࡁࡓ 2)ࠋ㏆ᖺࠊᡃࠎࡣ᫬ィⲡ࠿ࡽᢳฟࡉ
ࢀࡿࣁ࣑ࣝࣥ࡟ὀ┠ࡋࠊࡇࡢ໬ྜ≀ࡀ㦵ⱆ⣽⬊ศ໬࡟ᚲせ࡞㌿෗ᅉᏊࡢቑຍࢆక࠸࡞ࡀࡽ
㦵ⱆ⣽⬊ศ໬࡜࣑ࢿࣛࣝ໬ࢆಁ㐍ࡍࡿࡇ࡜ࢆⓎぢࠊ㦵⢒㧼⑕ࡸṑ࿘⑓἞⒪࡬ࡢᛂ⏝ࢆ᳨ウࡋ࡚࠸ࡿ 3)ࠋࡺ࠼࡟ᮏ◊✲࡛ࡣ H-D ஺᥮཯ᛂࢆ⏝࠸ࡓࣁ࣑ࣝࣥࡢ㔜Ỉ⣲໬ࢆ᳨ウࡋࡓࠋ࠙᪉ἲࠚ࣑ࢽࣂ࣮࣒࢟ࣗࢳ࣮ࣗࣈ࡟ࣁ࣑ࣝࣥ㸦ᮾி໬ᡂᕤᴗ♫〇㸧ࢆ 5.0 mg (24 Pmol)ࠊ 5%
Pt/C ࢆ 2.0 mg 㔞ࡾ᥇ࡾࠊ㔜Ỉ 2.0 mL ࢆຍ࠼࡚ศᩓࡉࡏࡓࠋᐜჾෆࢆỈ⣲࢞ࢫ࡟⨨᥮ࡋࠊ
120Υ࡛ 24 ᫬㛫཯ᛂࡉࡏࡓᚋࠊ཯ᛂᾮ࡟⣙ 10 mL ࡢ࢔ࢭࢺࢽࢺࣜࣝࢆຍ࠼࡚ࢁ㐣ࡋࠊPt/Cࢆ㝖ཤࠊࢁᾮࢆ⃰⦰஝⇱ࡋ࡚ⓑⰍ⢊ᮎ≧ࡢ㔜Ỉ⣲໬ࣁ࣑ࣝࣥࢆᚓࡓࠋ
࠙⤖ᯝ࡜⪃ᐹࠚᚓࡽࢀࡓ㔜Ỉ⣲໬ࣁ࣑ࣝࣥࢆ LC/MS ࡛☜ㄆࡋࡓ࡜ࡇࢁࠊཎᩱࡢࣁ࣑ࣝࣥ࡜
࡯ࡰྠࡌ UV ࠾ࡼࡧ඲࢖࢜ࣥࢡ࣐ࣟࢺࢢ࣒ࣛࢆ♧ࡋࡓࠋࡲࡓࠊ⁐ฟࣆ࣮ࢡࡢ MS ࢫ࣌ࢡࢺࣝ
࡛ࡣཎᩱࡢࣁ࣑࡛ࣝࣥࡣࣉࣟࢺࣥ௜ຍయࡢ m/z 213 ࡢࣆ࣮ࢡࡢࡳࡀ኱ࡁࡃほࡉࢀࡓࡀࠊ㔜

Ỉ⣲໬ࣁ࣑࡛ࣝࣥࡣ m/z 220 ࢆ᭱኱ᙉᗘ࡜ࡍࡿ」ᩘࡢࣆ࣮ࢡࡀ m/z 213-221 ࡟ࢃࡓࡾほ ࡉ
ࢀࡓࠋPt/C ゐ፹ࡣⰾ㤶⎔࡟࠾ࡅࡿ C-H ࢆ C-D ࡬࡜ኚ᥮ࡉࡏࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸ࡿࡓࡵࣁ
࣑࡛ࣝࣥࡣ㍍Ỉ⣲ࡀ㔜Ỉ⣲࡟⨨᥮ࡉࢀࡿࡣ᭱኱ 5 ࡘࡲ࡛࡜ண᝿ࡉࢀ࡚࠸ࡓࠋࡋ࠿ࡋࠊᐇ㝿࡟ࡣ᭱኱ 8 ಶࡢ㔜Ỉ⣲⨨᥮ࡀ㉳ࡇࡗ࡚࠸ࡓࡓࡵࠊ஧㔜⤖ྜࡢ㑏ඖ཯ᛂࡸⅣ⣲̿Ⅳ⣲⤖ྜࡢษ᩿࡞࡝ࡀᠱᛕࡉࢀࡓࡀࠊ1H-NMR ࡛ゎᯒࡋࡓ⤖ᯝࠊⓑ㔠Ⅳ⣲ࡀゐ፹ࡍࡿ࣋ࣥࢮࣥ⎔ࡢỈ⣲௨እ࡟࣓ࢳࣝᇶ࡟࠾࠸࡚ࡶ㔜Ỉ⣲໬཯ᛂࡀ㐍⾜ࡋ࡚࠸ࡿࡇ࡜ࡀุ᫂ࡋࡓࠋ

1) H. Sajiki et al., Bull. Chem. Soc. Jpn, 81, 278-286 (2008).
2) S. Hirano et al., JSBMS letters, 39, 110 (2014).
3) T. Yonezawa et al., Biochem. Biophys. Res. Commun., 409, 260–265 (2011).

́́

P-40
MALDI-TOF MS ࡟࠾ࡅࡿ Neisseria meningitidis ࡢㄗྠᐃ୍౛኱㔝ᬛᏊឡ▱་⛉኱Ꮫ⑓㝔ឤᰁไᚚ㒊

Example of misidentification of Neisseria meningitidis in MALDI-TOF MS
Tomoko Ohno
Aichi Medical University Hospital Infection Control Team࠙ࡣࡌࡵ࡟ࠚMALDI-TOF MS ࢆ⏝࠸ࡓᚤ⏕≀ྠᐃࡀ฼⏝ࡉࢀࡿࡼ࠺࡟࡞ࡾࠊ㎿㏿ྠᐃࢆ⾜࠺ࡇ࡜ࡀ࡛ࡁࡿࡼ࠺࡟࡞ࡗࡓࠋ
ᙜ㝔ࡢ⾑ᾮᇵ㣴ࡣ MALDI-TOF MS ࢆ౑⏝ࡋ㎿㏿ྠᐃࢆ⾜ࡗ࡚࠸ࡿࠋ
ࡑࡇ࡛⾑ᾮᇵ㣴࠿ࡽ Neisseria meningitidis ࡜ MALDI-TOF MS ࡛ྠᐃࠊ5 㢮ឤᰁ⑕ࡢ౵くᛶ㧊⭷⅖⳦ឤᰁ⑕࡛ᒆࡅฟࡀᚲせ࡛࠶ࡿ⤖ᯝ࡜࡞ࡗࡓࡀࠊ᭱⤊ⓗ࡟ Neisseria cinerea ࡜ྠᐃࡉࢀࡓ୍౛ࢆሗ࿌ࡍࡿࠋ
࠙⑕౛ࠚ30 ṓ௦⏨ᛶࠊBurkitt ࣜࣥࣃ⭘デ᩿࡛ධ㝔 4 ᪥┠ࡼࡾ໬Ꮫ⒪ἲᐇ᪋୰ࠊ⾑ᾮᇵ㣴 2ࢭࢵࢺࡀ㝧ᛶ࡜࡞ࡾࠊMALDI-TOF MS㸦Burker Daltnics ♫㸧࡟࠾࠸࡚ࠊN. meningitidis (bestmatch:Score Value 2.024, second best math:Score Value 1.966)࡜ྠᐃࡉࢀࡓࠋࡑࡇ࡛
⾑ᾮᇵ㣴ᾮỿ´ࢆ⏝࠸ PASTREX ࣓ࢽࣥࢪࣕ࢖ࢸ࢕ࢫࢆ⾜ࡗࡓ࡜ࡇࢁࠊ㠀≉␗ⓗ཯ᛂ࡟ࡼࡿ
จ㞟ࢆㄆࡵࡓࠋࡉࡽ࡟ᖹᯈᇵᆅࡢࢥࣟࢽ࣮࡛ ID ࢸࢫࢺ HN-20 ࣛࣆࢵࢻ ࢽࢵࢫ࢖(᪥Ỉ〇⸆ᰴᘧ఍♫)ࢆ⾜ࡗࡓ࡜ࡇࢁࠊNeisseria 2 㸦60㸣㸧,N. gonorrhoeae 㸦30㸣㸧,Neisseria
3 㸦7㸣㸧࡜ྠᐃࡉࢀࡓࠋࢥࣟࢽ࣮ᙧ≧ࡣ N. meningitidis ࡜ࡣ␗࡞ࡾ⢓ᛶ࡛ࢥࣟࢽ࣮ࡶᑠ
ࡉࡃࠊឤཷᛶ᳨ᰝࡣ⪏ᛶഴྥࢆ♧ࡋࡓࠋNeisseria 2 ࡟ヱᙜࡍࡿ⳦✀ࡣ N. cinerea, N.

flavescens ࡀྵࡲࢀ࡚࠸ࡿࠋ᭱⤊ⓗ࡟ࡣ 16S rRNA 㡿ᇦ㑇ఏᏊ BLAST ゎᯒ࡛ࡣ N㸬cinerea
㸦100㸣㸧࡜ྠᐃࡉࢀࡓࠋ
࠙⪃ᐹࠚ௒ᅇᡃࠎࡣ MALDI-TOF MS ࡛ N. meningitidis ࡜ྠᐃࡉࢀࡓ N. cinerea ࢆ⤒㦂ࡋࡓࠋ᳨ฟ㢖ᗘࡢ㧗ࡃ࡞࠸⳦ྡࡀྠᐃࡉࢀࡓሙྜࠊScore Value ᩘ್ࡢ☜ㄆࠊࢥࣟࢽ࣮ࡢ⏕໬Ꮫⓗᛶ≧࡞࡝ࡶ㋃ࡲ࠼ྠᐃࢆ⾜ࢃ࡞ࡅࢀࡤ࡞ࡽ࡞࠸⑕౛࡛࠶ࡗࡓࠋ
Ꮫ఍እ༠ຊ⪅㸸ᮎᯇᐶஅ ᒣᓊ⏤ె ୕㬞ᘅ⦾

́́

P-41
MALDI-TOF MS ࡟ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃ࡟ࡘ࠸࡚
ụࣨ㇂ెᑑᏊ, ᅵᒇ ᠇㟼ᒸᕷ❧ΎỈ⑓㝔 ᳨ᰝᢏ⾡⛉Direct identification of bacteria in positive blood culture bottles by MALDI-TOF
MS
Kazuko Ikegaya, Ken Tsuchiya
Department of Clinical Laboratory,Shizuoka City Shimizu Hospital࠙┠ⓗࠚMALDI-TOF MS ࡣᚤ⏕≀ྠᐃࡢ་⒪ᶵჾ࡜ࡋ࡚ᅜෆ࡛ࡢ฼⏝ࡀᣑ኱ࡋ࡚࠸ࡿࠋᚑ᮶ࡢ
ᚤ⏕≀ྠᐃࡣࠊᵝࠎ࡞ᡭἲࢆ⏝࠸࡚ᩘ᪥࠿ࡅ࡚≉ᚩࢆᑟࡁฟࡋࠊࢹ࣮ࢱ࣮࣋ࢫ࡜↷ྜࡋ࡚⳦ྡࢆỴᐃࡋ࡚࠸ࡓࠋࡋ࠿ࡋࠊMALDI-TOF MS ࢆ⏝࠸ࡓᚤ⏕≀ྠᐃ࡛ࡣᩘ༑ศ࡛⤖ᯝࡀᚓࡽࢀࡿࠋ௒ᅇࠊ⮫ᗋⓗ࡟㔜せ࡞⾑ᾮᇵ㣴࡟↔Ⅼࢆ࠶࡚ࠊMALDI-TOF MS ࡟ࡼࡿ⾑ᾮᇵ㣴㝧ᛶ࣎ࢺࣝᇵ㣴ᾮࢆ⏝࠸ࡓ┤᥋ྠᐃࡢ᭷⏝ᛶ࡟ࡘ࠸᳨࡚ウࡋࡓࠋ
࠙᪉ἲࠚ2013 ᖺ 9 ᭶㹼2014 ᖺ 12 ᭶ࡲ࡛࡟ᥦฟࡉࢀࠊ
㝧ᛶ࡜࡞ࡗࡓ⾑ᾮᇵ㣴 466 ᳨యࡢ࠺ࡕࠊ
༢⊂⳦ࡀ᳨ฟࡉࢀࡓ 407 ᳨యࢆᑐ㇟࡜ࡋࡓࠋ⾑ᾮᇵ㣴⿦⨨࡛㝧ᛶࢩࢢࢼࣝࡀฟࡓ࣎ࢺࣝᇵ
㣴ᾮࢆᢤࡁྲྀࡾࠊ⣽⳦ᅇ཰ࡢ๓ฎ⌮ࢆ⾜ࡗࡓฎ⌮῭ࡳ᳨యࢆ MALDI-TOF MS ࡛

ᐃࡋࡓ㸦┤

᥋ྠᐃ㸧
ࠋྠ᫬࡟ࢢ࣒ࣛᰁⰍ࠾ࡼࡧᖹᯈᇵᆅ࡬ࢧࣈ࢝ࣝࢳ࣮ࣕࢆᐇ᪋ࡋࠊ⩣᪥Ⓨ⫱ࢥࣟࢽ࣮ࢆ MALDI-TOF MS ࡛ ᐃࡋࡓ㸦ࢥࣟࢽ࣮ྠᐃ㸧ࠋࢥࣟࢽ࣮ྠᐃࢆṇ࡜ࡋ࡚ࠊࡑࢀࡒࢀࡢ⤖ᯝࢆẚ㍑ࡋࡓࠋ࡞࠾ࠊ㉁㔞ศᯒィࡣ VITEK MS v2㸦ࢩࢫ࣓ࢵࢡࢫ㸧ࢆ౑⏝ࡋࡓࠋ࠙⤖ᯝࠚ༢⊂⳦ࡀ᳨ฟࡉࢀࡓ 407 ᳨యࡢ࠺ࡕࠊ┤᥋ྠᐃ࡛⳦ྡࡀᚓࡽࢀࡓࡢࡣ 351 ᳨య
㸦86.2%㸧࡛࠶ࡾࠊ┤᥋ྠᐃ⳦ྡ࡜ࢥࣟࢽ࣮ྠᐃࡀ୍⮴ࡋࡓࡢࡣ 343 ᳨య㸦97.7%㸧࡛࠶ࡗࡓࠋ
┤᥋ྠᐃ࡟ࡼࡾ⳦ྡࡀᚓࡽࢀࠊ࠿ࡘࢥࣟࢽ࣮ྠᐃ࡜୍⮴ࡍࡿ๭ྜࡣ 84.3%࡛࠶ࡗࡓࠋ⳦ྡ୙
୍⮴ࡢ 8 ᳨యࡢ࠺ࡕࠊ6 ᳨యࡣ࣎ࢺࣝᇵ㣴ᾮࡢࢢ࣒ࣛᰁⰍᙧែ࡜┤᥋ྠᐃ࡛ᚓࡽࢀࡓ⳦ྡࡢ
⳦ᙧែࡀ୙୍⮴࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚMALDI-TOF MS ࡟ࡼࡿ┤᥋ྠᐃࡣࠊ⤖ᯝ࡟ᙳ㡪ࢆ୚࠼ࡿ࡜ᛮࢃࢀࡿᇵ㣴ᾮෆࡢ⳦௨እ
ࡢᡂศࢆዴఱ࡟ࡋ࡚㝖ཤࡋࠊ⳦ᾮ࡟㏆࠸≧ែ࡟๓ฎ⌮࡛ࡁࡿ࠿ࡀ࣏࢖ࣥࢺ࡛࠶ࡿࠋࡲࡓࠊ
┤᥋ྠᐃࢆ⮫ᗋ࡟ά࠿ࡍࡓࡵ࡟ࡣࢥࣟࢽ࣮ྠᐃ࡜ࡢ㧗࠸୍⮴⋡ࡀồࡵࡽࢀࡿࠋ⌧⾜ࡢ๓ฎ⌮᪉ἲࡣࠊ࣎ࢺࣝྲྀࡾฟࡋ࠿ࡽ 45 ศ௨ෆ࡛ 86%⛬ᗘࡢྠᐃ⋡ࡀᚓࡽࢀ࡚࠸ࡿࠋ┤᥋ྠᐃ࡛⳦ྡࢆᚓࡿࡇ࡜ࡀ࡛ࡁࢀࡤࠊࢥࣟࢽ࣮ྠᐃ࡜ࡢ୍⮴⋡ࡣ 97.7%࡜㧗࠸ࠋ࣎ࢺࣝᇵ㣴ᾮࡢࢢ࣒ࣛᰁⰍ⤖ᯝ࡜ేࡏࡿࡇ࡜࡛ࠊࡉࡽ࡟⢭ᗘ㧗ࡃ⮫ᗋ࡟ሗ࿌ࡍࡿࡇ࡜ࡀྍ⬟࡛࠶ࡿࠋ⾑ᾮᇵ㣴ࡢ┤᥋ྠᐃࢆ⾜࠺ࡇ࡜ࡣ᪩ᮇ࡟ࠊࡼࡾ㐺ษ࡞ᢠ⳦⸆ࡢ㑅ᢥ࡟⧅ࡀࡿࡶࡢ࡜⪃࠼ࡿࠋ

́́

P-42
MALDI mass spectrometry imaging ࡟ࡼࡿ෾⤖⤌⧊࢔ࣞ࢖ໟᇙஙࡀࢇ⤌⧊ࡢపศᏊ௦ㅰ⏘≀ࣉࣟࣇ࢓࢖ࣜࣥࢢ
ᐥ⏣ಙ༤ 1, ஂಖ ┿ 1, ୕ᾆ኱඾ 3, ኱ෆ⏣◊ᐂ 1, ᐑᓮဴஅ 2, ⸨ᮧ⏤⣖ 3, ᪩ᕝⱥ௓ 3,኱ሯ㝯⏕ 1, ᐑᆏ⩏ᾈ 1, ┿㘠㐩ஓ 1, ᑠ⏣⩏┤ 2, Ỉඖ୍༤ 4, ୰ᮧ㞞ྐ 11஑ᕞ኱Ꮫ⮫ᗋ࣭⭘⒆እ⛉, 2 ஑ᕞ኱Ꮫᙧែᶵ⬟⑓⌮, 3 ஑ᕞ኱Ꮫඛ➃⼥ྜ་⒪ࣞࢻࢵࢡࢫࢼ
ࣅ◊✲ᣐⅬ, 4 ஑ᕞ኱Ꮫ⑓㝔 ࡀࢇࢭࣥࢱ࣮MALDI mass spectrometry imaging profiling of low molecular metabolites withfrozen tissue microarray embedded breast cancer tissues.
N.Torata1, M.Kubo1, D.Miura3, K. Ohuchida1, T.Miyazaki2, Y.Fujimura3, E.Hayakawa1, T.Otsuka1,
Y.Miyasaka1, T Manabe1, Y.Oda2, K.Mizumoto4, M.Nakamura1
1

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University,
Departments of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University,
3
Innovation Center for Medical Redox Navigation, Kyushu University, 4Kyushu University Hospital
Cancer Center2࠙┠ⓗࠚࣄࢺ⏤᮶⤌⧊ࢆ⏝࠸ࡓ㉁㔞ศᯒἲ࡛ࡣࠊࣃࣛࣇ࢕ࣥࣈࣟࢵࢡ໬ࡸᢳฟࡢᙳ㡪࡟ࡼࡾࠊᦆ࡞ࢃࢀ࡚ࡋࡲ࠺᝟ሗࡀ࠶ࡿࠋࡑࡇ࡛⊂⮬ᢏ⾡ࢆ⏝࠸࡚ࠊங⒴⤌⧊ࡢ෾⤖⤌⧊࢔ࣞ࢖(fTMA)ࢆᵓ⠏ࡋࠊMALDI mass spectrometry imaging (MALDI-MSI)࡟ࡼࡿపศᏊ௦ㅰ⏘≀ࡢ࣐ࢵࣆࣥࢢࢆ⾜ࡗࡓࠋࡇࡢ᪉ἲ࡟ࡼࡾࠊ」ᩘࢧࣥࣉࣝࡢ⒴㛵㐃௦ㅰ⏘≀ࢆຠ⋡ࡼࡃศᯒࡍ
ࡿࡇ࡜ࡀ࡛ࡁࡓࡢ࡛⭘⒆ࠊṇᖖ㒊࡟࠾ࡅࡿࣉࣟࣇ࢓࢖ࣝ⤖ᯝࡢẚ㍑࡜࡜ࡶ࡟ሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚ99 ⑕౛࠿ࡽ᥇ྲྀࡋࡓங⭢⤌⧊ 119 ࢧࣥࣉࣝ㸦⭘⒆ 84ࠊṇᖖ 35㸧ࢆ⏝࠸࡚ࠊfTMAࣈࣟࢵࢡࢆస〇ࡋࠊ9̺࢔࣑ࣀ࢔ࢡࣜࢪࣥ࠾ࡼࡧ AXIMA Confidence㸦ᓥὠ〇సᡤ㸧ࢆ⏝࠸ࡓ
MADLI-MSI ࢆ⾜ࡗࡓ(m/z range㸸50㹼1000ࠊ㝜࢖࣮࢜ࣥࣔࢻ)ࠋศᯒᚋࡢࣉࣞࣃ࣮ࣛࢺ࡟࡚ࠊ
⭘⒆࣭㠀⭘⒆㒊ࢆ☜ㄆࡋࠊ୧㒊ࡢ m/z ࢩࢢࢼࣝศᕸࢆ BioMap ࡟࡚ᢳฟ࣭ẚ㍑ࢆ⾜ࡗࡓࠋ࠙⤖ᯝࠚ᳨ฟ࡛ࡁࡓ 1915 ಶࡢࣆ࣮ࢡࡢ࠺ࡕࠊ60㸣௨ୖࡢࢧࣥࣉ࡛ࣝඹ㏻࡟᳨ฟࡉࢀࠊ㧗࠸ࢩࢢࢼࣝࢆ♧ࡍ 185 ࣆ࣮ࢡࢆゎᯒᑐ㇟࡜ࡋࡓࠋᑐᛂࡍࡿ௦ㅰ≀ࡀ᥎ᐃ࡛ࡁࡓ m/z ✀ࡣ 18 ࡛ࠊ
ከࡃࡣ ATP ࡞࡝࢚ࢿࣝࢠ࣮௦ㅰ࡟㛵ࡍࡿࡶࡢ࡛࠶ࡗࡓࠋ⭘⒆ࠊṇᖖࡢ Energy Charge(EC)࠾
ࡼࡧ ATP+ADP+AMP ⥲࿴㔞(AXP)ࡢẚ㍑࡛ࠊ࠸ࡎࢀࡶ⭘⒆㒊࡟࠾࠸࡚᭷ព࡟㧗್ࢆ♧ࡋࡓࠊ㸯ಶ௨ୖࡢࣜࣥࣃ⠇㌿⛣᭷↓࠾ࡼࡀ㸦EC; T : N = 0.56 : 0.35ࠊAXP; 17453 : 2066, p<0.0001㸧
ࡧ⤌⧊ᆺࠊ⭘⒆ᚄ࡜ࡣ᫂ࡽ࠿࡞┦㛵ࡣ↓࠿ࡗࡓࠋ࠙⪃ᐹࠚfTMA ࡜ MADLI-MSI ࢆ⤌ࡳྜࢃࡏࡿࡇ࡜࡟ࡼࡾࠊ࣓ࢱ࣎ࣜࢵࢡ࣐ࢵࣆࣥࢢࢆຠ⋡ࡼࡃ⾜࠸ࡇ࡜ࡀ࡛ࡁࠊங⭢⤌⧊⭘⒆㒊࡛ࠊṇᖖࡼࡾࡶ㧗࠸ EC ್ࢆㄆࡵࡓࠋ⌧᫬Ⅼࡢ᳨ウ࡛ࡣ᪂つࡢࣂ࢖࣐࣮࣮࢜࢝ೃ⿵࡜࡞ࡿ௦ㅰ≀ࡣྠᐃ࡛ࡁ࡞࠿ࡗࡓࡀࠊࢧࣥࣉࣝ୰ࡢ໬ྜ≀ࡢࡼࡾヲ⣽࡞ᵓ㐀ゎᯒࢆ㐍ࡵࡿࡇ࡜࡛ࠊࡼࡾከࡃࡢ᝟ሗࡀᚓࡽࢀࡿࡇ࡜ࡀᮇᚅࡉࢀࡿࠋ

́́

P-43
ᚠ⎔ჾ⑓㛵㐃⤌⧊࡟࠾ࡅࡿ㹊㹇㹋ࢻ࣓࢖ࣥࢱࣥࣃࢡ㉁」ྜయゎᯒᒣ୰ᐶ᫂ 1, ᑎ⏣ ᜨ 1, ⳥ᆅἋ⪨Ꮚ 1, ᔱ⏣ᓫྐ 2, ᳜⏣ึỤ 3, 㣤ཎᘯ஧ 4, ụᕝ㞞ဢ 11ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉, 2 ᓥὠ〇సᡤᇶ┙ᢏ⾡◊✲ᡤ, 㸱ᅜ❧ᚠ⎔ჾ⑓◊✲ࢭࣥࢱ࣮⑓⌮㒊, 4 ஑ᕞ኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲㝔⬻⚄⤒እ⛉

Multiple protein complex analysis of LIM domain proteins in the cardiovascularsystems
Hiroaki Yamanaka1, Megumi Terada2, Sayako Kikuchi2, Takashi Shimada1, Hatsue Ueda2, Koji
Iihara1, Masaya Ikegawa3
1
Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha
University
2
Life Science Research Center, Shimadzu Corporation
3
Department of Pathology, National Cerebral and Cardiovascular Center
4
Department of Neurosurgery, Postgraduate school of Medicine, Kyushu University㏆ᖺࠊᚰ⮚ࠊ⾑⟶ࠊ⫵࡜࠸ࡗࡓᚠ⎔ჾ⑓㛵㐃⤌⧊ࡢࣉࣟࢸ࣮࣒࢜ゎᯒ࡟ὀ┠ࡀ㞟ࡲࡗ࡚࠸ࡿࠋࢃࢀࢃࢀࡣࠊࡇࢀࡲ࡛ᚠ⎔ჾ⑓㛵㐃⤌⧊ࢆᑐ㇟࡟ Blue Native PAGE ἲࢆ⏝࠸ࡓࢱࣥ
ࣃࢡ㉁」ྜయゎᯒࢆ⾜ࡗ࡚ࡁࡓࠋᮏ◊✲࡛ࡣࠊࡑࡢ࡞࠿࠿ࡽ LIM ࢻ࣓࢖ࣥࢆᣢࡘࢱࣥࣃࢡ㉁ࣇ࢓࣑࣮ࣜ࡟ὀ┠ࡋࡓࠋLIM ࢻ࣓࢖ࣥࡣࠊ㑇ఏᏊⓎ⌧ࠊ⣽⬊᥋╔ࠊ⣽⬊㐠ືࠊ࠾ࡼࡧࢩ
ࢢࢼࣝఏ㐩ࡢㄪ⠇ᅉᏊ࡜ࡋ࡚ࠊᶵ⬟ⓗ࡟ከᵝ࡞ᙺ๭ࢆᣢࡘࠋ࡞࠿࡛ࡶࠊfour and a half LIM(FHL)ࣇ࢓࣑࣮ࣜ࡟ศ㢮ࡉࢀᚰ⮚⾑⟶⣔࡛ࡢⓎ⌧ࡢㄆࡵࡽࢀࡿ FHL-1 (Kyo-T㸯)ࡣࠊ
skeletalmuscle LIM 1 (SLIM1)࡜ࡋ࡚ࡶ▱ࡽࢀࠊ୺࡟࣐࢘ࢫ⑌ᝈࣔࢹࣝࡸࣄࢺࢤࣀ࣒ゎᯒࡢ⤖ᯝ࠿ࡽ⫧኱ᆺᚰ➽⑕ࡸ⫵㧗⾑ᅽ⑕࡞࡝ࡢᚠ⎔ჾ⑓࡜ࡢ㛵㐃ࡀ♧၀ࡉࢀ࡚࠸ࡿࠋ௒ᅇࡢゎᯒࡢ⤖
ᯝࠊFHL-1 ࡣ࣐࢘ࢫ⫵࡟࠾࠸࡚㢧ⴭ࡞ࢱࣥࣃࢡ㉁Ⓨ⌧ࡢ࠶ࡿࡇ࡜ࠊẚ㍑ᑐ㇟࡜ࡋ࡚ᚰᐊࠊᚰ
ᡣࠊ኱ື⬦ྛ㒊࡟࠾ࡅࡿ⤌⧊ࣉࣟࢸ࣮࣒࢜࡜ẚ㍑ࡍࡿࡇ࡜࡟ࡼࡾ」ྜయᙧᡂࡢ␗࡞ࡿࡇ࡜
ࡀ♧၀ࡉࢀࡓࠋᮏ◊✲࡛ࡣࠊᚠ⎔ჾ⑓㛵㐃⤌⧊ࡢࣉࣟࢸ࣮࣒࢜ゎᯒࡢᡭἲ࡜ࡋ࡚ࠊBlue
Native PAGE ἲ࡟ຍ࠼ࠊᢠయࢆ⏝࠸ࡓ affinity purification ࡢᚋࡢ⥙⨶ⓗ」ྜయゎᯒࢆᑟධࡍࡿࡇ࡜࡛⤌⧊ࡢ௦ㅰࡸᶵ⬟ࠊࡑࡢ◚⥢࡜ࡋ࡚ࡢ⑌ᝈ࡜ࡢ㛵㐃௜ࡅࢆ᥈⣴࡛ࡁࡿ࠿ࠊⱝ
ᖸࡢ⪃ᐹࢆ⾜ࡗࡓࠋ

́́

P-44
ࣄࢺ⫾┙࡟࠾ࡅࡿ⤊ᮎ⤧ẟ࡜ᖿ⤧ẟ࡟࠾ࡅࡿࣜࣥ⬡㉁ศᕸࣃࢱ࣮ࣥࡢ≉ᚩ࡜⫾┙⑓⌮ᡤぢࡢ┦㛵࡟ࡘ࠸࡚ᒣ㷂㤶⧊ 1, ṇᮌ⣖㝯㸰, ᖾᮧ཭ᏘᏊ 1, ᪩ᆏᏕᏹ 3, ఀᮾᏹ᫭ 1, 㔠ᒣᑦ⿱ 1, ℩⸨ග฼㸰
1὾ᯇ་⛉኱Ꮫ⏘፬ே⛉Ꮫㅮᗙ, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 3 ໭ᾏ㐨኱Ꮫ኱Ꮫ㝔ಖ೺⛉Ꮫ◊✲㝔Imaging Mass Spectrometry Analysis of Differential Expression Patterns ofPhospholipid Molecular Species in Terminal and Stem Villi associated with
Pathological Findings in the Human Term Placentas
Kaori Yamazaki1, Noritaka Masaki, 2, Yukiko Kohmura-Kobayashi1, Takahiro Hayasaka3, Hiroaki
Itoh1, Naohiro Kanayama1, Mitsutoshi Setou2
1
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine
2
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine
3
Department of Health Science, School of Medicine, Hokkaido University࠙┠ⓗࠚᡃࠎࡣࠊࡇࢀࡲ࡛ࠊ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ(IMS)ࢆ⏝࠸࡚⫾┙⤧ẟ⤌⧊ࢆホ౯ࡋࠊ⤊ᮎ⤧ẟ࡛ࡣ phosphatidylcholine (PC)(16:0/20:4)ࡀࠊᖿ⤧ẟ࡛ࡣ sphingomyelin (SM)(d18:1/16:0)ࡢⓎ⌧ࡀஹ㐍ࡋ࡚࠸ࡿࡇ࡜ࢆ᫂ࡽ࠿࡟ࡋࡓࠋ
⑓⌮ᡤぢ࡜ࡢ㛵㐃ᛶࢆㄪ࡭ࡿࡓࡵࠊ
௒ᅇࠊዷፎ㧗⾑ᅽ⑕ೃ⩌(PIH)ࡲࡓࡣ⫾ඣⓎ⫱୙඲(FGR)ྜేዷፎࡢ⫾┙ࢆゎᯒࡋࡓࠋ࠙᪉ἲࠚ೔⌮ጤဨ఍ࡢ஢ᢎࡢୗࠊዷፎᮎᮇࡢ FGR ࢆకࢃ࡞࠸ PIH ⑕౛ 4 ౛(PIH ⩌)ࠊPIH ࢆకࢃ࡞࠸ FGR ⑕౛ 5 ౛(FGR ⩌)ࡢ⫾┙࠿ࡽ෾⤖ษ∦ࢆసᡂࡋࡓࠋ࣐ࢺࣜࢵࢡࢫᨭ᥼࣮ࣞࢨ࣮
⬺㞳࢖࢜ࣥ໬㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲ(MALDI-IMS)࡟ࡼࡾࠊษ∦ୖ 25 μm ᅄ᪉ࡢ㡿ᇦࢆゎᯒࡋࡓࠋ㐃⥆ษ∦ࡢ HE ᰁⰍീ࡜ࡢẚ㍑࡟ࡼࡾ⤧ẟ⤌⧊࡟࠾ࡅࡿࣜࣥ⬡㉁Ⓨ⌧ࣃࢱ࣮ࣥࢆホ౯ࡋࠊ⫾┙ࡢ⑓⌮⤌⧊Ꮫⓗᡤぢ㸦villitis of unknown etiology, thrombus, atherosis,chorioammnionitis
immature terminal villi, multiply branched terminal villi㸧ࡢⓎ⌧࡜ࡢ㛵ಀࢆㄪ࡭ࡓࠋ
࠙⤖ᯝࠚ6 ಶࡢ⫾┙⑓⌮ᡤぢࡢ࠺ࡕ 3 ಶ௨ୖࡢᡤぢࡀ࠶ࡗࡓ 2 ౛࡛ࡣࠊ⤊ᮎ⤧ẟ࡟࠾ࡅࡿ PC(16:0/20:4)ࡢⓎ⌧ࠊᖿ⤧ẟ࡟࠾ࡅࡿ SM (d18:1/16:0)ࡢⓎ⌧ࡀ࡜ࡶ࡟పୗࡋ࡚࠸ࡓࠋ⑓⌮ᡤぢࡀ 2 ಶ௨ୗࡢࡶࡢ࡟ࡘ࠸࡚ࡣࠊ⤊ᮎ⤧ẟ࡟࠾࠸࡚ PC (16:0/20:4)ࡢࡳࡀⓎ⌧ࡋ࡚࠸ࡓࡶࡢࡀ 4 ౛ࠊ⤊ᮎ⤧ẟ࡟࠾ࡅࡿ PC (16:0/20:4)ࡢⓎ⌧ࠊᖿ⤧ẟ࡟࠾ࡅࡿ SM (d18:1/16:0)
ࡢⓎ⌧ࡀ࡜ࡶ࡟ࡳࡽࢀࡓࡶࡢࡀ 3 ౛࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚྜే⑕ዷፎ࡛ࡣࠊ⫾┙ࡢ⑓⌮ᡤぢ࡟ᚑ࠸⤧ẟ⤌⧊࡟࠾ࡅࡿࣜࣥ⬡㉁⤌ᡂ࡟ኚ໬ࡀࡳ
ࡽࢀࡓࠋ≉࡟⑓⌮ᡤぢࡢⓎ⌧ᩘࡀከ࠸ࡶࡢ࡯࡝ࠊ⤧ẟ⤌⧊≉᭷ࡢࣜࣥ⬡㉁ࡢⓎ⌧ࡀపୗࡍࡿࡇ࡜ࡀࢃ࠿ࡗࡓࠋ

́́

P-45
⫵⥺⥔໬࡟㛵㐃ࡋࡓ⬡㉁ࡢ⥙⨶ゎᯒ኱ᒣྜྷᖾ 1,2, ṇᮌ⣖㝯 2, Ἑ㔝㞞ே 1, ᴮᮏ⣖அ 1, ୰ᮧ♸ኴ㑻 1, ⸨⃝᭸ᖾ 1, ஝ ┤㍤ 1,
㡲⏣㝯ᩥ 1, ℩⸨ග฼ 21὾ᯇ་⛉኱Ꮫ ෆ⛉Ꮫ➨஧ㅮᗙ, 2 ྠ ゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝Comprehensive analysis of lipids related with pulmonary fibrosis
Yoshiyuki Oyama1,2, Noritaka Masaki2, Masato Kono1, Noriyuki Enomoto1, Yutaro Nakamura1,
Tomoyuki Fujisawa1, Naoki Inui1, Takafumi Suda1, Mitsutoshi Setou2
1Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
2
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine,࠙⫼ᬒࠚ⫵ࡢ⥺⥔໬࡟࠾࠸࡚ࠊ⫵ࢧ࣮ࣇ࢓ࢡࢱࣥࢺࡢ୺せᡂศ࡛࠶ࡿࣜࣥ⬡㉁ࡢ⤌ᡂࡀኚ໬ࡍࡿࡇ࡜ࡀẼ⟶ᨭ⫵⬊Ὑίᾮ㸦BALF㸧ࢆ⏝࠸ࡓ᳨ウ࡛♧၀ࡉࢀ࡚࠸ࡿࡀࠊᐇ㝿࡟⥺⥔໬ࡋࡓ㒊఩࡟࠾ࡅࡿࣜࣥ⬡㉁⤌ᡂࢆㄪ࡭ࡓሗ࿌ࡣᮍࡔ࡞࠸ࠋ㉁㔞㢧ᚤ㙾ἲ㸦MALDI-IMS㸧ࡣࠊ⤌⧊ෆᒁᅾ࡟ᚑ࠺ศᏊ⤌ᡂཬࡧࡑࡢⓎ⌧㔞ࡢྍど໬ࢆྍ⬟࡜ࡍࡿࠋᵝࠎ࡞ศᏊ✀ࢆゎᯒࡍࡿࡇ࡜ࡀྍ⬟࡛࠶ࡾࠊ≉࡟⬡⫫㓟⤌ᡂࡢ␗࡞ࡿ⬡㉁ࡢ
༊ูࡀྍ⬟࡛࠶ࡿࡇ࡜࠿ࡽ⬡㉁ゎᯒ࡟ࡑࡢጾຊࢆⓎ᥹ࡋࠊ⑌⑓デ᩿࣐࣮࣮࢝ࡢ᳨ฟ࠾ࡼࡧ
ࡑࡢ⑓ែゎᯒ࡟ᐤ୚ࡋ࡚᮶ࡓࠋ
࠙┠ⓗࠚ㉁㔞㢧ᚤ㙾ἲࢆ⏝࠸࡚ື≀ࣔࢹࣝࡢ⫵ᒁᡤ࡟࠾ࡅࡿ⫵⥺⥔໬࡟㛵㐃ࡋࡓ⬡㉁ࡢኚ໬
ࢆ᫂ࡽ࠿࡟ࡍࡿࠋ
࠙᪉ἲࠚ⬚㒌࠿ࡽྲྀࡾฟࡋࡓ⫵ࡣࡑࡢࡲࡲ࡛ࡣ⹫⬺ࡋ࡚࠸ࡿࡓࡵ⫵⬊㡿ᇦࡢᵓ㐀ࡀኻࢃࢀ࡚ࡋ ࡲ ࠺ ࠋ ࡑ ࡢ ࡓ ࡵ ㉁ 㔞 㢧 ᚤ 㙾 ἲ ࡢ ㉁ 㔞 ศ ᯒ ࢫ ࣌ ࢡ ࢺ ࣝ ࡟ ୚ ࠼ ࡿ ᙳ 㡪 ࡀ ᑡ ࡞ ࠸ 2%
carboxymethyl cellulose ࢆẼ⟶ෆࡼࡾὀධࡋࠊ⫵ࢆ inflation ࡋࡓᚋ࡟෾⤖ࡋࠊษ∦ࢆసᡂࡋࡓࠋ
ヨᩱ࡜ࡋ࡚ṇᖖ࣐࢘ࢫ࡜ࣈ࣐ࣞ࢜࢖ࢩࣥ㸦BLM㸧⫵⥺⥔⑕ࣔࢹ࣐ࣝ࢘ࢫࡢ㐃⥆ษ∦ࢆసᡂࡋࠊ㉁㔞㢧ᚤ㙾ἲ࡟ࡼࡾゎᯒࡋࡓࠋࡲࡓ㐃⥆ษ∦࡟ᑐࡋ࡚࣐࣊ࢺ࢟ࢩ࣭࢚ࣜࣥ࢜ࢪࣥ㸦HE㸧
ᰁⰍ࡟ࡼࡿᙧែほᐹࢆ⾜ࡗࡓࠋ࠙⤖ᯝࠚṇᖖ࣐࢘ࢫࠊBLM ࣔࢹ࣐ࣝ࢘ࢫࡢṇᖖ㒊఩ཬࡧ⥺⥔໬㒊఩ࢆẚ㍑ࡍࡿ࡜ࠊ⥺⥔໬ࡀ㐍⾜ࡍࡿ࡟ࡘࢀࠊ⫵ࢧ࣮ࣇ࢓ࢡࢱࣥࢺࡢ୺せᵓᡂᡂศ࡛࠶ࡿ PC(16:0/16:0)ࡀῶᑡࡋ࡚࠸ࡓࠋ
࠙⤖ㄒࠚBALF ゎᯒ࡛ࡣ඲యⓗ࡞ኚ໬࡜ࡋ࡚ࡋ࠿ᤊ࠼ࡽࢀ࡚࠸࡞࠿ࡗࡓ PC(16:0/16:0)ࡢῶᑡ
ࡀࠊ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ┤᥋ほᐹ࡟ࡼࡾṇᖖ㒊఩࡟࠾ࡅࡿῶᑡ࡜ࠊ⥺⥔໬㒊఩࡟࠾ࡅࡿࡼ
ࡾⴭࡋ࠸ῶᑡࡢ஧✀㢮ࡢኚ໬࡟ࡼࡿࡶࡢ࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋ

́́

P-46
ࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈங⒴ࡢ෌ⓎணᅉᏊࡢ㉁㔞㢧ᚤ㙾ࢆ⏝࠸ࡓ᥈ồ⣽ᕝඃᏊ 1, ṇᮌ⣖㝯 2, ᯇୗ⚈Ꮚ 2, ᮡᒣᰤ஧ 2, ᑠ಴༤அ 1, ᳝㇂⣖ᙪ 1, ℩⸨ග฼ 21὾ᯇ་⛉኱Ꮫ➨୍እ⛉, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝Investigation of predictive factor of recurrence in triple negative breast cancer
using mass microscope
Yuko Hosokawa1, Noritaka Masaki2, Shoko Matsushita2, Eiji Sugiyama2, Hiroyuki Ogura1,
Norihiko Shiiya1, Mitsutoshi Setou2
1
Hamamatsu University School of Medicine Department of 1st Surgery
2
Hamamatsu University School of Medicine Department of Cell Biology and Anatomy࠙┠ⓗࠚங⒴ࡣୡ⏺ⓗ࡟ዪᛶࡢ⒴࡟ࡼࡿṚஸࡢ୺࡞せᅉ࡛࠶ࡿࠋங⒴ࡣ࣍ࣝࣔࣥཷᐜయࡸ
HER2 ཷᐜయࡢ᭷↓, Ki67 ࡢ㧗ప࡛ 5 ࡘࡢࢧࣈࢱ࢖ࣉ࡟ศ㢮ࡉࢀࡿࠋ୰࡛ࡶ࣍ࣝࣔࣥཷᐜ
య࡛࠶ࡿ࢚ࢫࢺࣟࢤࣥཷᐜయ࡜ࣉࣟࢤࢫࢸࣟࣥཷᐜయ㝜ᛶ, HER2 ཷᐜయ㝜ᛶࡢࢺࣜࣉࣝࢿ
࢞ࢸ࢕ࣈங⒴ࡣ඲యࡢ 10-15㸣ࢆ༨ࡵ, ᪩ᮇ࡟෌Ⓨࡋணᚋࡀᝏ࠸ࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࠋ
୍᪉࡛ࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈங⒴ࡢ୰࡟ࡶணᚋࡢⰋ࠸⑕౛ࡶᏑᅾࡍࡿࡀ, ⑓ᮇࡢࡼ࠺࡟᫂
☜࡞ணᚋᅉᏊࡣࢃ࠿ࡗ࡚࠸࡞࠸ࠋࡲࡓங⒴⤌⧊୰࡛ࡣṇᖖ⤌⧊࡜ẚ㍑ࡋ࡚⬡㉁⤌ᡂࡀ␗࡞ࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾ, ⬡㉁௦ㅰࡀ⭘⒆ࡢ㐍ᒎ࡟㛵ಀࡋ࡚࠸ࡿ࡜ࡢሗ࿌ࡶ࠶ࡿࡇ࡜࠿ࡽ,෌Ⓨ࡟ࡶᙳ㡪ࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋᮏ◊✲࡛ࡣ㉁㔞㢧ᚤ㙾ࢆ⏝࠸࡚ࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈ
ங⒴࡟࠾ࡅࡿ⬡㉁⤌ᡂࢆゎᯒࡋ, ෌Ⓨ࡟㛵ಀࡍࡿᅉᏊࢆ᥈ồࡍࡿࠋ࠙᪉ἲࠚᡭ⾡᫬࡟᥇ྲྀᚋ෾⤖ಖᏑࡉࢀࡓࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈங⒴ࡢ᳨య 9 ౛ࢆ⏝࠸࡚㉁㔞㢧
ᚤ㙾㸦mass microscope, ᓥὠ〇సᡤ㸧࡛⥙⨶ⓗ࡟ゎᯒࢆ⾜ࡗࡓࠋほᐹᮇ㛫ࡢ୰ኸ್ࡣ 34
࠿᭶࡛, ෌Ⓨ౛ࡣ 3 ౛࡛࠶ࡗࡓࠋ࣐ࢺࣜࢵࢡࢫࡣ 125㹫M ࡢ◲㓟࢔ࣥࣔࢽ࣒࢘ࢆຍ࠼ࡓ 2,5ࢪࣄࢻࣟ࢟ࢩ࢔ࢭࢺࣇ࢙ࣀࣥࢆ౑⏝ࡋࡓࠋ㉁㔞⠊ᅖࡀ m/z700 ࠿ࡽ 900 ࡢ㝧࢖࢜ࣥ࡜ m/z650
࠿ࡽ 950 ࡢ㝜࢖࢜ࣥࢆࡑࢀࡒࢀゎᯒࡋࡓࠋࢹ࣮ࢱࡢゎᯒࡣᑓ⏝ࢯࣇࢺ(Imaging MS
Solution, ᓥὠ〇సᡤ)࡛⾜ࡗࡓࠋࡲࡓィ ⤖ᯝࡼࡾᚓࡽࢀࡓࢩࢢࢼࣝ࡟ᑐᛂࡍࡿ⬡㉁໬ྜ≀ࡢ᳨⣴࡟ࡣ HMDB(http://www.hmdb.ca/spectra/ms/search)ࢆ⏝࠸ࡓࠋ࠙⤖ᯝࠚ㠀෌Ⓨ⩌࡜෌Ⓨ⩌ࢆẚ㍑ࡋࡓ࡜ࡇࢁ, 㝧࢖࣮࢜ࣥࣔࢻࡢゎᯒ࡛ࡣ m/z706.5 ࡢࢩࢢࢼࣝࡀ෌Ⓨ⩌࡛᭷ព࡟ቑຍࡋ࡚࠸ࡓࠋHMDB ࡜ࡢẚ㍑࠿ࡽࡇࡢࢩࢢࢼࣝࡣࣜࣥ⬡㉁ࡢ୍ࡘ࡛
࠶ࡿࣇ࢛ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥ(phosphatidylcholine, PC) (30:0)࡜᥎ᐃࡉࢀࡓࠋ㝜࢖࣮࢜ࣥࣔ
ࢻࡢゎᯒ࡛ࡣ஧⩌㛫࡟᭷ព࡞ᕪࡣㄆࡵࡽࢀ࡞࠿ࡗࡓࠋ
࠙⪃ᐹࠚᚑ᮶ࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈ࡜ࡋ࡚ศ㢮ࡉࢀࡓங⒴ヨᩱࢆ㉁㔞㢧ᚤ㙾ゎᯒࡍࡿࡇ࡜࡟ࡼ
ࡾ, ෌Ⓨ⩌࡜㠀෌Ⓨ⩌࡛ࡣ⣽⬊⭷ࡢ୺せ࡞ᵓᡂᡂศ࡛࠶ࡿ PC ࡢ⤌ᡂࡀ␗࡞ࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋᮏ◊✲࡟ࡼࡗ࡚ PC(30:0)ࡣࢺࣜࣉࣝࢿ࢞ࢸ࢕ࣈங⒴ࡢ෌Ⓨண ᅉᏊ࡜ࡋ࡚ぢ࠸ࡔࡉࢀ,⭘⒆ࡢ㐍ᒎ࡟࠿࠿ࢃࡗ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡓࠋ

́́

P-47
⏕య࢔࣑ࣥ໬ྜ≀ࢆᑐ㇟࡜ࡋࡓ᪂つㄏᑟయ໬ἲ࡟ࡼࡿ࣐࢘ࢫ⬻ࡢ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ῝㔝 ⳹ 1, ⬥ ⣖ᙪ 1, Ṋ஭ྐ㑻 1,2, ℩⸨ග฼ 2, ▮ᑿ⫱Ꮚ 11὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 2 ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝Imaging mass spectrometry of mouse brain tissues using a new derivatization
method targeting biogenic amines
Hana Fukano1, Michihiko Waki 1,, Shiro Takei1, 2, Mitsutoshi Setou2, Ikuko Yao1
1
Medical Photonics Center, Hamamatsu University School of Medicine
2
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine࠙┠ⓗࠚ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ (IMS) ࡣࠊ⤌⧊ษ∦୰ࡢ⏕యศᏊࡢᒁᅾࢆほᐹࡍࡿᡭἲ
࡜ࡋ࡚ὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋࡇࢀࡲ࡛⬡㉁ࡸ⺮ⓑ㉁➼ࡀྍど໬ࡉࢀࠊᐃᑐ㇟࡜࡞ࡿศᏊ

✀ࡣቑ࠼⥆ࡅ࡚࠸ࡿࠋ௒ᅇᡃࠎࡣࠊ࢔࣑ࣀ㓟ࡸࣔࣀ࢔࣑ࣥ⣔⚄⤒ఏ㐩≀㉁ࢆྵࡴ⏕య࢔࣑ࣥ໬ྜ≀ࡢຠ⋡ⓗ࡞᳨ฟࢆ┠ᣦࡋࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࡢࡓࡵࡢ࢔࣑ࣀᇶࡢ໬Ꮫⓗㄏᑟయ໬ἲࡢ☜❧ࢆヨࡳࡓࠋ࠙᪉ἲࠚㄏᑟయ໬ヨ⸆࡜ࡋ࡚ࠊsuccinimidyl 4- [3,5-Dimethyl-4- (4-nitrobenzyloxy) phenyl]-4-oxobutyrate (S0808) ࢆ౑⏝ࡋࡓࠋ࣐࢘ࢫ⬻ษ∦ࢆ ȝm ࡢཌࡉ࡟ࢫࣛ࢖ࢫࡋࠊᑟ㟁ᛶࢫࣛ࢖ࢻ࢞ࣛࢫ࡟᥋╔ࡋࡓࠋసᡂࡋࡓヨᩱୖ࡟ࠊ࢔ࢭࢺࢽࢺࣜࣝࢆ⁐፹࡜ࡋࡓ 5.5mM ࡢ
S0808 ࢆࢫࣉ࣮ࣞࢆ⏝࠸࡚ᆒ୍࡟ᄇ㟝ࡋࡓࠋ ᐃ࡟ࡣᓥὠ〇సᡤࡢ iMScope prototype ࢆ౑⏝ࡋࠊゎᯒ࡟ࡣ Imaging MS SolutionTM ࢆ౑⏝ࡋࡓࠋ࠙⤖ᯝࠚㄏᑟయ໬ฎ⌮ࢆ᪋ࡋࡓ࣐࢘ࢫ⬻ษ∦ࡢᐃ࠿ࡽࠊ࢔ࣛࢽࣥࠊGABAࠊࢭࣜࣥࠊࢩ

ࢫࢸ࢖ࣥࠊࢱ࢘ࣜࣥࠊࢢࣝࢱ࣑ࣥ㓟ࠊࢻ࣮ࣃ࣑ࣥࠊࢭࣟࢺࢽࣥࡢ 8 ࡘࡢ≉␗ⓗ࡞ࣆ࣮ࢡࡀほࡉࢀࡓࠋ୍᪉ࠊㄏᑟయ໬ヨ⸆ࢆࢫࣛ࢖ࢻ࢞ࣛࢫ࡟ᄇ㟝ࡋ࡞࠿ࡗࡓ࣐࢘ࢫ⬻ษ∦࡛ࡣࠊࣆ࣮ࢡࡀほࡉࢀ࡞࠿ࡗࡓࠋࡇࢀࡽࡢࣆ࣮ࢡࡢ㉁㔞㟁Ⲵẚ (m/z) ࡣࠊ࢔࣑ࣀ㓟ࡸࣔࣀ࢔࣑ࣥ⣔⚄⤒ఏ㐩≀㉁ࡢศᏊ㔞࠿ࡽィ⟬ࡋࡓㄏᑟయ໬≀ࡢ m/z ࡜୍⮴ࡋࡓࠋࡉࡽ࡟ࡇ
ࢀࡽࡢࣆ࣮ࢡ୰࡛ࢩࢢࢼࣝᙉᗘࡢᙉ࠿ࡗࡓࢢࣝࢱ࣑ࣥ㓟ࠊࢱ࢘ࣜࣥࠊࢭࣟࢺࢽࣥ࡟㛵ࡋ࡚ࠊㄏᑟయ໬≀ࡢ࣐࢘ࢫ⬻ษ∦࡟࠾ࡅࡿศᕸࢆྍど໬ࡋࠊ␗࡞ࡿศᕸࢆ♧ࡍࡇ࡜ࢆ᫂ࡽ
࠿࡟ࡋࡓࠋ࠙⪃ᐹࠚ௒ᅇࠊ࣐࢘ࢫ⬻ษ∦࡟࠾࠸࡚ㄏᑟయ໬ฎ⌮ࢆ⾜࠸ࠊ⏕య࢔࣑ࣥ໬ྜ≀ࢆ IMS ࡛ྠ᫬࡟᳨ฟࡋࠊྍど໬ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋ⏕య࢔࣑ࣥ໬ྜ≀ࢆ IMS ࡛ほ ࡍࡿᡭἲࡣࠊ⚄⤒⢭⚄⑌ᝈࡢ⑓ែゎᯒ࡟ᛂ⏝࡛ࡁࡿ࡜ᮇᚅࡉࢀࡿࠋ

́́

P-48
⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈᢞ୚࣐࢘ࢫ⫢⤌⧊࡟ᑐࡍࡿྛ✀࢖࣓࣮ࢪࣥࢢᢏ⾡ࡢ㐺⏝ᒣཱྀ ு 1, ᒣᮏ༟ᚿ 1, ୰ᕝ ⸅ 1, Ώ㒊┤ᶞ 2, ➉ෆ ྖ 1, ᑿᓥ඾⾜ 11ᰴᘧ఍♫ ᓥὠ〇సᡤ, 2 ࣞࢽࢩ࣮ࣙᰴᘧ఍♫Multiple Imaging analysis using MSI and Raman technique in inflamed mouse
liver dozed with fluorescent imaging probe
Ryo Yamaguchi1, Takushi Yamamoto1, Kaoru Nakagawa1, Naoki Watabe2, Tsukasa Takeuchi1,
Noriyuki Ojima1
1
Shimadzu Corporation
2
Renishaw࠙┠ⓗࠚᓥὠ〇సᡤ࡛ࡣᚑ᮶⏝࠸ࡽࢀ࡚࠸ࡿ㏆㉥እ⺯ගἼ㛗ࡼࡾࡶ᭦࡟㛗࠸ NIR-ϩ㸦1000nm௨ୖ㸧㡿ᇦࡢἼ㛗ࢆ⏝࠸ࡓ in vivo ㏆㉥እ⺯ග࢖࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࢆ㛤Ⓨࡋ࡚࠸ࡿࠋ⺯ග࢖࣓࣮ࢪࣥࢢ࡟ᚲせ࡞࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆඹྠ◊✲⪅࡜㛤Ⓨࡋ࡚࠸ࡿࡀ㸪㧗⢭⣽࡞⏬ീࡀᚓࡽࢀࡿ཯㠃㸪⌧≧ࡢࣉ࣮ࣟࣈࡣ⫢⮚࡬ࡢ㢧ⴭ࡞㞟✚ࡀぢࡽࢀࡿࡓࡵ㸪ࡇࢀࢆᨵၿ
ࡋ࡚࠸ࡃᚲせࡀ࠶ࡿࠋᮏ᳨ウ࡛ࡣ㸪⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢ⫢⮚࡬ࡢ㞟✚ࡀ࢖࣓࣮ࢪ
ࣥࢢ࡟౪ࡍࡿ࣐࢘ࢫ࡟࡝ࡢࡼ࠺࡞ᙳ㡪ࢆཬࡰࡋ࡚࠸ࡿ࠿ࠊᵝࠎ࡞ゅᗘ࠿ࡽ᳨ウࢆ⾜ࡗࡓࠋ௒ᅇࡣ㸪㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ࡛ࡢゎᯒ࡟ຍ࠼㸪⺯ග࢖࣓࣮ࢪࣥࢢ୪ࡧ࡟࣐ࣛࣥศගἲ࡟
ࡼࡿ࢖࣓࣮ࢪࣥࢢࢹ࣮ࢱࡶ࠶ࢃࡏ࡚ሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚ⺯ග࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࢆ 100ȣ㹪(100mg/ml㸧ࢆᑿ㟼⬦ᢞ୚ࡋࡓ BALB/c-nu ࣐࢘ࢫࢆᢞ୚ 48 ᫬㛫ᚋ࡟㸪῝㯞㓉ୗ࡛ᏳᴦṚࡉࡏ⫢⤌⧊ࢆ᦬ฟࡋࡓࠋ᦬ฟࡋࡓ⫢⤌⧊ࢆ 10umཌ࡟ⷧษࡋ㸪ᑟ㟁ᛶࢫࣛ࢖ࢻࢢࣛࢫ࡟ᦚ㍕ࡋࡓࠋ࣐ࢺࣜࢡࢫ࡜ࡋ࡚ࡣ 9-AA ࢆ౑⏝ࡋࡓࡢࡕ㸪࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆᐇ᪋ࡋࡓࠋࡲࡓ㸪㐃⥆ษ∦ࢆ౑⏝ࡋ࡚࣐ࣛࣥศගἲ࡛ࡢゎᯒࢆᐇ᪋ࡋࡓࠋ࠙⤖ᯝࠚపศᏊ௦ㅰ≀࡜ࡋ࡚ࡢ ATP࣭ADP࣭AMP ࡟ຍ࠼㸪⫹Ồ㓟ࡢศᕸ⏬ീࡀྲྀᚓࡉࢀࡓࠋ
ྛ✀࢖࣓࣮ࢪࣥࢢࣉ࣮ࣟࣈࡢᢞ୚࠶ࡾ/࡞ࡋ࡟࡚㸪㢧ⴭ࡞ศᕸኚ໬ࡣぢ࠸ࡔࡏ࡞࠿ࡗࡓࡶࡢ
ࡢ㸪ྛᐃࢹ࣮ࢱ࡟ᑐࡋ࡚ࡢ┦ᑐᙉᗘẚ㍑࡟ࡼࡾᏑᅾ㔞ࡢቑῶࢆ᳨ฟ࡛ࡁࡓࠋ୍᪉㸪࣐ࣛࣥศගἲ࡟ࡼࡿྍど໬࡛ࡣ⸆๣ࡑࡢࡶࡢࡢྍど໬࡟ࡶᡂຌࡋ࡚࠾ࡾ㸪ู㏵ྲྀᚓࡋࡓᰁⰍ⏬
ീ࡜ẚ㍑ࡍࡿࡇ࡜࡛㸪⫢㞀ᐖ࡜ࡢ㛵㐃ᛶࡀ♧၀ࡉࢀࡓࠋ
࠙⪃ᐹࠚᮏ౛࡛ࡣ㸪ྠ୍ࢧࣥࣉࣝ࡟ᑐࡋ࡚␗࡞ࡗࡓཎ⌮ࡢ࢖࣓࣮ࢪࣥࢢᢏ⾡ࢆ฼⏝ࡍࡿࡇ࡜࡛㸪௦ㅰ≀ࡢศᕸྍど໬࡜㸪⸆๣ࡑࡢࡶࡢࡢྍど໬࡟ᡂຌࡋࡓࠋࡇࡢࡼ࠺࡟⺯ග࢖࣓࣮ࢪ
ࣥࢢ㸪㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ㸪࣐ࣛࣥ࢖࣓࣮ࢪࣥࢢࡢే⏝ࡣ㸪⸆๣ࡢస⏝ᶵᗎゎ࣭᫂ẘᛶ࣓࢝ࢽࢬ࣒ゎ᫂࡟᭷ຠ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡿࠋ

́́

P-49
㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࢹ࣮ࢱࢆ⏝࠸ࡓ⤌⧊ษ∦ࡢ࢚ࣥࢺࣟࣆ࣮࢖࣓࣮ࢪࣥࢢゎᯒబ⸨㥴ᖹ, బ⸨ᬛோ, ṇᮌ⣖㝯, ℩⸨ග฼὾ᯇ་⛉኱Ꮫ ゎ๗Ꮫㅮᗙ ⣽⬊⏕≀Ꮫศ㔝

Entropy Imaging of Tissue Sections from Mass Spectrometry Imaging Data.
Shumpei Sato, Tomohito Sato, Noritaka Masaki, Mitsutoshi Setou
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicin࠙┠ⓗࠚ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲࡣ⤌⧊ษ∦࡟ᑐࡋ࡚࣮ࣞࢨ࣮ࢆ㉮ᰝࡍࡿࡇ࡜࡛✵㛫᝟ሗࢆ
ྵࡵࡓ㉁㔞ศᯒࢆ⾜࠺᪉ἲ࡛࠶ࡿࠋ୍⯡ⓗ࡞ゎᯒ࡛ࡣࠊ┠ⓗࡢศᏊࡢ m/z ࡔࡅ࡟ὀ┠ࡋࠊࡑࡢศᕸࢆゎᯒࡍࡿࠋ୍᪉ࠊ⏕≀ࡣከᵝ࡞ศᏊࢆෆໟࡋࠊ⪁໬ࡸ⑌ᝈ࡞࡝࡟ࡼࡿศᏊ࡬ࡢᙳ
㡪ࡣ㠀ᖖ࡟ከᒱ࡟Ώࡿࠋࡇࡢࡼ࠺࡞⭾኱࡞ศᏊࡢኚືࢆಠ▔ࡋ࡚ᤊ࠼ࡿࡓࡵ࡟ࠊᡃࠎࡣ㉁㔞ศᯒࢹ࣮ࢱࢆ⏝࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ⟬ฟࡋࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࡢྛⅬẖࡢࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ⤌⧊ୖ࡟ᥥฟࡍࡿࡇ࡜ࢆヨࡳࡓࠋࡇࢀ࡟ࡼࡾ⭾኱࡞ศᏊ࠿ࡽ࡞ࡿ
ྛⅬࡢ㉁㔞ศᯒࢫ࣌ࢡࢺࣝࡢ≉ᚩࢆ⤌⧊ୖ࡛ẚ㍑ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ࠙᪉ἲࠚ⏕≀ヨᩱ࡟࠾࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ࢖࣓࣮ࢪࣥࢢࡍࡿヨࡳࡣᮏ◊✲ࡀึࡵ࡚࡛࠶ࡿࡓࡵࠊࡲࡎࡣ࣐࢘ࢫ⫢⮚ࢆ⏝࠸࡚㐺ษ࡞᮲௳ࢆ᳨ウࡋࡓࠋ࣐࢘ࢫ⮚ჾࡣ㢁᳝⬺⮻ᚋࠊ⣲᪩ࡃྲྀࡾฟࡉࢀ࡚ࢻࣛ࢖࢔࢖ࢫ࡟ࡼࡾ෾⤖ࡉࢀࡓࠋ⫢⮚ࡣࢡࣛ࢖࢜ࢫࢱࢵࢺ࡛ 10 ȝm ཌ࡟ⷧษࡉࢀࠊITO ࢥ࣮ࢺࢫࣛ࢖ࢻ࡟㈞ࡾ௜ࡅࡽࢀࡓࠋࡇࡢࢫࣛ࢖ࢻࡣ࣐ࢺࣜࢡࢫ(9AA)ࢆ⵨
╔ࡉࢀࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ⿦⨨(ultraflexII, Bruker Daltonics)࡟ࡼࡾ ᐃࡉࢀࡓࠋ ᐃࡉࢀࡓࢹ࣮ࢱࡣ SIMentorpy (ᓥὠ〇సᡤ)ࢯࣇࢺ࢙࢘࢔࡟ࡼࡗ࡚ኚ᥮ࡉࢀࠊࢩࣕࣀ࢚ࣥࣥࢺࣟ
ࣆ࣮ീ࡜ࡋ࡚⤌⧊ୖ࡟ᥥฟࡉࢀࡓࠋ᮲௳᳨ウ࡛ࡣᐃࣃ࣓࣮ࣛࢱ࣮ࢆኚ᭦ࡋࠊࢩࣕࣀ࢚ࣥ

ࣥࢺࣟࣆ࣮ീ࡟࠾ࡅࡿ್ࡢᖹᆒࡸศᩓ࡞࡝ࢆᇶ࡟㐺ษ࡞᮲௳ࢆỴᐃࡋࡓࠋᐃ᮲௳ࡢỴᐃ

ᚋࠊ࣐࢘ࢫࡢ⫢⮚ࠊ⬻ࠊ⭈⮚ࡢࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ീࢆ㐌㱋ẖ࡟ẚ㍑ࡋࠊ⏕≀ヨᩱ࡟࠾࠸࡚ࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡀຍ㱋࡟ࡼࡾ࡝࠺ኚ໬ࡍࡿࡢ࠿ࢆㄪ࡭ࡓࠋ
࠙⤖ᯝࠚ ᐃ᮲௳᳨ウ࡜ࡋ࡚ࠊ ᐃ m/z ⠊ᅖ,࣮ᙉᗘ,ᐃ࢖࣮࢜ࣥࣔࢻ, ࣮ࣞࢨ࣮↷ᑕᅇᩘ, ࣮ࣞࢨᐃⅬ㛫㝸, ࣛࣥࢲ࣒࢛࣮࢘ࢡࡢ᭷↓࡟ࡘ࠸᳨࡚ウࡋࡓࠋྛ᮲௳ࢆኚ໬ࡉࡏࡓ࡜ࡁ

ࡢࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢᖹᆒཬࡧศᩓ࡟ᑐࡋ࡚

ᐃ㛫ࡢࡤࡽࡘࡁࡀᑡ࡞࠸᮲௳ࢆỴᐃࡋࡓࠋỴᐃࡉࢀࡓ᮲௳ࢆ⏝࠸࡚࣐࢘ࢫࡢ⬻, ⫢⮚, ⭈⮚ࢆ 1, 2, 4, 8, 16 㐌㱋࡛ẚ㍑ࡋࡓ⤖ᯝࠊࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢᙉᗘ࡜ศᕸࡢኚ໬ࡀ㐌㱋࡜㛵ಀࡋ࡚࠸ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ
ࡲࡓࠊ࣐࢘ࢫ⬻ࡢᵓ㐀ࡀࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࡢኚ໬࡛ᤊ࠼ࡽࢀࡿࡇ࡜ࡀศ࠿ࡗࡓࠋ
࠙⪃ᐹࠚ௒ᅇࡢ᮲௳᳨ウ࡟ࡼࡾࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢࡢࢹ࣮ࢱ࠿ࡽࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮ࢆ
⤌⧊ୖ࡛࢖࣓࣮ࢪࣥࢢ࡛ࡁࡿࡼ࠺࡟࡞ࡗࡓࠋᮏᡭἲࡣࢩࣕࣀ࢚ࣥࣥࢺࣟࣆ࣮࡟ࡼࡾ⬻ࡢ⤌⧊ᵓ㐀ࢆ཯ᫎࡍࡿ࡛ࣞ࣋ࣝ㉁㔞ศᯒࢫ࣌ࢡࢺࣝࡢ≉ᚩࢆẚ㍑ࡍࡿࡇ࡜ࡀ࡛ࡁࡿࠋࡲࡓࠊ⤌⧊ࡢ㐌㱋࡟కࡗࡓኚ໬ࡶᤊ࠼ࡿࡇ࡜ࡀ࡛ࡁࡓࡓࡵࠊ௒ᚋࠊ௚ࡢゎᯒ࡬࡜ᛂ⏝ࡋ࡚⾜ࡁࡓ࠸ࠋ

́́

P-50
࢔ࣥࢺࢩ࢔ࢽࣥࡢయෆືែゎᯒ㈈‶ಙᏹ 1, ✄ⴥᰭ㔛 1, ⸨᳃㝯㐨 1, Ⲯཝဴဢ 2, ᑠᯘἋ⧊ 2, ᳃ᒣ㐩ဢ 1
1㏆␥኱Ꮫ㎰Ꮫ㒊2ᰴᘧ఍♫࣡࢝ࢧ⏕ά

Pharmacokinetic analysis of anthocyanins in mouse
Nobuhiro Zaima1, Shiori Inaba1, Takamichi Fujimori1, Tetsuya Sogon2, Saori Kobayashi2, Tatsuya
Moriyama 1
1
Kinki University
2
Wakasa Seikatsu Corporation࠙┠ⓗࠚ࢔ࣥࢺࢩ࢔ࢽࣥࡣ᳜≀࡟࠾࠸࡚ᗈࡃᏑᅾࡍࡿⰍ⣲࡛࠶ࡿࠋᢠ㓟໬ᛶࢆ᭷ࡍࡿࡇ࡜࠿
ࡽࠊᶵ⬟ᛶ㣗ရ⣲ᮦ࡞࡝࡜ࡋ࡚ࡶ╔┠ࡉࢀࠊࡑࡢ⏕⌮άᛶ࡟㛵ࡍࡿ◊✲ࡀከࡃ⾜ࢃࢀ࡚࠸ࡿࠋ࢔ࣥࢺࢩ࢔ࢽࣥࡢ⏕⌮άᛶࢆ⌮ゎࡍࡿୖ࡛ࠊ࢔ࣥࢺࢩ࢔ࢽࣥࡢయෆືែࢆゎᯒࡍࡿࡇ࡜ࡀ㔜せ࡛࠶ࡿࡀࠊࡇࢀ࡟㛵ࡋ࡚ࡣ୙᫂࡞Ⅼࡀከ࠸ࠋᮏ◊✲࡛ࡣࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ
ἲ㸦matrix-assisted laser desorption/ionization (MALDI)–Imaging mass spectrometry (IMS)ࢆ⏝࠸࡚ࠊ࢔ࣥࢺࢩ࢔ࢽࣥࢆྍど໬ࡍࡿࡇ࡜࡟ࡼࡗ࡚ࠊయෆືែࢆ᫂ࡽ࠿࡟ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ࠙᪉ἲࠚື≀ᐇ㦂ࡣ㏆␥኱Ꮫື≀ᐇ㦂つ⛬࡟ᚑࡗ࡚⾜ࡗࡓࠋddy ࣐࢘ࢫ㸦࢜ࢫࠊ6 㐌㱋㸧ࡣ22±2Υࠊ12 ᫬㛫ࡢ᫂ᬯࢧ࢖ࢡࣝࡢ⎔ቃୗ࡛㣫⫱ࡋࡓࠋ㥆໬ᚋࠊࣅ࣮ࣝ࣋ࣜࡼࡾᢳฟࡋࡓ࢔
ࣥࢺࢩ࢔ࢽࣥΰྜ≀ࢆ⤒ཱྀཬࡧ⭡⭍ෆᢞ୚ࡋࡓࠋ₤ὶᚋ࡟║ࢆ᥇ྲྀࡋࠊᾮయ❅⣲࡛෾⤖ࡋࡓᚋࠊࢡࣛ࢖࢜ࢫࢱࢵࢺ㸦Leica Microsystems㸧࡛ ȝP ࡢษ∦࡜ࡋࡓࠋసᡂࡋࡓษ∦࡟࣐ࢺࣜࢵࢡࢫ࡜ࡋ࡚ DHB㸦2,5-Dihydroxybenzonic acid㸧⁐ᾮࢆሬᕸࡋࠊ㉁㔞ศᯒ⿦⨨㸦MALDI
LTQ-XL (ThermoFisher Scientific)㸧 ࡟౪ࡋࡓࠋࣉ࢚ࣛࣜࣥࡢື ែࡢྍど໬࡟ࡣࠊ Image
Quest(ThermoFisher Scientific)ࢆ⏝࠸ࡓࠋ࠙⤖ᯝࠚࣅ࣮ࣝ࣋ࣜ࡟Ꮡᅾࡍࡿ୺࡞࢔ࣥࢺࢩ࢔ࢽࣥศᏊ✀ࡢ୍ࡘ࡛࠶ࡿ Cyanidin 3-glucoside㸦m/z 449 ĺP] 287㸧ࢆ ᐃࡋࡓ⤖ᯝࠊ⤒ཱྀᢞ୚⩌࡛ࡣ᫂░࡞ࣆ࣮ࢡࡣ᳨ฟࡉࢀ࡞࠿ࡗࡓࠋ
⭡⭍ෆᢞ୚⩌࡟࠾࠸࡚ࡣࠊ⥙⭷እᒙࡢ➽ᒙ࿘㎶࡟ࣆ࣮ࢡࡀほᐹࡉࢀࡓࠋᮏ◊✲ࡢ⤖ᯝ࠿ࡽࠊ⭡⭍ෆᢞ୚ࡉࢀࡓ࢔ࣥࢺࢩ࢔ࢽࣥࡣ║⤌⧊ࡲ࡛⛣⾜ࡍࡿࡇ࡜ࡀ♧ࡉࢀࡓࠋ⤒ཱྀᢞ୚ࡉࢀࡓ
࢔ࣥࢺࢩ࢔ࢽࣥࡣࠊᮏ◊✲᮲௳࡛ࡣほᐹࡉࢀ࡞࠿ࡗࡓࡓࡵࠊ௒ᚋࡉࡽ࡟᳨ウࢆ㐍ࡵࡿணᐃ
࡛࠶ࡿࠋ

́́

P-51
◲㓟࢔ࣥࣔࢽ࣒࢘ࡣ࣐ࢺࣜࢵࢡࢫῧຍ๣࡜ࡋ࡚ MALDI-IMS ࡟࠾ࡅࡿ⬻ෆ࢝ࣝࢽࢳࣥࠊ࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥࠊࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ⏤᮶ࡢࢩࢢࢼࣝࢆ 10 ಸ௨ୖቑᙉࡍࡿᮡᒣᰤ஧, ṇᮌ⣖㝯, ᯇୗ⚈Ꮚ, ℩⸨ග฼὾ᯇ་⛉኱Ꮫ་Ꮫ⣔◊✲⛉ゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝

Ammonium sulfate improves signal intensities of carnitine, acetylcarnitine, andglycerophocholine more than ten times higher in matrix-assisted laser
desorption/ionization imaging mass spectrometry as a matrix additive
Eiji Sugiyama, Noritaka Masaki, Shoko Matsushita, Mitsutoshi Setou
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine࠙┠ⓗࠚ࣐ࢺࣜࢵࢡࢫᨭ᥼࣮ࣞࢨ࣮⬺㞳࢖࢜ࣥ໬࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒἲࡣ」ᩘࡢศᏊࡢศ
ᕸࢆ୍ᩧ࡟ゎᯒ࡛ࡁࡿᡭἲ࡛࠶ࡾࠊࡉࡽ࡟ከࡃࡢศᏊࢆ᳨ฟࡍࡿࡓࡵ࡟ᡭἲࡢ㛤ⓎࠊᨵⰋࡀ┒ࢇ࡟⾜ࢃࢀ࡚࠸ࡿࠋ◲㓟࢔ࣥࣔࢽ࣒࢘(AmS)ࡣ࣐ࢺࣜࢵࢡࢫῧຍ๣ࡢ୍ࡘ࡛࠶ࡾࠊ࢔ࣝ
࢝ࣜ㔠ᒓ࢖࢜ࣥࡢᖸ΅ࢆጉࡆࡿ࡯࠿㧗࠸ሷᯒຠᯝ➼ࢆࡶࡓࡽࡍࡇ࡜࡛࣌ࣉࢳࢻࡸ⢾⬡㉁ࡢ
࢖࢜ࣥ໬ࢆ㢧ⴭ࡟ಁ㐍ࡍࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊAmS ࡢ࢖࢜ࣥ໬ಁ㐍ຠᯝ࡟ࡘ࠸࡚ࡢᇶ♏ⓗ࡞᳨ウࡣ༑ศ⾜ࢃࢀ࡚࠾ࡽࡎࠊࡑࡢ฼⏝ᑐ㇟ࡣ㝈ࡽࢀ࡚࠸ࡿࠋࡑࡇ࡛ᮏ◊✲
࡛ࡣࠊAmS ࡟ࡼࡾ࢖࢜ࣥ໬ࡀᨵၿࡍࡿపศᏊࢆ᥈⣴ࡋࠊ࢖࣓࣮ࢪࣥࢢ࡬ࡢᛂ⏝ࢆヨࡳࡓࠋ࠙᪉ἲࠚ8 㐌㱋ࡢ C57BL/6J ࣐࢘ࢫ⬻ࢆ᥇ྲྀࡋゎᯒࡋࡓࠋࡲࡎࠊ࣍ࣔࢪࢿ࣮ࢺ(100 mg tissue/mL)
ࢆ AmS(0, 16, 31, 63, 125, and 250 mM)ࢆྵࡴ࣐ࢺࣜࢵࢡࢫ⁐ᾮ(DHB 50 mg/mL in 50%
methanol)࡜➼㔞ΰྜࡋࡓᚋࠊᑟ㟁ᛶࢫࣛ࢖ࢻ࢞ࣛࢫୖ࡟⁲ୗࡋᐃࡋࡓࠋ╔┠ࡋࡓࣆ࣮ࢡ

ࡣከẁ㝵㉁㔞ศᯒ(MS/MS)࡟ࡼࡾྠᐃࡋࡓࠋ⥆࠸࡚ࠊí20°C ࡢᗜෆ࡛ཌࡉ 10 μm ࡜ࡋࡓ▮≧ษ∦ࢆᑟ㟁ᛶࢫࣛ࢖ࢻ࢞ࣛࢫ࡟㈞௜ࡋࡓᚋࠊ࣐ࢺࣜࢵࢡࢫ⁐ᾮ(DHB 50 mg/mL in 50%
methanol with/without 250 mM AmS)ࢆᡭືࢫࣉ࣮ࣞἲ࡟࡚ሬᕸࡋ ᐃࡋࡓࠋ࠙⤖ᯝࠚAmS 250 mM ࡢῧຍ࡟ࡼࡾࠊ⬻࣍ࣔࢪࢿ࣮ࢺ୰ࡢ࢝ࣝࢽࢳࣥ(Car)ࠊ࢔ࢭࢳࣝ࢝ࣝࢽࢳࣥ(AcCar)࠾ࡼࡧࢢࣜࢭࣟ࣍ࢫ࣍ࢥࣜࣥ(GPC)⏤᮶ࡢᖹᆒࢩࢢࢼࣝᙉᗘࡀࡑࢀࡒࢀ⣙ 300,
700, 2500 ಸቑᙉࡋࡓࠋ
ࡇࡢ࢖࢜ࣥ໬ಁ㐍ຠᯝࡣ 63 mM ௨ୖࡢ⃰ᗘ࡛㢧ⴭ࡟⌧ࢀࡓࠋ
ࡉࡽ࡟ࠊ
AmS 250 mM ࡢῧຍ࡟ࡼࡾ⤌⧊ษ∦୰ࡢ Car, AcCar, GPC ⏤᮶ࡢᖹᆒࢩࢢࢼࣝᙉᗘࡣࡑࢀࡒ
ࢀ⣙ 10, 20, 40 ಸቑᙉࡋࠊ࠸ࡎࢀࡢ⤌⧊ෆศᕸࡶ᫂░࡟ྍど໬ࡉࢀࡓࠋ
࠙⪃ᐹࠚCar, AcCar, GPC ࡣ࠸ࡎࢀࡶศᏊෆ࡟Ᏻᐃࡋࡓṇ㟁Ⲵࢆᣢࡘ➨ᅄ⣭࢔ࣥࣔࢽ࣒࢘໬ྜ
≀࡛࠶ࡾ࢖࢜ࣥ໬ࡉࢀࡸࡍ࠸ࡓࡵࠊAmS ῧຍࡢᜠᜨࢆ኱ࡁࡃཷࡅࡓ࡜⪃࠼ࡽࢀࡿࠋAmS ࡣ௚ࡢ࣐ࢺࣜࢵࢡࢫࡸ㧗ឤᗘ໬ᡭἲ࡜ᐜ᫆࡟⤌ࡳྜࢃࡏࡿࡇ࡜ࡀྍ⬟࡛࠶ࡾࠊAmS ࢆᵝࠎ࡞ศᯒ᮲௳࡟ᛂ⏝ࡍࡿࡇ࡜࡛ࡼࡾከࡃࡢศᏊࡢゎᯒࡀྍ⬟࡟࡞ࡿࡇ࡜ࡀᮇᚅࡉࢀࡿࠋ

́́

P-52
⾪✺᩿㠃✚࡟ᇶ࡙ࡃ MALDI ࢖࣓࣮ࢪࣥࢢཬࡧ MS/MS ࣇࣛࢢ࣓ࣥࢺࢹ࣮ࢱࡢ㛵㐃௜ࡅ࡟ࡼࡿ⬡㉁ࡢྠᐃ࡜ᒁᅾ໬ゎᯒᑎᓮ┿ᶞ 1, Mark Towers 2, Emmanuelle Claude 2 Johannes PC Vissers 21᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫, 2 ࢛࣮࢘ࢱ࣮ࢬ࣭ࢥ࣮࣏࣮ࣞࢩࣙࣥ

LIPID VISUALISATION AND IDENTIFICATION THROUGH COLLISIONCROSS SECTION AIDED CORRELATION OF MALDI IMAGING AND MS/MSFRAGMENTATION DATA SETS
Maki Terasaki1, Mark Towers2, Emmanuelle Claude2, Johannes PC Vissers2
1
Nihon Waters K.K., 2Waters Corporation[INTRODUCTION] Mass spectrometry imaging (MSI) is rapidly becoming an establishedtechnique within lipidomics research. Using MSI, a broad range and number of species can bevisualised within a tissue section. However, subsequent identification can be challenging due to thelarge number of isobaric or near isobaric species. Lipids can be identified by subsequently extracting
them from the same, or a consecutive, tissue section and performing MS/MS. However, whencorrelating the datasets, identifications can become obfuscated due to lack of certainty that the lipids
extracted and identified, relate to the m/z peaks seen in the imaging data, especially when relying on
accurate mass alone as the identification is not being performed in-situ. Here, we demonstrate theuse of ion mobility to differentiate ions and calculate collision cross sections (CCS). This is utilised
along with accurate mass to add confidence to the correlation between the MALDI imaging andextracted lipids datasets and the subsequent identifications by MS/MS.
[Methods] A thin section of a rat brain section was produced using a cryotome. 9-Aminoacridine(9-AA) matrix was applied evenly to the sample in several coats using a Suncollect™ sprayer. Lipids
were extracted from consecutive tissue sections. Droplets were placed on to the tissue section using apipette then drawn off and pooled prior to spotting on a target plate. The same 9-AA matrix solution
was mixed on target with the extract samples. Data were acquired using a SYNAPT HDMS G2-Si
mass spectrometer in HDMS mode.
[Results] After peak picking the imaging data set with an ion intensity cut off of 50, 7,598 peaks
were detected in the range of m/z 400-1150. Matching the peaks using accurate mass against a subsetof the lipid maps structural database, resulted in 195 matching peaks (+/-3ppm). Plotting thematching peaks as m/z vs CCS area, a general lipid trend line can be observed as well as several CCS
outliers. By estimating the CCS area trend line, a broad based filter can be applied to remove theoutliers. After CCS filtering, 165 lipid candidates remained.

́́

P-53
๓㢌ഃ㢌ⴥኚᛶ⑕ᝈ⪅⬻ෆ࡟࠾ࡅࡿࢱ࢘ࣜࣥࡢ⃰ᗘ࠾ࡼࡧศᕸゎᯒᯇୗ⚈Ꮚ 1, ṇᮌ⣖㝯 1, ㏆⸨ ㇦ 1, Ṋ஭ྐ㑻 1, ㉥ὠ⿱ᗣ 2,3, ⛅⏣ኳᖹ 4, ᮡᒣᰤ஧ 1,⚟⏣ᩔኵ 4, ▮ᑿ⫱Ꮚ 5, ℩⸨ග฼ 11὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ⣽⬊⏕≀Ꮫศ㔝, 2 ⚟♴ᮧ⑓㝔㛗ᑑ་Ꮫ◊✲ᡤ, 3 ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔་Ꮫ◊✲⛉ᆅᇦ་⒪ᩍ⫱Ꮫ, 4 ὾ᯇ་⛉኱Ꮫ⚄⤒⏕⌮Ꮫㅮᗙ, 5 ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝
ࣝࣇ࢛ࢺࢽࢡࢫࢭࣥࢱ࣮ග࢖࣓࣮ࢪࣥࢢ◊✲ᐊ

Taurine concentration and distribution in brain of frontaltemporal lobar
degeneration patients
Shoko Matsushita1, Noritaka Masaki1, Takeshi Kondo1, Shiro Takei1, Hiroyasu Akatsu2,3, Tenpei
Akita4, Eiji Sugiyama1, Atsuo Fukuda4, Ikuko Yao5, Mitsutoshi Setou1
1
Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, 2Choju
Medical Institute, Fukushimura Hospital, 3Department of Medicine for Aging in Place andCommunity-Based Medical Education, Nagoya City University Graduate School of Medical
Sciences, 4Department of Neurophysiology, Hamamatsu University School of Medicine,5
Department of Optical Imaging, Medical Photonics Research Center, Hamamatsu University Schoolof Medicine࠙┠ⓗࠚ๓㢌ഃ㢌ⴥኚᛶ⑕(FTLD)ࡣ๓㢌ⴥ࣭ഃ㢌ⴥࡀ㢧ⴭ࡟ⴎ⦰ࡍࡿ⚄⤒ኚᛶ⑌ᝈ࡛࠶ࡾࠊ
㓟໬ࢫࢺࣞࢫ➼࡟ࡼࡾ␗ᖖࣜࣥ㓟໬ࡉࢀࡓࢱ࢘ࡸ TDP-43 ࡞࡝ࡢࢱࣥࣃࢡ㉁ࡢ⵳✚ࡀぢࡽࢀࡿࠋᢠ㓟໬స⏝ࢆᣢࡘࢱ࢘ࣜࣥࡣ㓟໬ࢫࢺࣞࢫࢆῶࡽࡍࡇ࡜࡛⚄⤒ಖㆤస⏝ࢆ♧ࡍࡇ࡜ࡀ▱ࡽࢀ࡚࠸ࡿࡀࠊFTLD ࡜ࡢ㛵ಀᛶࡣ୙࡛᫂࠶ࡿࠋࡑࡇ࡛ࠊLC-ESI-MS ࡟ࡼࡿᐃ㔞ゎᯒࠊ
MALDI-IMS ࡟ࡼࡿศᕸゎᯒࢆ⾜࠸ࠊFTLD ࡟࠾ࡅࡿࢱ࢘ࣜࣥࡢኚ໬࡟ὀ┠ࡋࠊゎᯒࡋࡓࠋ
࠙᪉ἲࠚFTLD ࠾ࡼࡧᑐ↷⩌ࡢࣄࢺṚᚋ⬻ 9 ⑕౛ࢆ⏝࠸ࠊྛ⑕౛ࡢ๓㢌ⴥ࣭ᚋ㢌ⴥࢆゎᯒࡋ
ࡓࠋLC-ESI-MS ࡛ࡣ෾⤖◚○ᚋࠊ࣓ࢱࣀ࣮ࣝᢳฟࡋࡓヨᩱࢆ

ᐃࡋࡓࠋMALDI-IMS ࡛ࡣ

10 Pm ࡢཌࡉ࡟⬻⤌⧊ࢆⷧษࡋࠊ9-࢔࣑ࣀ࢔ࢡࣜࢪࣥࢆࢫࣉ࣮ࣞἲ࡟࡚ሬᕸᚋࠊ

ᐃࡋࡓࠋ࠙⤖ᯝࠚ⬻ෆࡢࢱ࢘ࣜࣥ⃰ᗘࡣࠊFTLD ⩌ࡢ๓㢌ⴥ࡛ 1.7±1.1 Pmol/g±SDࠊᚋ㢌ⴥ࡛ 1.4±0.6
Pmol/g±SD ࡛࠶ࡾࠊᑐ↷⩌ࡢ๓㢌ⴥ࡛ 1.5±0.5 Pmol/g±SDࠊᚋ㢌ⴥ࡛ 1.5±0.6 Pmol/g±SD ࡛࠶ࡗࡓࠋࢱ࢘ࣜࣥࡣⓑ㉁࡟ẚ㍑ⓗከࡃศᕸࡋ࡚࠸ࡿ࡜࠸࠺▱ぢࡀᚓࡽࢀࡓࠋFTLD ⩌ࡢ๓㢌ⴥ࡟࠾࠸࡚ࠊࢱ࢘ࣜࣥ⃰ᗘࡀ 3.1Pmol/g ࠾ࡼࡧ 4.0Pmol/g ࡜௚ࡼࡾ᭷ព࡟㧗್ࢆ♧ࡋࡓ⑕౛ࢆ
ㄆࡵࠊ࠸ࡎࢀࡶࣜࣥ㓟໬ TDP-43 ࡀ㝧ᛶ࡛࠶ࡗࡓࠋ
࠙⪃ᐹࠚⓑ㉁࡟ࡣ⾑ᾮ⬻㛵㛛ࢆᙧᡂࡍࡿ⥺⥔ᛶ࢔ࢫࢺࣟࢧ࢖ࢺࡀከࡃᏑᅾࡍࡿࡇ࡜ࡀ▱ࡽࢀ࡚࠾ࡾࠊࢱ࢘ࣜࣥࡢὶධ࡟㛵ࢃࡿࢺࣛࣥࢫ࣏࣮ࢱ࣮ࡢ㛵୚ࡀண᝿ࡉࢀࡓࠋࢱ࢘ࣜࣥࡢ⃰ᗘୖ᪼ࡀࡳࡽࢀࡓࡢࡣ㢧ⴭ࡞⬻ࡢⴎ⦰ࡀࡳࡽࢀࡿ๓㢌ⴥ࡛࠶ࡾࠊࣜࣥ㓟໬ TDP-43 ࡜ࡢ㛵㐃ᛶࡀ♧၀ࡉࢀࡓࠋ

́́

P-54
㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓ࢜ࣜࢦࢹࣥࢻࣟࢧ࢖ࢺศ໬㐣⛬ࡢྍど໬ᖹཎᖾᜨ㸯, ⱝᯘẎಇ㸯, ᳃ ᚭ⮬㸯,㸰, ▮ᑿ⫱Ꮚ 3, ὠ⏣㞞அ 4, ᮏᐙᏕ୍㸳, ᑠụኴ㑻㸯,ᚋ⸨ோᚿ 6, ᑠ㔝຾ᙪ 6, ᒣ⏣ஂኵ㸯
1
㛵す་኱࣭་࣭ゎ๗Ꮫ➨୍, 2 㫽ྲྀ኱Ꮫ࣭་࣭ಖ೺Ꮫ⛉, 3 ὾ᯇ་኱࣭࣓ࢹ࢕࢝ࣝࣇ࢛ࢺ
ࢽࢡࢫ◊✲ࢭࣥࢱ࣮, 4 㧘▱኱Ꮫ࣭⥲◊, 5 㧘▱኱Ꮫ࣭་࣭⏕໬Ꮫ, 6 ி㒔ᗓ་኱࣭⏕≀Ꮫ

Visualization of oligodendrocyte differentiation processes by using imaging mass
spectrometry
Yukie HIRAHARA1, Taketoshi WAKABAYAHSHI1, Tetuji MORI 1, 2, Ikuko Yao3, Masayuki
TSUDA4, Koichi HONKE5, Taro KOIKE1, Hitoshi Gotoh6, Katsuhiko ONO6, Hisao YAMADA1
1
Department of Anatomy and Cell Science, Kansai Medical University, 2 Faculty of Medicine,
Tottori Universitye, 3Medical Photonics Research Center, Hamamatsu University School of
Medicine, 4 Science Research Center, 5 Department of Biochemistry, Kochi University Medical
School, 6 Department of Biology, Kyoto Prefectural University of Medicine࣑࢚ࣜࣥᙧᡂ⣽⬊࢜ࣜࢦࢹࣥࢻࣟࢧ࢖ࢺ㸦OL㸧ࡣࠊ⬡㉁࡟ᐩࡴ⣽⬊࡛࠶ࡾࠊศ໬࣐࣮࢝
࣮࡟⢾⬡㉁ࡀ౑ࢃࢀ࡚࠸ࡿࠋO4 ࣔࣀࢡ࣮ࣟࢼࣝᢠయࡣࠊ⫾⏕ᮇ OL ๓㥑య⣽⬊࠿ࡽ⏕ᚋࡢ㧊㠧ᙧᡂ࡟⮳ࡿࡲ࡛ࡢ OL ศ໬࣭ᡂ⇍㐣⛬ࢆㄆ㆑ࡍࡿศ໬࣐࣮࣮࢝࡜ࡋ࡚ࠊୡ⏺୰࡛౑ࢃࢀ࡚
࠸ࡿࠋO4 ᢠయࡢㄆ㆑㒊఩࡟㛵ࡋ࡚ࡣࠊ◲㓟໬⢾⬡㉁ࠊࢫࣝࣇ࢓ࢳࢻ࡛࠶ࡿ࡜Ỵᐃࡉࢀ࡚࠸
ࡿࡀࠊ⫾⏕ᮇࡢ⬨㧊⭡ഃ㒊࠿ࡽⓎ⏕ࡍࡿ OL ⣔㆕Ỵᐃ⮫⏺Ⅼࢆ♧ࡍ O4 㝧ᛶ๓㥑⣽⬊࡛ࡣࠊࢫࣝࣇ࢓ࢳࢻྜᡂࡀ☜ㄆࡉࢀ࡚࠸࡞࠿ࡗࡓࠋᚑࡗ࡚ࠊ⫾⏕ᮇ O4 ㄆ㆑ᢠཎࡣࠊࢫࣝࣇ࢓ࢳࢻ
௨እࡢࡶࡢ࡛࠶ࡿྍ⬟ᛶࡀ⪃࠼ࡽࢀ࡚ࡁࡓࠋࡑࡇ࡛ࠊ⤌⧊ᶆᮏ୰ࡢ⬡㉁ศᕸᐦᗘࢆ㧗࠸ゎീᗘ᳨࡛ฟ࡛ࡁࡿ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲࢆ౑࠸ࠊࡇࡢ⫾⏕ᮇ࡟ฟ⌧ࡍࡿ O4 ㄆ㆑࢚ࣆࢺ࣮
ࣉࡢᐇែࢆ᳨ドࡋࡓࠋ࢘ࢩ⬻⏤᮶ࡢᵝࠎ࡞⬡⫫㓟ࢆࡶࡗࡓ 12 ✀㢮ࡢࢫࣝࣇ࢓ࢳࢻࡢࢫ࣌ࢡ
ࢺࣝࢆྠᐃࡋࡓᚋࠊO4 㝧ᛶ OL ๓㥑⣽⬊Ⓨ⌧㡿ᇦ࡜ࡋ࡚ሗ࿌ࡉࢀ࡚࠸ࡿࢽ࣡ࢺࣜ⬇ 8 ᪥┠⬨㧊⤌⧊࡟ᑐࡋ࡚ࠊ࣐ࢺࣜࢵࢡࢫᨭ᥼࣮ࣞࢨ࣮⬺㞳࢖࢜ࣥ໬ἲ࡟ࡼࡿ㉁㔞ศᯒࢆ࠾ࡇ࡞ࡗࡓࠋ
ᐃࢹ࣮ࢱ࠿ࡽྵ᭷ศᏊࡢ࢖࢜ࣥศᕸࢆ⏬ീ໬ࡋࠊࢫࣝࣇ࢓ࢳࢻศᕸࡢẚ㍑ࢆ⾜ࡗࡓ⤖ᯝࠊ⬨㧊⤌⧊඲య࡟ᗈࡀࡗ࡚ศᕸࡍࡿ࣍ࢫࣇ࢓ࢳࢪࣝ࢖ࣀࢩࢺ࣮ࣝ࡟ᑐࡋ࡚ࠊ⬨㧊⭡ഃ㒊≉␗ⓗ࡟⬡⫫㓟ࡢ▷࠸ C16 ࢫࣝࣇ࢓ࢳࢻ࡜ C18 ࢫࣝࣇ࢓ࢳࢻࡢࢩࢢࢼࣝࢆㄆࡵࡓࠋࡇࢀࡽࡣࠊ
࣑࢚ࣜࣥ㠧࡟㇏ᐩ࡟Ꮡᅾࡍࡿ C24 ࢫࣝࣇ࢓ࢳࢻ࡜ࡣ␗࡞ࡿࡶࡢ࡛࠶ࡗࡓࠋ୍᪉࡛ࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲ࡟࠾࠸࡚ࠊᡂ⋇࣑࢚ࣜࣥ㠧࡛ࡣࠊᵝࠎ࡞㛗ࡉࡢ⬡⫫㓟ࢆࡶࡗࡓࢫࣝࣇ࢓
ࢳࢻࡀ᳨ฟྍ⬟࡛࠶ࡿࡀࠊࢫࣝࣇ࢓ࢳࢻࢆྜᡂࡍࡿ㓝⣲ࠊࢭࣞࣈࣟࢩࢻ◲㓟ᇶ㌿⛣㓝⣲(CST)ࢆḞᦆࡍࡿ࣐࢘ࢫ⬻࡛ࡣࠊ㧊㠧࡟ྵࡲࢀࡿࡍ࡭࡚ࡢࢫࣝࣇ࢓ࢳࢻࡣᾘ⁛ࡋ࡚࠸ࡓࠋCSTḞᦆ࣐࢘ࢫࡣࠊ⏕໬Ꮫⓗゎᯒ࡟࠾࠸࡚ࡶࢫࣝࣇ࢓ࢳࢻࡣྜᡂࡉࢀ࡞࠸࡜ඹ࡟ O4 㝧ᛶ⣽⬊ࡶฟ⌧ࡋ࡞࠸ࠋᚑࡗ࡚ࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢἲ࡛♧ࡍࢫࣝࣇ࢓ࢳࢻࡢ್ࡀಙ㢗ᛶࡢ㧗࠸ࡶࡢ࡛࠶ࡿ࡜࠸࠼ࡿࠋࡉࡽ࡟ࠊ࣐࢘ࢫ⫾⏕ᮇࡢ OL ๓㥑య⣽⬊Ⓨ⏕ẕᆅ࡛ࡣࠊC18-OH ࡀඃ఩࡟᳨ฟࡉࢀࠊࡇࢀࡽࡣࠊ⬨㧊୰ᚰ⟶㏆ഐ࠿ࡽᘏ㧊ࠊᶫ࡬࡜ OL Ⓨ⏕࡟కࡗ࡚ᒁᅾࡍࡿᵝᏊࡀᤊ࠼ࡽࢀࡓࠋࢫࣝࣇ࢓ࢳࢻࡣࠊ⫾⏕ᮇࡢ OL ⣔㆕Ỵᐃ⮫⏺Ⅼ࠿ࡽ࣑࢚ࣜࣥ㠧ᵓ⠏࡟⮳ࡿࡲ࡛ࡢ OL ศ໬㐣⛬ࢆ㏻ࡌ࡚ྜᡂࡉࢀ࡚࠸ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ

́́

P-55
⫢ษ㝖㔞࡟╔┠ࡋࡓ࣐࢘ࢫ⫢ษ㝖ᚋ⫢෌⏕ࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ஭ཱྀබኴ 1, ㎷ 㞝኱ 2, ୰ᕝ♸㍤ 2, ୰㑦ᬛஅ 3, Ἴከ㔝ᝋᮁ 1, ୖᮏఙ஧ 1, ụᕝ㞞ဢ 21ி㒔኱Ꮫ་Ꮫ◊✲⛉⫢⫹⮅⛣᳜እ⛉, 2 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉,3
㛵す་⛉኱Ꮫ⸆⌮Ꮫㅮᗙ

Imaging mass spectrometry of liver regeneration after partial hepatectomy in mice,focusing on the resected liver volume
Kohta Iguchi1, Yudai Tsuji 2, Yuki Nakagawa2, Tomoyuki Nakamura3, Etsuro Hatano1,
Shinji Uemoto1, Masaya Ikegawa2
1
Department of Surgery, Graduate School of Medicine, Kyoto University
2
Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha
University
3
Department of Pharmacology, Kansai Medical University⫢ษ㝖⾡ࡣࠊ⫢⣽⬊⒴ࠊ㌿⛣ᛶ⫢⒴࡟ᑐࡋ࡚᰿἞ࡢᮇᚅฟ᮶ࡿ୰ᚰⓗ἞⒪ἲ࡛࠶ࡿࠋ୍
᪉ࠊ⾡ᚋ⫢୙඲(Posthepatectomy liver failure; PHLF)ࡣ୺࡟኱㔞⫢ษ㝖࡟క࠺㐣ᑠṧ⫢ࡢ෌⏕୙༑ศ࡟㉳ᅉࡍࡿ⮴Ṛⓗྜే⑕࡛࠶ࡾࠊᝈ⪅ಶࠎࡢ⫢ᶵ⬟࡟ᛂࡌࡓ⫢ษ㝖㔞ࡀ PHLF
Ⓨ⑕࡜῝ࡃ㛵㐃ࡍࡿࠋࡋ࠿ࡋࠊᐇ㝿࡟⮫ᗋᛂ⏝ྍ⬟࡞ PHLF Ⓨ⑕ࢆࣔࢽࢱ࣮ࡍࡿ㗦ᩄ࡞࣐࣮࣮࢝ࡸ἞⒪⸆ࡣᏑᅾࡏࡎࠊ௒ᚋࡢ☜❧ࡀᮇᚅࡉࢀࡿࠋ⫢෌⏕࡟㛵ࡍࡿ◊✲࡟ࡣ⸆≀ㄏᑟᛶ⫢യᐖࣔࢹࣝࡸ 70%㒊ศ⫢ษ㝖㸦70%PHx㸧ࣔࢹࣝࡀ▱ࡽࢀ࡚࠸ࡿࠋᡃࠎࡣ㐣ཤ࡟ࠊ࣐࢘ࢫᅄ
ሷ໬Ⅳ⣲⫢യᐖࣔࢹࣝ࡟࠾࠸࡚ࠊ⾑Ύ⫹Ồ㓟ࡢࣂ࢖࣐࣮࣮࢜࢝࡜ࡋ࡚ࡢ᭷⏝ᛶࢆࠊᐃ㔞ᛶࠊ⫢⤌⧊ୖࡢศᕸࡢഃ㠃࠿ࡽሗ࿌ࡋࡓ㸦Shimada, J Proteome Res, 2010㸧ࠋ௒ᅇࠊ࣐࢘ࢫ PHx
ࣔࢹࣝࢆ౑⏝ࡋࠊ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟ࡼࡿṧᏑ⫢ෆࡢ௦ㅰ≀ࡢ᫬㛫࣭✵㛫ⓗኚ໬ࢆゎᯒࡋࡓࠋᮏᐇ㦂࡛ࡣࠊࢹ࣮ࢱ ᐃࠊゎᯒࡣ MALDI ᆺ㉁㔞㢧ᚤ㙾㸦iMScope, ᓥὠ〇సᡤ㸧ࢆ౑⏝ࡋࠊ9-࢔࣑ࣀ࢔ࢡࣜࢪࣥࢆ࣐ࢺࣜࢵࢡࢫ࡜ࡋࡓ㝜࢖࣮࢜ࣥࣔࢻ࡟࡚ 300-900m/z ࡢศᏊࢆᐃࡋࡓࠋ㏻ᖖࡢ⫢෌⏕㐣⛬ࢆ᳨ウࡍࡿࡢ࡟㢖⏝ࡉࢀࡿ 70%PHx ࣔࢹࣝ࡟࠾࠸࡚ࡣࠊ⫢⣽⬊ෆࡢ୍ḟ⫹Ồ㓟࡞ࡽࡧ࡟⬦⟶ෆ ATP㸦࢔ࢹࣀࢩࣥ 3 ࣜࣥ㓟㸧࡟≉ᚩⓗ࡞ᙉᗘ࣭ศᕸኚ໬ࡢ
࠶ࡿࡇ࡜ࡀ᫂ࡽ࠿࡜࡞ࡗࡓࠋ୍᪉ࠊ⫢ษ㝖㔞ࢆቑῶࡋࡓࣔࢹࣝࠊ༶ࡕ 30%PHx ࡣ⫢⣽⬊ࡢศ⿣ࢆకࢃ࡞࠸⫢⫧኱ࣔࢹࣝࠊ90%PHx ࡣ㏻ᖖ⫢෌⏕࠿ࡽ㐓⬺ࡋࡓ⮴Ṛⓗ PHLF ࣔࢹࣝ࡜⪃࠼ࡽࢀ࡚࠸ࡿࠋᡃࠎࡣ࣐࢘ࢫ 30%ࠊ90%PHx ࣔࢹࣝ࡜ࠊ70%PHx ࣔࢹࣝࡢẚ㍑᳨ウࢆ⾜࠺ࡇ࡜࡟ࡼ
ࡗ࡚ࠊ୍ḟ⫹Ồ㓟ࠊ⬦⟶ෆ ATP ࢆྵࡵࡓࠊ⫢෌⏕࣭PHLF ࡢ࣐࣮࣮࢝࡜࡞ࡾᚓࡿศᏊࢆ᫬㛫࣭✵㛫ⓗ࡟᳨ウࡋࠊሗ࿌ࡍࡿࠋ

́́

P-56
㉁㔞㢧ᚤ㙾࡟ࡼࡿࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝࡢ࣐࢘ࢫ⢭ᕢ࡟࠾ࡅࡿྍど໬⇃⏣࢔ࣥࣜ࢜ࣂࢹ࢕࢔㸯, ㇂ཱྀஂဴ㸰, ▮ᑿ⫱Ꮚ㸱, ྂ⏣ாྐ㸲, ᯇ⏣බᚿ㸰, ఀ⸨ㄔ஧㸯㸯㛵す་⛉኱Ꮫ་໬Ꮫㅮᗙ, 㸰⭈Ἢᒀჾእ⛉Ꮫㅮᗙ, 㸱὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ
◊✲ࢭࣥࢱ࣮, 㸲ᒱ㜧኱Ꮫ་Ꮫ⣔◊✲⛉Visualization of testosterone sulfate ester on mouse testis with imaging mass
spectrometry
Henri-Obadja Kumada1, Hisanori Taniguchi2, Ikuko Yao3, Kyoji Furuta4, Tadashi Matsuda2, Seiji Ito1
1
Departments of Medical Chemistry and 2Urology and Andrology of Kansai Medical University,
3
Medical Photonics Research Center, Hamamatsu University School of Medicine, 4Gifu University
Graduate School of Medicine࠙┠ⓗࠚࢸࢫࢺࢫࢸࣟࣥ(௨ୗࠊTs)ࡣ⢭ᕢࡢ Leydig ⣽⬊࡟࡚ࢥࣞࢫࢸ࣮ࣟࣝࢆฟⓎ≀㉁࡜ࡋ
࡚ྜᡂࡉࢀࡿ⏨ᛶ࣍ࣝࣔࣥࡢࡦ࡜ࡘ࡛࠶ࡿࠋ⏕ᡂࡉࢀࡿ࡜㏿ࡸ࠿࡟⾑୰࡟ᨺฟࡉࢀࠊᶆⓗ⮚ჾ࡟స⏝ࡍࡿࠋTs ࡣ⾑୰⃰ᗘࢆ ELISA ࡟ࡼࡗ࡚ ᐃ࡛ࡁࡿࡀࠊ⢭ᕢ࠿ࡽᨺฟࡉࢀࡿࡇ࡜
࠿ࡽࠊ⢭ᕢ࡛ࡢ᳨ฟࡣᅔ㞴࡜ࡉࢀ࡚࠸ࡓࠋࡑࡇ࡛ࠊᮏ◊✲࡛ࡣ㉁㔞㢧ᚤ㙾ࢆ౑࠸࣐࢘ࢫ⢭ᕢษ∦ୖ࡟࡚ Ts ࢆྍど໬ࡍࡿࡇ࡜ࢆ┠ⓗ࡜ࡋࡓࠋ࠙᪉ἲࠚTs ࡣ༢య࡛ࡣ࢖࢜ࣥ໬ࡉࢀ࡟ࡃ࠸ࡀࠊỈ㓟ᇶࢆࡶࡘࡓࡵࠊ୕㓟໬◲㯤ࣆࣜࢪࣥ㘒య(௨ୗࠊSO3Py)ࢆຍ࠼࡚ 55Υ 2 ᫬㛫ຍ ࡋ࡚ࢸࢫࢺࢫࢸࣟࣥ◲㓟࢚ࢫࢸࣝ(௨ୗࠊTsS)࡟ㄏ
ᑟయ໬ࡋࡓࠋࡇࢀ࡟ matrix ࡜ࡋ࡚ ǂ-ࢩ࢔ࣀ-4-ࣄࢻࣟ࢟ࢩࢣ࢖⓶㓟(௨ୗࠊCHCA)ࢆຍ࠼ࠊ
㉁㔞㢧ᚤ㙾ࡣࣉࣟࢺࢱ࢖ࣉᶵ(ᓥὠ〇సᡤ)ࢆ⏝࠸ࡓࠋ࣐࢘ࢫ⢭ᕢࡣ↓ฎ⌮ࡢࡶࡢ࡜ࢦࢼࢺࣟ
ࣆࣥ(hCG)2000 ༢఩/20Pl ࢆ࣐࢘ࢫ࡟⓶ୗὀᑕࡋ࡚ Ts ࡢ⏕ᡂࢆㄏᑟࡋ 1 ᫬㛫ᚋ࡟᦬ฟࡋࡓ
⢭ᕢࡢ୧⪅ࢆ౪ࡋࡓࠋ෾⤖⤌⧊ໟᇙ๣ࡣ㉁㔞ศᯒ࡟ᖸ΅ࡋ࡞࠸࢝ࣝ࣎࢟ࢩ࣓ࢳࣝࢭ࣮ࣝࣟ
ࢫࢼࢺ࣒ࣜ࢘(CMC)ࢆ⏝࠸ࡓࠋࡇࢀࡽࡢ࣐࢘ࢫ⢭ᕢࡢ⤌⧊ษ∦࡟ࡶ SO3Py ࢆᄇᑕࡋࠊ55Υ 2᫬㛫ຍ ࡢࡢࡕ CHCA ࢆᄇᑕࡋ࡚㉁㔞㢧ᚤ㙾࡛ ᐃࡋࡓࠋ ᐃ᮲௳ࡣ㈇࢖࢜ࣥࠊ᳨ฟჾ㟁ᅽ 2.1kV ࠊ㢧ᚤ㙾ಸ⋡ 20 ಸ࡛ࠊMS ࡢሙྜࡣ↷ᑕᚄ 0ࠊ࣮ࣞࢨ࣮ᙉᗘ 80%(100%ࡢ᫬ࡢࣞ
࣮ࢨ࣮࢚ࢿࣝࢠ࣮㸸0.010PJ)ࠊMS/MS ࡛ࡣ↷ᑕᚄ 4ࠊ࣮ࣞࢨ࣮ᙉᗘ 80%࡛࠶ࡗࡓࠋ⏬ീ໬࡟ࡣ Imaging Mass Solution (Ver.1.01.02)ࡢ࢖࣓࣮ࢪᶵ⬟ࢆ⏝࠸ࡓࠋ࠙⤖ᯝࠚTsS ᶆ‽ရ࡛ࡣ MS (m/z=367.15, TsS C19H27O5S), MS/MS (m/z=96.96, fragment
HSO4-)୧᪉࡟ࣆ࣮ࢡࢆㄆࡵࡓࠋ↓ฎ⌮ࡢ࣐࢘ࢫ⢭ᕢ࡛ࡣࡇࢀࡽࡢࣆ࣮ࢡࡀㄆࡵࡽࢀ࡞࠿ࡗ
ࡓࡀࠊhCG ࡛ฎ⌮ࡋࡓ⢭ᕢ࡛ࡣ࠸ࡎࢀࡢࣆ࣮ࢡࡶ᳨ฟࡉࢀࠊ⤌⧊ษ∦ୖ࡛ࡣ MS ࡢࣆ࣮ࢡࢆ♧ࡍ㯤ⰍࡢᩬⅬࡀ୍㠃࡟ㄆࡵࡽࢀࡓࠋࡲࡓ MS/MS ࡶ⤌⧊ษ∦ୖ࡟ࣆ࣮ࢡࢆ♧ࡍ㯤Ⰽࡢᩬ
Ⅼࡀ MS ࡜୍⮴ࡋ࡚ᗈ࠸⠊ᅖ࡛ㄆࡵࡽࢀࡓࠋ
࠙⪃ᐹࠚMS ࡢ࡯࠿࡟ MS/MS ࡛ࡶࣆ࣮ࢡࡀ᳨ฟࡉࢀࡓ㒊఩ࡢ⏬ീࢆᥥฟ࡛ࡁࡓࡢ࡛ࠊ
◲㓟࢚ࢫࢸࣝ໬ࡉࢀࡓ Ts ࡢ⢭ᕢ࡛ࡢ᳨ฟࡀ㉁㔞ศᯒ࡛ࡣࡌࡵ࡚ྍ⬟࡜࡞ࡗࡓࠋ

́́

P-57
㹑㹂㹒ࣛࢵࢺࡢ⮅⮚ࢆᑐ㇟࡜ࡋࡓࣉࣟࢸ࣑࢜ࢵࢡ㉁㔞࢖࣓࣮ࢪࣥࢢ┈ᒣ ៞ 1, ᒾᓮ஢ᩍ 2, ⴱཎ⏤㈗ 3, ⱝᅬ ༤ 1, 㡞⃝ ᓫ 2, ⸨ࣨ㇂ᾈᩥ 1, ᮾᒣ┿⃈ 1,᪥ẚ኱௓ 1, ᰗᾈ⏤⣖ 1, ᐟ㇂┿⏤ 3, ụᕝ㞞ဢ 31ᑠ㔝⸆ရᕤᴗ, 2 ࣈ࣮ࣝ࢝ࢲࣝࢺࢽࢡࢫ, 3 ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉Proteomic Mass Imaging of Pancreas from SDT Rat Model
Kei Masuyama1, Noriyuki Iwasaki2, Yuki Kuzuhara 2, Hiroshi Wakazono1, Takashi Nirasawa2,
Hirofumi Fujigaya1, Masumi Higashiyama1, Daisuke Hibi1, Hiroyuki Yanagi1, Mayu Shukutani3,
Masaya Ikegawa3
1
Ono Pharmaceutical Co., Ltd.
2
Bruker Daltonics K.K.
3
Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha
University⌧ᅾࠊ⢾ᒀ⑓ᝈ⪅ᩘࡣᡃࡀᅜࡢࡳ࡞ࡽࡎୡ⏺࡛ᖺࠎቑຍࡋ࡚࠸ࡿࠋ⢾ᒀ⑓ࡣ඲㌟⑓࡛࠶
ࡾࠊ⑓Ẽࡢ㐍⾜࡜࡜ࡶ࡟࢖ࣥࢫࣜࣥឤཷᛶࡸ⪏⢾⬟࡟ኚ໬ࡀ⾲ࢀࠊࡸࡀ࡚㧗⾑⢾ࠊ㧗⬡㉁⾑⑕ࠊࡦ࠸࡚ࡣ⮅⮚ࡢș⣽⬊ࡢ࢖ࣥࢫࣜࣥศἪపୗ࡟ࡼࡾ࢖ࣥࢫࣜࣥ୙㊊ࡀᘬࡁ㉳ࡇࡉࢀࡿࠋ⢾ᒀ⑓ࡢⓎ⑕ᶵᗎࡸ⑓Ẽࡢ㐍⾜ࢆゎᯒࡍࡿୖ࡛⮅⮚ࣛࣥࢤࣝࣁࣥࢫᓥࡢ⑓⌮Ꮫⓗኚ໬ࡸࡑࡢศᏊᇶ┙࡟ࡘ࠸࡚ゎᯒࡍࡿࡇ࡜ࡣ᭱ࡶ㔜せ࡛࠶ࡿࠋᮏ◊✲࡛ࡣࠊ᪥ᮏே࡟ከࡃぢࡽࢀࡿ⫧‶ࢆకࢃ࡞࠸㸰ᆺ⢾ᒀ⑓ࡢࣔࢹࣝື≀࡜ࡋ࡚ Spontaneously Diabetic Torii (SDT)ࣛࢵ
ࢺࢆ⏝࠸ࡓࠋᑐ↷⩌㸦SD ࣛࢵࢺ 9 㐌㱋㸧ཬࡧ 9ࠊ16ࠊ20 㐌㱋ࡢ SDT ࣛࢵࢺࡢ⮅⮚ษ∦ࢆ⏝࠸࡚ࢱࣥࣃࢡ㉁ࣞ࣋ࣝࡢ࢖࣓࣮ࢪࣥࢢ࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ࣮ࣜ㸦Imaging Mass Spectrometry :IMS㸧ࢆᐇ᪋ࡋࡓࠋIMS ࡟ࡣ MALDI-TOF MS㸸ultraflextreme㸦Bruker Daltonics㸧ࢆ⏝࠸ࠊ50ȣm ࡢ✵㛫ศゎ⬟࡛ ᐃࢆ⾜ࡗࡓࠋ⤌⧊ࡣࠊon tissue ࡛ࢺࣜࣉࢩࣥฎ⌮ࢆ⾜࠸ࠊࡉࡽ࡟
LC-MALDI-MS ཬࡧ LC-ESI-MS ࡢ஧ࡘࡢᡭἲ࡛⥙⨶ⓗࢱࣥࣃࢡྠᐃࢆᐇ᪋ࡋࡓࠋ
ࡑࡢ⤖ᯝࠊ⤌⧊ࡈ࡜࡟⣙ 200 ಶࡢࢱࣥࣃࢡ㉁ࡀྠᐃࡉࢀࡓࠋᮏࣔࢹࣝ࡟࠾ࡅࡿ⮅ᓥࡢึᮇ⑓ኚ࡜ࡋ࡚
⾑⟶ᣑᙇࡸฟ⾑ࡀㄆࡵࡽࢀ࡚࠸ࡿࡀࠊ⢾ᒀ⑓ࡢ㐍⾜࡟క࠸ࠊ࢖ࣥࢫࣜࣥࠊࢢࣝ࢝ࢦࣥࡢศ
ᕸࢆᣦᶆ࡟⮅ᓥ࠾ࡼࡧ⮅ᓥ࿘㎶࡟ศᕸࡍࡿࢱࣥࣃࢡ㉁ࢆ᥈⣴ࡋࡓࠋ≉ᚩⓗ࡞ศᕸ࡜ࡋ࡚ࠊ
⢾ᒀ⑓ࡢึᮇ≧ែ࡛࠶ࡿ 9 㐌㱋ࡢ SDT ࣛࢵࢺࡢ⑓ኚ㒊ࡢࡳ࡛ᙉࡃⓎ⌧ࡍࡿࢱࣥࣃࢡ㉁ࡀ☜ㄆࡉࢀࡓࠋࡲࡓࠊᑐ↷⩌ࡢࡳ࡛Ⓨ⌧ࡋ࡚࠸ࡿࢱࣥࣃࢡ㉁ࡸࠊ⢾ᒀ⑓ࡢ㐍⾜࡟క࠸ࢩࢢࢼࣝ
ࡀቑᙉࡋࡓࢱࣥࣃࢡ㉁ࡶᢳฟࡉࢀࡓࠋᮏ◊✲࡟ࡼࡾᚓࡽࢀࡓ⮅ᓥࣉࣟࢸ࣮࣒࢜ࡢᐇ㦂ⓗࠊ⮫ᗋⓗ᳨ドࡢᚲせᛶࡀ♧၀ࡉࢀࡓࠋ

́́

P-58
⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࡟࠾ࡅࡿ⬨㧊ᚋゅࡢ⬡㉁ኚ໬
ᆏ㔝཭ၨ 1, ṇᮌ⣖㝯㸯, ኱ᮧጾኵ㸯, ୕ཎ၏ᬦ㸯, ᚎ෤㛼㸯, ᯇᒣᖾᘯ 1, ℩⸨ග฼㸯
1὾ᯇ་⛉኱Ꮫ་Ꮫ⣔◊✲⛉Analysis of lipid distribution in dorsal horn using matrix-assisted laser
desorption/ionization imaging mass spectrometry in neuropathic pain model mice
Tomohiro Banno1, Noritaka Masaki1, Takao Omura1, Yuuki Mihara1, Dongmin Xu 1, Yukihiro
Matsuyama1, Mitsutoshi Setou1
1
Hamamatsu University School of Medicine࠙┠ⓗࠚ㏆ᖺࠊ⚄⤒㞀ᐖᛶ⑊③࡟࠾࠸࡚⬡㉁ࡢᯝࡓࡍᙺ๭ࡀὀ┠ࢆ㞟ࡵ࡚࠸ࡿࠋ࢖࣓࣮ࢪࣥ
ࢢ㉁㔞ศᯒἲ㸦MALDI-IMS㸧ࡣ⤌⧊ෆ࡟࠾ࡅࡿ⬡㉁ࡢᒁᅾࢆ⬡⫫㓟⤌ᡂ࡛ࣞ࣋ࣝ༊ูࡋࠊ
ྠᐃࡍࡿࡇ࡜ࡀྍ⬟࡞ᡭἲ࡛࠶ࡿࠋᮏ◊✲ࡢ┠ⓗࡣࠊMALDI-IMS ࢆ⏝࠸࡚⚄⤒㞀ᐖᛶࣔࢹ࣐ࣝ࢘ࢫࡢ⬨㧊ᚋゅ࡟࠾ࡅࡿࣜࣥ⬡㉁ศᕸࡢኚ໬ࢆゎᯒࡍࡿࡇ࡜࡛ࠊ⚄⤒㞀ᐖᛶ⑊③࡟ᑐࡍࡿ⬡㉁ࡢᙺ๭ࢆゎ᫂ࡍࡿࡇ࡜࡛࠶ࡿࠋ࠙᪉ἲࠚC57BL6J 㞝 8 㐌㱋࣐࢘ࢫࢆ⏝࠸ࡓࠋᮎᲈ⚄⤒㞀ᐖᛶ⑊③ࣔࢹࣝ࡜ࡋ࡚ spared nerve
injury (SNI) model ࢆసᡂࡋࠊẚ㍑ᑐ㇟࡜ࡋ࡚ sham model ࢆ⏝࠸ࡓࠋ⑊③ホ౯࡜ࡋ࡚ von Frey
test ࢆ⾜ࡗࡓࠋ⾡ᚋ 3ࠊ7ࠊ21 ᪥࡟ L5 ࣞ࣋ࣝࡢ⬨㧊ࢆ᦬ฟࡋࠊ᪂㩭෾⤖ษ∦ࢆసᡂࡋࡓࠋ࣐
ࢺࣜࢡࢫ࡜ࡋ࡚ DHB ࢆ⏝࠸ࠊ㝧࢖࣮࢜ࣥࣔࢻࡢ MALDI-IMS ࡛ࣜࣥ⬡㉁ࡢ 1 ࡘ࡛࠶ࡿࣇ࢛
ࢫࣇ࢓ࢳࢪࣝࢥࣜࣥ㸦PC㸧ࡢ⬨㧊ෆ࡟࠾ࡅࡿศᕸࢆゎᯒࡋࡓࠋࡲࡓࠊ࢔ࢫࢺࣟࢧ࢖ࢺࡸ࣐
࢖ࢡࣟࢢࣜ࢔ࡢᒁᅾ࡜ẚ㍑ࡍࡿࡓࡵ GFAPࠊIba1 ࡟ࡼࡿ㐃⥆ษ∦ࡢච␿ᰁⰍࡶ⾜ࡗࡓࠋ࠙⤖ᯝࠚvon Frey test ࡛ࡣ SNI ⩌࡟࠾࠸࡚ᦆയ┤ᚋ࠿ࡽ᭷ព࡟⑊③㜈್ࡀపୗࡋ 21 ᪥ࡲ࡛ᣢ⥆ࡋ࡚࠸ࡓࠋMALDI-IMS ࡟ࡼࡿ PC ࡢゎᯒ࡛ࡣᦆയᚋ 7 ᪥ࡢ᫬Ⅼ࡛ SNI ⩌࡟࠾࠸࡚࢔ࣛ࢟
ࢻࣥ㓟ྵ᭷ࣜࣥ⬡㉁ (AA-PC)ࡢ 1 ࡘ࡛࠶ࡿ PC(diacyl-16:0/20:4)ࡀ⬨㧊ᚋゅ࡛ቑຍࡋ࡚࠸ࡓࠋ
୍᪉࡛ࠊᦆയᚋ 3 ᪥ࠊ21 ᪥ࡢ᫬Ⅼ࡛ࡣྛ✀ PC ࡟᭷ព࡞ኚ໬ࡣࡳࡽࢀ࡞࠿ࡗࡓࠋච␿ᰁⰍീ
࡛ ࡶ SNI ⩌ ࡟ ࠾ ࠸ ࡚ ඲ ほ ᐹ ᮇ 㛫 ࡛ ࣐ ࢖ ࢡ ࣟ ࢢ ࣜ ࢔ ࡢ ቑ ຍ ࡀ ⬨ 㧊 ᚋ ゅ ࡛ ࡳ ࡽ ࢀ ࠊPC(diacyl-16:0/20:4)࡜ྠᵝ࡟ᦆയᚋ 7 ᪥ࡢ᫬Ⅼ࡛᭱ࡶ㞟✚ࡀከ࠿ࡗࡓࠋ
࠙⪃ᐹࠚ⚄⤒㞀ᐖᛶ⑊③ࣔࢹ࣐ࣝ࢘ࢫ࡟࠾࠸࡚ᦆയᚋ 7 ᪥࡛⬨㧊ᚋゅ࡟࠾࠸࡚ AA-PC ࡀୖ᪼ࡋ࡚࠸ࡓࠋⓎ⌧ࡢศᕸࡣ࣐࢖ࢡࣟࢢࣜ࢔ࡢ㞟✚࡜㢮ఝࡋ࡚࠸ࡓࡓࡵࠊPC(diacyl-16:0/20:4)
ࡢኚ໬ࡣ࣐࢖ࢡࣟࢢࣜ࢔ࡢ㞟✚࡜ࡑࢀ࡟క࠺⅖⑕࡟㛵୚ࡋ࡚࠸ࡿ࡜⪃࠼ࡽࢀࡿࠋ

́́

P-59
ࡆࡗṑ㢮⢭ᕢ࡟࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ୰す຾அ 1, ㎷ 㞝኱ 1, ୰ᕝ♸㍤ 1, ஭ཱྀබኴ 1, ゅ⏣ఙே 1, ୰㑦ᬛஅ 2, ᯇ஭႐அ 3, ᕷᒸ೺ኴ㑻 4, ᑠᕝ ಟ 3, ụᕝ㞞ဢ 11ྠᚿ♫኱Ꮫ⏕࿨་⛉Ꮫ㒊་⏕࿨ࢩࢫࢸ࣒Ꮫ⛉, 2 㛵す་⛉኱Ꮫ⸆⌮Ꮫㅮᗙ, 3 ி㒔኱Ꮫ኱Ꮫ㝔Ἢᒀჾ⛉Ꮫ, 4 ࠸ࡕ࠾࠿Ἢᒀჾ⛉ࢡࣜࢽࢵࢡ

Imaging Mass Spectrometry of rodent testis focusing on nucleotides
Katsuyuki Nakanishi1, Yudai Tsuji2, Yuki Nakagawa2, Kohta Iguchi1, Nobuto Kakuda1, Tomoyuki
Nakamura2, Yoshiyuki Matsui1, Kentaro Ichioka4, Osamu Ogawa3, Masaya Ikegawa1
1
Department of Life and Medical Systems, Faculty of Life and Medical Sciences, Doshisha
University
2
Department of Pharmacology, Kansai Medical University
3
Department of Urology, Graduate School of Medicine, Kyoto University
4
Ichioka Urological Clinic⏨ᛶ୙ዷ⑕ࡢデ᩿࡟⢭ᕢ⤌⧊ࡢ⏕᳨ࡣ㠀ᖖ࡟㔜せ࡛࠶ࡿࠋᮏ◊✲࡛ࡣࠊᑗ᮶ⓗ࡟⢭ᕢ⤌⧊ࡢ⑓⌮デ᩿࡟౪ࡍࡿࡓࡵࠊ኱Ẽᅽ MALDI 㢧ᚤ㉁㔞ィࢆ⏝࠸࡚ࠊ࣐࢘ࢫ࠾ࡼࡧࣛࢵࢺ⢭ᕢ࡟࠾ࡅࡿࢾࢡࣞ࢜ࢳࢻࡢ࢖࣓࣮ࢪࣥࢢࢆヨࡳࡓࠋゎᯒ࡟ࡣ 5 㐌㱋 ICR ࣐࢘ࢫ࠾ࡼࡧ 5 㐌㱋
Wistar ࣛࢵࢺ⢭ᕢࢆ⏝࠸ࡓࠋ㢁᳝⬺⮻ᚋࠊ30 ⛊௨ෆ࡟ࡍࡤࡸࡃ⢭ᕢࢆྲྀࡾฟࡋࠊᾮయ❅⣲࡛ᛴ㏿෭෾ࡋࡓࠋ෾⤖⤌⧊࠿ࡽࢡࣜ࢜ࢫࢱࢵࢺ࡛ཌࡉ 10ȣm ࡢⷧษ∦ࢆసࡾࠊ㏱᫂ᑟ㟁ᛶࢫࣛ࢖ࢻࢢࣛࢫ(ITO)࡟⼥ゎ᥋╔ࡋࡓࠋ࣐ࢺࣜࢵࢡࢫ࡟ࡣ㸷㸫࢔࣑ࣀ࢔ࢡࣜࢪࣥࢆ⏝࠸
negative mode ࡟࡚ゎᯒࢆ⾜ࡗࡓࠋ୧ഃ⢭ᕢࡢෆࠊ୍᪉࡟ࡣṚᚋኚ໬ࢆᢚไࡍࡿ┠ⓗ࡛⇕ฎ⌮ࢆຍ࠼ࠊࡑࡢຠᯝࢆẚ㍑᳨ウࡋࡓࠋ㢧ᚤ㉁㔞ィ࡟ࡣࠊiMScope(ᓥὠ〇సᡤ)ࢆ⏝࠸ DHB(2,5-dihydroxybenzoic acid)࡛࢟ࣕࣜࣈ࣮ࣞࢩࣙࣥࢆ࠾ࡇ࡞ࡗࡓࠋࢹ࣮ࢱࡣࠊImaging MS
Solution (ᓥὠ〇సᡤ)ࢆ⏝࠸࡚ゎᯒࡋࡓࠋm/z ࡢ್࠿ࡽ௦ㅰ≀ࡢ≉ᐃ࡟ࡣࠊMETLIN ࢆཧ↷ࡋࡓࠋࡑࡢ⤖ᯝࠊࡇࢀࡲ࡛ሗ࿌ࡢ࠶ࡗࡓ Seminolipids ࡢศᕸ࡟ࡃࢃ࠼ ATP, ADP, AMP ࡞࡝ࡢࢾࢡࣞ࢜ࢳࢻࡢศᕸࢆほᐹࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋ௒ᚋࡣࠊ⢭Ꮚᙧᡂࡸ୙ዷ⑕࡜ࡢ㛵㐃࡟࠾࠸࡚⢭ᕢࡢࢾࢡࣞ࢜ࢳࢻࢆᑐ㇟࡜ࡋࡓ࢖࣓࣮ࢪࣥࢢࢆ⾜࠸ࠊ᳨ドࢆ⾜࠺ࠋ

́́

P-60
㉁㔞࢖࣓࣮ࢪࣥࢢἲࢆ⏝࠸ࡓࣁࣟ࣌ࣜࢻ࣮ࣝ⏤᮶ࣆࣜࢪࢽ࣒࢘௦ㅰ≀ࡢ⬻ෆศᕸ࡟㛵ࡍࡿྍど໬ࡢ᳨ウྜྷ⏣ཎつ 1, ୰す㇏ᩥ 2, ᮡᮏ㤶ዉ 3, ᕴ ಙ஧ 1, ஬༑ᔒ୍㞝 4
1㏆␥኱Ꮫ་Ꮫ㒊ἲ་Ꮫ, 2 ኱㜰་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫ, 3 ኱㜰኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ἲ་Ꮫ,4୍⯡♫ᅋἲே་⸆ศᯒ༠఍MALDI mass spectrometry imaging for direct measurement of the neurotoxic
pyridinium metabolite (HPP+) of haloperidol in mouse brain tissue
Motonari Yoshida1, Toyofumi Nakanishi2, Kana Sugimoto3, Shinji Tatsumi1, Kazuo Igarashi4
Department of Legal Medicine, Faculty of Medicine, Kinki University, 2Department of Clinical andLaboratory Medicine, Osaka Medical College, 3Department of Legal Medicine, Osaka University
Graduate School of Medicine, 4Department of Research Development, Association of Medicinal
Analysis1࠙┠ⓗࠚ⤫ྜኻㄪ⑕἞⒪⸆ࣁࣟ࣌ࣜࢻ࣮ࣝ㸦HP㸧ࡣࠊ➨୍ୡ௦ࡢᢠ⢭⚄⑓⸆࡛࠶ࡿࡀࠊ⤫ྜኻㄪ⑕ࡢ୰࡛ࡶᗁ⫈ࡸዶ᝿࡞࡝ࡢ⑕≧ᨵၿࡢࡓࡵ࡟ᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋ୍᪉ࠊࡇࡢ἞⒪⸆ࡢ㛗ᮇ౑⏝࡟ࡼࡾࠊ
๪స⏝࡜ࡋ࡚⸆๣ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒ࡀㄏᑟࡉࢀࡿࡇ࡜ࡶ▱ࡽࢀ࡚࠸ࡿࠋ
ࡇࡢ HP ࡟ࡼࡿ⸆๣ᛶࣃ࣮࢟ࣥࢯࢽࢬ࣒Ⓨ⌧ࡢせᅉ࡜ࡋ࡚ࠊIgarashi ➼ࡣ HP ࡟ࡼࡿ⚄⤒ẘᛶ௦ㅰ≀ࣆࣜࢪࢽ࣒࢘㸦HPP+㸧ࡢ㛵୚ࢆሗ࿌ࡋ࡚࠸ࡿࠋࡇࡢ௦ㅰ≀ HPP+ࡣ⚄⤒ẘᛶㄏⓎ≀㉁
MPTP ࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ MPP+࡟໬Ꮫᵓ㐀ⓗ࡟㢮ఝࡋ࡚࠸ࡿࡇ࡜࠿ࡽࠊ㢮ఝࡋࡓ⬻⚄⤒ẘᛶࢆ᭷ࡍࡿ࡜⪃࠼ࡽࢀࡿࠋࡲࡓࠊHP ᢞ୚ᚋࡢືែ࡜ࡋ࡚ࠊLC/MS ศᯒ࡟ࡼࡾ⬻ෆࣆࣜࢪࢽ࢘
࣒௦ㅰ≀ HPP+ࡢᏑᅾࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋ௒ᅇࡣࠊࡇࡢࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡢ⬻ෆศᕸ࡟ࡘ࠸࡚ࠊ㉁㔞࢖࣓࣮ࢪࣥࢢᡭἲ࡟ࡼࡿྍど໬ࢆ᳨ウࡋࡓࠋ࠙᪉ἲࠚᢞ୚ື≀࡜ࡋ࡚ࠊICR ⣔࣐࢘ࢫ㸦8 㐌௧ࠊ㞝㸧ࢆ౑⏝ࡋࡓࠋHP ᢞ୚㔞ࡣ⬻ෆศᕸࢆ᫂░࡟ࡍࡿࡓࡵ࡟ࠊ㏻ᖖ⏝㔞ࡼࡾ㧗⏝㔞ࢆ౑⏝ࡋࡓࠋHP ⁐ᾮࢆ 20 mg/kg ⭡⭍ෆὀᑕࡋࠊᢞ
୚ᚋ 1 ᫬㛫࡟⬻ࢆ᦬ฟࡋࡓࠋ᦬ฟ⬻ࡣ┤ࡕ࡟ 16ȣm.ཌࡢ෾⤖ษ∦ࢆసᡂࡋࡓࠋ࢖࢜ࣥ໬ヨ⸆࡟ HCCA-Matrix ࢆ౑⏝ࡋࠊMALDI-TOF-MS ⿦⨨㸦Bruker Daltonics Autofelex III-OM㸧࡟ࡼࡿ㉁㔞࢖࣓࣮ࢪࣥࢢࢆ⾜ࡗࡓࠋ௦ㅰ≀ HPP+ ᐃ࡟ࠊm/z 354.1 ࢆࣉ࣮ࣜ࢝ࢧ࣮࢖࢜ࣥ࡜ࡋ
࡚ࠊm/z 165.4 ࢆࢻ࣮ࢱ࣮࢖࢜ࣥ࡜ࡋ࡚⏝࠸ࡓࠋศᯒࢯࣇࢺ࡟ࡣ Flex Imaging V3.0 ࢆ౑⏝ࡋࡓࠋ࠙⤖ᯝ࠾ࡼࡧ⪃ᐹࠚHP ᢞ୚࣐࢘ࢫ࡟࠾ࡅࡿ⚄⤒ẘᛶࣆࣜࢪࢽ࣒࢘௦ㅰ≀ HPP+ࡢ⬻ෆศᕸࢆࠊ
㉁㔞࢖࣓࣮ࢪࣥࢢἲࢆ⏝࠸࡚ྍど໬ࢆ᳨ウࡋࡓࠋ⬻ษ∦ୖࡢ≉ᐃ㒊఩࡟ࠊ௦ㅰ≀ HPP+ᅛ᭷ࡢ㉁㔞ࢆྍど໬ࡍࡿࡇ࡜ࡀฟ᮶ࡓࠋࡇࡢ㒊఩࡟ࡘ࠸࡚ࠊ⬻⚄⤒⣽⬊ࠊ≉࡟ࢻࣃ࣑ࣥ⚄⤒⣽⬊➼ࡢ☜ᐃࢆࠊච␿⤌⧊ᏛᰁⰍ➼࡟ࡼࡾ᳨ウ୰࡛࠶ࡿࠋ

́́

P-61
᪂㩭෾⤖ங⒴⤌⧊ษ∦ࢆ⏝࠸ࡓ MALDI-IMS ゎᯒ࡟ࡼࡿங⒴≉␗ࢱࣥࣃࢡศᏊ
ೃ⿵ࡢྠᐃబ⸨୐ኤᏊ㸯,2, ୰す㇏ᩥ 2, ᒾᮏ඘ᙪ㸯, ෆᒣ࿴ஂ㸯㸯኱㜰་⛉኱Ꮫ㝃ᒓ⑓㝔ங⭢ෆศἪእ⛉, 㸰኱㜰་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫᩍᐊ

Identifications of candidate breast cancer-specific biomarkers in fresh frozen
breast tissue sections by the MALDI-imaging coupled with on-tissue digestion
Nayuko Sato1,2, Toyofumi Nakanishi2, Mitsuhiko Iwamoto1, Kazuhisa Uchiyama㸯
Department of Breast and Endocrine Surgery, Osaka Medical College Hospital,
2
Department of Clinical and Laboratory Medicine, Osaka Medical College

1࠙┠ⓗࠚ㏆ᖺࠊࢯࣇࢺ࢖࢜ࣥ໬㉁㔞ศᯒἲࡢⓏሙ࡟ࡼࡾࠊゎᯒᑐ㇟ࡀపศᏊ࠿ࡽ⏕య㧗ศᏊ࡬࡜ᗈࡀࡾࠊ⏕࿨⌧㇟ࢆྖࡿࢱࣥࣃࢡ㉁ࡢྠᐃࡀྍ⬟࡜࡞ࡗࡓࠋ᭦࡟ࠊ㉁㔞࢖࣓࣮ࢪࣥࢢ
ᡭἲ࡟ࡼࡾࠊ㉁㔞ศᯒ࡛ᚓࡽࢀࡓศᏊෆᵓ㐀᝟ሗ࡜ྠ᫬࡟ࡑࡢ⤌⧊ෆᒁᅾࢆྍど໬ࡍࡿࡇ࡜࡛ࠊᚑ᮶ࡢ⑓⌮⤌⧊ീ࡟㢮ఝࡍࡿ࣐ࢫ࢖࣓࣮ࢪ㸦Heat map㸧ࡀᚓࡽࢀࡿࡼ࠺࡟࡞ࡗࡓࠋ
௒ᅇࠊங⒴ษ㝖᪂㩭⤌⧊ษ∦ࢆゎᯒᑐ㇟࡟ࠊ࣐ࢺࣜࢵࢡࢫᨭ᥼࣮ࣞࢨ࣮⬺㞳㣕⾜᫬㛫ᆺ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ㸦௨ୗ MALDI-IMS㸧ἲࢆ⏝࠸ࠊ⤌⧊ษ∦ୖ࡛┤᥋ࢺࣜࣉࢩࣥᾘ໬ࢆ⾜࠺ࠊon-tissue digestion ࢆ⏝࠸࡚ங⒴⤌⧊࡟≉ᚩⓗ࡞ࢱࣥࣃࢡ㉁ࢆ」ᩘྠᐃࡋࡓࡢ࡛ࠊᩥ
⊩ⓗ⪃ᐹࢆຍ࠼࡚ሗ࿌ࡍࡿࠋ
࠙᪉ἲࠚங⒴ᡭ⾡࡟㝿ࡋ࡚᦬ฟࡋࡓ᪂㩭෾⤖ங⒴⤌⧊㸰㸮౛ࢆࠊon-tissue digestion ᚋ
MALDI-IMS㸦Autoflex speed㸸Bruker Daltonics ♫〇㸧ゎᯒࡋࠊྍど໬ࡉࢀࡓ Heat map ࢆHE ᰁⰍീ࡜ẚ㍑ࡋࠊ⒴㒊ࠊṇᖖ⤌⧊࡟㛵ᚰ㡿ᇦ㸦ROI :Region of interests㸧ࢆタᐃࡋࠊ
ࢱࣥࣃࢡ㉁ࣉࣟࣇ࢓࢖ࣝࢆྍど໬ࡋࡓࠋࡑࢀࡒࢀࡢ ROI ࡛ศ㢮ࡋࠊ୧⪅࡛␗࡞ࡿศᏊ࢖࢜
ࣥࢆ㑅ฟࡋࠊࢥࣥࣆ࣮ࣗࢱ࣮ゎᯒ࡟ࡼࡾ᭷ពᕪࡢ࠶ࡿศᏊ࢖࢜ࣥࢆぢฟࡋࡓࠋࡑࢀࡽ࡟ᑐ
ࡋ࡚ࠊon-tissue 㓝⣲ᾘ໬㸭࣮ࣞࢨ࣮࢖࢜ࣥ໬ᅄ㔜ᴟ࢖࢜ࣥࢺࣛࢵࣉ㣕⾜᫬㛫ᆺ㉁㔞ศᯒ
㸦MALDI-

QIT-TOFMS㸸ᓥὠ〇సᡤ〇㸧ἲ࡟࡚ࠊ୧⪅㛫࡛Ⓨ⌧ࡢ␗࡞ࡿࢱࣥࣃࢡ㉁ࢆྠᐃࡋ

ࡓࠋ࠙⤖ᯝࠚࢺࣜࣉࢩࣥᾘ໬≀࠿ࡽ࠸ࡃࡘ࠿ࡢங⒴≉␗࣌ࣉࢳࢻ㸦MH㸩㸧ࡀぢฟࡉࢀࠊMSMS ゎᯒࡢ⤖ᯝࠊࡑࢀࡽࡢ࣌ࣉࢳࢻࡣ Peptidylprolyl isomerase A. (PPIA)ࠊI ᆺ &ROODJHQȘ-2(COL1A2)ࠊHistone4 (H4)ࠊHistone2A (H2A1A)࡜ྠᐃฟ᮶ࡓࠋ
࠙⥲ᣓࠚங⒴ࡢᝏᛶᗘ࡜ࡢ㛵୚ࢆ♧ࡍ࡜⪃࠼ࡽࢀࡿࢱࣥࣃࢡ㉁ࢆᩘ✀㢮ྠᐃࡍࡿࡇ࡜ࡀ࡛ࡁ
ࡓࠋ௒ᚋࠊ≉␗ᢠయࢆ⏝࠸ࡓච␿⤌⧊໬ᏛᰁⰍ࡟࡚㉁㔞ศᯒ࡛ᚓࡽࢀࡓ⤖ᯝࢆ᳨ドࡋࠊELISAἲ ࡛ࢱࣥࣃࢡ㉁ࡢᐃ㔞ࢆ⾜࠸ࠊ᪂つᝏᛶᗘ㛵㐃ࢱࣥࣃࢡ࡜࡞ࡿ࠿ྰ࠿ࢆぢᴟࡵࠊᐇ㝿ࡢᶆⓗࢱࣥࣃࢡศᏊೃ⿵࡜ࡋࡓ࠸ࠋ

́́

P-62
LC/MS ゎᯒ࡟ࡼࡿ⾑୰ CRP 」ྜయ࡟ࡘ࠸࡚ࡢ᳨ウᑠ಴ᙬୡᏊ 1,3ࠊ㔛ᮧཌྖ 1ࠊᫍ㔝 ᛅ 1ࠊⲨᓥᗣ཭ 1ࠊᚿ᪉࠼ࡾࡉ 1ࠊ⸨ᒸ࿴⨾ 1ࠊୗ⃝㐩㞝 3ࠊ୰ᒣᬛ⚈ 11᪥ᮏ኱Ꮫ་Ꮫ㒊 ⑓ែ⑓⌮Ꮫ⣔ ⮫ᗋ᳨ᰝ་Ꮫศ㔝ࠊ2 ᪥ᮏ኱Ꮫ⑓㝔 ⮫ᗋ᳨ᰝ་Ꮫ⛉ࠊ
3ᮾி኱Ꮫ་Ꮫ㒊௜ᒓ⑓㝔 ᳨ᰝ㒊Proteome analysis of CPR binding protein
Sayoko Ogura1,3, Atsushi Satomura1, Tadashi Hoshino1, Yasutomo Arashima1, Erisa Shikata1,
Kazumi Fujioka1, Tatsuo Shimosawa3, Tomohiro Nakayama1
Division of Laboratory Medicine, Department of Pathology and Microbiology, Faculty of Medicine,
Nihon University School of Medicine࠙⫼ᬒ࣭┠ⓗࠚC-reactive protein(CRP)ࡣ⫢⮚࡛⏘⏕ࡉࢀࠊ⅖⑕࡞࡝ࡢ่⃭࡟ࡼࡗ࡚ᩘⓒಸ࡟ࡶ⏘⏕ࡀቑຍࡋࠊ⾑Ύ୰ࡢ CRP ⃰ᗘࡣឤᰁ⑕ࡢ㔜⑕ᗘࡸ⤌⧊യᐖࡢ᭷↓ࡢุᐃ࡟ᗈࡃ⏝࠸ࡽࢀ࡚࠸
ࡿࠋCRP ࡣከ⢾యࡸࣜࣥ㓟࡞࡝࡜⤖ྜࡋ࡚࠾ࡾࠊ」ྜయࢆᙧᡂࡋ࡚࠸ࡿࡇ࡜ࡀሗ࿌ࡉࢀ࡚࠸
ࡿࠋࡇࢀࡽࡢ CRP ࡢ」ྜయ࡟ࡘ࠸࡚ࡣ࠸ࡃࡘ࠿ ᐃࡢሗ࿌ࡀ࠶ࡿࡀࠊ⮫ᗋⓗព⩏࠾ࡼࡧ⑓ែ࡜ࡢ㛵㐃࡟ࡘ࠸࡚ࡣ୙᫂࡞ࡇ࡜ࡶከ࠸ࠋ
࠙᪉ἲ᳨࣭ウ㡯┠ࠚCRP ࡟⤖ྜࡋ࡚࠸ࡿ」ྜయ࠾ࡼࡧࠊCRP ࡜ࡢ⤖ྜࡋ࡚࠸ࡿ complex ࢆච␿ỿ㝆ἲ᳨࡛ฟࡋ CRP ṇᖖࠊ࠾ࡼࡧ㧗್ࡢ⾑Ύ࡛ẚ㍑ࡋࡓࠋ⾑Ύࡣ 2012 ᖺ࠿ࡽ 2014 ᖺ࡟᪥ᮏ኱Ꮫ⑓㝔ࢆཷデࡋࡓእ᮶࣭ධ㝔ᝈ⪅ṧ⾑Ύ㸦೔⌮ጤဨ఍ᢎㄆ῭㸧ࢆ෾⤖ࡋࠊTranditional ࠾ࡼࡧ Magnet
ࢆ⏝࠸ࡓච␿ỿ㝆ἲ࡛ᢠ CRP ᢠయ㸦Thermo㸧࡜ Negative control (mouse IgG) ࢆ࠾ࡼࡧ Cross
link Magnet(Pearce)ࢆ⤖ྜࡉࡏࠊࡑࡢᚋ⾑Ύ࡜࡜ࡶ࡟ 1 ᫬㛫ᇵ㣴ࡋࡓࠋ⤖ྜࡋࡓ⺮ⓑࢆ 2 ḟඖ㟁ẼὋື(pH3㸫10)࡟࡚ὋືࡋࠊGel spot ࢆ⏬ീゎᯒ࢙࢘࢔㸦SameSpots㸧࡟࡚ゎᯒࡋࠊⓎ⌧㔞ࡢ㐪࠸ࡢㄆࡵࡽࢀࡿࢫ࣏ࢵࢺࢆษࡾฟࡋࠊLC/MS ゎᯒࢆ⾜ࡗࡓࠋ࠙⤖ᯝࠚᢠ CRP ᢠయ࡛ච␿ỿ㝆ࡋࡓࡶࡢ࡜ Negative control (mouse IgG)࡛ච␿ỿ㝆ࡋࡓࡶࡢ࡛Ⓨ⌧㔞ࡢ␗࡞ࡿࢫ࣏ࢵࢺࡣ኱ࡁࡃ 3 ࡘ࠶ࡗࡓࠋࡑࡢ࠺ࡕ᭱ࡶᕪࡢ࠶ࡿࡶࡢࢆ LC/MS ࡢゎᯒ࡟࡚VitaminD binding protein ࡀྠᐃࡉࢀࡓࠋ
࠙⪃ᐹ࣭⤖ㄒࠚ
௒ᅇࡢ⤖ᯝ࠿ࡽ CRP 」ྜయ࡜ࡋ࡚ Vitamin D binding protein ࡀ᪂ࡓ࡟ྠᐃࡉࢀࡓࠋ
Vitamin D binding protein ࡣࣅࢱ࣑ࣥ㹂࡜⤖ྜࡋࠊ⾑୰࡛ࡢ VitaminD ࡢ⃰ᗘࡸ Vitamin D
binding protein ࡢ⃰ᗘࡣෙື⬦⑌ᝈ࡜┦㛵ࡀࡿ࡜ࡢሗ࿌ࡀ࠶ࡿࠋ௒ᚋࡣ CRP 」ྜయ࡜ࡋ࡚
ࡢ VitaminD binding protein 㔞ࢆ ᐃࡋࠊ⮫ᗋⓗព⩏ࢆ᳨ウࡍࡿࠋ

́́

ㅮ₇せ᪨
㸦LS㸸ࣛࣥࢳࣙࣥࢭ࣑ࢼ࣮࣭MS㸸࣮ࣔࢽࣥࢢࢭ࣑ࢼ࣮㸧

́́

LS-1
࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ࡟࠾ࡅࡿ㧗ศゎ⬟࣭㧗⢭ᗘࣁ࢖ࢫ࣮ࣝࣉࢵࢺࡢ౑࠸ศࡅ㡞⃝ ᓫ 11ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫How to choose the high resolution or high throughput instrument for Imaging
applications.
Takashi Nirasawa1
1
Bruker Daltonics K.K.
᫖௒ࠊ͆࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒ͇࡟㛵ࡍࡿሗ࿌ࢆ┠࡟ࡍࡿᶵ఍ࡀቑ࠼࡚ࡁࡲࡋࡓࠋ་⒪࡛
⏝࠸ࡽࢀ࡚࠸ࡿ CT㸦ࢥࣥࣆ࣮ࣗࢱ᩿ᒙ᧜ᙳ㸧
ࠊMRI㸦᰾☢Ẽඹ㬆⏬ീἲ㸧ࡸ PET㸦࣏ࢪࢺ᩿ࣟࣥᒙἲ㸧࡞࡝ࡢ㠀◚ቯ࡛ࡢྍど໬ἲ࡜ࡣ␗࡞ࡾࠊ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡣ◚ቯศᯒࡢ୍
ࡘ࡛ࡍࡀࠊ≀㉁ᅛ᭷ࡢ㉁㔞ࢆ⏝࠸࡚ྍど໬ࡍࡿࡓࡵࠊࡑࡢ≀㉁ࡢヲ⣽࡞ᒁᅾࢆᤊ࠼ࡿࡇ࡜
ࡀᮇᚅ࡛ࡁࡲࡍࠋ
⏕య⤌⧊ษ∦ࢆࡣࡌࡵ࡜ࡍࡿ 2 ḟඖ࣭ᖹ㠃≧ࢧࣥࣉࣝ࡟ࡘ࠸࡚ࠊࢫ࢟ࣕࣥࡍࡿࡼ࠺࡟ᚤ
ᑠ㡿ᇦࡢ㉁㔞ศᯒࢆᩘ༓㹼ᩘ୓ᅇ⾜࠸ࡲࡍࠋࡑࢀ࡟ࡼࡗ࡚ࠊࢧࣥࣉࣝෆࡢ࠶ࡿ≉ᐃࡢ≀㉁ࡢᒁᅾࢆ⢭ᐦ࡟ྍど໬ࡍࡿࡇ࡜ࡀ࡛ࡁࡿࡼ࠺࡟࡞ࡾࡲࡍࠋ
㏆ᖺࠊᵝࠎ࡞࢖࢜ࣥ໬ἲ࠾ࡼࡧศ㞳ศᯒἲࢆ⤌ࡳྜࢃࡏࡓ㉁㔞ศᯒ⿦⨨࡟ࡼࡿྍど໬ࡀヨࡳࡽࢀ࡚࠸ࡲࡍࡀࠊࡑࡢ୰࡛ࡶ MALDI-TOF ᆺ㉁㔞ศᯒ⿦⨨࡟ࡼࡿࢱࣥࣃࢡ㉁࣭⬡㉁ࡢྍ
ど໬ࡸࠊFT-ICR ᆺ㉁㔞ศᯒ⿦⨨ࢆ⏝࠸ࡓ⸆≀࣭௦ㅰ≀ࡢྍど໬ࡀࠊ࢖࣓࣮ࢪࣥࢢࡢ௦⾲౛࡜ࡋ࡚ᣲࡆࡽࢀࡲࡍࠋ
ᮏㅮ₇࡛ࡣࠊᗈ࠸㡿ᇦࡢྍど໬ࢆ⾜࠺᭱᪂࣭㧗㏿ MALDI-TOF ᆺ㉁㔞ศᯒ⿦⨨㸸rapiflex
࡜ࠊ㉸㧗㉁㔞ศゎ࣭㧗㉁㔞⢭ᗘࢆഛ࠼ࡓ FT-ICR ᆺ㉁㔞ศᯒ⿦⨨㸸solariX-XR ࢆ⏝࠸ࡓࠊ᭱᪂ࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢆࡈ⤂௓⮴ࡋࡲࡍࠋ࠙ᑠᆺࣂ࣮ࢳࣕࣝࢫࣛ࢖ࢻࢫ࢟ࣕࢼ NanoZoomer-SQ ࡟ࡘ࠸࡚ࠚMALDI-TOF ࢩࢫࢸ࣒ࡢࡳ࡛⾜࠺࢖࣓࣮ࢪࣥࢢศᯒࡢ㞴Ⅼࡣࠊ⤌⧊ࢆ ᐃࡋࡓศᯒࢹ࣮ࢱ࡜
㧗ゎീᗘ࡞⤌⧊⏬ീࢆ⤌ࡳྜࢃࡏ࡚ほᐹࡍࡿࡀᅔ㞴࡞≧ἣ࡛ࡋࡓࠋࡑࡢㄢ㢟ࢆゎỴࡍࡿࡢࡀࠊ὾ᯇ࣍ࢺࢽࢡࢫ♫〇 ᑠᆺࣂ࣮ࢳࣕࣝࢫࣛ࢖ࢻࢫ࢟ࣕࢼ NanoZoomer-SQ ࡜ࣈ࣮࣭ࣝ࢝
ࢲࣝࢺࢽࢡࢫ♫ᵝࡢ MALDI-TOF ࢩࢫࢸ࣒࡜ࢆ⤌ࡳྜࢃࡏࡓ㐠⏝࡛ࡍࠋࡇࡢࢩࢫࢸ࣒ࡢ⤌ࡳྜࢃࡏ࡟ࡼࡾࠊࢱࣥࣃࢡ㉁ࡸ௦ㅰ≀➼ࡢᑐ㇟≀࡜⤌⧊ᙧែ࡜ࢆ↷ࡽࡋྜࢃࡏ࡞ࡀࡽࡢほᐹࡀྍ⬟࡜࡞ࡾࡲࡍࠊNanoZoomer-SQ ࡣᑠᆺ࣭ప౯᱁࡟ᑐ㇟⤌⧊ࡢࣂ࣮ࢳࣕࣝࢫࣛ࢖ࢻࢆసᡂ
ࡍࡿ⿦⨨࡛࠶ࡾࠊ⡆༢࡞᧯స࡛ࣂ࣮ࢳࣕࣝࢫࣛ࢖ࢻࡢྲྀᚓࡀྍ⬟࡛ࡍࠋ㸦࠙ࣂ࣮ࢳࣕࣝࢫࣛ
࢖ࢻࠚ࡜ࡣࠊࣉࣞࣃ࣮ࣛࢺ໬ࡉࢀࡓ⤌⧊ࡸ⣽⬊࡞࡝ࡢࢧࣥࣉࣝ඲యࢆ㧗ゎീᗘ࡟ࢹࢪࢱࣝ
໬ࡋࡓ⏬ീࢹ࣮ࢱࢆᣦࡋࡲࡍ㸧

́́

LS-2
࣐ࣝࢳ࣑࢜ࢵࢡࢫ࡞ࢹ࣮ࢱゎᯒࠊಖ⟶ࠊඹ᭷ࢆྍ⬟࡟ࡍࡿ BaseSpace ࢡࣛ࢘ࢻ㛵 ඾ᗈ 11࢖࣑ࣝࢼᰴᘧ఍♫ ࣉࣟࢲࢡࢺ࣐࣮ࢣࢸ࢕ࣥࢢ㒊 ࣉࣟࢲࢡࢺ࣐ࢿ࣮ࢪ࣮ࣕ

The BaseSpace Cloud enabled multi-omics data analysis, storage and sharing
Norihiro Seki1
1
Product Marketing Manager, Regional Marketing, Illumina K.K. Japan
BaseSpace ࢡࣛ࢘ࢻࢹ࣮ࢱゎᯒࢧ࣮ࣅࢫࢆᥦ౪ࡍࡿ࢖࣑ࣝࢼࡣࠊḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࢆጞ
ࡵ࡜ࡍࡿࢤࣀ࣒ゎᯒ࡟ᚲせ࡞〇ရࢆࠕSample to Answerࠖ࡜࠸࠺ࢥࣥࢭࣉࢺࡢඖ࡟୍㈏ࡋ
ࡓࢯ࣮ࣜࣗࢩࣙࣥࢆᥦ౪ࡋ࡚࠸ࡲࡍࠋ୺ຊࡢḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࡣࠊࡇࢀࡲ࡛࡟ࠊᵝࠎ࡞ᅜ㝿ࢤࣀ࣒ࣉࣟࢪ࢙ࢡࢺ࡛᥇⏝ࡉࢀࠊᩘከࡃࡢ᪂ࡓ࡞Ⓨぢ࡟㈉⊩ࡋ࡚ࡁࡲࡋࡓࠋ⌧ᅾ࡛ࡣࠊ
1 ᗘ࡟᭱኱ 16 ேศࡢ඲ࢤࣀ࣒ゎᯒ࡟ᚲせ࡞ࢹ࣮ࢱࢆࢧࣥࣉࣝ࠶ࡓࡾ 1000 ࢻ࡛ࣝ⏘ฟࡍࡿࡇ࡜ࡀྍ⬟࡟࡞ࡾࡲࡋࡓࠋ୍᪉࡛ࠊḟୡ௦ࢩ࣮ࢣࣥࢧ࣮ࡣ᪂ࡓ࡞ၥ㢟ࢆ⏕ࡳฟࡋࡲࡋࡓࠋ
ࡑࢀࡣࠊ᪥ࠎቑ኱ࡍࡿࢤࣀ࣒ࢹ࣮ࢱࢆຠ⋡ࡼࡃゎᯒ࠾ࡼࡧಖ⟶ࡍࡿ⎔ቃࢆᩚ࠼ࡿᚲせࡀ࠶ࡿ࡜࠸࠺ࡇ࡜࡛ࡍࠋ
ࡇࢀࡽࡢၥ㢟ࢆゎỴࡍࡿࡓࡵ࡟ࠊ࢖࣑ࣝࢼࡣ BaseSpace ࢡࣛ࢘ࢻࢹ࣮ࢱゎᯒࢧ࣮ࣅࢫࡢ
ᥦ౪ࢆ㛤ጞࡋࡲࡋࡓࠋࡇࢀ࡟ࡼࡾࠊࡇࢀࡲ࡛ከࡃࡢ࣮ࣘࢨ࣮ࡢ㢌ࢆᝎࡲࡋ࡚࠸ࡓࠊ↹㞧࡞᧯సࢆᚲせ࡜ࡍࡿࢹ࣮ࢱゎᯒࠊ኱㔞ࢹ࣮ࢱࡢಖ⟶࠾ࡼࡧඹྠ◊✲⪅࡜ࡢゎᯒ⤖ᯝࡢඹ᭷࡜
࠸࠺ၥ㢟ࢆ୍ᗘ࡟ゎỴࡍࡿࡇ࡜ࡀྍ⬟࡟࡞ࡾࡲࡋࡓࠋࡇࡢ BaseSpace ࢡࣛ࢘ࢻࡣࢤࣀ࣒ゎᯒ࡟≉໬ࡋࡓࡶࡢ࡛ࡣ࡞ࡃࠊ⮬⏤ᗘࡢ㧗࠸ࣉࣛࢵࢺࣇ࢛࣮࣒࡜ࡋ࡚タィࡉࢀ࡚࠸ࡿࡢ࡛ࠊ
ࢤࣀ࣒௨እࡢࢹ࣮ࢱࢆゎᯒࡍࡿࡇ࡜ࡶྍ⬟࡛ࡍࠋ≉࡟ࠊ࣐ࢫࢫ࣌ࢡࢺࣝࡢࢹ࣮ࢱࡢゎᯒࡣࠊࡑࢀࡒࢀࡢ

ᐃ⤖ᯝࢆ༢⊂࡛ゎᯒࡍࡿࡔࡅ࡛

࡞ࡃࠊࢤࣀ࣒ࡸ㑇ఏᏊⓎ⌧ゎᯒࡢ⤖ᯝ࡜⤌ྜࡏࡓ࣑࢜ࢵࢡࢫゎᯒࢆ⾜࠺ࡇ࡜࡛᪂ࡓ࡞Ⓨぢ࡟ࡘ࡞ࡀࡿࡇ࡜ࡀᮇᚅࡉࢀࡲࡍࠋࡇࡇ࡛ࡣࠊBaseSpace ࢡࣛ࢘ࢻࢆ฼⏝ࡍࡿ࣓ࣜࢵࢺ࠾ࡼࡧ
ᾏእ࡛ࡢ฼⏝౛࡟ࡘ࠸࡚⤂௓ࡋࡲࡍࠋ

́́

LS-3
LC-QTOF ࢆ⏝࠸ࡓ༴㝤ࢻࣛࢵࢢࡢศᯒ
⁪ᇣᫀᙪ 11࢔ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫Analysis of designer drugs by LC-QTOF
Masahiko Takino1
1
Agilent Technologies Japan, Ltd.
㯞⸆࡜ྠᵝࡢస⏝࠾ࡼࡧ༴㝤ᛶࢆᣢࡗࡓ༴㝤ࢻࣛࢵࢢࡀࠊ኱ࡁ࡞♫఍ၥ㢟࡜࡞ࡗ࡚࠸ࡿࠋ
ࡇࢀࡽ༴㝤ࢻࣛࢵࢢࡣつไ⸆≀ࡢศᏊᵓ㐀ࡢ୍㒊ࢆኚ࠼ࡓྜᡂ⸆≀࡛࠶ࡾࠊᶆ‽ရࡢ㎿㏿࡞ධᡭࡀᅔ㞴࡞ሙྜࡀከ࠸ࠋ୺࡞༴㝤ࢻࣛࢵࢢࡢᡂศࡣࠊྜᡂ࢝ࢳࣀࣥ㢮ࡸྜᡂ࢝ࣥࢼࣅ
ࣀ࢖ࢻ㢮࡛࠶ࡿࡀࠊ᭱㏆࡛ࡣࣇ࢙ࢿࢳࣝ࢔࣑ࣥ㢮ࠊྜᡂ࢜ࣆ࢜࢖ࢻࠊ࣋ࣥࢰࣇࣛࣥ㢮ࠊ࢔࣑ࣀ࢖ࣥࢲࣥ㢮࡞࡝ᵝࠎ࡞༴㝤ࢻࣛࢵࢢࡀሗ࿌ࡉࢀ࡚࠸ࡿࠋࡋࡓࡀࡗ࡚ࠊ༴㝤ࢻࣛࢵࢢࡢ
ศᯒ࡛ࡣᐃᛶศᯒ࠿ࡽጞࡲࡿࠋࡉࡽ࡟ࠊྜᡂ࢝ࣥࢼࣅࣀ࢖ࢻ㢮ࡣ⾑ᾮࡸᒀ࡞࡝ࡢ⏕యヨᩱ࠿ࡽࡣᮍኚ໬యࡢ⃰ᗘࡀᴟࡵ࡚పࡃࠊ௦ㅰ≀ࡢ᥈⣴ࡣ౑⏝ࡋࡓ༴㝤ࢻࣛࢵࢢࡢ᥎ᐃ࡟㔜せ࡛࠶ࡿࠋࡋ࠿ࡋࠊ༴㝤ࢻࣛࢵࢢࡣ᪂つ໬ྜ≀ࡀከ࠸ࡇ࡜࠿ࡽ⏕యෆ࡛ࡢ௦ㅰ࡟㛵ࡍࡿሗ࿌ࡣᴟࡵ࡚ᑡ࡞࠸ࠋࡇࢀࡲ࡛₇⪅ࡽࡣࠊᅄ㔜ᴟ-㣕⾜᫬㛫ᆺ㉁㔞ศᯒィࢆ⏝࠸ࡓ LC-QTOF ࢆ⏝࠸࡚༴㝤ࢻࣛࢵࢢࢆྵࡵࡓᵝࠎ࡞⸆≀ࡢศᯒᡭἲࢆ㛤Ⓨࡋ࡚ࡁࡓࠋLC-QTOF ࡣ㧗ศゎ⬟࡛⢭
ᐦ㉁㔞

ᐃࡀྍ⬟࡞ࡇ࡜࠿ࡽࠊ༴㝤ࢻࣛࢵࢢศᯒ࡟ࡣ㠀ᖖ࡟᭷ຠ࡞⿦⨨࡛࠶ࡿࠋࡋ࠿ࡋࠊ

LC-QTOF ࡣᵝࠎ࡞ ᐃᡭἲࠊࢹ࣮ࢱゎᯒᡭἲࡀሗ࿌ࡉࢀ࡚࠾ࡾࠊࡇࢀࡽ ᐃᡭἲࡸゎᯒᡭἲࡢ≉ᚩࢆ༑ศ࡟⌮ゎࡍࡿᚲせࡀ࠶ࡿࠋࡑࡇ࡛ᮏࢭ࣑ࢼ࣮࡛ࡣ༴㝤ࢻࣛࢵࢢศᯒ࡟⏝࠸ࡽࢀࡿ LC/QTOF ࡢ ᐃᡭἲࡸࢹ࣮ࢱゎᯒᡭἲ࡟ࡘ࠸࡚ゎㄝࡍࡿࠋࡉࡽ࡟ࠊMetaboliteID ࢯࣇࢺ࢚࢘࢔࡟ࡼࡿ༴㝤ࢻࣛࢵࢢࡢ௦ㅰ≀ศᯒ౛ࡸ࢖࢜ࣥࣔࣅࣜࢸ࢕࣮ᢏ⾡ࢆഛ࠼ࡓ LC-QTOF ࡟ࡼࡿ༴㝤ࢻࣛࢵࢢศᯒ࡟ࡘ࠸࡚ࡶ⤂௓ࡍࡿࠋ

́́

MS-1
LC/MS/MS ࡢ⮫ᗋ᳨ᰝᛂ⏝࡬ࡢྲྀࡾ⤌ࡳబ⸨ Ᏺ 1 ඛ⏕
1༓ⴥ኱Ꮫ་Ꮫ㒊㝃ᒓ⑓㝔࣐ࢫࢫ࣌ࢡࢺ࣓ࣟࢺ᳨࣮ࣜᰝデ᩿Ꮫ

Clinical application of LC/MS/MS- focusing on vitamin D metabolites testing -Mamoru Sato1
1
Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospitalࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫ࡣ 2015 ᖺ 5 ᭶࡟㉁㔞ศᯒィࢆ᳨ฟჾ࡜ࡍࡿ㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇศᯒ⿦⨨ࢆ་⒪ᶵჾ㸦Ⓩ㘓␒ྕ㸸14B3X00012000030㸧࡜ࡋ࡚᪥ᮏᅜෆ࡛Ⓩ㘓ࡋࡲࡋࡓࠋࣁ࢖ࢫ࣮ࣝࣉࢵࢺ࡛ࠊ࠿ࡘᏳᐃࡋࡓࢩࢫࢸ࣒ࡀせồࡉࢀࡿデ᩿ᶵჾ࡜ࡋ࡚ࠊ㸰ࢳࣕࣥࢿࣝࡢ 2 ḟඖ LC ᵓᡂ࡜࡞ࡗ࡚࠸ࡲࡍࠋ1 ḟඖ┠࡛㉁㔞ศᯒィࡸศᯒ࣒࢝ࣛࡢởࢀࢆ㍍ῶࡍࡿࡓࡵࡢ㝖ࢱࣥࣃࢡ㉁ฎ⌮ࢆ⾜࠸ࠊ2 ḟඖ┠࡛㏻ᖖࡢ LC ศ㞳ࢆ⾜࠸ࡲࡍࠋࡲࡓࠊศᯒ᫬㛫ࢆ▷⦰ࡍࡿࡓࡵ࡟ 2 ࢳࣕࣥࢿࣝᵓᡂ࡜ࡋࠊ୍᪉ࡀ LC-MS ศᯒࢆ⾜ࡗ࡚࠸ࡿ㛫࡟ࡶ࠺୍᪉ࡀ 1 ḟඖ┠ࡢ๓ฎ⌮ࡸ 2 ḟඖ┠ࡢ࣒࢝ࣛࡢᖹ⾮໬ࢆ⾜࠼ࡿࡼ࠺࡟࡞
ࡗ࡚࠸ࡲࡍࠋྛࢳࣕࣥࢿࣝࡢὶ㊰ࠊ⛣ື┦࣎ࢺࣝࡣ⊂❧ࡋ࡚࠾ࡾࠊ」ᩘࡢ࢔ࢵࢭ࢖ࢆ 1 ྎࡢࢩࢫࢸ࣒࡟⤌ࡳ㎸ࢇ࡛࠾ࡃࡇ࡜ࡶྍ⬟࡛ࠊ࢔ࢵࢭ࢖ࡈ࡜࡟⛣ື┦ࡸ࣒࢝ࣛࢆ஺᥮ࡍࡿᚲ
せࡣ࠶ࡾࡲࡏࢇࠋ
ᮏࢭ࣑ࢼ࣮࡛ࡣࠊྠࢩࢫࢸ࣒ࢆ౑⏝ࡉࢀ࡚࠸ࡿ༓ⴥ኱Ꮫ௜ᒓ⑓㝔ࡢబ⸨ඛ⏕࡟ LC-MS ࡢ⮫ᗋ᳨ᰝᛂ⏝࡟ࡘ࠸࡚ࡈㅮ₇࠸ࡓࡔࡁࡲࡍࠋ
࠙ࡈㅮ₇せ᪨ࠚ
⌧ᅾࡢ⮫ᗋ᳨ᰝᐊ࡛ࡣࠊྛ✀ࢫࢸࣟ࢖ࢻ࣭࣍ࣝࣔࣥࣅࢱ࣑ࣥ D ௦ㅰ≀࡞࡝ࡢపศᏊ໬ྜ
≀ࡢศᯒ࡟ࡣᢠయ࡟ࡼࡿච␿Ꮫⓗᐃἲࡀ୺࡟⏝࠸ࡽࢀ࡚࠸ࡿࠋච␿Ꮫⓗᐃἲࡣ᳨యฎ

⌮⬟ຊࡀ㧗ࡃࠊ⮫ᗋ᳨ᰝ࡟࠾࠸࡚ᚲ㡲࡛࠶ࡿ୍᪉ࠊ஺ᕪ཯ᛂࡢᏑᅾࡸ࢟ࢵࢺ㛫ᕪ࣭᪋タ㛫ᕪࡢၥ㢟ࡀᣦ᦬ࡉࢀ࡚࠸ࡿࠋపศᏊ໬ྜ≀ࡣഃ㙐ᵓ㐀࡞࡝ࡢᚤᑠ࡞㐪࠸࡟ࡼࡾ⏕≀Ꮫⓗάᛶࡀ኱ࡁࡃ␗࡞ࡿࡓࡵࠊ⢭ᐦ࡞௦ㅰືែࡢホ౯࡟ࡣࠊᚤᑠᵓ㐀ᕪࢆᘚูࡍࡿࡇ࡜ࡢ࡛ࡁࡿ
LC/MS/MS ࡛ࡢ ᐃࡀ㠀ᖖ࡟᭷⏝࡛࠶ࡿࠋᮏⓎ⾲࡛ࡣࠊLC/MS/MS ࡢ⮫ᗋ᳨ᰝᐊᑟධࡢ㸯౛࡜ࡋ࡚ࠊࣅࢱ࣑ࣥ D ௦ㅰ≀ࡢศᯒࢆ⤂௓ࡍࡿࠋᡃࠎࡣࠊάᛶᆺࣅࢱ࣑ࣥ D ࡜ᐦ᥋࡞㛵ಀ࡟࠶ࡿ୙άᛶᆺࣅࢱ࣑ࣥ D㸦24,25(OH)2D3㸧ࡶྵࡵࡓ 4 ✀ࡢࣅࢱ࣑ࣥ D ௦ㅰ≀࡟ࡘ࠸᳨࡚ᰝ
ᛂ⏝ࢆ┠ⓗ࡜ࡋ࡚ࠊ⮫ᗋ᳨ᰝࢆ⾜࠺㝿࡟⤯ᑐ࡟ồࡵࡽࢀࡿṇ☜ᗘ࣭෌⌧ᛶ࣭Ᏻᐃᛶ࣭᭱ప
ᐃ㔞ឤᗘ࣭࣐ࢺࣜࢡࢫࡢᖸ΅࣭᥇⾑⟶✀ࡢᙳ㡪࣭ᚑ᮶ἲ࡜ࡢ┦㛵࡟ࡘ࠸࡚ヲ⣽࡟᳨ウࢆ⾜
ࡗࡓࠋ

́́

ㅮ₇せ᪨
㸦TF㸸ࢸࢡࣀࣟࢪ࣮ࣇ࢛࣮࣒ࣛ㸧

́́

TF-1
᭱᪂ࡢ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ࡜࢖࢜ࣥࣔࣅࣜࢸ࢕࣮QTof
ᑎᓮ┿ᶞ 1, ࢱࢼ࢖ ࣃࢡࢫࢺࣥ 1
1᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫Waters Full Spectrum molecular imaging and Ion mobility Mass Spectromerty
QTof – Vion IMS QTof
Maki Terasaki1, Thanai Paxton1
LC/MS ศᯒ࡟ᚲせ࡞ヨ⸆࠿ࡽࠊ๓ฎ⌮〇ရࠊᾮయࢡ࣐ࣟࢺࢢࣛࣇࠊศ㞳࣒࢝ࣛࠊ㉁㔞ศᯒィࠊゎᯒࢯࣇࢺࠊࢧ࣏࣮ࢺࢧ࣮ࣅࢫࡲ࡛ࠊࢺ࣮ࢱࣝ࡟〇ရࢆࡈᥦ౪ࡍࡿ࢛࣮࢘ࢱ࣮ࢬࡼࡾࠊ
᭱᪂ࡢ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ࡜࢖࢜ࣥࣔࣅࣜࢸ࢕࣮QTof ࢆࡈ⤂௓ࡋࡲࡍࠋ
࠙ࣇࣝࢫ࣌ࢡࢺࣝศᏊ࢖࣓࣮ࢪࣥࢢࠚࣉࣟࢸ࣑࢜ࢡࢫࠊ࣓ࢱ࣑࣎ࣟࢡࢫࠊ⣽⬊⏕≀Ꮫࡸ⤌⧊⏕≀Ꮫࠊ⑓⌮◊✲࠾ࡼࡧ⤌⧊Ꮫ࡜࠸ࡗࡓศ㔝࡟࠾࠸࡚࠶ࡽࡺࡿಶูࡢ࢖࣓࣮ࢪࣥࢢᢏ⾡ࢆ㉸࠼ࡿヲ⣽࡜ศᏊ᝟ሗࡢྲྀᚓࢆᐇ⌧ࡍࡿࡓࡵ࡟ࠊMALDI㸦࣐ࢺࣜࢡࢫᨭ᥼࣮ࣞࢨ࣮⬺㞳࢖࢜ࣥ໬㸧ࠊDESI㸦⬺㞳࢚ࣞࢡࢺࣟࢫࣉ࣮ࣞ࢖࢜ࣥ໬㸧ࠊ࢖࢜ࣥࣔࣅࣜࢸ࢕࣮ศ㞳ࢆ⤫ྜࡋࡓ
Waters ࣇࣝࢫ࣌ࢡࢺࣝศᏊ࢖࣓࣮ࢪࣥࢢࣉࣛࢵࢺ࣮࣒࣍ࢆ Pittcon 2015 ࡛Ⓨ⾲ࡋࠊ
Editor's Award 㖟㈹ࢆཷ㈹ࡋࡲࡋࡓࠋࣇࣝࢫ࣌ࢡࢺࣝศᏊ࢖࣓࣮ࢪࣥࢢࢩࢫࢸ࣒ࡣࠊ≉ᐃࡢࢱ࢖ࣉࡢศᏊ㸦࣌ࣉࢳࢻࠊ⬡㉁ࠊపศᏊ௦ㅰ≀ࠊ⢾㢮࡞࡝㸧ࢆศᯒࡍࡿࡢ࡟㠀ᖖ࡟㐺ࡋࡓ㉁㔞ศᯒᢏ⾡ࡢ⤌ࡳྜࢃࡏ࡛ࡍࠋࡇࢀࡽࡢᢏ⾡ࡣࠊ㉁㔞ศᯒ࢖࣓࣮ࢪࣥࢢ࡛ᚓࡽࢀࡿ᝟
ሗࢆ᭱኱㝈ໟᣓⓗ࡞ࡶࡢ࡜ࡍࡿࡓࡵ࡟࠾஫࠸࡟⿵᏶ࡋྜ࠺ࡶࡢ࡛ࡍࠋ
࠙Vion IMS QTof ㉁㔞ศᯒィࠚ࣋ࣥࢳࢺࢵࣉᆺ⿦⨨࡜ࡋ࡚ᅄ㔜ᴟ㣕⾜᫬㛫ᆺ㉁㔞ศᯒ࡜࢖࢜
ࣥࣔࣅࣜࢸ࢕࣮ศ㞳ࡢ฼Ⅼࢆ⤌ࡳྜࢃࡏࡓ Vion IMS QTof ㉁㔞ศᯒィ ࡟ࡼࡾࠊ᫂░࡛ಙ㢗ᛶࡢ࠶ࡿ࣮ࣝࢳࣥศᯒࢆ⾜࠺ࡇ࡜ࡀ࡛ࡁࡿࡼ࠺࡟࡞ࡾࡲࡍࠋ
࢖࢜ࣥࣔࣅࣜࢸ࢕࣮࡛ࡣࠊ࢖࢜ࣥࢆࡑࢀࡒࢀࡢᙧࠊ㉁㔞ࠊ࠾ࡼࡧ㟁Ⲵ࡟ࡼࡾ஫࠸࡟ศ㞳ࡍࡿࡇ࡜࡛ࠊศ㞳࡟࠾࠸࡚ࡶ࠺ 1 ࡘูࡢḟඖࡀᚓࡽࢀࡲࡍࠋ࢖࢜ࣥࣔࣅࣜࢸ࢕࣮ࡢ㑅ᢥᛶ࡟ࡼࡾࢫ࣌ࢡࢺࣝᖸ΅ࡀ㝖ཤࡉࢀࠊࢧࣥࣉࣝ࢖࢜ࣥࡣࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮࡛ඹ⁐ฟࡉࢀࡿ໬ྜ≀ࡸࣂࢵࢡࢢࣛ࢘ࣥࢻᖸ΅࠿ࡽ༊ูࡉࢀࡿࡓࡵࠊࡍ࡭࡚ࡢࢫ࣌ࢡࢺࣝࡀ᫂░࡟࡞ࡾࠊ☜ಙ࡛ࡁࡿ໬ྜ≀ࡢ≉ᛶゎᯒࢆ⾜࠺ࡇ࡜ࡀ࡛ࡁࡲࡍࠋࡉࡽ࡟ࡍ࡭࡚ࡢ࢖࢜ࣥ࡟ࡘ࠸࡚⾪✺᩿㠃✚ (CCS) ್ࡀ⏕ᡂࡉࢀࡿࡓࡵࠊᚑ᮶ࡢ LC-MS ᐇ㦂ࡼࡾከࡃࡢ᝟ሗࢆᚓࡿࡇ࡜ࡀ࡛ࡁ
ࡲࡍࠋ

́́

TF-2
Agilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF ࡢ⤂௓⁪ᇣᫀᙪ 11࢔ࢪࣞࣥࢺ㺃ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫Agilent 6560 Ion Mobility Q-TOF LC/MSC-QTOF
Masahiko Takino1
1
Agilent Technologies Japan, Ltd.
Ion Mobility Spectrometry (IMS)ࡣࠊ1950 ᖺ௦࡟㛤Ⓨࡉࢀࡓ࢖࢜ࣥࡢ⛣ືᗘ࡟ࡼࡾ࢖࢜
ࣥࢆศ㞳ࡍࡿᢏ⾡࡛࠶ࡾࠊྍᦙᆺࡢ⌧ሙ࡛ࡢ⇿Ⓨ≀ศᯒ࡞࡝࡟⏝࠸ࡽࢀ࡚ࡁࡓࠋࡇࡢศ㞳ᢏ⾡ࡣ LC-MS ࡞࡝࡜⤌ࡳྜࢃࡏࡿ࡜➨ 3 ࡢศ㞳ᢏ⾡࡛࠶ࡾࠊࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮ࡸ㉁㔞ศᯒィ࡛ࡣ୙ྍ⬟࡞㉁㔞ࡀྠ୍ࡢጉᐖ࢖࢜ࣥࡢศ㞳ࡸࠊ࢖࢜ࣥࡢ❧యᵓ㐀ゎᯒࢆྍ⬟࡜ࡋࠊࡼࡾ≉␗ⓗ࡛ヲ⣽࡞᝟ሗࢆᚓࡿࡇ࡜ࡀྍ⬟࡛࠶ࡿ Agilent 6560 Ion Mobility Q-TOF LC/MSࢩࢫࢸ࣒ࡣࠊࡇࡢ᪂ࡓ࡞ศ㞳ᢏ⾡࡛࠶ࡿ IMS ࢆഛ࠼᪂ࡓ࡞ศᯒࢆᥦ౪ࡍࡿ㉁㔞ศᯒィ࡛࠶ࡿࠋᮏ࣮࣡ࢡࢩࣙࢵࣉ࡛ࡣ IMS ࡟ࡼࡿᵓ㐀␗ᛶయࡢศ㞳ࠊࢻࣜࣇࢺࢫ࣌ࢡࢺࣝࢆ฼⏝ࡋࡓ㑅ᢥᛶࡢᨵၿࠊAll Ions MSMS ἲ࡜ IMS ࡢ⤌ࡳྜࢃࡏ࡟ࡼࡿࣇࣛࢢ࣓ࣥࢺ࢖࢜ࣥࡢ㛵㐃௜ࡅ࡞࡝ࡢᡭἲ࡟ࡘ࠸࡚⤂௓ࡍࡿࠋ

́́

TF-3
࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࡢ࣎ࢺࣝࢿࢵࢡࢆゎᾘࡍࡿ rapifleXTM MALDI Tissuetyper TM๓⏣ᩧ჆ 11ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫High Speed Scan instrument, rapifleXTM MALDI TissuetyperTM break though MS
imaging bottleneck
Masahiro Maeda1
1
Bruker Daltonics K.K.
㉁㔞ศᯒ࡟ࡼࡿ⤌⧊࢖࣓࣮ࢪࣥࢢᢏ⾡ࡢ㐍Ṍࡣ᪂ࡋ࠸◊✲ศ㔝ࢆ㛤ᣅࡋࠊ≉࡟⑓⌮ศ㔝࡛ከࡃࡢᐇ⦼ࢆୖࡆ࡚࠸ࡿࠋ

ึᮇࡢẁ㝵࡛ࡣ⤌⧊ୖ࠿ࡽ┤᥋㉁㔞ศᯒࢆ⾜࠺ࡇ࡜ࡀ◊✲ࢸ࣮࣐࡛࠶ࡗࡓࡀࠊ⌧ᅾࡣከࡃࡢ᝟ሗࢆ࡛ࡁࡿ㝈ࡾ⤌⧊ୖ࠿ࡽᚓ࡚ࠊ᭷ព࡞᝟ሗ࡜ࡋ࡚ᚓ
ࡿࡇ࡜ࡀࢸ࣮࣐ࡢ୍ࡘ࡟࡞ࡗ࡚࠸ࡿࠋ

ከࡃࡢ᝟ሗࢆ୍ᅇࡢᐃ࡛ᚓࡿⅭ࡟ࡣ࠸ࡃࡘ࠿ࡢ

࣏࢖ࣥࢺ࡛ᢏ⾡ࡢᨵၿࡀồࡵࡽࢀ࡚࠸ࡿࠋࡑࡢ࠺ࡕࡢ࠸ࡃࡘ࠿ࢆୖࡆ࡚ࡳࡿ࡜ࠊ࣮ࣞࢨ࣮
ࢆᚤ⣽࡟↷ᑕࡍࡿᢏ⾡ࠊ⤌⧊ୖ࡟ᒁᅾ໬ࡍࡿࢱ࣮ࢤࢵࢺ≀㉁ࡢຠ⋡ࡢࡼ࠸࢖࢜ࣥ໬ࠊ࢖࢜
ࣥ໬ࡋࡓ≀㉁ࡢ⢭ᗘࡢࡼ࠸ศᯒࠊឤᗘࡢᨵၿࠊ

ᐃࢫࣆ࣮ࢻࡢᨵၿ࡞࡝࡛࠶ࡿࠋࡑࢀࡒࢀ

ࡢᨵⰋࡣ㉁㔞ศᯒ⿦⨨ࡢྛᶵ⬟ࡢᨵⰋ࡟ࡼࡾ㐩ᡂࡉࢀࡿ࡜ᮇᚅࡉࢀࡿࠋ
௒ᅇ⤂௓ࡍࡿ rapifleXTM MALDI Tissuetyper TM ࡣ࣮ࣞࢨ࣮↷ᑕࡢ࣓࢝ࢽࢬ࣒ࢆᨵⰋࡋࠊ
ᚑ᮶ࡢ⤌⧊ษ∦࡟↷ᑕࡍࡿࢫࣆ࣮ࢻࢆ㸯㸮ಸ௨ୖᨵၿࡋ࡚࠸ࡿࠋ

࢖࢜ࣥ໬ࡉࢀࡓ≀㉁ࡣ

㣕⾜᫬㛫࡟ࡼࡾศ㞳ࡉࢀࠊࢹ࣮ࢱ࡜ࡋ࡚⵳✚ࡉࢀࡿࠋ཰㞟ࡋࡓⳘ኱࡞᝟ሗࡣ MALDI
Tissuetyper ⏝ࡢᑓ⏝ࢯࣇࢺ㸦flexImaging,SCiLS Lab,SCiLS Lab 3D㸧࡟࡚㉁㔞ศᯒࢹ࣮ࢱࢆྍ
ど໬ࡉࢀࡿࠋ
᭱᪂ࡢ࢖࣓࣮ࢪࣥࢢ㉁㔞ศᯒࢩࢫࢸ࣒ rapifleXTM MALDI Tissuetyper TM ࡟ࡼࡗ࡚ᚓࡽࢀ
ࡿ⤖ᯝࡸࡑࡢᶵ⬟࡟ࡘ࠸࡚ゎㄝࡍࡿࠋ

́́

TF-4
㉁㔞ศᯒィࢆ᳨ฟჾ࡜ࡍࡿయእデ᩿⏝་⒪ᶵჾ Prelude MD ࡢ⤂௓❑⏣㞞அ 11ࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫Prelude MD liquid chromatograph equipped with mass spectrometer for clinicaldiagnostics
Masayuki Kubota1
1
Thermo Fisher Scientific K.K.
㏆ᖺࠊḢ⡿࡛ࡣᾮయࢡ࣐ࣟࢺࢢࣛࣇ㉁㔞ศᯒィ㸦LC-MS㸧ࡢデ᩿་⒪ᛂ⏝ࡢ⠊ᅖࡀᗈࡀࡾ
ࡘࡘ࠶ࡾࠊ᪥ᮏ࡛ࡶ᭱ඛ➃デ᩿ᢏ⾡ࡢࡦ࡜ࡘ࡜ࡋ࡚ὀ┠ࡉࢀ࡚࠸ࡲࡍࠋࢧ࣮ࣔࣇ࢕ࢵࢩࣕ
࣮ࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫ࡣ 2015 ᖺ 5 ᭶࡟㉁㔞ศᯒィࢆ᳨ฟჾ࡜ࡍࡿ㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇศᯒ⿦⨨ࢆ་⒪ᶵჾ㸦Ⓩ㘓␒ྕ㸸14B3X00012000030㸧࡜ࡋ࡚᪥ᮏᅜෆ࡛Ⓩ㘓ࡋࡲࡋࡓࠋLC-MS ࡣ」ᩘࡢศᯒᑐ㇟ࢆྠ᫬࡟᳨ฟ࡛ࡁࠊLC ࡢศᯒ᮲௳ࡀྠࡌ࡛࠶ࢀࡤ」ᩘࡢ
᳨ᰝ㡯┠ࢆ୍ᗘ᳨࡛ᰝ࡛ࡁࡿࡢࡀ኱ࡁ࡞࣓ࣜࢵࢺ࡛ࡍࠋࡋ࠿ࡋࠊᐇ㝿࡟ࡣ LC ࡢ᮲௳ࢆࡦ࡜
ࡘ࡟⤫୍ࡍࡿࡇ࡜ࡣᅔ㞴࡛ࠊ」ᩘࡢ᮲௳ࢆࢭࢵࢺ࢔ࢵࣉ࡛ࡁࡿࡇ࡜ࡀ᳨ᰝᐊࡢ⮬ື໬ࠊ┬ຊ໬ࠊࡑࡋ࡚ศᯒ᫬㛫ࡢ▷⦰࡟㔜せ࡜࡞ࡾࡲࡍࠋࡲࡓࠊࢧࣥࣉࣝࡢ๓ฎ⌮ࡢ⮬ື໬ࡶ㔜せ࡛ࡍࠋࡇࡇ࡛ࡈ⤂௓ࡍࡿ Thermo Scientific™ Prelude MD™ࡣࠊࣁ࢖ࢫ࣮ࣝࣉࢵࢺ࡛ࠊ࠿ࡘᏳᐃᛶࡀ
せồࡉࢀࡿデ᩿ᶵჾ࡜ࡋ࡚ࠊ2 ࢳࣕࣥࢿࣝࡢ 2 ḟඖ LC ᵓᡂ࡜࡞ࡗ࡚࠸ࡲࡍࠋ2 ḟඖ LC ࡢ
1 ḟඖ┠࡛㉁㔞ศᯒィࡸศᯒ࣒࢝ࣛࡢởࢀࢆ㍍ῶࡍࡿࡓࡵࡢ㝖ࢱࣥࣃࢡ㉁ฎ⌮ࢆ⾜࠸ࠊ2 ḟඖ┠࡛㏻ᖖࡢ LC ศ㞳ࢆ⾜࠸ࡲࡍࠋࡲࡓࠊศᯒ᫬㛫ࢆ▷⦰ࡍࡿࡓࡵ࡟๓㏙ࡢ 2 ḟඖ LC ࢆ 2ࢳࣕࣥࢿࣝᵓᡂ࡜ࡋࠊ୍᪉ࡀ LC-MS ศᯒࢆ⾜ࡗ࡚࠸ࡿ㛫࡟ࡶ࠺୍᪉ࡀ 1 ḟඖ┠ࡢ๓ฎ⌮ࡸ
2 ḟඖ┠ࡢ࣒࢝ࣛࡢᖹ⾮໬ࢆ⾜࠼ࡿࡼ࠺࡟࡞ࡗ࡚࠸ࡲࡍࠋྛࢳࣕࣥࢿࣝࡢὶ㊰ࠊ⛣ື┦࣎ࢺࣝࡣ⊂❧ࡋ࡚࠾ࡾࠊ」ᩘࡢ࢔ࢵࢭ࢖ࢆ 1 ྎࡢࢩࢫࢸ࣒࡟⤌ࡳ㎸ࢇ࡛࠾ࡃࡇ࡜ࡶྍ⬟࡛ࠊ࢔ࢵࢭ࢖ࡈ࡜࡟⛣ື┦ࡸ࣒࢝ࣛࢆ஺᥮ࡍࡿᚲせࡣ࠶ࡾࡲࡏࢇࠋ
ᮏㅮ₇࡛ࡣࠊPrelude MD ࡢࢩࢫࢸ࣒ᴫせ࡟ࡘ࠸࡚ࡈ⤂௓ࡋࡲࡍࠋ

́́

TF-5
SWATH® Next-Generation Proteomics ࡜ OneOmicsτ࡟ࡼࡿ⥙⨶ⓗ࡞ࢱ࣮ࢤࢵࢺᐃ
㔞ࣉࣟࢸ࣮࣒࢜ゎᯒᰘ⏣ ⊛ 11ࢧ࢖࢚ࢵࢡࢫ ࢔ࣉࣜࢣ࣮ࢩࣙࣥࢧ࣏࣮ࢺ

Comprehensive Targeted Quantitative Proteomics using SWATH® Next-Generation
Proteomics and OneOmics
Takeshi Sibata1
1
K.K. SCIEX Application Support⏕యෆࡢࢱࣥࣃࢡ㉁ࡢኚືࢆᐃ㔞ⓗ࡟ゎᯒࡍࡿ஦ࡣ⏕࿨⌧㇟ࡢ⌮ゎࡢࡓࡵ࡟㔜せ࡛ࡍࠋ㉁㔞ศᯒᢏ⾡ࢆ୰ᚰ࡜ࡋࡓࣉࣟࢸ࣮࣒࢜ゎᯒᢏ⾡ࡢⓎᒎ࡟క࠸ࠊᩘ༓ࡢࢱࣥࣃࢡ㉁ࡢྠᐃ
ࡀྍ⬟࡜࡞ࡾࠊࡲࡓᐃ㔞ᢏ⾡ࡶ㐍ᒎࡋࡘࡘ࠶ࡾࡲࡍࠋᚑ᮶ࡢࢱࣥࣃࢡ㉁ᐃ㔞ἲ࡛ࡣឤᗘࡸ
≉␗ᛶࠊࢲ࢖ࢼ࣑ࢵࢡࣞࣥࢪࡸࢫ࣮ࣝࣉࢵࢺ࡞࡝࠸ࡃࡘ࠿ࡢၥ㢟Ⅼࡀᣦ᦬ࡉࢀ࡚࠸ࡲࡋࡓࡀࠊ኱つᶍ࡞ࢹ࢕ࣇ࢓ࣞࣥࢩࣕࣝゎᯒ࡬ࡢᛂ⏝࡜ࡋ࡚ࠊ୍ᗘࡢ ᐃ࡛ Data independent ࡟඲࡚ࡢ࢖࢜ࣥࢆྲྀᚓྍ⬟࡞ᡭἲ࡛࠶ࡿ SWATH® Next-Generation Proteomics ࡀ㛤Ⓨࡉࢀࡲࡋࡓࠋࡇࢀ࡟ࡼࡾࠊ୍ᗘ࡟㠀ᖖ࡟ከࡃࡢࢱࣥࣃࢡ㉁ࡢᐃ㔞᝟ሗࢆ⥙⨶ⓗ࡟ྲྀᚓࡍࡿࡇ࡜ࡀ
ྍ⬟࡜࡞ࡾࡲࡋࡓࠋ୍᪉࡛ࡣࠊ⭾኱࡞ࣉࣟࢸ࣑࢜ࢡࢫࡢຠ⋡ⓗ࡞ࢹ࣮ࢱゎᯒࠊ⟶⌮࡞࡝ࡢ᪂ࡓ࡞ㄢ㢟࡟┤㠃ࡋ࡚࠸ࡲࡍࠋ
᭱㏆ࠊ࢖࣑ࣝࢼ♫࡟ࡼࡿ BaseSpace®ୖࡢ࢔ࣉࣜࢣ࣮ࢩࣙࣥ࡜ࡋ࡚㛤Ⓨࡉࢀࡓ OneOmics™
ࡣࠊࢡࣛ࢘ࢻࢥࣥࣆ࣮ࣗࢸ࢕ࣥࢢࢆ฼⏝ࡋࡓ㉁㔞ศᯒࢹ࣮ࢱࡢᐃ㔞ゎᯒࡤ࠿ࡾ࡛ࡣ࡞ࡃࠊ
ࢹ࣮ࢱࡢ⤫ィฎ⌮࡜ࣃࢫ࢙࢘࢖ゎᯒ࡜࠸ࡗࡓ⏕≀Ꮫⓗ࡞ព࿡௜ࡅࡢ࠶ࡿゎᯒࡸࠊ࢖࣑ࣝࢼ
♫ࡢḟୡ௦ࢩ࣮ࢡ࢚ࣥࢧ࣮ࢆࡣࡌࡵ࡜ࡍࡿࢤࣀ࣒᝟ሗ࡜ࡢ⤫ྜゎᯒࢆ Web ୖࡢ⡆౽࡞࢖ࣥࢱ࣮ࣇ࢙࢖ࢫࢆ⏝࠸࡚ྍ⬟࡜࡞ࡾࡲࡋࡓࠋ
௒ᅇࡣࠊSWATH®࡟ࡼࡾᚓࡽࢀࡓࢩࢢࢼࣝఏ㐩ࢿࢵࢺ࣮࣡ࢡࡢ⥙⨶ⓗ࡞ࣜࣥ㓟໬ࣉࣟࢸ࢜
࣑ࢡࢫࢹ࣮ࢱࢆ OneOmics™ ࡟࡚ά⏝ࡋࡓ౛ࢆ⤂௓ࡉࡏ࡚࠸ࡓࡔࡁࡲࡍࠋࢩࢢࢼࣝఏ㐩⣔࡟࠾ࡅࡿ࢟ࢼ࣮ࢮࢿࢵࢺ࣮࣡ࢡࡸ」ᩘࡢࢩࢢࢼࣝఏ㐩⣔࡜ࡢẚ㍑ࢆ⾜࠺ࡇ࡜ࡀ࡛ࡁࠊࢩࢢࢼ
ࣝఏ㐩⣔඲యࡢࢩࢫࢸ࣒࡜ࡋ࡚ࡢ⌮ゎ࡟᭷ຠ࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀࡲࡋࡓࠋBaseSpace®ୖࡢྛ✀ࢤࣀ࣒ࢶ࣮ࣝࡸ OneOmicsτࡢά⏝࡟ࡼࡾࠊ࡝ࢇ࡞㑇ఏᏊࡀⓎ⌧ࡋ࡚࠸ࡿ࠿(ࢤࣀ࣑ࢡࢫ)ࠊ
ࡲࡓࠊ࡝ࡢࡼ࠺࡞ࢱࣥࣃࢡ㉁ࡀാ࠸࡚࠸ࡿ࠿(ࣉࣟࢸ࣑࢜ࢡࢫ)࡞࡝ࡢ࣑࢜ࢵࢡࢫ㸦Omics㸧᝟ሗࢆ㥑౑ࡋࠊࣂ࢖࣐࣮࣮࢜࢝ࡢⓎぢࡸࠊࡀࢇ࡞࡝ࡢྛ✀⑌ᝈࡢ๰⸆◊✲࡬ࡢά⏝ࡀᮇᚅ
ࡉࢀࡲࡍࠋ

́́

TF-6
ࣜࣥ⬡㉁ࡢ㝖ཤ࡜ࣜࣥ⬡㉁ࢆᢳฟࡍࡿ๓ฎ⌮〇ရ࡟ࡘ࠸࡚㕥ᮌ೺୍, ኴ⏣ⱱᚨ, ⏤஭ኤ†ࢪ࣮࢚ࣝࢧ࢖࢚ࣥࢫᰴᘧ఍♫The introduction for products of phospholipids removal and phospholipids
enrichment
Kenichi Suzuki, Shigenori Ota, Yuko Yui
GL Sciences Inc.
࠙せ᪨ᮏᩥࠚ㏆ᖺࠊLC/MS/MS ࡢឤᗘྥୖ࡟క࠸⏕యヨᩱࡢ๓ฎ⌮ࡶ⡆౽࡞㝖ࢱࣥࣃࢡฎ⌮ࡀᖜᗈࡃ⏝࠸ࡽࢀ࡚࠸ࡿࠋࡋ࠿ࡋࠊ㝖ࢱࣥࣃࢡ㉁ฎ⌮࡛ࡣࠊࣜࣥ⬡㉁࡞࡝ࡀヨᩱ࡟ṧᏑࡋ࡚࠾ࡾࠊ࢖࢜ࣥࢧࣉࣞࢵࢩࣙࣥࡢせᅉ࡟࡞ࡗ࡚࠸ࡿࠋࡲࡓࠊṧᏑࡋ࡚࠸ࡿࣜࣥ⬡㉁ࡢ㔞ࡣࠊヨᩱࡈ࡜࡟㐪࠸ࠊ࢖࢜ࣥࢧࣉࣞࢵࢩࣙࣥࡢ≧ἣࡶヨᩱ࡟ࡼࡾ␗࡞ࡿࡓࡵࠊࡇࢀࡀ

ᐃ⤖ᯝࡢࣂࣛࡘࡁ࡟ࡘ࡞ࡀࡿࡇ࡜ࡀゎ࠿ࡗ࡚࠸ࡿࠋࡇࢀࢆᨵၿࡍࡿ᪉ἲ࡜ࡋ࡚ࠊ᫖ᖺࡢᮏᏛ఍࡟
࠾࠸࡚ࠊ96WellPlate ࣇ࢛࣮࣐ࢵࢺࡢ㝖ࢱࣥࣃࢡࣉ࣮ࣞࢺ࡟ࢳࢱࢽ࢔࡜ࢪࣝࢥࢽ࢔ࢆ඘ሸࡋ
ࡓࣜࣥ⬡㉁㝖ཤᶵ⬟ࢆᣢࡓࡏࡓࣇ࢕ࣝࢱ࣮ࣉ࣮ࣞࢺࢆ⤂௓ࡋࡓࠋࢳࢱࢽ࢔࡜ࢪࣝࢥࢽ࢔ࡣࠊ
ྵࣜࣥ㓟໬ྜ≀࡟ᑐࡋ࡚ࠊ໬Ꮫⓗ࡞࢔ࣇ࢕ࢽࢸ࢕࣮࡟ࡶఝࡓ⤖ྜ≉ᛶࢆᣢࡗ࡚࠸ࡿࡓࡵࠊ
ࡼࡾ㑅ᢥⓗ࡞ࣜࣥ⬡㉁ࡢ㝖ཤࡀྍ⬟࡟࡞ࡿࠋ௒ᅇࡣࠊࣇ࢕ࣝࢺ࣮ࣞࢩࣙࣥἲࢆ⏝࠸࡞࠸ሙྜ࡟ࠊฎ⌮ࡋࡓヨᩱ୰ࡢࣜࣥ⬡㉁ࡢ㝖ཤࡍࡿࡓࡵࡢࢶ࣮ࣝࢆ㛤Ⓨࡋࡓࡢ࡛⤂௓ࡍࡿࠋࡲࡓࠊ㏆ᖺࡣࠊ࣓ࢱ࣑࣎ࣟࢡࢫ◊✲࡞࡝࡛ࠊࣜࣥ⬡㉁⮬యࢆࢱ࣮ࢤࢵࢺ࡜ࡍࡿ◊✲ࡀቑ࠼࡚ࡁ࡚࠾ࡾࠊヨᩱ୰ࡢࣜࣥ⬡㉁ࢆ㑅ᢥⓗ࡟ᢳฟࡍࡿ᪉ἲࡀồࡵࡽࢀ࡚ࡁ࡚࠸ࡿࠋ๓㏙ࡢࣜࣥ⬡㉁ࢆ㝖ཤࡍࡿ〇ရ࡟౑⏝ࡋ࡚࠸ࡿ඘ሸ๣ࡣࠊࣜࣥ⬡㉁࡜ࡢ໬Ꮫⓗ⤖ྜࡀᙉࡃ⬺╔ࡀᝏ࠸ഴྥࡀ࠶ࡾࠊ๓ฎ⌮⏝඘ሸ๣࡜ࡋ࡚ࡣࠊ᭱㐺࡛ࡣ࡞࠸ࠋ
ᚤᑡヨᩱᑐᛂࡢࢫࣆ࣒ࣥ࢝ࣛᆺᅛ┦ᢳฟ࣒࡛࢝ࣛ࠶ࡿ MonoSpin ࡟ࢳࢱࢽ࢔࡜ࢪࣝࢥࢽ࢔
ࢆࢥ࣮ࢸ࢕ࣥࢢࡉࡏࡓ࣒࢝ࣛࡀࣜࣥ⬡㉁ࡢ㑅ᢥⓗ྾╔⬟ࡣ⥔ᣢࡋࡓࡲࡲࠊ⬺╔ຠ⋡࡟ඃࢀ࡚࠾ࡾࠊࣜࣥ⬡㉁⏝ᅛ┦ᢳฟ࣒࢝ࣛ࡜ࡋ࡚᭱㐺໬ࡍࡿࡇ࡜ࡀ࡛ࡁࡓࠋࡲࡓࠊᚑ᮶ࡢࢫࣆࣥ
࣒࢝ࣛࡔࡅ࡛ࡣ࡞ࡃࠊࢹࢵࢻ࣮࣒࣎ࣜࣗࡀᑡ࡞ࡃ┦ᑐⓗ࡟ᑡ㔞⁐ฟࡀྍ⬟࡞≉ᛶࢆ⥔ᣢࡋࡓࡲࡲ࡟ࠊ10mL ࡲ࡛ࡢヨᩱ࡟㐺ᛂࡍࡿࡓࡵࡢ MonoSpin L ࡶୖᕷࡋ࡚࠸ࡿࠋࡇࡢࣜࣥ⬡㉁ฎ
⌮⏝ࡢ࣒࢝ࣛࡶ L ᆺࢆ‽ഛࡋࡓࡢ࡛ࡇࡇ࡛ేࡏ࡚⤂௓ࡍࡿࠋ

́́

TF-7
Hybrid SPE®-Phospholipid ࢆ⏝࠸ࡓࣜࣥ⬡㉁㝖ཤ࡟ࡼࡿ㧗ឤᗘศᯒᯇᓥỤ㔛㤶 11ࢩࢢ࣐࢔ࣝࢻࣜࢵࢳ ࢪࣕࣃࣥྜྠ఍♫High sensitive analysis by the removal of phospholipids using “Hybrid
SPE-Phospholipid”
Erika Matsushima1
1
Sigma-Aldrich Japan⾑₢ࡸ⾑Ύ࡞࡝ࡢ⏕యヨᩱ୰ࡢ໬ྜ≀ࡸ௦ㅰ≀ࡢ LC-MS ࡢศᯒ࡟࠾࠸࡚ࠊ」㞧࡞ࢧࣥࣉ࣐ࣝࢺࣜࢵࢡࢫ࠿ࡽࡢᖸ΅࡟࠶࠺ࡇ࡜ࡀከࡃ࠶ࡾࠊࡑࡢཎᅉࡢ୍ࡘ࡜ࡋ࡚ࣜࣥ⬡㉁ጉᐖࡀ
▱ࡽࢀ࡚࠸ࡿࠋ
ᮏⓎ⾲࡛ࡣࠊࣜࣥ⬡㉁㝖ཤཬࡧ⃰⦰ࡀྍ⬟࡞๓ฎ⌮⏝ᅛ┦ᢳฟ⟶ Hybrid SPE-Phospholipidࢆ⏝࠸ࡓࣜࣥ⬡㉁ࡢ㝖ཤࢆ୰ᚰ࡟ࠊ⏕యヨᩱ୰ࡢ໬ྜ≀ࡢྠᐃ࡜ᐃ㔞࡟㛵ࡋࠊ㎿㏿࠿ࡘ㧗࠸ಙ㢗ᛶࢆᐇ⌧ࡍࡿࠊHPLC ⏝࣒࢝ࣛ࠿ࡽㄆドᶆ‽≀㉁(CRM)ࡲ࡛ ᐃ࡟౑⏝ࡍࡿ୍㐃ࡢࢶ࣮ࣝࢆ⤂௓ࡍࡿࠋ

́́

TF-8
LC-MS/MS ࡟ࡼࡿ⾑୰་⸆ရศᯒࡢࡓࡵࡢ඲⮬ື๓ฎ⌮ࢩࢫࢸ࣒ᑿᓥ඾⾜ 1, ✄ᇉ▱Ꮚ 1, ሯᮏከ▴ 1, ᰘ⏣ ග 1,2, ᕝୖ኱㍜ 1
1(ᰴ)ᓥὠ〇సᡤ ศᯒィ ஦ᴗ㒊ࠊ2Shimadzu Scientific Instruments Inc.

Clinical laboratory automated modules for the extraction of medical drugs fromblood prior to LC-MS/MS analysis
Noriyuki Ojima1, Tomoko Inagaki1, Taku Tsukamoto1, Hikaru Shibata1,2, Daisuke Kawakami1
1
Shimadzu Corporation, Analytical & Measuring Instruments Division
2
Shimadzu Scientific Instruments Inc.
㉁㔞ศᯒᢏ⾡ࡢⓎ㐩࡟ࡼࡿศᯒࡢ㧗ឤᗘ໬ࡣせồࡉࢀࡿヨᩱࡢ㔞ࢆῶࡽࡋࠊᚤ㔞ᡂศࡢ᳨ฟࢆᐜ᫆࡟ࡋ࡚ࡁࡲࡋࡓࠋࡉࡽ࡟ࡇࡇᩘᖺࡢศᯒࡢ㧗㏿໬ࡣ⤖ᯝࡀ࡛ࡿࡲ࡛ࡢ᫬㛫ࢆ኱ᖜ࡟▷⦰ࡋࠊ㉁㔞ศᯒィࡢᮏ᱁ⓗ࡞⮫ᗋ⌧ሙ࡛ࡢᛂ⏝ࢆ⌧ᐇⓗ࡟ࡋ࡚࠸ࡲࡍࠋࡋ࠿ࡋ࡞ࡀ
ࡽࠊ㉁㔞ศᯒィࡀ㧗㏿࡟࡞ࢀࡤ࡞ࡿ࡯࡝ࠊࡑࡢ๓ẁࡢᡭసᴗ࡛ࡢ๓ฎ⌮᧯సࡀ࣎ࢺࣝࢿࢵ
ࢡ࡜࡞ࡗ࡚ࡁ࡚࠸ࡲࡍࠋ
ࡑࡇ࡛ࠊᙜ♫ࡣ㛗ᖺᇵࡗ࡚ࡁࡓ⾑ᾮจᅛศᯒ⿦⨨ࡢᢏ⾡ࢆ᥇⏝ࡋࠊ᥇⾑⟶࡞࡝ࢆࢭࢵࢺ
ࡍࡿࡔࡅ࡛⾑ᾮ࡞࡝ᾮయ⏕యヨᩱࢆศᯒࡍࡿࡓࡵࡢ๓ฎ⌮࠿ࡽ LCMS ศᯒࡲ࡛ࢆ඲⮬ື࡛⾜࠺ࢩࢫࢸ࣒ࢆ㛤Ⓨࡋࡲࡋࡓࠋࡇࡢࢩࢫࢸ࣒࡟ࡼࡾேᡭࢆ┬ࡅࡿࡔࡅ࡛࡞ࡃࠊ๓ฎ⌮ࡢᡭᢏ࡟ࡼࡿ࣑ࢫࡸࣂࣛࢶ࢟ࢆపῶࡋ෌⌧ᛶࡢ㧗࠸ศᯒࢆ⾜࠺ࡇ࡜ࡀ࡛ࡁࡲࡍࠋ㸯᳨యࡈ࡜ࡢ㏲
ḟ୪ิฎ⌮ࢆ⾜࠼ࡿࡓࡵ࡟ࠊฎ⌮୰࡛ࡶ᪂ࡓ࡞᳨యヨᩱࢆ㏣ຍࡍࡿࡇ࡜ࡶྍ⬟࡟࡞ࡗ࡚࠸
ࡲࡍࠋᮏ࣮࣡ࢡࢩࣙࢵࣉ࡛ࡣࡇࡢ඲⮬ື LC-MS/MS ᳨యศᯒ⿦⨨ࢆ⏝࠸ࡓ඲⮬ືศᯒࡢ୍౛࡜ࡋ
࡚⾑ᾮ୰ࡢ་⸆ရࡢ⃰ᗘศᯒࡢᐇ౛ࢆ♧ࡋ࡞ࡀࡽࠊヨ⸆ࠊࢥࣥࢺ࣮ࣟࣝヨᩱࠊ⿦⨨ಖᏲࡢ⟶⌮ᶵ⬟࡞࡝⮫ᗋศᯒ࡟ᚲせ࡞⢭ᗘ⟶⌮ᶵ⬟ࢆྵࢇࡔࢯ࣮ࣜࣗࢩࣙࣥ౛ࢆࡈ⤂௓ࡋࡲࡍࠋ
἞⒪⸆≀ࣔࢽࢱࣜࣥࢢ࡬ࡢᛂ⏝ࡔࡅ࡛࡞ࡃࠊ⌧ᅾ㛤Ⓨ୰ࡢศᯒἲࡢ඲⮬ື໬ࡢࡓࡵࡢ㑅ᢥ⫥ࡢ୍ࡘ࡟ຍ࠼࡚࠸ࡓࡔࡅࢀࡤᖾ࠸࡛ࡍࠋ

́́́́

Ꮫ఍㈶ຓ఍ဨ୍ぴ㸦ᖹᡂ 27 ᖺᗘ㸧ᰴᘧ఍♫ᓥὠ〇సᡤ᪥ᮏ㟁Ꮚᰴᘧ఍♫ᰴᘧ఍♫㈨⏕ᇽࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫ᰴᘧ఍♫࢚ࢫ࢔࣮࢚ࣝࣝ
ᰴᘧ఍♫࢚࣮ࣅ࣮࣭ࢧ࢖࢚ࢵࢡࢫ
᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫୸▼〇⸆ᰴᘧ఍♫
㸦9 ♫㸧

́́

ᖺ఍༠㈶௻ᴗ୍ぴࡇࡢᗘࡢᖺ఍㛤ദ࡟࠶ࡓࡾࠊ௻ᴗ࣭ᅋయࡢⓙᵝ࠿ࡽ༠㈶㔠ࠊᒎ♧ࠊᗈ࿌ᥖ㍕ࠊࡑࡢ௚ࡢ
ࡈ༠ຊࢆ࠸ࡓࡔࡁࡲࡋࡓࠋࡇࡇ࡟௻ᴗྡࢆᥖ㍕ࡋࠊ῝ࡃឤㅰ⏦ࡋୖࡆࡲࡍࠋ
㸦2015 ᖺ 8 ᭶ 14 ᪥㸧࢔ࢧࣄࢢ࣮ࣝࣉ࣮࣍ࣝࢹ࢕ࣥࢢࢫᰴ
ᘧ఍♫ࢩࢢ࣐࢔ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ఍♫ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ఍♫࢔ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫ࢩࣗࣉ࣮࣭ࣜࣥ࢞ࢪࣕࣃࣥᰴᘧ఍♫㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡᣺⯆㈈ᅋ

✚Ỉ࣓ࢹ࢕࢝ࣝᰴᘧ఍♫኱ሯ〇⸆ᰴᘧ఍♫ࢽࢵࢺ࣮࣮࣓࣎ࢹ࢕࢝ࣝᰴᘧ఍♫ᰴᘧ఍♫ఀ⸨ᅬ

᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫ᰴᘧ఍♫࢚࣮ࣅ࣮࣭ࢧ࢖࢚ࢵࢡࢫ

᪥ᮏ㟁Ꮚᰴᘧ఍♫ᰴᘧ఍♫࣮࢝ࢡ

ࣂ࢖࢜ࢱ࣮ࢪ࣭ࢪࣕࣃࣥᰴᘧ఍♫ᰴᘧ఍♫㈨⏕ᇽ὾ᯇ࣍ࢺࢽࢡࢫᰴᘧ఍♫ᰴᘧ఍♫ᓥὠ〇సᡤࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫ᰴᘧ఍♫ࢶ࣒ࣛ

࣐ࢺࣜࢵࢡࢫࢧ࢖࢚ࣥࢫᰴᘧ఍♫ᰴᘧ఍♫⨺ᅵ♫࣐ࣝࣁࢽࢳࣟᰴᘧ఍♫࢟ࣜࣥᰴᘧ఍♫୕஭᝟ሗᰴᘧ఍♫ࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ
࢕ࢵࢡᰴᘧ఍♫ࣛ࢖࢜ࣥᰴᘧ఍♫⌮⛉◊ᰴᘧ఍♫ࢧࢵ࣏ࣟࣅ࣮ࣝᰴᘧ఍♫ࢪ࣮࢚ࣝࢧ࢖࢚ࣥࢫᰴᘧ఍♫㸦30 ♫ࠊ஬༑㡢㡰ࠊᩗ⛠␎㸧́́ᒎ♧௻ᴗ୍ぴ࢔ࢪࣞࣥࢺ࣭ࢸࢡࣀࣟࢪ࣮ᰴᘧ఍♫㹋㹑㹒 ୍⯡㈈ᅋἲே ᮦᩱ⛉Ꮫᢏ⾡᣺⯆㈈ᅋ
኱ሯ〇⸆ᰴᘧ఍♫ᰴᘧ఍♫࢚࣮ࣅ࣮࣭ࢧ࢖࢚ࢵࢡࢫ
ᰴᘧ఍♫ᓥὠ〇సᡤࢧ࣮ࣔࣇ࢕ࢵࢩ࣮ࣕࢧ࢖࢚ࣥࢸ࢕ࣇ࢕ࢵࢡᰴᘧ఍♫ࢪ࣮࢚ࣝࢧ࢖࢚ࣥࢫᰴᘧ఍♫ࢩࢢ࣐࢔ࣝࢻࣜࢵࢳࢪࣕࣃࣥྜྠ఍♫ࢩࢫ࣓ࢵࢡࢫ࣭ࣅ࣓࣮࢜ࣜࣗᰴᘧ఍♫᪥ᮏ࢛࣮࢘ࢱ࣮ࢬᰴᘧ఍♫ࣈ࣮࣭ࣝ࢝ࢲࣝࢺࢽࢡࢫᰴᘧ఍♫㸦11 ♫ࠊ஬༑㡢㡰ࠊᩗ⛠␎㸧́́ᖺ఍㐠Ⴀጤဨ୍ぴ
ᖺ఍㛗
℩⸨ ග฼

὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ㐠Ⴀጤဨࢫࢱࢵࣇ㸦஬༑㡢㡰㸧᭷ಙ ဴဢឡ▱་⛉኱Ꮫ་Ꮫ㒊໬Ꮫᩍᐊ⊦㣫 ㄃཭ឡ▱┴⾨⏕◊✲ᡤụୖ ᾈྖ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ▼஭ ᫭ྡྂᒇ኱Ꮫ኱Ꮫ㝔་Ꮫ⣔◊✲⛉ἲ་࣭⏕࿨೔⌮Ꮫᑠᕝ ໷அឡ▱་⛉኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙᮌᮧ ⰾ⁠⚄ዉᕝ┴❧ಖ೺⚟♴኱Ꮫே㛫⥲ྜ࣭ᑓ㛛ᇶ♏
㏆⸨ ㇦὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ㏆⸨ ᩥ㞝ឡ▱་⛉኱Ꮫ་Ꮫ㒊⸆⌮Ꮫㅮᗙ⤃㔝 ᅾ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮୕ᯞ ኱㍜ᮾ໭኱Ꮫᮾ໭࣓ࢹ࢕࣭࣓࢝ࣝ࢞ࣂࣥࢡᶵᵓబ⸨ 㥴ᖹ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙబ⸨ ᬛோ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ㔜ᯇ 㝧௓⚟஭኱Ꮫ་Ꮫ㒊೺ᗣ⛉Ꮫᮡᒣ ᰤ஧὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ㕥ᮌ ಟ὾ᯇ་⛉኱Ꮫ⌮஦ጒᑿ ὒឡ▱་⛉኱Ꮫ་Ꮫ㒊ἲ་Ꮫㅮᗙ
὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ
Ṋ஭ ྐ㑻
ሐෆ せ
୰㒊኱Ꮫᛂ⏝⏕≀Ꮫ㒊ᛂ⏝⏕≀໬Ꮫ⛉୰す ㇏ᩥ኱㜰་⛉኱Ꮫ⥲ྜ་Ꮫㅮᗙ⮫ᗋ᳨ᰝ་Ꮫᩍᐊ୹⩚ ฼඘ಟᩥ኱Ꮫ೺ᗣᰤ㣴Ꮫ㒊⟶⌮ᰤ㣴Ꮫ⛉ẚ௻ ⬟அ⸨⏣ಖ೺⾨⏕኱Ꮫ⭈⮚ෆ⛉๓⏣ ᗣ༤ྡྂᒇᕷ❧኱Ꮫ኱Ꮫ㝔⸆Ꮫ◊✲⛉⑓㝔⸆๣Ꮫศ㔝๓ᕝ ┿ே὾ᯇ་⛉኱Ꮫ⮫ᗋ᳨ᰝ་Ꮫㅮᗙṇᮌ ⣖㝯὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙᯇୗ ⚈Ꮚ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙᐑᇛ ᦶ㔛Ꮚ ὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙᐑᔱ ⿱᫂὾ᯇ་⛉኱Ꮫෆ⛉Ꮫ➨୍ㅮᗙ▮ᑿ ⫱Ꮚ὾ᯇ་⛉኱Ꮫ࣓ࢹ࢕࢝ࣝࣇ࢛ࢺࢽࢡࢫ◊✲ࢭࣥࢱ࣮ᒣᓮ ᩥ⩏὾ᯇ་⛉኱Ꮫゎ๗Ꮫㅮᗙ

́́



ἇὅἩἽЭϼྸỆỊ第 41 回
年 会 長：妹尾日本医用マススペクトル学会年会のお知らせ
洋（愛知医科大学法医学講座）

会

期：平成 28 年 9 月 15 日（木）、16 日（金）（9 月 17 日：医用質量分析認定士 第 4 回講習会開催予定）

場

所：ウインクあいち

一般社団法人 日本医用マススペクトル学会

JSBMS Letters Vol.40 Supplement, 2015

第 40 回 日本医用マススペクトル学会年会プログラム・抄録集

発行

日： 平成 27 年 8 月 20 日

編

集者： 第 40 回日本医用マススペクトル学会年会（年会長）瀬藤光利

発行責任者： 丹羽利充
編集委員会：（委員長）瀬藤光利／浅井清文／有田 誠／五十嵐一雄／伊藤哲哉／
妹尾発

行洋／谷口寿章／中西豊文

所： 一般社団法人 日本医用マススペクトル学会事務局〒491-0938
修文大学

愛知県一宮市日光町 6

健康栄養学部内

E-mail：jsbms.office@gmail.com
ホームページ：http://www.jsbms.jp/
印

刷所： オオゼキ写真印刷株式会社〒433-8111

静岡県浜松市中区葵西 2‐5‐20

TEL／053-436-1956

FAX／053-437-6095